{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0b47aa21",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import requests\n",
    "import plotly.graph_objects as go\n",
    "import matplotlib.pyplot as plt\n",
    "import matplotlib.colors as mcolors\n",
    "import plotly.express as px\n",
    "import seaborn as sns\n",
    "import matplotlib.patches as mpatches\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "d6575815",
   "metadata": {},
   "outputs": [],
   "source": [
    "# This is the relative path of the assets directory, if the assets are in another location please change the path accordingly.\n",
    "assets = \"../assets\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "9e9a2f66",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_gse16 = f\"{assets}/GSE161529/GSE161529_DE_oncogenes.csv\"\n",
    "df_gse18 = f\"{assets}/GSE180286/GSE180286_DE_oncogenes.csv\"\n",
    "\n",
    "# Load the datasets and tag with dataset source\n",
    "df_16 = pd.read_csv(df_gse16)\n",
    "df_16[\"Dataset\"] = \"GSE161529\"\n",
    "\n",
    "df_18 = pd.read_csv(df_gse18)\n",
    "df_18[\"Dataset\"] = \"GSE180286\"\n",
    "\n",
    "# Standardize gene column if needed\n",
    "df_16[\"gene\"] = df_16[\"gene\"].str.upper()\n",
    "df_18[\"gene\"] = df_18[\"gene\"].str.upper()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "7c9fd0a1",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Combine both\n",
    "combined_df = pd.concat([df_18, df_16], ignore_index=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "2708f9d3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Combined_de_genes.csv created successfully.\n"
     ]
    }
   ],
   "source": [
    "# Save combined file\n",
    "combined_df.to_csv(f\"{assets}/Combined_DE.csv\", index=False)\n",
    "print(\"Combined_de_genes.csv created successfully.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "b1cf4f29",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load DGIdb interaction data and extract druggable genes\n",
    "dgidb_df = pd.read_csv(f\"{assets}/interactions.tsv\", sep=\"\\t\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "0a2ecad3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of druggable genes from DGIdb: 3579\n"
     ]
    }
   ],
   "source": [
    "# Filter druggable genes: approved or anti-neoplastic\n",
    "dgidb_filtered = dgidb_df[\n",
    "    (dgidb_df[\"approved\"] == True) | (dgidb_df[\"anti_neoplastic\"] == True)\n",
    "]\n",
    "\n",
    "# Unique druggable gene symbols (uppercased for consistency)\n",
    "druggable_genes = dgidb_filtered[\"gene_name\"].dropna().str.upper().unique()\n",
    "print(f\"Number of druggable genes from DGIdb: {len(druggable_genes)}\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6c314ba3",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bc2f2fa6",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4cf63348",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "7f029da2",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Query Open Targets API for breast cancer target association scores\n",
    "url = \"https://api.platform.opentargets.org/api/v4/graphql\"\n",
    "query = \"\"\"\n",
    "    query BreastCancerTargets($efoId: String!, $size: Int!) {\n",
    "        disease(efoId: $efoId) {\n",
    "            associatedTargets(page: { index: 0, size: $size }) {\n",
    "                rows {\n",
    "                    target {\n",
    "                        approvedSymbol\n",
    "                    }\n",
    "                    score\n",
    "                }\n",
    "            }\n",
    "        }\n",
    "    }\n",
    "\"\"\"\n",
    "variables = {\n",
    "    \"efoId\": \"EFO_0000305\",  # Breast cancer EFO ID\n",
    "    \"size\": 500\n",
    "}\n",
    "\n",
    "response = requests.post(url, json={\"query\": query, \"variables\": variables})\n",
    "data = response.json()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "c99ec0de",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'data': {'disease': {'associatedTargets': {'rows': [{'target': {'approvedSymbol': 'BRCA2'},\n",
       "      'score': 0.9015570127068824},\n",
       "     {'target': {'approvedSymbol': 'BRCA1'}, 'score': 0.8750451744229439},\n",
       "     {'target': {'approvedSymbol': 'PIK3CA'}, 'score': 0.8559343029703544},\n",
       "     {'target': {'approvedSymbol': 'PALB2'}, 'score': 0.8550810037606932},\n",
       "     {'target': {'approvedSymbol': 'TP53'}, 'score': 0.8521601650622082},\n",
       "     {'target': {'approvedSymbol': 'CHEK2'}, 'score': 0.8323434664299262},\n",
       "     {'target': {'approvedSymbol': 'CDH1'}, 'score': 0.8296330440284129},\n",
       "     {'target': {'approvedSymbol': 'ESR1'}, 'score': 0.8245563043802553},\n",
       "     {'target': {'approvedSymbol': 'ERBB2'}, 'score': 0.8200202466263291},\n",
       "     {'target': {'approvedSymbol': 'RAD51C'}, 'score': 0.8184892879756712},\n",
       "     {'target': {'approvedSymbol': 'AKT1'}, 'score': 0.8127212288178087},\n",
       "     {'target': {'approvedSymbol': 'ATM'}, 'score': 0.810702935283194},\n",
       "     {'target': {'approvedSymbol': 'BRIP1'}, 'score': 0.7962149278398519},\n",
       "     {'target': {'approvedSymbol': 'FGFR2'}, 'score': 0.7828585559425397},\n",
       "     {'target': {'approvedSymbol': 'RAD51D'}, 'score': 0.7781192086124116},\n",
       "     {'target': {'approvedSymbol': 'PTEN'}, 'score': 0.7742617426378924},\n",
       "     {'target': {'approvedSymbol': 'MAP3K1'}, 'score': 0.7726806062037287},\n",
       "     {'target': {'approvedSymbol': 'TBX3'}, 'score': 0.7500586968963144},\n",
       "     {'target': {'approvedSymbol': 'BARD1'}, 'score': 0.7500526018007222},\n",
       "     {'target': {'approvedSymbol': 'GATA3'}, 'score': 0.7448189455530099},\n",
       "     {'target': {'approvedSymbol': 'KRAS'}, 'score': 0.7382889306780871},\n",
       "     {'target': {'approvedSymbol': 'KMT2C'}, 'score': 0.7346182204259835},\n",
       "     {'target': {'approvedSymbol': 'NCOR1'}, 'score': 0.7291027873924836},\n",
       "     {'target': {'approvedSymbol': 'MAP2K4'}, 'score': 0.7255112460735786},\n",
       "     {'target': {'approvedSymbol': 'FOXA1'}, 'score': 0.7159267124135291},\n",
       "     {'target': {'approvedSymbol': 'POLD1'}, 'score': 0.7123158061508487},\n",
       "     {'target': {'approvedSymbol': 'CDK6'}, 'score': 0.7107364363037431},\n",
       "     {'target': {'approvedSymbol': 'NF1'}, 'score': 0.709118753293071},\n",
       "     {'target': {'approvedSymbol': 'TERT'}, 'score': 0.7055470571171543},\n",
       "     {'target': {'approvedSymbol': 'ERBB4'}, 'score': 0.7034305870240418},\n",
       "     {'target': {'approvedSymbol': 'POLE'}, 'score': 0.6985587227735499},\n",
       "     {'target': {'approvedSymbol': 'EGFR'}, 'score': 0.6980969916919698},\n",
       "     {'target': {'approvedSymbol': 'RB1'}, 'score': 0.696427062978585},\n",
       "     {'target': {'approvedSymbol': 'ARID1A'}, 'score': 0.6951731231513211},\n",
       "     {'target': {'approvedSymbol': 'CDK4'}, 'score': 0.6932629507685144},\n",
       "     {'target': {'approvedSymbol': 'C11orf65'}, 'score': 0.6923979902862939},\n",
       "     {'target': {'approvedSymbol': 'MSH2'}, 'score': 0.690988396539427},\n",
       "     {'target': {'approvedSymbol': 'MLH1'}, 'score': 0.6895836285593833},\n",
       "     {'target': {'approvedSymbol': 'PPM1D'}, 'score': 0.6869914692728277},\n",
       "     {'target': {'approvedSymbol': 'EBF1'}, 'score': 0.6864035992337864},\n",
       "     {'target': {'approvedSymbol': 'RAD51B'}, 'score': 0.6862158027430181},\n",
       "     {'target': {'approvedSymbol': 'CUX1'}, 'score': 0.6847308608350618},\n",
       "     {'target': {'approvedSymbol': 'RAD50'}, 'score': 0.6846055488640792},\n",
       "     {'target': {'approvedSymbol': 'CBFB'}, 'score': 0.6831141340326508},\n",
       "     {'target': {'approvedSymbol': 'MSH6'}, 'score': 0.6819309661393363},\n",
       "     {'target': {'approvedSymbol': 'NBN'}, 'score': 0.6807413014476248},\n",
       "     {'target': {'approvedSymbol': 'FBXO11'}, 'score': 0.6806325578615184},\n",
       "     {'target': {'approvedSymbol': 'PMS2'}, 'score': 0.670816979849896},\n",
       "     {'target': {'approvedSymbol': 'TUBB2B'}, 'score': 0.6694086881042376},\n",
       "     {'target': {'approvedSymbol': 'FOXP1'}, 'score': 0.6679766942473697},\n",
       "     {'target': {'approvedSymbol': 'MLLT10'}, 'score': 0.666343901767738},\n",
       "     {'target': {'approvedSymbol': 'TUBB4B'}, 'score': 0.666335425047462},\n",
       "     {'target': {'approvedSymbol': 'TCF7L2'}, 'score': 0.663922429978204},\n",
       "     {'target': {'approvedSymbol': 'TUBB2A'}, 'score': 0.6599958528416666},\n",
       "     {'target': {'approvedSymbol': 'SETBP1'}, 'score': 0.6597389551036729},\n",
       "     {'target': {'approvedSymbol': 'TUBB'}, 'score': 0.6591293375180699},\n",
       "     {'target': {'approvedSymbol': 'TUBB6'}, 'score': 0.658388754471144},\n",
       "     {'target': {'approvedSymbol': 'SF3B1'}, 'score': 0.6539727769219796},\n",
       "     {'target': {'approvedSymbol': 'CDKN1B'}, 'score': 0.6499120943590406},\n",
       "     {'target': {'approvedSymbol': 'CDC73'}, 'score': 0.6491142068961752},\n",
       "     {'target': {'approvedSymbol': 'AR'}, 'score': 0.6476008160429277},\n",
       "     {'target': {'approvedSymbol': 'NOTCH2'}, 'score': 0.6458330781592272},\n",
       "     {'target': {'approvedSymbol': 'FHIT'}, 'score': 0.6440903303159997},\n",
       "     {'target': {'approvedSymbol': 'PIK3CB'}, 'score': 0.6406393118089563},\n",
       "     {'target': {'approvedSymbol': 'SUZ12'}, 'score': 0.637312179526419},\n",
       "     {'target': {'approvedSymbol': 'BLM'}, 'score': 0.6350541679663257},\n",
       "     {'target': {'approvedSymbol': 'MUTYH'}, 'score': 0.6341870024039463},\n",
       "     {'target': {'approvedSymbol': 'POLD2'}, 'score': 0.633400150251017},\n",
       "     {'target': {'approvedSymbol': 'DROSHA'}, 'score': 0.6333484953332625},\n",
       "     {'target': {'approvedSymbol': 'H3C2'}, 'score': 0.6326965279192959},\n",
       "     {'target': {'approvedSymbol': 'TGFBR2'}, 'score': 0.6318031274234464},\n",
       "     {'target': {'approvedSymbol': 'CYP19A1'}, 'score': 0.6311866235908714},\n",
       "     {'target': {'approvedSymbol': 'NRG1'}, 'score': 0.6275552149679772},\n",
       "     {'target': {'approvedSymbol': 'MYC'}, 'score': 0.6265912902458359},\n",
       "     {'target': {'approvedSymbol': 'POLD3'}, 'score': 0.626108449155979},\n",
       "     {'target': {'approvedSymbol': 'POLE2'}, 'score': 0.6250868848777388},\n",
       "     {'target': {'approvedSymbol': 'ARID1B'}, 'score': 0.6238332843379497},\n",
       "     {'target': {'approvedSymbol': 'TET2'}, 'score': 0.6235189274121294},\n",
       "     {'target': {'approvedSymbol': 'TP63'}, 'score': 0.621597502524139},\n",
       "     {'target': {'approvedSymbol': 'MRTFA'}, 'score': 0.61825714197433},\n",
       "     {'target': {'approvedSymbol': 'GRIN2A'}, 'score': 0.6178270066983459},\n",
       "     {'target': {'approvedSymbol': 'NTRK3'}, 'score': 0.6164665019922481},\n",
       "     {'target': {'approvedSymbol': 'FOXO3'}, 'score': 0.6148591839147917},\n",
       "     {'target': {'approvedSymbol': 'JAK1'}, 'score': 0.6145182000562924},\n",
       "     {'target': {'approvedSymbol': 'MECOM'}, 'score': 0.6135815484839577},\n",
       "     {'target': {'approvedSymbol': 'ATP2B3'}, 'score': 0.6127521927456887},\n",
       "     {'target': {'approvedSymbol': 'KDM6A'}, 'score': 0.6124543458976558},\n",
       "     {'target': {'approvedSymbol': 'MDM2'}, 'score': 0.6114405112321094},\n",
       "     {'target': {'approvedSymbol': 'CACNA1D'}, 'score': 0.6111287643872062},\n",
       "     {'target': {'approvedSymbol': 'MAML2'}, 'score': 0.6103190099626628},\n",
       "     {'target': {'approvedSymbol': 'TOP2A'}, 'score': 0.6095761339552933},\n",
       "     {'target': {'approvedSymbol': 'TUBB3'}, 'score': 0.6088522406973587},\n",
       "     {'target': {'approvedSymbol': 'HMGA2'}, 'score': 0.6087018009475075},\n",
       "     {'target': {'approvedSymbol': 'STAG2'}, 'score': 0.6080312328895626},\n",
       "     {'target': {'approvedSymbol': 'KAT6B'}, 'score': 0.6078642837066036},\n",
       "     {'target': {'approvedSymbol': 'EXO1'}, 'score': 0.6076720869096744},\n",
       "     {'target': {'approvedSymbol': 'NCOR2'}, 'score': 0.6065811042358579},\n",
       "     {'target': {'approvedSymbol': 'FGFR4'}, 'score': 0.606226875073298},\n",
       "     {'target': {'approvedSymbol': 'PRDM16'}, 'score': 0.6062107444924374},\n",
       "     {'target': {'approvedSymbol': 'RAF1'}, 'score': 0.6061161039521248},\n",
       "     {'target': {'approvedSymbol': 'MDM4'}, 'score': 0.6054231155611528},\n",
       "     {'target': {'approvedSymbol': 'FAT4'}, 'score': 0.6047112235107833},\n",
       "     {'target': {'approvedSymbol': 'MYH9'}, 'score': 0.6016252984534595},\n",
       "     {'target': {'approvedSymbol': 'TUBB1'}, 'score': 0.6013694153351085},\n",
       "     {'target': {'approvedSymbol': 'TUBB8'}, 'score': 0.6013694153351085},\n",
       "     {'target': {'approvedSymbol': 'TUBB4A'}, 'score': 0.6013694153351085},\n",
       "     {'target': {'approvedSymbol': 'HRAS'}, 'score': 0.6005445011511256},\n",
       "     {'target': {'approvedSymbol': 'ABI1'}, 'score': 0.599194485410051},\n",
       "     {'target': {'approvedSymbol': 'MAPK1'}, 'score': 0.5985500812020287},\n",
       "     {'target': {'approvedSymbol': 'ZFHX3'}, 'score': 0.5983621924239368},\n",
       "     {'target': {'approvedSymbol': 'NCOA2'}, 'score': 0.5983365213898671},\n",
       "     {'target': {'approvedSymbol': 'TYMS'}, 'score': 0.5977363055670477},\n",
       "     {'target': {'approvedSymbol': 'PTPN13'}, 'score': 0.5969782967533555},\n",
       "     {'target': {'approvedSymbol': 'FANCC'}, 'score': 0.5952911181006463},\n",
       "     {'target': {'approvedSymbol': 'FANCD2'}, 'score': 0.5952391231121411},\n",
       "     {'target': {'approvedSymbol': 'TBL1XR1'}, 'score': 0.5950066325692307},\n",
       "     {'target': {'approvedSymbol': 'KLF4'}, 'score': 0.5948214492302903},\n",
       "     {'target': {'approvedSymbol': 'WWTR1'}, 'score': 0.5947718037677657},\n",
       "     {'target': {'approvedSymbol': 'KAT6A'}, 'score': 0.5928561097989206},\n",
       "     {'target': {'approvedSymbol': 'CDKN2A'}, 'score': 0.5924677775259918},\n",
       "     {'target': {'approvedSymbol': 'SYK'}, 'score': 0.5924465364677763},\n",
       "     {'target': {'approvedSymbol': 'MN1'}, 'score': 0.5923198970617595},\n",
       "     {'target': {'approvedSymbol': 'ERBB3'}, 'score': 0.591867970018281},\n",
       "     {'target': {'approvedSymbol': 'SND1'}, 'score': 0.5914200276865273},\n",
       "     {'target': {'approvedSymbol': 'CDK12'}, 'score': 0.5894236114364189},\n",
       "     {'target': {'approvedSymbol': 'RAD51'}, 'score': 0.5884950664473374},\n",
       "     {'target': {'approvedSymbol': 'POLA1'}, 'score': 0.5877080239860563},\n",
       "     {'target': {'approvedSymbol': 'GPC3'}, 'score': 0.5873896020352417},\n",
       "     {'target': {'approvedSymbol': 'POLA2'}, 'score': 0.5872973797030732},\n",
       "     {'target': {'approvedSymbol': 'HIF1A'}, 'score': 0.5861963757504658},\n",
       "     {'target': {'approvedSymbol': 'RET'}, 'score': 0.5856493486138504},\n",
       "     {'target': {'approvedSymbol': 'LRP1B'}, 'score': 0.58551533456645},\n",
       "     {'target': {'approvedSymbol': 'TOP1'}, 'score': 0.585323070871845},\n",
       "     {'target': {'approvedSymbol': 'ITPR1'}, 'score': 0.5828598369426049},\n",
       "     {'target': {'approvedSymbol': 'EPS15'}, 'score': 0.5828051988504008},\n",
       "     {'target': {'approvedSymbol': 'TOX3'}, 'score': 0.582603100274098},\n",
       "     {'target': {'approvedSymbol': 'MITF'}, 'score': 0.5823778890703183},\n",
       "     {'target': {'approvedSymbol': 'CASP8'}, 'score': 0.5819879846695651},\n",
       "     {'target': {'approvedSymbol': 'CDH11'}, 'score': 0.5808835048178301},\n",
       "     {'target': {'approvedSymbol': 'NDRG1'}, 'score': 0.5806732153741399},\n",
       "     {'target': {'approvedSymbol': 'TRIM24'}, 'score': 0.5803697364967826},\n",
       "     {'target': {'approvedSymbol': 'POLQ'}, 'score': 0.5789897430288539},\n",
       "     {'target': {'approvedSymbol': 'IKBKB'}, 'score': 0.5789678969208499},\n",
       "     {'target': {'approvedSymbol': 'ESR2'}, 'score': 0.5788601378173522},\n",
       "     {'target': {'approvedSymbol': 'DDR2'}, 'score': 0.5781201833373687},\n",
       "     {'target': {'approvedSymbol': 'TRRAP'}, 'score': 0.5779490355261628},\n",
       "     {'target': {'approvedSymbol': 'ARHGAP35'}, 'score': 0.5778204848969293},\n",
       "     {'target': {'approvedSymbol': 'NUP98'}, 'score': 0.5766264785229321},\n",
       "     {'target': {'approvedSymbol': 'RANBP2'}, 'score': 0.5765197679709207},\n",
       "     {'target': {'approvedSymbol': 'GNAQ'}, 'score': 0.5762700235440487},\n",
       "     {'target': {'approvedSymbol': 'WRN'}, 'score': 0.5756734247648178},\n",
       "     {'target': {'approvedSymbol': 'PLAG1'}, 'score': 0.5741809479353893},\n",
       "     {'target': {'approvedSymbol': 'PREX2'}, 'score': 0.5735673265992564},\n",
       "     {'target': {'approvedSymbol': 'USP8'}, 'score': 0.5733617921768839},\n",
       "     {'target': {'approvedSymbol': 'NTRK2'}, 'score': 0.5728621374265072},\n",
       "     {'target': {'approvedSymbol': 'PIK3R1'}, 'score': 0.5714589802479894},\n",
       "     {'target': {'approvedSymbol': 'EPAS1'}, 'score': 0.571095543765291},\n",
       "     {'target': {'approvedSymbol': 'ELL'}, 'score': 0.5702032283421287},\n",
       "     {'target': {'approvedSymbol': 'CLTC'}, 'score': 0.5701583789366086},\n",
       "     {'target': {'approvedSymbol': 'PBX1'}, 'score': 0.5699021844626382},\n",
       "     {'target': {'approvedSymbol': 'ARHGEF5'}, 'score': 0.569600214188608},\n",
       "     {'target': {'approvedSymbol': 'CREB1'}, 'score': 0.5689058748562488},\n",
       "     {'target': {'approvedSymbol': 'DUSP4'}, 'score': 0.5688709640377748},\n",
       "     {'target': {'approvedSymbol': 'CCND1'}, 'score': 0.5687106090199208},\n",
       "     {'target': {'approvedSymbol': 'UBR5'}, 'score': 0.56863661586572},\n",
       "     {'target': {'approvedSymbol': 'ABL2'}, 'score': 0.5681047384063375},\n",
       "     {'target': {'approvedSymbol': 'RRM1'}, 'score': 0.5675996981406937},\n",
       "     {'target': {'approvedSymbol': 'PTPRK'}, 'score': 0.5650769708789418},\n",
       "     {'target': {'approvedSymbol': 'FANCM'}, 'score': 0.5649167511516586},\n",
       "     {'target': {'approvedSymbol': 'ARHGEF12'}, 'score': 0.5648292571137584},\n",
       "     {'target': {'approvedSymbol': 'ZFPM2'}, 'score': 0.5646840622726819},\n",
       "     {'target': {'approvedSymbol': 'RSPO2'}, 'score': 0.5639818611365874},\n",
       "     {'target': {'approvedSymbol': 'PTPRC'}, 'score': 0.5630057532133447},\n",
       "     {'target': {'approvedSymbol': 'POLD4'}, 'score': 0.5624928231764463},\n",
       "     {'target': {'approvedSymbol': 'POT1'}, 'score': 0.5623941853725611},\n",
       "     {'target': {'approvedSymbol': 'POLE3'}, 'score': 0.5621232433217616},\n",
       "     {'target': {'approvedSymbol': 'MYB'}, 'score': 0.5618458781848477},\n",
       "     {'target': {'approvedSymbol': 'PRIM1'}, 'score': 0.5617536634670769},\n",
       "     {'target': {'approvedSymbol': 'PRIM2'}, 'score': 0.5617536634670769},\n",
       "     {'target': {'approvedSymbol': 'FTO'}, 'score': 0.5611883716823698},\n",
       "     {'target': {'approvedSymbol': 'MAX'}, 'score': 0.5610689014156622},\n",
       "     {'target': {'approvedSymbol': 'TNFSF10'}, 'score': 0.561050649571795},\n",
       "     {'target': {'approvedSymbol': 'KIT'}, 'score': 0.560003326322802},\n",
       "     {'target': {'approvedSymbol': 'KDR'}, 'score': 0.5597760363523583},\n",
       "     {'target': {'approvedSymbol': 'DNMT3A'}, 'score': 0.5590550525895099},\n",
       "     {'target': {'approvedSymbol': 'ZMIZ1'}, 'score': 0.5557456701323281},\n",
       "     {'target': {'approvedSymbol': 'AFDN'}, 'score': 0.5531443420437283},\n",
       "     {'target': {'approvedSymbol': 'MSI2'}, 'score': 0.5531213548088374},\n",
       "     {'target': {'approvedSymbol': 'SLC6A3'}, 'score': 0.5530596222717675},\n",
       "     {'target': {'approvedSymbol': 'EZH2'}, 'score': 0.5530521847325579},\n",
       "     {'target': {'approvedSymbol': 'BUB1B'}, 'score': 0.5526146493693207},\n",
       "     {'target': {'approvedSymbol': 'CCDC170'}, 'score': 0.5506728874764347},\n",
       "     {'target': {'approvedSymbol': 'AFF3'}, 'score': 0.5505301823239099},\n",
       "     {'target': {'approvedSymbol': 'PDGFRB'}, 'score': 0.5503641860652148},\n",
       "     {'target': {'approvedSymbol': 'CBLB'}, 'score': 0.5500711547106498},\n",
       "     {'target': {'approvedSymbol': 'ATF7IP'}, 'score': 0.5482507414782015},\n",
       "     {'target': {'approvedSymbol': 'LPP'}, 'score': 0.5482488251962265},\n",
       "     {'target': {'approvedSymbol': 'ATRX'}, 'score': 0.5481617797517319},\n",
       "     {'target': {'approvedSymbol': 'PTPN11'}, 'score': 0.5479820741399604},\n",
       "     {'target': {'approvedSymbol': 'CAMTA1'}, 'score': 0.5472409658476093},\n",
       "     {'target': {'approvedSymbol': 'ARNT'}, 'score': 0.5456875657149246},\n",
       "     {'target': {'approvedSymbol': 'PDGFRA'}, 'score': 0.5456728483745805},\n",
       "     {'target': {'approvedSymbol': 'DNM2'}, 'score': 0.5452348454094008},\n",
       "     {'target': {'approvedSymbol': 'WIF1'}, 'score': 0.5448699817544271},\n",
       "     {'target': {'approvedSymbol': 'ETNK1'}, 'score': 0.544582372360655},\n",
       "     {'target': {'approvedSymbol': 'BMPR1A'}, 'score': 0.5439324276731865},\n",
       "     {'target': {'approvedSymbol': 'PRC1'}, 'score': 0.5437503634967239},\n",
       "     {'target': {'approvedSymbol': 'RUNX1'}, 'score': 0.5433579933955777},\n",
       "     {'target': {'approvedSymbol': 'BCL2'}, 'score': 0.5426061933696946},\n",
       "     {'target': {'approvedSymbol': 'ZNF521'}, 'score': 0.5422564937228093},\n",
       "     {'target': {'approvedSymbol': 'EXT1'}, 'score': 0.5416640582767124},\n",
       "     {'target': {'approvedSymbol': 'PTPRT'}, 'score': 0.541239024624636},\n",
       "     {'target': {'approvedSymbol': 'NEK10'}, 'score': 0.5403431143683802},\n",
       "     {'target': {'approvedSymbol': 'HIP1'}, 'score': 0.5399440450747142},\n",
       "     {'target': {'approvedSymbol': 'MET'}, 'score': 0.539556157723632},\n",
       "     {'target': {'approvedSymbol': 'DNER'}, 'score': 0.5389330278997234},\n",
       "     {'target': {'approvedSymbol': 'CTCF'}, 'score': 0.5382248142927412},\n",
       "     {'target': {'approvedSymbol': 'MTCP1'}, 'score': 0.5373906361095545},\n",
       "     {'target': {'approvedSymbol': 'ADAM29'}, 'score': 0.5373268878042371},\n",
       "     {'target': {'approvedSymbol': 'BRAF'}, 'score': 0.5367289145122806},\n",
       "     {'target': {'approvedSymbol': 'CCND3'}, 'score': 0.5365252799918622},\n",
       "     {'target': {'approvedSymbol': 'IKZF3'}, 'score': 0.5362243237048848},\n",
       "     {'target': {'approvedSymbol': 'FBXW7'}, 'score': 0.5354856925840391},\n",
       "     {'target': {'approvedSymbol': 'NOTCH1'}, 'score': 0.5351269680361672},\n",
       "     {'target': {'approvedSymbol': 'QKI'}, 'score': 0.5351103965558743},\n",
       "     {'target': {'approvedSymbol': 'FLT4'}, 'score': 0.535052643952737},\n",
       "     {'target': {'approvedSymbol': 'RANBP9'}, 'score': 0.5349261307561404},\n",
       "     {'target': {'approvedSymbol': 'BCL11A'}, 'score': 0.5337226781131387},\n",
       "     {'target': {'approvedSymbol': 'ACVR1'}, 'score': 0.5335793438581186},\n",
       "     {'target': {'approvedSymbol': 'ARHGAP26'}, 'score': 0.5335793438581186},\n",
       "     {'target': {'approvedSymbol': 'NFATC2'}, 'score': 0.5334207915414053},\n",
       "     {'target': {'approvedSymbol': 'DDX10'}, 'score': 0.5329762100674873},\n",
       "     {'target': {'approvedSymbol': 'AKT2'}, 'score': 0.5322910697662221},\n",
       "     {'target': {'approvedSymbol': 'CREBBP'}, 'score': 0.5316768180274546},\n",
       "     {'target': {'approvedSymbol': 'ABCC1'}, 'score': 0.5315329741193355},\n",
       "     {'target': {'approvedSymbol': 'AFF4'}, 'score': 0.5311283107940638},\n",
       "     {'target': {'approvedSymbol': 'RAP1GDS1'}, 'score': 0.5300888674527631},\n",
       "     {'target': {'approvedSymbol': 'JAK2'}, 'score': 0.5299332326263771},\n",
       "     {'target': {'approvedSymbol': 'SDHC'}, 'score': 0.5297087386492783},\n",
       "     {'target': {'approvedSymbol': 'MRPS30'}, 'score': 0.5296500721655255},\n",
       "     {'target': {'approvedSymbol': 'GNRHR'}, 'score': 0.5296341145218765},\n",
       "     {'target': {'approvedSymbol': 'SPEN'}, 'score': 0.5291739934967351},\n",
       "     {'target': {'approvedSymbol': 'BCORL1'}, 'score': 0.5288841712144201},\n",
       "     {'target': {'approvedSymbol': 'MEN1'}, 'score': 0.5285773516384004},\n",
       "     {'target': {'approvedSymbol': 'APC'}, 'score': 0.5282210582522796},\n",
       "     {'target': {'approvedSymbol': 'VEGFA'}, 'score': 0.5279616996133037},\n",
       "     {'target': {'approvedSymbol': 'MTOR'}, 'score': 0.5274019341543704},\n",
       "     {'target': {'approvedSymbol': 'NSD2'}, 'score': 0.5273204993806127},\n",
       "     {'target': {'approvedSymbol': 'BCL9'}, 'score': 0.5272704834963204},\n",
       "     {'target': {'approvedSymbol': 'EP300'}, 'score': 0.527066825792016},\n",
       "     {'target': {'approvedSymbol': 'ATR'}, 'score': 0.5255456094860074},\n",
       "     {'target': {'approvedSymbol': 'PAX9'}, 'score': 0.5253357756510477},\n",
       "     {'target': {'approvedSymbol': 'SDHB'}, 'score': 0.5250290957881134},\n",
       "     {'target': {'approvedSymbol': 'MRE11'}, 'score': 0.5249094211409872},\n",
       "     {'target': {'approvedSymbol': 'CCNE1'}, 'score': 0.52481007418909},\n",
       "     {'target': {'approvedSymbol': 'ACVR1B'}, 'score': 0.5245326943205397},\n",
       "     {'target': {'approvedSymbol': 'PTCH1'}, 'score': 0.5244268019626899},\n",
       "     {'target': {'approvedSymbol': 'MAP3K13'}, 'score': 0.5235635943114847},\n",
       "     {'target': {'approvedSymbol': 'BCOR'}, 'score': 0.5228232425930162},\n",
       "     {'target': {'approvedSymbol': 'CREB3L2'}, 'score': 0.5220453725598335},\n",
       "     {'target': {'approvedSymbol': 'PDCD1LG2'}, 'score': 0.5209947622967296},\n",
       "     {'target': {'approvedSymbol': 'ETV6'}, 'score': 0.5209398164792188},\n",
       "     {'target': {'approvedSymbol': 'STK11'}, 'score': 0.5205748045703105},\n",
       "     {'target': {'approvedSymbol': 'HGF'}, 'score': 0.5205545164881642},\n",
       "     {'target': {'approvedSymbol': 'KNL1'}, 'score': 0.5204161926976338},\n",
       "     {'target': {'approvedSymbol': 'TSC1'}, 'score': 0.5203446329155014},\n",
       "     {'target': {'approvedSymbol': 'HCN1'}, 'score': 0.5202496452135162},\n",
       "     {'target': {'approvedSymbol': 'RUNX1T1'}, 'score': 0.5200013247167774},\n",
       "     {'target': {'approvedSymbol': 'PAX5'}, 'score': 0.5198641555523936},\n",
       "     {'target': {'approvedSymbol': 'DEK'}, 'score': 0.5190670338244264},\n",
       "     {'target': {'approvedSymbol': 'TFEB'}, 'score': 0.517917090463574},\n",
       "     {'target': {'approvedSymbol': 'RRAS2'}, 'score': 0.5178693056203609},\n",
       "     {'target': {'approvedSymbol': 'PTPRB'}, 'score': 0.5174271435519378},\n",
       "     {'target': {'approvedSymbol': 'HNF4G'}, 'score': 0.5170273964422857},\n",
       "     {'target': {'approvedSymbol': 'CD274'}, 'score': 0.5150132312800388},\n",
       "     {'target': {'approvedSymbol': 'ETV5'}, 'score': 0.5146825163379354},\n",
       "     {'target': {'approvedSymbol': 'MAP2K2'}, 'score': 0.5136672867694714},\n",
       "     {'target': {'approvedSymbol': 'BCL11B'}, 'score': 0.513013764860976},\n",
       "     {'target': {'approvedSymbol': 'SMAD4'}, 'score': 0.5127932728863001},\n",
       "     {'target': {'approvedSymbol': 'BAP1'}, 'score': 0.5127591437434812},\n",
       "     {'target': {'approvedSymbol': 'RMI2'}, 'score': 0.5121892359992898},\n",
       "     {'target': {'approvedSymbol': 'NSD3'}, 'score': 0.5121676732290034},\n",
       "     {'target': {'approvedSymbol': 'ZBTB16'}, 'score': 0.5120866726223255},\n",
       "     {'target': {'approvedSymbol': 'FLT3'}, 'score': 0.5117890061047563},\n",
       "     {'target': {'approvedSymbol': 'FCRL4'}, 'score': 0.5114733018281209},\n",
       "     {'target': {'approvedSymbol': 'XRCC2'}, 'score': 0.5114325403416558},\n",
       "     {'target': {'approvedSymbol': 'ABL1'}, 'score': 0.5113711910529836},\n",
       "     {'target': {'approvedSymbol': 'FKBP1A'}, 'score': 0.5112482251172261},\n",
       "     {'target': {'approvedSymbol': 'CTNNB1'}, 'score': 0.5109584220282535},\n",
       "     {'target': {'approvedSymbol': 'TACSTD2'}, 'score': 0.5103892944623726},\n",
       "     {'target': {'approvedSymbol': 'CBFA2T3'}, 'score': 0.5102034180493111},\n",
       "     {'target': {'approvedSymbol': 'USP6'}, 'score': 0.5098774691496935},\n",
       "     {'target': {'approvedSymbol': 'STAT3'}, 'score': 0.5097900465935611},\n",
       "     {'target': {'approvedSymbol': 'KCNU1'}, 'score': 0.5094503168809271},\n",
       "     {'target': {'approvedSymbol': 'TNP1'}, 'score': 0.5085491259472444},\n",
       "     {'target': {'approvedSymbol': 'TRIM33'}, 'score': 0.5084648842430903},\n",
       "     {'target': {'approvedSymbol': 'CLTCL1'}, 'score': 0.5081363688167039},\n",
       "     {'target': {'approvedSymbol': 'MAP2K1'}, 'score': 0.5071865729538917},\n",
       "     {'target': {'approvedSymbol': 'CCDC91'}, 'score': 0.5071435469091662},\n",
       "     {'target': {'approvedSymbol': 'TSC2'}, 'score': 0.5071243036903412},\n",
       "     {'target': {'approvedSymbol': 'PARP1'}, 'score': 0.5065584067173681},\n",
       "     {'target': {'approvedSymbol': 'EIF3E'}, 'score': 0.5062862623302594},\n",
       "     {'target': {'approvedSymbol': 'PIP4K2A'}, 'score': 0.5053566110399607},\n",
       "     {'target': {'approvedSymbol': 'CDKN2B'}, 'score': 0.5053048632567833},\n",
       "     {'target': {'approvedSymbol': 'NRIP1'}, 'score': 0.5048485329634388},\n",
       "     {'target': {'approvedSymbol': 'RHOH'}, 'score': 0.5048030415103331},\n",
       "     {'target': {'approvedSymbol': 'ELF4'}, 'score': 0.5043314554804255},\n",
       "     {'target': {'approvedSymbol': 'LSP1'}, 'score': 0.5039028594736286},\n",
       "     {'target': {'approvedSymbol': 'CSF3R'}, 'score': 0.5034783273621161},\n",
       "     {'target': {'approvedSymbol': 'CRTC1'}, 'score': 0.5026448710082217},\n",
       "     {'target': {'approvedSymbol': 'PLCG1'}, 'score': 0.5025999571360605},\n",
       "     {'target': {'approvedSymbol': 'FOXO1'}, 'score': 0.502400450183966},\n",
       "     {'target': {'approvedSymbol': 'FGFR1'}, 'score': 0.501991899539538},\n",
       "     {'target': {'approvedSymbol': 'KDM7A'}, 'score': 0.5018777261303172},\n",
       "     {'target': {'approvedSymbol': 'NT5C2'}, 'score': 0.5016019916637369},\n",
       "     {'target': {'approvedSymbol': 'NFIB'}, 'score': 0.500563141656517},\n",
       "     {'target': {'approvedSymbol': 'PEX14'}, 'score': 0.49975941203719587},\n",
       "     {'target': {'approvedSymbol': 'HLF'}, 'score': 0.49975362577687416},\n",
       "     {'target': {'approvedSymbol': 'H3-3B'}, 'score': 0.4996873626943286},\n",
       "     {'target': {'approvedSymbol': 'LEF1'}, 'score': 0.499657853393767},\n",
       "     {'target': {'approvedSymbol': 'EXT2'}, 'score': 0.49955072080916607},\n",
       "     {'target': {'approvedSymbol': 'JAK3'}, 'score': 0.499283941129891},\n",
       "     {'target': {'approvedSymbol': 'SMARCA4'}, 'score': 0.498239326353047},\n",
       "     {'target': {'approvedSymbol': 'KMT2D'}, 'score': 0.4979176358939832},\n",
       "     {'target': {'approvedSymbol': 'CCDC88C'}, 'score': 0.49777290846678895},\n",
       "     {'target': {'approvedSymbol': 'PPP2R1A'}, 'score': 0.49767505365811193},\n",
       "     {'target': {'approvedSymbol': 'JUN'}, 'score': 0.4972607556597406},\n",
       "     {'target': {'approvedSymbol': 'KMT2A'}, 'score': 0.49713449166980733},\n",
       "     {'target': {'approvedSymbol': 'COX11'}, 'score': 0.4963109920883485},\n",
       "     {'target': {'approvedSymbol': 'LCK'}, 'score': 0.49600672053072914},\n",
       "     {'target': {'approvedSymbol': 'CHD4'}, 'score': 0.4958951365076024},\n",
       "     {'target': {'approvedSymbol': 'CBL'}, 'score': 0.4952731947309496},\n",
       "     {'target': {'approvedSymbol': 'SETD2'}, 'score': 0.4949783183446116},\n",
       "     {'target': {'approvedSymbol': 'PHF6'}, 'score': 0.4945378182601849},\n",
       "     {'target': {'approvedSymbol': 'RHOA'}, 'score': 0.4940827856151698},\n",
       "     {'target': {'approvedSymbol': 'XPO1'}, 'score': 0.4938285372436782},\n",
       "     {'target': {'approvedSymbol': 'ERCC4'}, 'score': 0.4937994748765349},\n",
       "     {'target': {'approvedSymbol': 'CDKN1A'}, 'score': 0.49364686428314786},\n",
       "     {'target': {'approvedSymbol': 'NTRK1'}, 'score': 0.49361683325847827},\n",
       "     {'target': {'approvedSymbol': 'ASXL1'}, 'score': 0.49248853223746636},\n",
       "     {'target': {'approvedSymbol': 'CARD11'}, 'score': 0.49226887754576615},\n",
       "     {'target': {'approvedSymbol': 'CREB3L1'}, 'score': 0.4922653033637263},\n",
       "     {'target': {'approvedSymbol': 'HNF1A'}, 'score': 0.4920119421904429},\n",
       "     {'target': {'approvedSymbol': 'PSIP1'}, 'score': 0.49188643826913403},\n",
       "     {'target': {'approvedSymbol': 'SH3GL1'}, 'score': 0.4917567949792194},\n",
       "     {'target': {'approvedSymbol': 'RPS23'}, 'score': 0.49151261136402535},\n",
       "     {'target': {'approvedSymbol': 'STAT5B'}, 'score': 0.4907381226379723},\n",
       "     {'target': {'approvedSymbol': 'RSPO3'}, 'score': 0.4907244352518001},\n",
       "     {'target': {'approvedSymbol': 'NF2'}, 'score': 0.4905583783121791},\n",
       "     {'target': {'approvedSymbol': 'DCLRE1B'}, 'score': 0.4904292548851718},\n",
       "     {'target': {'approvedSymbol': 'AXIN1'}, 'score': 0.4898158334511511},\n",
       "     {'target': {'approvedSymbol': 'FCGR2B'}, 'score': 0.4896039907425998},\n",
       "     {'target': {'approvedSymbol': 'ERCC2'}, 'score': 0.48855379936007837},\n",
       "     {'target': {'approvedSymbol': 'PBRM1'}, 'score': 0.48808448370214946},\n",
       "     {'target': {'approvedSymbol': 'KDM5A'}, 'score': 0.48807390972271925},\n",
       "     {'target': {'approvedSymbol': 'MCM8'}, 'score': 0.4874060996102723},\n",
       "     {'target': {'approvedSymbol': 'CARS1'}, 'score': 0.4869984543501539},\n",
       "     {'target': {'approvedSymbol': 'CYLD'}, 'score': 0.4868782782760539},\n",
       "     {'target': {'approvedSymbol': 'PRLR'}, 'score': 0.4855967345834565},\n",
       "     {'target': {'approvedSymbol': 'SMAD2'}, 'score': 0.4851466579500381},\n",
       "     {'target': {'approvedSymbol': 'ARID2'}, 'score': 0.48500432237373564},\n",
       "     {'target': {'approvedSymbol': 'PRDM1'}, 'score': 0.48486721232778535},\n",
       "     {'target': {'approvedSymbol': 'ZNF462'}, 'score': 0.483240607311512},\n",
       "     {'target': {'approvedSymbol': 'LMO2'}, 'score': 0.4830716683941289},\n",
       "     {'target': {'approvedSymbol': 'BCL6'}, 'score': 0.48304205594021954},\n",
       "     {'target': {'approvedSymbol': 'DAXX'}, 'score': 0.4822937271980211},\n",
       "     {'target': {'approvedSymbol': 'STXBP4'}, 'score': 0.48213289452819086},\n",
       "     {'target': {'approvedSymbol': 'COL2A1'}, 'score': 0.4821176424031602},\n",
       "     {'target': {'approvedSymbol': 'PDGFB'}, 'score': 0.4814042139609791},\n",
       "     {'target': {'approvedSymbol': 'H3-3A'}, 'score': 0.48138802683389864},\n",
       "     {'target': {'approvedSymbol': 'ZNF331'}, 'score': 0.48122376912070547},\n",
       "     {'target': {'approvedSymbol': 'ATP1A1'}, 'score': 0.48054410361275945},\n",
       "     {'target': {'approvedSymbol': 'REL'}, 'score': 0.48044066551467257},\n",
       "     {'target': {'approvedSymbol': 'ZNF365'}, 'score': 0.4802770783934041},\n",
       "     {'target': {'approvedSymbol': 'ERCC3'}, 'score': 0.4799996145005471},\n",
       "     {'target': {'approvedSymbol': 'DNAJC1'}, 'score': 0.4795575286529997},\n",
       "     {'target': {'approvedSymbol': 'KDM5C'}, 'score': 0.4789405540230946},\n",
       "     {'target': {'approvedSymbol': 'SMAD3'}, 'score': 0.4788434353458258},\n",
       "     {'target': {'approvedSymbol': 'DHFR'}, 'score': 0.47867765535273177},\n",
       "     {'target': {'approvedSymbol': 'RAD21'}, 'score': 0.47841336617221986},\n",
       "     {'target': {'approvedSymbol': 'BIRC3'}, 'score': 0.47796420201892587},\n",
       "     {'target': {'approvedSymbol': 'SLC34A2'}, 'score': 0.4778798699108035},\n",
       "     {'target': {'approvedSymbol': 'MPL'}, 'score': 0.477731321034452},\n",
       "     {'target': {'approvedSymbol': 'MED12'}, 'score': 0.4776843973816245},\n",
       "     {'target': {'approvedSymbol': 'TNS1'}, 'score': 0.4776022870839868},\n",
       "     {'target': {'approvedSymbol': 'RARA'}, 'score': 0.47691802731759303},\n",
       "     {'target': {'approvedSymbol': 'TNFAIP3'}, 'score': 0.47618433033936375},\n",
       "     {'target': {'approvedSymbol': 'EED'}, 'score': 0.47553950953843593},\n",
       "     {'target': {'approvedSymbol': 'L3MBTL3'}, 'score': 0.4752365391177417},\n",
       "     {'target': {'approvedSymbol': 'FAS'}, 'score': 0.47479875682278255},\n",
       "     {'target': {'approvedSymbol': 'KEAP1'}, 'score': 0.4743815464928254},\n",
       "     {'target': {'approvedSymbol': 'WDR43'}, 'score': 0.4742054418994572},\n",
       "     {'target': {'approvedSymbol': 'GATA1'}, 'score': 0.47395456268641417},\n",
       "     {'target': {'approvedSymbol': 'PML'}, 'score': 0.47382735666146},\n",
       "     {'target': {'approvedSymbol': 'TRPS1'}, 'score': 0.47361157357402944},\n",
       "     {'target': {'approvedSymbol': 'DDB2'}, 'score': 0.47340611087895074},\n",
       "     {'target': {'approvedSymbol': 'BTK'}, 'score': 0.4728530953099494},\n",
       "     {'target': {'approvedSymbol': 'NRAS'}, 'score': 0.4727297692066863},\n",
       "     {'target': {'approvedSymbol': 'CBX8'}, 'score': 0.47193747057711716},\n",
       "     {'target': {'approvedSymbol': 'SUB1'}, 'score': 0.47190349077061766},\n",
       "     {'target': {'approvedSymbol': 'FANCA'}, 'score': 0.47176251324978796},\n",
       "     {'target': {'approvedSymbol': 'AXIN2'}, 'score': 0.47123251434668495},\n",
       "     {'target': {'approvedSymbol': 'ALK'}, 'score': 0.4708095461935294},\n",
       "     {'target': {'approvedSymbol': 'CBLC'}, 'score': 0.47059834829852026},\n",
       "     {'target': {'approvedSymbol': 'DLX2'}, 'score': 0.4702589302870558},\n",
       "     {'target': {'approvedSymbol': 'MALT1'}, 'score': 0.4700270158782752},\n",
       "     {'target': {'approvedSymbol': 'ERCC5'}, 'score': 0.4696675335900886},\n",
       "     {'target': {'approvedSymbol': 'TENT5C'}, 'score': 0.4695968246609039},\n",
       "     {'target': {'approvedSymbol': 'FAR2'}, 'score': 0.46931031215983277},\n",
       "     {'target': {'approvedSymbol': 'PAX3'}, 'score': 0.4691886078111713},\n",
       "     {'target': {'approvedSymbol': 'XPC'}, 'score': 0.4689368519957275},\n",
       "     {'target': {'approvedSymbol': 'DDX3X'}, 'score': 0.46870924728188196},\n",
       "     {'target': {'approvedSymbol': 'ANXA13'}, 'score': 0.46839997023593527},\n",
       "     {'target': {'approvedSymbol': 'THSD4'}, 'score': 0.46756504230177737},\n",
       "     {'target': {'approvedSymbol': 'ARRDC3'}, 'score': 0.4670474887491943},\n",
       "     {'target': {'approvedSymbol': 'FAT1'}, 'score': 0.4670146568920635},\n",
       "     {'target': {'approvedSymbol': 'PRKACA'}, 'score': 0.46668781727351416},\n",
       "     {'target': {'approvedSymbol': 'GNAS'}, 'score': 0.4662601630684513},\n",
       "     {'target': {'approvedSymbol': 'EMID1'}, 'score': 0.466088961022956},\n",
       "     {'target': {'approvedSymbol': 'ERC1'}, 'score': 0.4660604408920228},\n",
       "     {'target': {'approvedSymbol': 'TMEM132E'}, 'score': 0.46575274575932085},\n",
       "     {'target': {'approvedSymbol': 'IRS4'}, 'score': 0.4654040055657767},\n",
       "     {'target': {'approvedSymbol': 'LATS1'}, 'score': 0.46467364461636645},\n",
       "     {'target': {'approvedSymbol': 'RAD54L'}, 'score': 0.46466286351782565},\n",
       "     {'target': {'approvedSymbol': 'HNF1B'}, 'score': 0.46365894164153715},\n",
       "     {'target': {'approvedSymbol': 'AMER1'}, 'score': 0.4631571605412219},\n",
       "     {'target': {'approvedSymbol': 'CNOT3'}, 'score': 0.46299126284521086},\n",
       "     {'target': {'approvedSymbol': 'PRKAR1A'}, 'score': 0.4627838013166728},\n",
       "     {'target': {'approvedSymbol': 'FOXO4'}, 'score': 0.4614015738914694},\n",
       "     {'target': {'approvedSymbol': 'TPM3'}, 'score': 0.46120568472332457},\n",
       "     {'target': {'approvedSymbol': 'RNF43'}, 'score': 0.4609463858095706},\n",
       "     {'target': {'approvedSymbol': 'KLF14'}, 'score': 0.46045776876733635},\n",
       "     {'target': {'approvedSymbol': 'SOX2'}, 'score': 0.45979730780027217},\n",
       "     {'target': {'approvedSymbol': 'NFKBIE'}, 'score': 0.4588126785232407},\n",
       "     {'target': {'approvedSymbol': 'LRRC41'}, 'score': 0.4587351219207324},\n",
       "     {'target': {'approvedSymbol': 'ETV1'}, 'score': 0.45777196083587096},\n",
       "     {'target': {'approvedSymbol': 'PPARG'}, 'score': 0.45757930700634697},\n",
       "     {'target': {'approvedSymbol': 'RAC1'}, 'score': 0.4574315768649902},\n",
       "     {'target': {'approvedSymbol': 'PDCD1'}, 'score': 0.45717508938521867},\n",
       "     {'target': {'approvedSymbol': 'SRC'}, 'score': 0.4571603731814686},\n",
       "     {'target': {'approvedSymbol': 'FGFR3'}, 'score': 0.4556084361436828},\n",
       "     {'target': {'approvedSymbol': 'TRAK2'}, 'score': 0.4550421335428598},\n",
       "     {'target': {'approvedSymbol': 'FANCE'}, 'score': 0.4548481985155503},\n",
       "     {'target': {'approvedSymbol': 'POU5F1B'}, 'score': 0.4544399801300096},\n",
       "     {'target': {'approvedSymbol': 'IL6ST'}, 'score': 0.4530242827962553},\n",
       "     {'target': {'approvedSymbol': 'SRGAP2C'}, 'score': 0.45244195511477986},\n",
       "     {'target': {'approvedSymbol': 'MAFB'}, 'score': 0.45234528547713343},\n",
       "     {'target': {'approvedSymbol': 'ACKR3'}, 'score': 0.45226963061158115},\n",
       "     {'target': {'approvedSymbol': 'GRHL2'}, 'score': 0.45180293805328975},\n",
       "     {'target': {'approvedSymbol': 'NFE2L2'}, 'score': 0.45095665744497826},\n",
       "     {'target': {'approvedSymbol': 'BAX'}, 'score': 0.4502006556089531},\n",
       "     {'target': {'approvedSymbol': 'ZBTB38'}, 'score': 0.4501544596311071},\n",
       "     {'target': {'approvedSymbol': 'SMARCE1'}, 'score': 0.4493726053845892},\n",
       "     {'target': {'approvedSymbol': 'TTC28'}, 'score': 0.4493542407646639},\n",
       "     {'target': {'approvedSymbol': 'SET'}, 'score': 0.4492076367527057},\n",
       "     {'target': {'approvedSymbol': 'MARCHF11'}, 'score': 0.44920397360376907},\n",
       "     {'target': {'approvedSymbol': 'ROS1'}, 'score': 0.44871108210801314},\n",
       "     {'target': {'approvedSymbol': 'TET1'}, 'score': 0.44868764477396844},\n",
       "     {'target': {'approvedSymbol': 'LZTR1'}, 'score': 0.44847488755281095},\n",
       "     {'target': {'approvedSymbol': 'BRD4'}, 'score': 0.4484133332228318},\n",
       "     {'target': {'approvedSymbol': 'FLCN'}, 'score': 0.44806937632336524},\n",
       "     {'target': {'approvedSymbol': 'SEC22B'}, 'score': 0.4477805817138252},\n",
       "     {'target': {'approvedSymbol': 'INHBB'}, 'score': 0.4477409078012817},\n",
       "     {'target': {'approvedSymbol': 'PHLDA3'}, 'score': 0.4472685931874101},\n",
       "     {'target': {'approvedSymbol': 'WAS'}, 'score': 0.44609467899949184},\n",
       "     {'target': {'approvedSymbol': 'TENT5A'}, 'score': 0.4452666315620938},\n",
       "     {'target': {'approvedSymbol': 'BCL10'}, 'score': 0.44456426216893813},\n",
       "     {'target': {'approvedSymbol': 'FUBP1'}, 'score': 0.4441077632922963},\n",
       "     {'target': {'approvedSymbol': 'ZNRF3'}, 'score': 0.44407430550154564},\n",
       "     {'target': {'approvedSymbol': 'FES'}, 'score': 0.44405575114491197},\n",
       "     {'target': {'approvedSymbol': 'RBBP4'}, 'score': 0.443963830701346},\n",
       "     {'target': {'approvedSymbol': 'GATA2'}, 'score': 0.4429382113513181},\n",
       "     {'target': {'approvedSymbol': 'PITPNB'}, 'score': 0.4428896272131635},\n",
       "     {'target': {'approvedSymbol': 'FGF10'}, 'score': 0.44217763667608473},\n",
       "     {'target': {'approvedSymbol': 'NFKB2'}, 'score': 0.44126389938634664},\n",
       "     {'target': {'approvedSymbol': 'RBBP7'}, 'score': 0.4410775310269821},\n",
       "     {'target': {'approvedSymbol': 'SMO'}, 'score': 0.4406930460782788},\n",
       "     {'target': {'approvedSymbol': 'SH2B3'}, 'score': 0.4405932933586953},\n",
       "     {'target': {'approvedSymbol': 'CTNNA1'}, 'score': 0.44021660468029605},\n",
       "     {'target': {'approvedSymbol': 'IDH2'}, 'score': 0.4398669963312607},\n",
       "     {'target': {'approvedSymbol': 'FANCG'}, 'score': 0.43951320107290387},\n",
       "     {'target': {'approvedSymbol': 'CNBP'}, 'score': 0.4393380522564393},\n",
       "     {'target': {'approvedSymbol': 'FMN1'}, 'score': 0.43891508864496676},\n",
       "     {'target': {'approvedSymbol': 'TLR1'}, 'score': 0.43829820943377445},\n",
       "     {'target': {'approvedSymbol': 'DICER1'}, 'score': 0.4379981122978907},\n",
       "     {'target': {'approvedSymbol': 'FANCF'}, 'score': 0.4376193353050539},\n",
       "     {'target': {'approvedSymbol': 'STAT6'}, 'score': 0.43648877560012583},\n",
       "     {'target': {'approvedSymbol': 'TAB2'}, 'score': 0.4361121060251173},\n",
       "     {'target': {'approvedSymbol': 'FILIP1L'}, 'score': 0.43608090932643134},\n",
       "     {'target': {'approvedSymbol': 'RB1CC1'}, 'score': 0.43605230695585134},\n",
       "     {'target': {'approvedSymbol': 'IL7R'}, 'score': 0.43518010792061557},\n",
       "     {'target': {'approvedSymbol': 'CDCA7'}, 'score': 0.4349039028786524},\n",
       "     {'target': {'approvedSymbol': 'SFPQ'}, 'score': 0.43439919627467616},\n",
       "     {'target': {'approvedSymbol': 'H4C9'}, 'score': 0.43398959997496184},\n",
       "     {'target': {'approvedSymbol': 'ERG'}, 'score': 0.43338691166817683},\n",
       "     {'target': {'approvedSymbol': 'CD79A'}, 'score': 0.4327112845721747},\n",
       "     {'target': {'approvedSymbol': 'PARP2'}, 'score': 0.43248531489745384},\n",
       "     {'target': {'approvedSymbol': 'VHL'}, 'score': 0.4324165070739215},\n",
       "     {'target': {'approvedSymbol': 'NPM1'}, 'score': 0.4322864902509435},\n",
       "     {'target': {'approvedSymbol': 'NCOA1'}, 'score': 0.43147734184715486}]}}}}"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "1b6d01a8",
   "metadata": {},
   "outputs": [],
   "source": [
    "rows = data[\"data\"][\"disease\"][\"associatedTargets\"][\"rows\"]\n",
    "\n",
    "open_targets_df = pd.DataFrame([\n",
    "    {\n",
    "        \"Gene\": row[\"target\"][\"approvedSymbol\"].upper(),\n",
    "        \"OpenTargets_Score\": row[\"score\"]\n",
    "    }\n",
    "    for row in rows if row.get(\"score\") is not None\n",
    "])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "b8e49958",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Number of genes strongly associated with breast cancer (Open Targets): 316\n"
     ]
    }
   ],
   "source": [
    "# Filter strong breast cancer associations\n",
    "open_targets_df = open_targets_df[open_targets_df[\"OpenTargets_Score\"] >= 0.5]\n",
    "\n",
    "print(f\"Number of genes strongly associated with breast cancer (Open Targets): {open_targets_df.shape[0]}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "3a6abe17",
   "metadata": {},
   "outputs": [],
   "source": [
    "open_targets_df.to_csv(f\"{assets}/OpenTargets_BreastCancer.csv\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1783659e",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c69455e4",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3a9d61f4",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "239b6016",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Merge DE genes with DGIdb and Open Targets info\n",
    "# Ensure gene symbols uppercase in DE dataframe for consistency\n",
    "combined_df[\"Gene\"] = combined_df[\"gene\"].str.upper()\n",
    "\n",
    "# Add DGIdb Status\n",
    "combined_df[\"DGIdb Status\"] = combined_df[\"Gene\"].apply(lambda x: \"Targeted\" if x in druggable_genes else \"Not Targeted\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "f68be2e9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>p_value</th>\n",
       "      <th>log2_fc</th>\n",
       "      <th>mean_diff</th>\n",
       "      <th>Dataset</th>\n",
       "      <th>Gene</th>\n",
       "      <th>DGIdb Status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PTEN</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>1.686214</td>\n",
       "      <td>0.081446</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>PTEN</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CDK4</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>3.222505</td>\n",
       "      <td>0.089603</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDK4</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>4.279113</td>\n",
       "      <td>0.062919</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>3.952025</td>\n",
       "      <td>0.123942</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>4.152696</td>\n",
       "      <td>0.070191</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>FGFR1</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>BCL2</td>\n",
       "      <td>6.880750e-252</td>\n",
       "      <td>1.470827</td>\n",
       "      <td>0.060847</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>BCL2</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>BRCA2</td>\n",
       "      <td>6.852575e-238</td>\n",
       "      <td>2.499320</td>\n",
       "      <td>0.025311</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>BRCA2</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>ATM</td>\n",
       "      <td>4.698129e-180</td>\n",
       "      <td>1.058718</td>\n",
       "      <td>0.071020</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>ATM</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>WT1</td>\n",
       "      <td>1.056194e-19</td>\n",
       "      <td>2.424174</td>\n",
       "      <td>0.001583</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>WT1</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>NTRK1</td>\n",
       "      <td>2.405955e-04</td>\n",
       "      <td>1.202924</td>\n",
       "      <td>0.000931</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>NTRK1</td>\n",
       "      <td>Targeted</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>78 rows  7 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      gene        p_value   log2_fc  mean_diff    Dataset    Gene DGIdb Status\n",
       "0     PTEN   0.000000e+00  1.686214   0.081446  GSE180286    PTEN     Targeted\n",
       "1     CDK4   0.000000e+00  3.222505   0.089603  GSE180286    CDK4     Targeted\n",
       "2   CDKN2A   0.000000e+00  4.279113   0.062919  GSE180286  CDKN2A     Targeted\n",
       "3   CDKN1A   0.000000e+00  3.952025   0.123942  GSE180286  CDKN1A     Targeted\n",
       "4    FGFR1   0.000000e+00  4.152696   0.070191  GSE180286   FGFR1     Targeted\n",
       "..     ...            ...       ...        ...        ...     ...          ...\n",
       "73    BCL2  6.880750e-252  1.470827   0.060847  GSE161529    BCL2     Targeted\n",
       "74   BRCA2  6.852575e-238  2.499320   0.025311  GSE161529   BRCA2     Targeted\n",
       "75     ATM  4.698129e-180  1.058718   0.071020  GSE161529     ATM     Targeted\n",
       "76     WT1   1.056194e-19  2.424174   0.001583  GSE161529     WT1     Targeted\n",
       "77   NTRK1   2.405955e-04  1.202924   0.000931  GSE161529   NTRK1     Targeted\n",
       "\n",
       "[78 rows x 7 columns]"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "combined_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "e9986d72",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Merge with Open Targets scores (left join to keep all DE genes)\n",
    "df = combined_df.merge(open_targets_df, how=\"left\", left_on=\"Gene\", right_on=\"Gene\")\n",
    "\n",
    "# Add breast cancer support flags\n",
    "df[\"BreastCancer_Supported\"] = df[\"OpenTargets_Score\"].notna()\n",
    "df[\"Strong_BreastCancer_Support\"] = df[\"OpenTargets_Score\"].fillna(0) >= 0.5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "42190d7f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>p_value</th>\n",
       "      <th>log2_fc</th>\n",
       "      <th>mean_diff</th>\n",
       "      <th>Dataset</th>\n",
       "      <th>Gene</th>\n",
       "      <th>DGIdb Status</th>\n",
       "      <th>OpenTargets_Score</th>\n",
       "      <th>BreastCancer_Supported</th>\n",
       "      <th>Strong_BreastCancer_Support</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PTEN</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>1.686214</td>\n",
       "      <td>0.081446</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>PTEN</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.774262</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CDK4</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>3.222505</td>\n",
       "      <td>0.089603</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDK4</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.693263</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>4.279113</td>\n",
       "      <td>0.062919</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.592468</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>3.952025</td>\n",
       "      <td>0.123942</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>4.152696</td>\n",
       "      <td>0.070191</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>FGFR1</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.501992</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>BCL2</td>\n",
       "      <td>6.880750e-252</td>\n",
       "      <td>1.470827</td>\n",
       "      <td>0.060847</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>BCL2</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.542606</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>BRCA2</td>\n",
       "      <td>6.852575e-238</td>\n",
       "      <td>2.499320</td>\n",
       "      <td>0.025311</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>BRCA2</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.901557</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>ATM</td>\n",
       "      <td>4.698129e-180</td>\n",
       "      <td>1.058718</td>\n",
       "      <td>0.071020</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>ATM</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.810703</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>WT1</td>\n",
       "      <td>1.056194e-19</td>\n",
       "      <td>2.424174</td>\n",
       "      <td>0.001583</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>WT1</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>NTRK1</td>\n",
       "      <td>2.405955e-04</td>\n",
       "      <td>1.202924</td>\n",
       "      <td>0.000931</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>NTRK1</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>78 rows  10 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      gene        p_value   log2_fc  mean_diff    Dataset    Gene  \\\n",
       "0     PTEN   0.000000e+00  1.686214   0.081446  GSE180286    PTEN   \n",
       "1     CDK4   0.000000e+00  3.222505   0.089603  GSE180286    CDK4   \n",
       "2   CDKN2A   0.000000e+00  4.279113   0.062919  GSE180286  CDKN2A   \n",
       "3   CDKN1A   0.000000e+00  3.952025   0.123942  GSE180286  CDKN1A   \n",
       "4    FGFR1   0.000000e+00  4.152696   0.070191  GSE180286   FGFR1   \n",
       "..     ...            ...       ...        ...        ...     ...   \n",
       "73    BCL2  6.880750e-252  1.470827   0.060847  GSE161529    BCL2   \n",
       "74   BRCA2  6.852575e-238  2.499320   0.025311  GSE161529   BRCA2   \n",
       "75     ATM  4.698129e-180  1.058718   0.071020  GSE161529     ATM   \n",
       "76     WT1   1.056194e-19  2.424174   0.001583  GSE161529     WT1   \n",
       "77   NTRK1   2.405955e-04  1.202924   0.000931  GSE161529   NTRK1   \n",
       "\n",
       "   DGIdb Status  OpenTargets_Score  BreastCancer_Supported  \\\n",
       "0      Targeted           0.774262                    True   \n",
       "1      Targeted           0.693263                    True   \n",
       "2      Targeted           0.592468                    True   \n",
       "3      Targeted                NaN                   False   \n",
       "4      Targeted           0.501992                    True   \n",
       "..          ...                ...                     ...   \n",
       "73     Targeted           0.542606                    True   \n",
       "74     Targeted           0.901557                    True   \n",
       "75     Targeted           0.810703                    True   \n",
       "76     Targeted                NaN                   False   \n",
       "77     Targeted                NaN                   False   \n",
       "\n",
       "    Strong_BreastCancer_Support  \n",
       "0                          True  \n",
       "1                          True  \n",
       "2                          True  \n",
       "3                         False  \n",
       "4                          True  \n",
       "..                          ...  \n",
       "73                         True  \n",
       "74                         True  \n",
       "75                         True  \n",
       "76                        False  \n",
       "77                        False  \n",
       "\n",
       "[78 rows x 10 columns]"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "efa2d69a",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Add FDA approval info from DGIdb data \n",
    "# To get FDA approval status, use the dgidb_filtered dataframe:\n",
    "# Extract gene-wise FDA approval flag\n",
    "\n",
    "# Prepare dictionary mapping gene -> FDA approved (True/False)\n",
    "fda_dict = dgidb_filtered.groupby(\"gene_name\")[\"approved\"].max().to_dict()\n",
    "\n",
    "# Map it onto df\n",
    "df[\"FDA_Approved_Drug\"] = df[\"Gene\"].map(fda_dict).fillna(False)\n",
    "df[\"FDA_Approved_Drug\"] = df[\"FDA_Approved_Drug\"].map({True: \"Yes\", False: \"No\"})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "91fe4e72",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Assign therapeutic categories specific to breast cancer\n",
    "def assign_targeting_category(row):\n",
    "    if row[\"Strong_BreastCancer_Support\"]:\n",
    "        if row[\"DGIdb Status\"] == \"Targeted\":\n",
    "            if row[\"FDA_Approved_Drug\"] == \"Yes\":\n",
    "                return \"FDA-approved for Cancer Therapy\"\n",
    "            else:\n",
    "                return \"Emerging Breast Cancer Target\"\n",
    "        else:\n",
    "            return \"Lacks Breast Cancer Evidence\"\n",
    "    else:\n",
    "        return \"Lacks Breast Cancer Evidence\"\n",
    "\n",
    "df[\"Targeting Category\"] = df.apply(assign_targeting_category, axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "42904479",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Save the annotated dataframe\n",
    "df.to_csv(f\"{assets}/Oncogene_therapeutic_stratification.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "567e596c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>p_value</th>\n",
       "      <th>log2_fc</th>\n",
       "      <th>mean_diff</th>\n",
       "      <th>Dataset</th>\n",
       "      <th>Gene</th>\n",
       "      <th>DGIdb Status</th>\n",
       "      <th>OpenTargets_Score</th>\n",
       "      <th>BreastCancer_Supported</th>\n",
       "      <th>Strong_BreastCancer_Support</th>\n",
       "      <th>FDA_Approved_Drug</th>\n",
       "      <th>Targeting Category</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>AKT1</td>\n",
       "      <td>4.110008e-296</td>\n",
       "      <td>3.674780</td>\n",
       "      <td>0.026305</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>AKT1</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.812721</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>MET</td>\n",
       "      <td>0.000000e+00</td>\n",
       "      <td>3.667057</td>\n",
       "      <td>0.130467</td>\n",
       "      <td>GSE161529</td>\n",
       "      <td>MET</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.539556</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>FGFR2</td>\n",
       "      <td>5.517819e-36</td>\n",
       "      <td>3.908594</td>\n",
       "      <td>0.002577</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>FGFR2</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.782859</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>BCL2</td>\n",
       "      <td>1.067443e-238</td>\n",
       "      <td>1.345055</td>\n",
       "      <td>0.054420</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>BCL2</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.542606</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>ATM</td>\n",
       "      <td>4.945179e-48</td>\n",
       "      <td>0.522267</td>\n",
       "      <td>0.029816</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>ATM</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.810703</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     gene        p_value   log2_fc  mean_diff    Dataset   Gene DGIdb Status  \\\n",
       "14   AKT1  4.110008e-296  3.674780   0.026305  GSE180286   AKT1     Targeted   \n",
       "71    MET   0.000000e+00  3.667057   0.130467  GSE161529    MET     Targeted   \n",
       "37  FGFR2   5.517819e-36  3.908594   0.002577  GSE180286  FGFR2     Targeted   \n",
       "19   BCL2  1.067443e-238  1.345055   0.054420  GSE180286   BCL2     Targeted   \n",
       "35    ATM   4.945179e-48  0.522267   0.029816  GSE180286    ATM     Targeted   \n",
       "\n",
       "    OpenTargets_Score  BreastCancer_Supported  Strong_BreastCancer_Support  \\\n",
       "14           0.812721                    True                         True   \n",
       "71           0.539556                    True                         True   \n",
       "37           0.782859                    True                         True   \n",
       "19           0.542606                    True                         True   \n",
       "35           0.810703                    True                         True   \n",
       "\n",
       "   FDA_Approved_Drug               Targeting Category  \n",
       "14               Yes  FDA-approved for Cancer Therapy  \n",
       "71               Yes  FDA-approved for Cancer Therapy  \n",
       "37               Yes  FDA-approved for Cancer Therapy  \n",
       "19               Yes  FDA-approved for Cancer Therapy  \n",
       "35               Yes  FDA-approved for Cancer Therapy  "
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Show some sample rows\n",
    "df.sample(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "42425840",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Targeting Category\n",
       "FDA-approved for Cancer Therapy    62\n",
       "Lacks Breast Cancer Evidence       14\n",
       "Emerging Breast Cancer Target       2\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Summary of therapeutic categories\n",
    "df['Targeting Category'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "f492ccfa",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>count</th>\n",
       "      <th>mean</th>\n",
       "      <th>std</th>\n",
       "      <th>min</th>\n",
       "      <th>25%</th>\n",
       "      <th>50%</th>\n",
       "      <th>75%</th>\n",
       "      <th>max</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Targeting Category</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>Emerging Breast Cancer Target</th>\n",
       "      <td>2.0</td>\n",
       "      <td>2.299515</td>\n",
       "      <td>0.654421</td>\n",
       "      <td>1.836769</td>\n",
       "      <td>2.068142</td>\n",
       "      <td>2.299515</td>\n",
       "      <td>2.530888</td>\n",
       "      <td>2.762261</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>FDA-approved for Cancer Therapy</th>\n",
       "      <td>62.0</td>\n",
       "      <td>2.799226</td>\n",
       "      <td>0.997994</td>\n",
       "      <td>0.522267</td>\n",
       "      <td>2.278064</td>\n",
       "      <td>2.645123</td>\n",
       "      <td>3.240478</td>\n",
       "      <td>6.202051</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>Lacks Breast Cancer Evidence</th>\n",
       "      <td>14.0</td>\n",
       "      <td>2.743829</td>\n",
       "      <td>0.820120</td>\n",
       "      <td>1.202924</td>\n",
       "      <td>2.427948</td>\n",
       "      <td>2.606678</td>\n",
       "      <td>2.906411</td>\n",
       "      <td>4.706735</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                 count      mean       std       min  \\\n",
       "Targeting Category                                                     \n",
       "Emerging Breast Cancer Target      2.0  2.299515  0.654421  1.836769   \n",
       "FDA-approved for Cancer Therapy   62.0  2.799226  0.997994  0.522267   \n",
       "Lacks Breast Cancer Evidence      14.0  2.743829  0.820120  1.202924   \n",
       "\n",
       "                                      25%       50%       75%       max  \n",
       "Targeting Category                                                       \n",
       "Emerging Breast Cancer Target    2.068142  2.299515  2.530888  2.762261  \n",
       "FDA-approved for Cancer Therapy  2.278064  2.645123  3.240478  6.202051  \n",
       "Lacks Breast Cancer Evidence     2.427948  2.606678  2.906411  4.706735  "
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Summary statistics for log2FC by category\n",
    "df.groupby('Targeting Category')['log2_fc'].describe()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "ad0b4b10",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "Category: FDA-approved for Cancer Therapy  31 unique genes\n",
      "['PTEN' 'CDK4' 'CDKN2A' 'FGFR1' 'MDM2' 'HRAS' 'FOXO3' 'CCND1' 'ERBB2'\n",
      " 'KRAS' 'AKT1' 'MYC' 'BRCA1' 'TP53' 'PIK3CA' 'BCL2' 'CDK6' 'RB1' 'NF1'\n",
      " 'BRCA2' 'ATR' 'SMAD4' 'CHEK2' 'TSC2' 'STK11' 'MET' 'EGFR' 'NOTCH1' 'ATM'\n",
      " 'NTRK2' 'FGFR2']\n",
      "\n",
      "Category: Lacks Breast Cancer Evidence  8 unique genes\n",
      "['CDKN1A' 'VHL' 'BAX' 'NRAS' 'NF2' 'SRC' 'WT1' 'NTRK1']\n",
      "\n",
      "Category: Emerging Breast Cancer Target  1 unique genes\n",
      "['CASP8']\n"
     ]
    }
   ],
   "source": [
    "# List unique genes per category\n",
    "for cat in df['Targeting Category'].unique():\n",
    "    genes = df.loc[df['Targeting Category'] == cat, 'gene'].unique()\n",
    "    print(f\"\\nCategory: {cat}  {len(genes)} unique genes\")\n",
    "    print(genes)  # print first 10 genes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "e4c9d2e3",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Drop duplicates based on 'gene' column, keeping the first occurrence\n",
    "df_unique = df.drop_duplicates(subset='gene', keep='first').reset_index(drop=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "06677cf6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Dynamically found 31 FDA-approved genes for breast cancer.\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "['PTEN',\n",
       " 'CDK4',\n",
       " 'CDKN2A',\n",
       " 'FGFR1',\n",
       " 'MDM2',\n",
       " 'HRAS',\n",
       " 'FOXO3',\n",
       " 'CCND1',\n",
       " 'ERBB2',\n",
       " 'KRAS',\n",
       " 'AKT1',\n",
       " 'MYC',\n",
       " 'BRCA1',\n",
       " 'TP53',\n",
       " 'PIK3CA',\n",
       " 'BCL2',\n",
       " 'CDK6',\n",
       " 'RB1',\n",
       " 'NF1',\n",
       " 'BRCA2',\n",
       " 'ATR',\n",
       " 'SMAD4',\n",
       " 'CHEK2',\n",
       " 'TSC2',\n",
       " 'STK11',\n",
       " 'MET',\n",
       " 'EGFR',\n",
       " 'NOTCH1',\n",
       " 'ATM',\n",
       " 'NTRK2',\n",
       " 'FGFR2']"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Dynamically find FDA-approved breast cancer genes\n",
    "fda_bc_specific_genes = df_unique[\n",
    "    (df_unique[\"FDA_Approved_Drug\"] == \"Yes\") &\n",
    "    (df_unique[\"OpenTargets_Score\"].fillna(0) >= 0.5)\n",
    "][\"Gene\"].unique().tolist()\n",
    "\n",
    "print(f\"Dynamically found {len(fda_bc_specific_genes)} FDA-approved genes for breast cancer.\")\n",
    "fda_bc_specific_genes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "id": "c1701931",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Filter FDA-approved Breast Cancer Therapy genes and assign subcategories\n",
    "# df_fda = df_unique[df_unique['Targeting Category'] == 'FDA-approved Breast Cancer Therapy'].copy()\n",
    "\n",
    "# df_fda['FDA_Subcategory'] = df_fda['Gene'].apply(\n",
    "#     lambda g: 'FDA-approved for Breast Cancer' if g in fda_bc_specific_genes else 'FDA-approved for Other Cancer/General'\n",
    "# )\n",
    "\n",
    "# print(\"\\nFDA Subcategory counts:\")\n",
    "# df_fda['FDA_Subcategory'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "9a0da317",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Combine back with other targeting categories\n",
    "# df_other = df_unique[df_unique['Targeting Category'] != 'FDA-approved Breast Cancer Therapy'].copy()\n",
    "\n",
    "# df_final = pd.concat([df_fda, df_other], ignore_index=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "b5745424",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Save the updated dataframe\n",
    "# output_path = \"~/Desktop/Cancer_project/ghost-cell-busters/final_therapeutic_subcategories_dynamic.csv\"\n",
    "# df_final.to_csv(output_path, index=False)\n",
    "# print(f\"\\nSaved file with FDA subcategories: {output_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "2ee75560",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>p_value</th>\n",
       "      <th>log2_fc</th>\n",
       "      <th>mean_diff</th>\n",
       "      <th>Dataset</th>\n",
       "      <th>Gene</th>\n",
       "      <th>DGIdb Status</th>\n",
       "      <th>OpenTargets_Score</th>\n",
       "      <th>BreastCancer_Supported</th>\n",
       "      <th>Strong_BreastCancer_Support</th>\n",
       "      <th>FDA_Approved_Drug</th>\n",
       "      <th>Targeting Category</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PTEN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.686214</td>\n",
       "      <td>0.081446</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>PTEN</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.774262</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   gene  p_value   log2_fc  mean_diff    Dataset  Gene DGIdb Status  \\\n",
       "0  PTEN      0.0  1.686214   0.081446  GSE180286  PTEN     Targeted   \n",
       "\n",
       "   OpenTargets_Score  BreastCancer_Supported  Strong_BreastCancer_Support  \\\n",
       "0           0.774262                    True                         True   \n",
       "\n",
       "  FDA_Approved_Drug               Targeting Category  \n",
       "0               Yes  FDA-approved for Cancer Therapy  "
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_unique.head(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "13935935",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "FDA_Subcategory\n",
       "FDA-approved, Other Indication    18\n",
       "FDA-approved for Breast Cancer    13\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "bc_approved_genes = [\n",
    "    'ERBB2', 'CDK4', 'CDK6', 'PIK3CA', 'FGFR1', 'FGFR2', 'EGFR', 'BRCA1', 'BRCA2',\n",
    "    'TP53', 'AKT1', 'MYC', 'KRAS'\n",
    "]\n",
    "\n",
    "def fda_subcategory(row):\n",
    "    if row['Targeting Category'] != 'FDA-approved for Cancer Therapy':\n",
    "        return None\n",
    "    if row['gene'] in bc_approved_genes:\n",
    "        return 'FDA-approved for Breast Cancer'\n",
    "    else:\n",
    "        return 'FDA-approved, Other Indication'\n",
    "\n",
    "df_unique['FDA_Subcategory'] = df_unique.apply(fda_subcategory, axis=1)\n",
    "df_unique['FDA_Subcategory'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "9e78b26b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>p_value</th>\n",
       "      <th>log2_fc</th>\n",
       "      <th>mean_diff</th>\n",
       "      <th>Dataset</th>\n",
       "      <th>Gene</th>\n",
       "      <th>DGIdb Status</th>\n",
       "      <th>OpenTargets_Score</th>\n",
       "      <th>BreastCancer_Supported</th>\n",
       "      <th>Strong_BreastCancer_Support</th>\n",
       "      <th>FDA_Approved_Drug</th>\n",
       "      <th>Targeting Category</th>\n",
       "      <th>FDA_Subcategory</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PTEN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.686214</td>\n",
       "      <td>0.081446</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>PTEN</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.774262</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>FDA-approved, Other Indication</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CDK4</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.222505</td>\n",
       "      <td>0.089603</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDK4</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.693263</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>FDA-approved for Breast Cancer</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.279113</td>\n",
       "      <td>0.062919</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.592468</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>FDA-approved, Other Indication</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.952025</td>\n",
       "      <td>0.123942</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Lacks Breast Cancer Evidence</td>\n",
       "      <td>None</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.152696</td>\n",
       "      <td>0.070191</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>FGFR1</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.501992</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>FDA-approved for Breast Cancer</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     gene  p_value   log2_fc  mean_diff    Dataset    Gene DGIdb Status  \\\n",
       "0    PTEN      0.0  1.686214   0.081446  GSE180286    PTEN     Targeted   \n",
       "1    CDK4      0.0  3.222505   0.089603  GSE180286    CDK4     Targeted   \n",
       "2  CDKN2A      0.0  4.279113   0.062919  GSE180286  CDKN2A     Targeted   \n",
       "3  CDKN1A      0.0  3.952025   0.123942  GSE180286  CDKN1A     Targeted   \n",
       "4   FGFR1      0.0  4.152696   0.070191  GSE180286   FGFR1     Targeted   \n",
       "\n",
       "   OpenTargets_Score  BreastCancer_Supported  Strong_BreastCancer_Support  \\\n",
       "0           0.774262                    True                         True   \n",
       "1           0.693263                    True                         True   \n",
       "2           0.592468                    True                         True   \n",
       "3                NaN                   False                        False   \n",
       "4           0.501992                    True                         True   \n",
       "\n",
       "  FDA_Approved_Drug               Targeting Category  \\\n",
       "0               Yes  FDA-approved for Cancer Therapy   \n",
       "1               Yes  FDA-approved for Cancer Therapy   \n",
       "2               Yes  FDA-approved for Cancer Therapy   \n",
       "3               Yes     Lacks Breast Cancer Evidence   \n",
       "4               Yes  FDA-approved for Cancer Therapy   \n",
       "\n",
       "                  FDA_Subcategory  \n",
       "0  FDA-approved, Other Indication  \n",
       "1  FDA-approved for Breast Cancer  \n",
       "2  FDA-approved, Other Indication  \n",
       "3                            None  \n",
       "4  FDA-approved for Breast Cancer  "
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_unique.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "8456881c",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Assuming df_unique is your deduplicated dataframe after previous steps\n",
    "\n",
    "# # Dynamically extract gene lists by category\n",
    "# fda_bc_genes = df_unique.loc[df_unique[\"Targeting Category\"] == \"FDA-approved for Cancer Therapy\", \"gene\"].unique().tolist()\n",
    "# emerging_bc_genes = df_unique.loc[df_unique[\"Targeting Category\"] == \"Emerging Cancer Target\", \"gene\"].unique().tolist()\n",
    "# lacks_bc_genes = df_unique.loc[df_unique[\"Targeting Category\"] == \"Lacks Cancer Evidence\", \"gene\"].unique().tolist()\n",
    "\n",
    "# print(f\"FDA-approved Breast Cancer Therapy genes ({len(fda_bc_genes)}): {fda_bc_genes}\")\n",
    "# print(f\"Emerging Breast Cancer Target genes ({len(emerging_bc_genes)}): {emerging_bc_genes}\")\n",
    "# print(f\"Lacks Breast Cancer Evidence genes ({len(lacks_bc_genes)}): {lacks_bc_genes}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "3c669426",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Create a new column FDA_Subcategory with subgroups (example below is simple)\n",
    "# def fda_subcategory(row):\n",
    "#     if row[\"gene\"] in fda_bc_genes:\n",
    "#         return \"FDA-approved for Breast Cancer\"\n",
    "#     elif row[\"gene\"] in emerging_bc_genes:\n",
    "#         return \"Emerging Breast Cancer Target\"\n",
    "#     elif row[\"gene\"] in lacks_bc_genes:\n",
    "#         return \"Lacks Breast Cancer Evidence\"\n",
    "#     else:\n",
    "#         return \"Other\"\n",
    "\n",
    "# df_unique[\"Therapeutic Subcategory\"] = df_unique.apply(fda_subcategory, axis=1)\n",
    "# df_unique.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "952689f0",
   "metadata": {},
   "outputs": [],
   "source": [
    "# 3. If you have pathway info in df_unique or a master file, merge here (assuming pathway column exists)\n",
    "# If separate master file:\n",
    "# master_df = pd.read_csv(\"path_to_master_with_pathways.csv\")\n",
    "# df_unique = df_unique.merge(master_df[['gene', 'Pathway Category']], on='gene', how='left')\n",
    "\n",
    "# 4. Add drug trial data\n",
    "# Assuming you have a dataframe trial_df with columns: ['gene', 'Breast Cancer Trial'] (True/False)\n",
    "# trial_df = pd.read_csv(\"path_to_trial_info.csv\")\n",
    "# df_unique = df_unique.merge(trial_df, on='gene', how='left')\n",
    "# Fill missing trial info as False\n",
    "# df_unique['Breast Cancer Trial'] = df_unique['Breast Cancer Trial'].fillna(False)\n",
    "\n",
    "# 5. Save the final dataframe\n",
    "# output_path = os.path.expanduser(\"~/Desktop/Cancer_project/ghost-cell-busters/final_therapeutic_subcategories_extended.csv\")\n",
    "# df_unique.to_csv(output_path, index=False)\n",
    "# print(f\" Saved final annotated therapeutic subcategories with pathways and trials to {output_path}\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "1290668f",
   "metadata": {},
   "outputs": [],
   "source": [
    "# df_unique.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "c4507451",
   "metadata": {},
   "outputs": [],
   "source": [
    "# To infer Clinical Trial Status from your existing columns related to breast cancer relevance, such as the Open Targets breast cancer trial flags\n",
    "def clinical_trial_status(row):\n",
    "    # Define trial status if strongly breast cancer supported or high OpenTargets score\n",
    "    if pd.notna(row['OpenTargets_Score']) and row['OpenTargets_Score'] >= 0.5:\n",
    "        return \"In Breast Cancer Trial\"\n",
    "    elif row['Strong_BreastCancer_Support']:\n",
    "        return \"In Breast Cancer Trial\"\n",
    "    else:\n",
    "        return \"No Breast Cancer Trial\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "b1c38634",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_unique['Clinical_Trial_Status'] = df_unique.apply(clinical_trial_status, axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "558288e9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>gene</th>\n",
       "      <th>p_value</th>\n",
       "      <th>log2_fc</th>\n",
       "      <th>mean_diff</th>\n",
       "      <th>Dataset</th>\n",
       "      <th>Gene</th>\n",
       "      <th>DGIdb Status</th>\n",
       "      <th>OpenTargets_Score</th>\n",
       "      <th>BreastCancer_Supported</th>\n",
       "      <th>Strong_BreastCancer_Support</th>\n",
       "      <th>FDA_Approved_Drug</th>\n",
       "      <th>Targeting Category</th>\n",
       "      <th>FDA_Subcategory</th>\n",
       "      <th>Clinical_Trial_Status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PTEN</td>\n",
       "      <td>0.0</td>\n",
       "      <td>1.686214</td>\n",
       "      <td>0.081446</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>PTEN</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.774262</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>FDA-approved, Other Indication</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CDK4</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.222505</td>\n",
       "      <td>0.089603</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDK4</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.693263</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>FDA-approved for Breast Cancer</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.279113</td>\n",
       "      <td>0.062919</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.592468</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>FDA-approved, Other Indication</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>0.0</td>\n",
       "      <td>3.952025</td>\n",
       "      <td>0.123942</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>NaN</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>Yes</td>\n",
       "      <td>Lacks Breast Cancer Evidence</td>\n",
       "      <td>None</td>\n",
       "      <td>No Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>0.0</td>\n",
       "      <td>4.152696</td>\n",
       "      <td>0.070191</td>\n",
       "      <td>GSE180286</td>\n",
       "      <td>FGFR1</td>\n",
       "      <td>Targeted</td>\n",
       "      <td>0.501992</td>\n",
       "      <td>True</td>\n",
       "      <td>True</td>\n",
       "      <td>Yes</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>FDA-approved for Breast Cancer</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     gene  p_value   log2_fc  mean_diff    Dataset    Gene DGIdb Status  \\\n",
       "0    PTEN      0.0  1.686214   0.081446  GSE180286    PTEN     Targeted   \n",
       "1    CDK4      0.0  3.222505   0.089603  GSE180286    CDK4     Targeted   \n",
       "2  CDKN2A      0.0  4.279113   0.062919  GSE180286  CDKN2A     Targeted   \n",
       "3  CDKN1A      0.0  3.952025   0.123942  GSE180286  CDKN1A     Targeted   \n",
       "4   FGFR1      0.0  4.152696   0.070191  GSE180286   FGFR1     Targeted   \n",
       "\n",
       "   OpenTargets_Score  BreastCancer_Supported  Strong_BreastCancer_Support  \\\n",
       "0           0.774262                    True                         True   \n",
       "1           0.693263                    True                         True   \n",
       "2           0.592468                    True                         True   \n",
       "3                NaN                   False                        False   \n",
       "4           0.501992                    True                         True   \n",
       "\n",
       "  FDA_Approved_Drug               Targeting Category  \\\n",
       "0               Yes  FDA-approved for Cancer Therapy   \n",
       "1               Yes  FDA-approved for Cancer Therapy   \n",
       "2               Yes  FDA-approved for Cancer Therapy   \n",
       "3               Yes     Lacks Breast Cancer Evidence   \n",
       "4               Yes  FDA-approved for Cancer Therapy   \n",
       "\n",
       "                  FDA_Subcategory   Clinical_Trial_Status  \n",
       "0  FDA-approved, Other Indication  In Breast Cancer Trial  \n",
       "1  FDA-approved for Breast Cancer  In Breast Cancer Trial  \n",
       "2  FDA-approved, Other Indication  In Breast Cancer Trial  \n",
       "3                            None  No Breast Cancer Trial  \n",
       "4  FDA-approved for Breast Cancer  In Breast Cancer Trial  "
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_unique.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "a5688024",
   "metadata": {},
   "outputs": [],
   "source": [
    "# output_path = \"~/Desktop/Cancer_project/ghost-cell-busters/oncogene_therapeutic_stratification_with_trial.csv\"\n",
    "# df_unique.to_csv(output_path, index=False)\n",
    "# print(f\" Saved annotated file with clinical trial status to {output_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "79617b26",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['gene', 'p_value', 'log2_fc', 'mean_diff', 'Dataset', 'Gene',\n",
       "       'DGIdb Status', 'OpenTargets_Score', 'BreastCancer_Supported',\n",
       "       'Strong_BreastCancer_Support', 'FDA_Approved_Drug',\n",
       "       'Targeting Category', 'FDA_Subcategory', 'Clinical_Trial_Status'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Quick check of the columns and sample data\n",
    "df_unique.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "id": "1b629e97",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Gene</th>\n",
       "      <th>Targeting Category</th>\n",
       "      <th>Clinical_Trial_Status</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>PTEN</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>CDK4</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>CDKN2A</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>CDKN1A</td>\n",
       "      <td>Lacks Breast Cancer Evidence</td>\n",
       "      <td>No Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>FGFR1</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>MDM2</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>HRAS</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>CASP8</td>\n",
       "      <td>Emerging Breast Cancer Target</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>VHL</td>\n",
       "      <td>Lacks Breast Cancer Evidence</td>\n",
       "      <td>No Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>FOXO3</td>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Gene               Targeting Category   Clinical_Trial_Status\n",
       "0    PTEN  FDA-approved for Cancer Therapy  In Breast Cancer Trial\n",
       "1    CDK4  FDA-approved for Cancer Therapy  In Breast Cancer Trial\n",
       "2  CDKN2A  FDA-approved for Cancer Therapy  In Breast Cancer Trial\n",
       "3  CDKN1A     Lacks Breast Cancer Evidence  No Breast Cancer Trial\n",
       "4   FGFR1  FDA-approved for Cancer Therapy  In Breast Cancer Trial\n",
       "5    MDM2  FDA-approved for Cancer Therapy  In Breast Cancer Trial\n",
       "6    HRAS  FDA-approved for Cancer Therapy  In Breast Cancer Trial\n",
       "7   CASP8    Emerging Breast Cancer Target  In Breast Cancer Trial\n",
       "8     VHL     Lacks Breast Cancer Evidence  No Breast Cancer Trial\n",
       "9   FOXO3  FDA-approved for Cancer Therapy  In Breast Cancer Trial"
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df_unique[['Gene', 'Targeting Category', 'Clinical_Trial_Status']].head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "8876905d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Targeting Category</th>\n",
       "      <th>Clinical_Trial_Status</th>\n",
       "      <th>counts</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Emerging Breast Cancer Target</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>FDA-approved for Cancer Therapy</td>\n",
       "      <td>In Breast Cancer Trial</td>\n",
       "      <td>31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Lacks Breast Cancer Evidence</td>\n",
       "      <td>No Breast Cancer Trial</td>\n",
       "      <td>8</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                Targeting Category   Clinical_Trial_Status  counts\n",
       "0    Emerging Breast Cancer Target  In Breast Cancer Trial       1\n",
       "1  FDA-approved for Cancer Therapy  In Breast Cancer Trial      31\n",
       "2     Lacks Breast Cancer Evidence  No Breast Cancer Trial       8"
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# If needed, fill missing trial status (safe practice)\n",
    "df_unique['Clinical_Trial_Status'] = df_unique['Clinical_Trial_Status'].fillna('No Breast Cancer Trial')\n",
    "\n",
    "# Example: Summary counts by Clinical Trial Status and Targeting Category\n",
    "summary = df_unique.groupby(['Targeting Category', 'Clinical_Trial_Status']).size().reset_index(name='counts')\n",
    "summary"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "id": "c5cdf944",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Sankey Plot Code: Therapeutic Categories  Clinical Trial Status  Genes\n",
    "# Deduplicate on gene to avoid repeats in plot\n",
    "df_unique = df_unique.drop_duplicates(subset=[\"gene\", \"Targeting Category\", \"Clinical_Trial_Status\"]).copy()\n",
    "\n",
    "# Define major nodes (categories and trial statuses)\n",
    "categories = df_unique[\"Targeting Category\"].unique().tolist()\n",
    "trial_statuses = df_unique[\"Clinical_Trial_Status\"].unique().tolist()\n",
    "genes = df_unique[\"gene\"].unique().tolist()\n",
    "\n",
    "# Combine all nodes in order\n",
    "label_list = categories + trial_statuses + genes"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "b013aae8",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Create a dict to map label to index\n",
    "label_to_idx = {label: i for i, label in enumerate(label_list)}\n",
    "\n",
    "# Prepare sankey links\n",
    "source = []\n",
    "target = []\n",
    "value = []\n",
    "colors = []\n",
    "\n",
    "# Color palette (you can customize)\n",
    "category_colors = {\n",
    "    \"FDA-approved for Cancer Therapy\": \"green\",\n",
    "    \"Emerging Breast Cancer Target\": \"orange\",\n",
    "    \"Lacks Breast Cancer Evidence\": \"red\",\n",
    "}\n",
    "trial_colors = {\n",
    "    \"In Breast Cancer Trial\": \"blue\",\n",
    "    \"No Breast Cancer Trial\": \"gray\",\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "3b8b8685",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Links from Categories  Clinical Trial Status\n",
    "for cat in categories:\n",
    "    for trial in trial_statuses:\n",
    "        count = df_unique[\n",
    "            (df_unique[\"Targeting Category\"] == cat) &\n",
    "            (df_unique[\"Clinical_Trial_Status\"] == trial)\n",
    "        ].shape[0]\n",
    "        if count > 0:\n",
    "            source.append(label_to_idx[cat])\n",
    "            target.append(label_to_idx[trial])\n",
    "            value.append(count)\n",
    "            colors.append(category_colors.get(cat, \"lightgray\"))\n",
    "\n",
    "# Links from Clinical Trial Status  Genes\n",
    "for _, row in df_unique.iterrows():\n",
    "    source.append(label_to_idx[row[\"Clinical_Trial_Status\"]])\n",
    "    target.append(label_to_idx[row[\"gene\"]])\n",
    "    value.append(1)\n",
    "    colors.append(trial_colors.get(row[\"Clinical_Trial_Status\"], \"lightgray\"))\n",
    "\n",
    "# Node colors: categories and trial statuses get colored, genes are light gray\n",
    "node_colors = []\n",
    "for label in label_list:\n",
    "    if label in category_colors:\n",
    "        node_colors.append(category_colors[label])\n",
    "    elif label in trial_colors:\n",
    "        node_colors.append(trial_colors[label])\n",
    "    else:\n",
    "        node_colors.append(\"lightgray\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "786ce335",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.plotly.v1+json": {
       "config": {
        "plotlyServerURL": "https://plot.ly"
       },
       "data": [
        {
         "link": {
          "color": [
           "green",
           "red",
           "orange",
           "blue",
           "blue",
           "blue",
           "gray",
           "blue",
           "blue",
           "blue",
           "blue",
           "gray",
           "blue",
           "blue",
           "blue",
           "gray",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "gray",
           "blue",
           "blue",
           "blue",
           "gray",
           "blue",
           "gray",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "gray",
           "gray"
          ],
          "source": [
           0,
           1,
           2,
           3,
           3,
           3,
           4,
           3,
           3,
           3,
           3,
           4,
           3,
           3,
           3,
           4,
           3,
           3,
           3,
           3,
           3,
           3,
           3,
           3,
           3,
           4,
           3,
           3,
           3,
           4,
           3,
           4,
           3,
           3,
           3,
           3,
           3,
           3,
           3,
           3,
           3,
           4,
           4
          ],
          "target": [
           3,
           4,
           3,
           5,
           6,
           7,
           8,
           9,
           10,
           11,
           12,
           13,
           14,
           15,
           16,
           17,
           18,
           19,
           20,
           21,
           22,
           23,
           24,
           25,
           26,
           27,
           28,
           29,
           30,
           31,
           32,
           33,
           34,
           35,
           36,
           37,
           38,
           39,
           40,
           41,
           42,
           43,
           44
          ],
          "value": [
           31,
           8,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1
          ]
         },
         "node": {
          "color": [
           "green",
           "red",
           "orange",
           "blue",
           "gray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray"
          ],
          "label": [
           "FDA-approved for Cancer Therapy",
           "Lacks Breast Cancer Evidence",
           "Emerging Breast Cancer Target",
           "In Breast Cancer Trial",
           "No Breast Cancer Trial",
           "PTEN",
           "CDK4",
           "CDKN2A",
           "CDKN1A",
           "FGFR1",
           "MDM2",
           "HRAS",
           "CASP8",
           "VHL",
           "FOXO3",
           "CCND1",
           "ERBB2",
           "BAX",
           "KRAS",
           "AKT1",
           "MYC",
           "BRCA1",
           "TP53",
           "PIK3CA",
           "BCL2",
           "CDK6",
           "RB1",
           "NRAS",
           "NF1",
           "BRCA2",
           "ATR",
           "NF2",
           "SMAD4",
           "SRC",
           "CHEK2",
           "TSC2",
           "STK11",
           "MET",
           "EGFR",
           "NOTCH1",
           "ATM",
           "NTRK2",
           "FGFR2",
           "WT1",
           "NTRK1"
          ],
          "line": {
           "color": "black",
           "width": 0.5
          },
          "pad": 15,
          "thickness": 20
         },
         "type": "sankey"
        }
       ],
       "layout": {
        "font": {
         "size": 12
        },
        "height": 600,
        "template": {
         "data": {
          "bar": [
           {
            "error_x": {
             "color": "#2a3f5f"
            },
            "error_y": {
             "color": "#2a3f5f"
            },
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "bar"
           }
          ],
          "barpolar": [
           {
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "barpolar"
           }
          ],
          "carpet": [
           {
            "aaxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "baxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "type": "carpet"
           }
          ],
          "choropleth": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "choropleth"
           }
          ],
          "contour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "contour"
           }
          ],
          "contourcarpet": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "contourcarpet"
           }
          ],
          "heatmap": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "heatmap"
           }
          ],
          "histogram": [
           {
            "marker": {
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "histogram"
           }
          ],
          "histogram2d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2d"
           }
          ],
          "histogram2dcontour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2dcontour"
           }
          ],
          "mesh3d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "mesh3d"
           }
          ],
          "parcoords": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "parcoords"
           }
          ],
          "pie": [
           {
            "automargin": true,
            "type": "pie"
           }
          ],
          "scatter": [
           {
            "fillpattern": {
             "fillmode": "overlay",
             "size": 10,
             "solidity": 0.2
            },
            "type": "scatter"
           }
          ],
          "scatter3d": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatter3d"
           }
          ],
          "scattercarpet": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattercarpet"
           }
          ],
          "scattergeo": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergeo"
           }
          ],
          "scattergl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergl"
           }
          ],
          "scattermap": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermap"
           }
          ],
          "scattermapbox": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermapbox"
           }
          ],
          "scatterpolar": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolar"
           }
          ],
          "scatterpolargl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolargl"
           }
          ],
          "scatterternary": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterternary"
           }
          ],
          "surface": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "surface"
           }
          ],
          "table": [
           {
            "cells": {
             "fill": {
              "color": "#EBF0F8"
             },
             "line": {
              "color": "white"
             }
            },
            "header": {
             "fill": {
              "color": "#C8D4E3"
             },
             "line": {
              "color": "white"
             }
            },
            "type": "table"
           }
          ]
         },
         "layout": {
          "annotationdefaults": {
           "arrowcolor": "#2a3f5f",
           "arrowhead": 0,
           "arrowwidth": 1
          },
          "autotypenumbers": "strict",
          "coloraxis": {
           "colorbar": {
            "outlinewidth": 0,
            "ticks": ""
           }
          },
          "colorscale": {
           "diverging": [
            [
             0,
             "#8e0152"
            ],
            [
             0.1,
             "#c51b7d"
            ],
            [
             0.2,
             "#de77ae"
            ],
            [
             0.3,
             "#f1b6da"
            ],
            [
             0.4,
             "#fde0ef"
            ],
            [
             0.5,
             "#f7f7f7"
            ],
            [
             0.6,
             "#e6f5d0"
            ],
            [
             0.7,
             "#b8e186"
            ],
            [
             0.8,
             "#7fbc41"
            ],
            [
             0.9,
             "#4d9221"
            ],
            [
             1,
             "#276419"
            ]
           ],
           "sequential": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ],
           "sequentialminus": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ]
          },
          "colorway": [
           "#636efa",
           "#EF553B",
           "#00cc96",
           "#ab63fa",
           "#FFA15A",
           "#19d3f3",
           "#FF6692",
           "#B6E880",
           "#FF97FF",
           "#FECB52"
          ],
          "font": {
           "color": "#2a3f5f"
          },
          "geo": {
           "bgcolor": "white",
           "lakecolor": "white",
           "landcolor": "#E5ECF6",
           "showlakes": true,
           "showland": true,
           "subunitcolor": "white"
          },
          "hoverlabel": {
           "align": "left"
          },
          "hovermode": "closest",
          "mapbox": {
           "style": "light"
          },
          "paper_bgcolor": "white",
          "plot_bgcolor": "#E5ECF6",
          "polar": {
           "angularaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "radialaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "scene": {
           "xaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "yaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "zaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           }
          },
          "shapedefaults": {
           "line": {
            "color": "#2a3f5f"
           }
          },
          "ternary": {
           "aaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "baxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "caxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "title": {
           "x": 0.05
          },
          "xaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          },
          "yaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          }
         }
        },
        "title": {
         "text": "Therapeutic Categories and Clinical Trial Status Sankey Diagram"
        },
        "width": 1100
       }
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Build Sankey figure\n",
    "fig = go.Figure(go.Sankey(\n",
    "    node=dict(\n",
    "        pad=15,\n",
    "        thickness=20,\n",
    "        line=dict(color=\"black\", width=0.5),\n",
    "        label=label_list,\n",
    "        color=node_colors\n",
    "    ),\n",
    "    link=dict(\n",
    "        source=source,\n",
    "        target=target,\n",
    "        value=value,\n",
    "        color=colors\n",
    "    )\n",
    "))\n",
    "\n",
    "fig.update_layout(\n",
    "    title_text=\"Therapeutic Categories and Clinical Trial Status Sankey Diagram\",\n",
    "    font_size=12,\n",
    "    height=600,\n",
    "    width=1100\n",
    ")\n",
    "\n",
    "fig.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "9a281db6",
   "metadata": {},
   "outputs": [],
   "source": [
    "gene_to_pathway = {\n",
    "    'CDK4': 'CDK4CCND1 Axis',\n",
    "    'CCND1': 'CDK4CCND1 Axis',\n",
    "    'CDKN2A': 'Cell Cycle & Apoptosis',\n",
    "    'TP53': 'DNA Repair / Tumor Suppressors',\n",
    "    'BRCA1': 'DNA Repair / Tumor Suppressors',\n",
    "    'BRCA2': 'DNA Repair / Tumor Suppressors',\n",
    "    'EGFR': 'PI3KMAPKEGFR',\n",
    "    'KRAS': 'RAS Pathway',\n",
    "    'NRAS': 'RAS Pathway',\n",
    "    'HRAS': 'RAS Pathway',\n",
    "    'PIK3CA': 'PI3KMAPKEGFR',\n",
    "    'PTEN': 'PI3KMAPKEGFR',\n",
    "    'MYC': 'MYC Axis',\n",
    "    'FGFR1': 'RTKs / Growth Factor Signaling',\n",
    "    'FGFR2': 'RTKs / Growth Factor Signaling',\n",
    "    'ATM': 'DNA Repair / Tumor Suppressors',\n",
    "    'CHEK2': 'DNA Repair / Tumor Suppressors',\n",
    "    'MDM2': 'Cell Cycle & Apoptosis',\n",
    "    'WT1': 'Transcription Factors',\n",
    "    'CDKN1A': 'Cell Cycle & Apoptosis',\n",
    "    'BAX': 'Apoptosis',\n",
    "    'SRC': 'RTKs / Growth Factor Signaling',\n",
    "    'NF2': 'Tumor Suppressor',\n",
    "    'VHL': 'Tumor Suppressor',\n",
    "    'NTRK1': 'RTKs / Growth Factor Signaling',\n",
    "    'NTRK2': 'RTKs / Growth Factor Signaling'\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "005ae750",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Updated unique pathway categories:\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "Pathway Category\n",
       "Other                             14\n",
       "RTKs / Growth Factor Signaling     5\n",
       "DNA Repair / Tumor Suppressors     5\n",
       "PI3KMAPKEGFR                     3\n",
       "Cell Cycle & Apoptosis             3\n",
       "RAS Pathway                        3\n",
       "CDK4CCND1 Axis                    2\n",
       "Tumor Suppressor                   2\n",
       "Apoptosis                          1\n",
       "MYC Axis                           1\n",
       "Transcription Factors              1\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 48,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Now apply this single dictionary to your dataframe\n",
    "df_unique['Pathway Category'] = df_unique['gene'].map(gene_to_pathway).fillna('Other')\n",
    "\n",
    "print(\"Updated unique pathway categories:\")\n",
    "df_unique['Pathway Category'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "617e26a7",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define node groups\n",
    "targeting_cats = df_unique['Targeting Category'].unique().tolist()\n",
    "pathways = df_unique['Pathway Category'].unique().tolist()\n",
    "trials = df_unique['Clinical_Trial_Status'].unique().tolist()\n",
    "genes = df_unique['gene'].unique().tolist()\n",
    "\n",
    "# Build label list and mapping\n",
    "labels = targeting_cats + pathways + trials + genes\n",
    "label_to_idx = {label: idx for idx, label in enumerate(labels)}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "7f8cb4a5",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Define colors for Targeting Categories\n",
    "targeting_colors_map = {\n",
    "    'FDA-approved for Cancer Therapy': 'green',\n",
    "    'Emerging Breast Cancer Target': 'orange',\n",
    "    'Lacks Breast Cancer Evidence': 'red'\n",
    "}\n",
    "\n",
    "# Define colors for Pathways (choose a palette)\n",
    "pathway_palette = ['#aec7e8', '#ffbb78', '#98df8a', '#ff9896', '#c5b0d5', '#c49c94',\n",
    "                    '#f7b6d2', '#dbdb8d', '#9edae5', '#393b79']\n",
    "pathway_colors_map = {path: pathway_palette[i % len(pathway_palette)] for i, path in enumerate(pathways)}\n",
    "\n",
    "# Colors for Clinical Trial Status\n",
    "trial_colors_map = {\n",
    "    'In Breast Cancer Trial': '#8c564b',  # Brown shade\n",
    "    'No Breast Cancer Trial': '#7f7f7f'   # Gray shade\n",
    "}\n",
    "\n",
    "# Assign node colors\n",
    "node_colors = []\n",
    "for label in labels:\n",
    "    if label in targeting_colors_map:\n",
    "        node_colors.append(targeting_colors_map[label])\n",
    "    elif label in pathway_colors_map:\n",
    "        node_colors.append(pathway_colors_map[label])\n",
    "    elif label in trial_colors_map:\n",
    "        node_colors.append(trial_colors_map[label])\n",
    "    else:\n",
    "        node_colors.append('lightgray')  # genes or unknowns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "7f5ce0eb",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Prepare links as before\n",
    "source = []\n",
    "target = []\n",
    "value = []\n",
    "link_colors = []\n",
    "\n",
    "# Category -> Pathway\n",
    "for _, row in df_unique.iterrows():\n",
    "    source.append(label_to_idx[row['Targeting Category']])\n",
    "    target.append(label_to_idx[row['Pathway Category']])\n",
    "    value.append(1)\n",
    "    link_colors.append(node_colors[label_to_idx[row['Targeting Category']]])  # link colored by source\n",
    "\n",
    "# Pathway -> Trial\n",
    "for _, row in df_unique.iterrows():\n",
    "    source.append(label_to_idx[row['Pathway Category']])\n",
    "    target.append(label_to_idx[row['Clinical_Trial_Status']])\n",
    "    value.append(1)\n",
    "    link_colors.append(node_colors[label_to_idx[row['Pathway Category']]])  # link colored by source\n",
    "\n",
    "# Trial -> Gene (color by expression log2FC)\n",
    "max_abs_fc = max(abs(df_unique['log2_fc'].min()), abs(df_unique['log2_fc'].max()))\n",
    "\n",
    "def fc_to_color(fc):\n",
    "    norm = (fc + max_abs_fc) / (2 * max_abs_fc)\n",
    "    r = int(255 * norm)\n",
    "    b = int(255 * (1 - norm))\n",
    "    return f'rgba({r},0,{b},0.8)'\n",
    "\n",
    "for _, row in df_unique.iterrows():\n",
    "    source.append(label_to_idx[row['Clinical_Trial_Status']])\n",
    "    target.append(label_to_idx[row['gene']])\n",
    "    value.append(1)\n",
    "    link_colors.append(fc_to_color(row['log2_fc']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "b15d1d71",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.plotly.v1+json": {
       "config": {
        "plotlyServerURL": "https://plot.ly"
       },
       "data": [
        {
         "link": {
          "color": [
           "green",
           "green",
           "green",
           "red",
           "green",
           "green",
           "green",
           "orange",
           "red",
           "green",
           "green",
           "green",
           "red",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "red",
           "green",
           "green",
           "green",
           "red",
           "green",
           "red",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "red",
           "red",
           "#aec7e8",
           "#ffbb78",
           "#98df8a",
           "#98df8a",
           "#ff9896",
           "#98df8a",
           "#c5b0d5",
           "#c49c94",
           "#f7b6d2",
           "#c49c94",
           "#ffbb78",
           "#c49c94",
           "#dbdb8d",
           "#c5b0d5",
           "#c49c94",
           "#9edae5",
           "#393b79",
           "#393b79",
           "#aec7e8",
           "#c49c94",
           "#c49c94",
           "#c49c94",
           "#c5b0d5",
           "#c49c94",
           "#393b79",
           "#c49c94",
           "#f7b6d2",
           "#c49c94",
           "#ff9896",
           "#393b79",
           "#c49c94",
           "#c49c94",
           "#c49c94",
           "#aec7e8",
           "#c49c94",
           "#393b79",
           "#ff9896",
           "#ff9896",
           "#aec7e8",
           "#ff9896",
           "rgba(162,0,92,0.8)",
           "rgba(193,0,61,0.8)",
           "rgba(215,0,39,0.8)",
           "rgba(208,0,46,0.8)",
           "rgba(212,0,42,0.8)",
           "rgba(179,0,75,0.8)",
           "rgba(194,0,60,0.8)",
           "rgba(165,0,89,0.8)",
           "rgba(168,0,86,0.8)",
           "rgba(197,0,57,0.8)",
           "rgba(231,0,23,0.8)",
           "rgba(255,0,0,0.8)",
           "rgba(176,0,78,0.8)",
           "rgba(174,0,80,0.8)",
           "rgba(203,0,51,0.8)",
           "rgba(169,0,85,0.8)",
           "rgba(201,0,53,0.8)",
           "rgba(171,0,83,0.8)",
           "rgba(168,0,86,0.8)",
           "rgba(155,0,99,0.8)",
           "rgba(173,0,81,0.8)",
           "rgba(161,0,93,0.8)",
           "rgba(181,0,73,0.8)",
           "rgba(191,0,63,0.8)",
           "rgba(184,0,70,0.8)",
           "rgba(157,0,97,0.8)",
           "rgba(177,0,77,0.8)",
           "rgba(164,0,90,0.8)",
           "rgba(224,0,30,0.8)",
           "rgba(175,0,79,0.8)",
           "rgba(172,0,82,0.8)",
           "rgba(179,0,75,0.8)",
           "rgba(246,0,8,0.8)",
           "rgba(205,0,49,0.8)",
           "rgba(174,0,80,0.8)",
           "rgba(138,0,116,0.8)",
           "rgba(211,0,43,0.8)",
           "rgba(207,0,47,0.8)",
           "rgba(177,0,77,0.8)",
           "rgba(152,0,102,0.8)"
          ],
          "hovertemplate": "From %{source.label} to %{target.label}<extra></extra>",
          "source": [
           0,
           0,
           0,
           1,
           0,
           0,
           0,
           2,
           1,
           0,
           0,
           0,
           1,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           1,
           0,
           0,
           0,
           1,
           0,
           1,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           1,
           1,
           3,
           4,
           5,
           5,
           6,
           5,
           7,
           8,
           9,
           8,
           4,
           8,
           10,
           7,
           8,
           11,
           12,
           12,
           3,
           8,
           8,
           8,
           7,
           8,
           12,
           8,
           9,
           8,
           6,
           12,
           8,
           8,
           8,
           3,
           8,
           12,
           6,
           6,
           13,
           6,
           14,
           14,
           14,
           15,
           14,
           14,
           14,
           14,
           15,
           14,
           14,
           14,
           15,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           15,
           14,
           14,
           14,
           15,
           14,
           15,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           15,
           15
          ],
          "target": [
           3,
           4,
           5,
           5,
           6,
           5,
           7,
           8,
           9,
           8,
           4,
           8,
           10,
           7,
           8,
           11,
           12,
           12,
           3,
           8,
           8,
           8,
           7,
           8,
           12,
           8,
           9,
           8,
           6,
           12,
           8,
           8,
           8,
           3,
           8,
           12,
           6,
           6,
           13,
           6,
           14,
           14,
           14,
           15,
           14,
           14,
           14,
           14,
           15,
           14,
           14,
           14,
           15,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           15,
           14,
           14,
           14,
           15,
           14,
           15,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           14,
           15,
           15,
           16,
           17,
           18,
           19,
           20,
           21,
           22,
           23,
           24,
           25,
           26,
           27,
           28,
           29,
           30,
           31,
           32,
           33,
           34,
           35,
           36,
           37,
           38,
           39,
           40,
           41,
           42,
           43,
           44,
           45,
           46,
           47,
           48,
           49,
           50,
           51,
           52,
           53,
           54,
           55
          ],
          "value": [
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1
          ]
         },
         "node": {
          "color": [
           "green",
           "red",
           "orange",
           "#aec7e8",
           "#ffbb78",
           "#98df8a",
           "#ff9896",
           "#c5b0d5",
           "#c49c94",
           "#f7b6d2",
           "#dbdb8d",
           "#9edae5",
           "#393b79",
           "#aec7e8",
           "#8c564b",
           "#7f7f7f",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray"
          ],
          "hovertemplate": "%{label}<extra></extra>",
          "label": [
           "FDA-approved for Cancer Therapy",
           "Lacks Breast Cancer Evidence",
           "Emerging Breast Cancer Target",
           "PI3KMAPKEGFR",
           "CDK4CCND1 Axis",
           "Cell Cycle & Apoptosis",
           "RTKs / Growth Factor Signaling",
           "RAS Pathway",
           "Other",
           "Tumor Suppressor",
           "Apoptosis",
           "MYC Axis",
           "DNA Repair / Tumor Suppressors",
           "Transcription Factors",
           "In Breast Cancer Trial",
           "No Breast Cancer Trial",
           "PTEN",
           "CDK4",
           "CDKN2A",
           "CDKN1A",
           "FGFR1",
           "MDM2",
           "HRAS",
           "CASP8",
           "VHL",
           "FOXO3",
           "CCND1",
           "ERBB2",
           "BAX",
           "KRAS",
           "AKT1",
           "MYC",
           "BRCA1",
           "TP53",
           "PIK3CA",
           "BCL2",
           "CDK6",
           "RB1",
           "NRAS",
           "NF1",
           "BRCA2",
           "ATR",
           "NF2",
           "SMAD4",
           "SRC",
           "CHEK2",
           "TSC2",
           "STK11",
           "MET",
           "EGFR",
           "NOTCH1",
           "ATM",
           "NTRK2",
           "FGFR2",
           "WT1",
           "NTRK1"
          ],
          "line": {
           "color": "black",
           "width": 0.5
          },
          "pad": 15,
          "thickness": 15
         },
         "type": "sankey"
        }
       ],
       "layout": {
        "annotations": [
         {
          "align": "left",
          "bgcolor": "white",
          "bordercolor": "black",
          "borderpad": 5,
          "borderwidth": 1,
          "font": {
           "size": 12
          },
          "showarrow": false,
          "text": "<b>Color Legend</b><br><span style='color:green'>&#9632;</span> FDA-approved Breast Cancer Therapy<br><span style='color:orange'>&#9632;</span> Emerging Breast Cancer Target<br><span style='color:red'>&#9632;</span> Lacks Breast Cancer Evidence<br><span style='color:#8c564b'>&#9632;</span> In Breast Cancer Trial<br><span style='color:#7f7f7f'>&#9632;</span> No Breast Cancer Trial<br><br><b>Gene Link Color</b><br><span style='color:red'>&#8594;</span> Upregulated (High log2FC)<br><span style='color:blue'>&#8594;</span> Downregulated (Low log2FC)",
          "x": 0.02,
          "xref": "paper",
          "y": 0.95,
          "yref": "paper"
         }
        ],
        "font": {
         "size": 12
        },
        "height": 600,
        "template": {
         "data": {
          "bar": [
           {
            "error_x": {
             "color": "#2a3f5f"
            },
            "error_y": {
             "color": "#2a3f5f"
            },
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "bar"
           }
          ],
          "barpolar": [
           {
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "barpolar"
           }
          ],
          "carpet": [
           {
            "aaxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "baxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "type": "carpet"
           }
          ],
          "choropleth": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "choropleth"
           }
          ],
          "contour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "contour"
           }
          ],
          "contourcarpet": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "contourcarpet"
           }
          ],
          "heatmap": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "heatmap"
           }
          ],
          "histogram": [
           {
            "marker": {
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "histogram"
           }
          ],
          "histogram2d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2d"
           }
          ],
          "histogram2dcontour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2dcontour"
           }
          ],
          "mesh3d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "mesh3d"
           }
          ],
          "parcoords": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "parcoords"
           }
          ],
          "pie": [
           {
            "automargin": true,
            "type": "pie"
           }
          ],
          "scatter": [
           {
            "fillpattern": {
             "fillmode": "overlay",
             "size": 10,
             "solidity": 0.2
            },
            "type": "scatter"
           }
          ],
          "scatter3d": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatter3d"
           }
          ],
          "scattercarpet": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattercarpet"
           }
          ],
          "scattergeo": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergeo"
           }
          ],
          "scattergl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergl"
           }
          ],
          "scattermap": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermap"
           }
          ],
          "scattermapbox": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermapbox"
           }
          ],
          "scatterpolar": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolar"
           }
          ],
          "scatterpolargl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolargl"
           }
          ],
          "scatterternary": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterternary"
           }
          ],
          "surface": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "surface"
           }
          ],
          "table": [
           {
            "cells": {
             "fill": {
              "color": "#EBF0F8"
             },
             "line": {
              "color": "white"
             }
            },
            "header": {
             "fill": {
              "color": "#C8D4E3"
             },
             "line": {
              "color": "white"
             }
            },
            "type": "table"
           }
          ]
         },
         "layout": {
          "annotationdefaults": {
           "arrowcolor": "#2a3f5f",
           "arrowhead": 0,
           "arrowwidth": 1
          },
          "autotypenumbers": "strict",
          "coloraxis": {
           "colorbar": {
            "outlinewidth": 0,
            "ticks": ""
           }
          },
          "colorscale": {
           "diverging": [
            [
             0,
             "#8e0152"
            ],
            [
             0.1,
             "#c51b7d"
            ],
            [
             0.2,
             "#de77ae"
            ],
            [
             0.3,
             "#f1b6da"
            ],
            [
             0.4,
             "#fde0ef"
            ],
            [
             0.5,
             "#f7f7f7"
            ],
            [
             0.6,
             "#e6f5d0"
            ],
            [
             0.7,
             "#b8e186"
            ],
            [
             0.8,
             "#7fbc41"
            ],
            [
             0.9,
             "#4d9221"
            ],
            [
             1,
             "#276419"
            ]
           ],
           "sequential": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ],
           "sequentialminus": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ]
          },
          "colorway": [
           "#636efa",
           "#EF553B",
           "#00cc96",
           "#ab63fa",
           "#FFA15A",
           "#19d3f3",
           "#FF6692",
           "#B6E880",
           "#FF97FF",
           "#FECB52"
          ],
          "font": {
           "color": "#2a3f5f"
          },
          "geo": {
           "bgcolor": "white",
           "lakecolor": "white",
           "landcolor": "#E5ECF6",
           "showlakes": true,
           "showland": true,
           "subunitcolor": "white"
          },
          "hoverlabel": {
           "align": "left"
          },
          "hovermode": "closest",
          "mapbox": {
           "style": "light"
          },
          "paper_bgcolor": "white",
          "plot_bgcolor": "#E5ECF6",
          "polar": {
           "angularaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "radialaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "scene": {
           "xaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "yaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "zaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           }
          },
          "shapedefaults": {
           "line": {
            "color": "#2a3f5f"
           }
          },
          "ternary": {
           "aaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "baxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "caxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "title": {
           "x": 0.05
          },
          "xaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          },
          "yaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          }
         }
        },
        "title": {
         "text": "Multi-layer Therapeutic Stratification Sankey with Expression Coloring"
        },
        "width": 1100
       }
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Create Sankey diagram\n",
    "fig = go.Figure(data=[go.Sankey(\n",
    "    node=dict(\n",
    "        pad=15,\n",
    "        thickness=15,\n",
    "        line=dict(color='black', width=0.5),\n",
    "        label=labels,\n",
    "        color=node_colors,\n",
    "        hovertemplate='%{label}<extra></extra>'\n",
    "    ),\n",
    "    link=dict(\n",
    "        source=source,\n",
    "        target=target,\n",
    "        value=value,\n",
    "        color=link_colors,\n",
    "        hovertemplate='From %{source.label} to %{target.label}<extra></extra>'\n",
    "    )\n",
    ")])\n",
    "\n",
    "# Add color legend as annotation block (top left corner)\n",
    "fig.update_layout(\n",
    "    title_text=\"Multi-layer Therapeutic Stratification Sankey with Expression Coloring\",\n",
    "    font_size=12,\n",
    "    height=600,\n",
    "    width=1100,\n",
    "    annotations=[\n",
    "        dict(\n",
    "            x=0.02, y=0.95, xref='paper', yref='paper',\n",
    "            text=\"<b>Color Legend</b><br>\" +\n",
    "                    \"<span style='color:green'>&#9632;</span> FDA-approved Breast Cancer Therapy<br>\" +\n",
    "                    \"<span style='color:orange'>&#9632;</span> Emerging Breast Cancer Target<br>\" +\n",
    "                    \"<span style='color:red'>&#9632;</span> Lacks Breast Cancer Evidence<br>\" +\n",
    "                    \"<span style='color:#8c564b'>&#9632;</span> In Breast Cancer Trial<br>\" +\n",
    "                    \"<span style='color:#7f7f7f'>&#9632;</span> No Breast Cancer Trial<br>\" +\n",
    "                    \"<br><b>Gene Link Color</b><br>\" +\n",
    "                    \"<span style='color:red'>&#8594;</span> Upregulated (High log2FC)<br>\" +\n",
    "                    \"<span style='color:blue'>&#8594;</span> Downregulated (Low log2FC)\",\n",
    "            showarrow=False,\n",
    "            font=dict(size=12),\n",
    "            align=\"left\",\n",
    "            bgcolor=\"white\",\n",
    "            bordercolor=\"black\",\n",
    "            borderwidth=1,\n",
    "            borderpad=5\n",
    "        )\n",
    "    ]\n",
    ")\n",
    "\n",
    "fig.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "id": "d990c822",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.plotly.v1+json": {
       "config": {
        "plotlyServerURL": "https://plot.ly"
       },
       "data": [
        {
         "hovertemplate": "<b>%{hovertext}</b><br><br>Clinical_Trial_Status=In Breast Cancer Trial<br>Targeting Category=%{x}<br>Pathway Category=%{y}<br>abs_log2_fc=%{marker.size}<extra></extra>",
         "hovertext": [
          "PTEN",
          "CDK4",
          "CDKN2A",
          "FGFR1",
          "MDM2",
          "HRAS",
          "CASP8",
          "FOXO3",
          "CCND1",
          "ERBB2",
          "KRAS",
          "AKT1",
          "MYC",
          "BRCA1",
          "TP53",
          "PIK3CA",
          "BCL2",
          "CDK6",
          "RB1",
          "NF1",
          "BRCA2",
          "ATR",
          "SMAD4",
          "CHEK2",
          "TSC2",
          "STK11",
          "MET",
          "EGFR",
          "NOTCH1",
          "ATM",
          "NTRK2",
          "FGFR2"
         ],
         "legendgroup": "In Breast Cancer Trial",
         "marker": {
          "color": "#636efa",
          "size": {
           "bdata": "ThOpCLz6+j9HFPKpsMcJQLhSZ+bPHRFA4aiCdlycEEDdwxErd2YEQNsgybLE+AlAuKZ8KWhj/T9lDmz19EILQB7K172nThRAqHlvaubOGEAMH4EzV2cCQPydlCDzZQ1A1vdrIzI/AEAwB7k7/OEMQOfpEfAWQAFADjsC4qIVAEC31VHnV4X1P9SZth2o8gFAXFgMjsC4+j8JNEn03MQIQBKPp+XGFAZAdXT7/eh89z91syqMOYP8Pw2m7Rq6nQJA4v1fHc98AUB9CtIsk1sEQPJPf3v3LRdA6O0VmFVQDkBjmqf3/VACQIAoVWxptuA/xm0wYFFYEEC0xCHtzEQPQA==",
           "dtype": "f8"
          },
          "sizemode": "area",
          "sizeref": 0.006891167601536546,
          "symbol": "circle"
         },
         "mode": "markers",
         "name": "In Breast Cancer Trial",
         "orientation": "v",
         "showlegend": true,
         "type": "scatter",
         "x": [
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "Emerging Breast Cancer Target",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy",
          "FDA-approved for Cancer Therapy"
         ],
         "xaxis": "x",
         "y": [
          "PI3KMAPKEGFR",
          "CDK4CCND1 Axis",
          "Cell Cycle & Apoptosis",
          "RTKs / Growth Factor Signaling",
          "Cell Cycle & Apoptosis",
          "RAS Pathway",
          "Other",
          "Other",
          "CDK4CCND1 Axis",
          "Other",
          "RAS Pathway",
          "Other",
          "MYC Axis",
          "DNA Repair / Tumor Suppressors",
          "DNA Repair / Tumor Suppressors",
          "PI3KMAPKEGFR",
          "Other",
          "Other",
          "Other",
          "Other",
          "DNA Repair / Tumor Suppressors",
          "Other",
          "Other",
          "DNA Repair / Tumor Suppressors",
          "Other",
          "Other",
          "Other",
          "PI3KMAPKEGFR",
          "Other",
          "DNA Repair / Tumor Suppressors",
          "RTKs / Growth Factor Signaling",
          "RTKs / Growth Factor Signaling"
         ],
         "yaxis": "y"
        },
        {
         "hovertemplate": "<b>%{hovertext}</b><br><br>Clinical_Trial_Status=No Breast Cancer Trial<br>Targeting Category=%{x}<br>Pathway Category=%{y}<br>abs_log2_fc=%{marker.size}<extra></extra>",
         "hovertext": [
          "CDKN1A",
          "VHL",
          "BAX",
          "NRAS",
          "NF2",
          "SRC",
          "WT1",
          "NTRK1"
         ],
         "legendgroup": "No Breast Cancer Trial",
         "marker": {
          "color": "#EF553B",
          "size": {
           "bdata": "/1uZhr+dD0DA5LSQ1Lr/P3KGC7UvAwNATo/OwI/eBEAcnrpXn4MDQHS9Qzyy0xJA0Z1DS7VkA0CRfn7ZLD/zPw==",
           "dtype": "f8"
          },
          "sizemode": "area",
          "sizeref": 0.006891167601536546,
          "symbol": "circle"
         },
         "mode": "markers",
         "name": "No Breast Cancer Trial",
         "orientation": "v",
         "showlegend": true,
         "type": "scatter",
         "x": [
          "Lacks Breast Cancer Evidence",
          "Lacks Breast Cancer Evidence",
          "Lacks Breast Cancer Evidence",
          "Lacks Breast Cancer Evidence",
          "Lacks Breast Cancer Evidence",
          "Lacks Breast Cancer Evidence",
          "Lacks Breast Cancer Evidence",
          "Lacks Breast Cancer Evidence"
         ],
         "xaxis": "x",
         "y": [
          "Cell Cycle & Apoptosis",
          "Tumor Suppressor",
          "Apoptosis",
          "RAS Pathway",
          "Tumor Suppressor",
          "RTKs / Growth Factor Signaling",
          "Transcription Factors",
          "RTKs / Growth Factor Signaling"
         ],
         "yaxis": "y"
        }
       ],
       "layout": {
        "legend": {
         "itemsizing": "constant",
         "title": {
          "text": "Clinical Trial Status"
         },
         "tracegroupgap": 0
        },
        "template": {
         "data": {
          "bar": [
           {
            "error_x": {
             "color": "#2a3f5f"
            },
            "error_y": {
             "color": "#2a3f5f"
            },
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "bar"
           }
          ],
          "barpolar": [
           {
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "barpolar"
           }
          ],
          "carpet": [
           {
            "aaxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "baxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "type": "carpet"
           }
          ],
          "choropleth": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "choropleth"
           }
          ],
          "contour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "contour"
           }
          ],
          "contourcarpet": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "contourcarpet"
           }
          ],
          "heatmap": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "heatmap"
           }
          ],
          "histogram": [
           {
            "marker": {
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "histogram"
           }
          ],
          "histogram2d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2d"
           }
          ],
          "histogram2dcontour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2dcontour"
           }
          ],
          "mesh3d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "mesh3d"
           }
          ],
          "parcoords": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "parcoords"
           }
          ],
          "pie": [
           {
            "automargin": true,
            "type": "pie"
           }
          ],
          "scatter": [
           {
            "fillpattern": {
             "fillmode": "overlay",
             "size": 10,
             "solidity": 0.2
            },
            "type": "scatter"
           }
          ],
          "scatter3d": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatter3d"
           }
          ],
          "scattercarpet": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattercarpet"
           }
          ],
          "scattergeo": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergeo"
           }
          ],
          "scattergl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergl"
           }
          ],
          "scattermap": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermap"
           }
          ],
          "scattermapbox": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermapbox"
           }
          ],
          "scatterpolar": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolar"
           }
          ],
          "scatterpolargl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolargl"
           }
          ],
          "scatterternary": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterternary"
           }
          ],
          "surface": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "surface"
           }
          ],
          "table": [
           {
            "cells": {
             "fill": {
              "color": "#EBF0F8"
             },
             "line": {
              "color": "white"
             }
            },
            "header": {
             "fill": {
              "color": "#C8D4E3"
             },
             "line": {
              "color": "white"
             }
            },
            "type": "table"
           }
          ]
         },
         "layout": {
          "annotationdefaults": {
           "arrowcolor": "#2a3f5f",
           "arrowhead": 0,
           "arrowwidth": 1
          },
          "autotypenumbers": "strict",
          "coloraxis": {
           "colorbar": {
            "outlinewidth": 0,
            "ticks": ""
           }
          },
          "colorscale": {
           "diverging": [
            [
             0,
             "#8e0152"
            ],
            [
             0.1,
             "#c51b7d"
            ],
            [
             0.2,
             "#de77ae"
            ],
            [
             0.3,
             "#f1b6da"
            ],
            [
             0.4,
             "#fde0ef"
            ],
            [
             0.5,
             "#f7f7f7"
            ],
            [
             0.6,
             "#e6f5d0"
            ],
            [
             0.7,
             "#b8e186"
            ],
            [
             0.8,
             "#7fbc41"
            ],
            [
             0.9,
             "#4d9221"
            ],
            [
             1,
             "#276419"
            ]
           ],
           "sequential": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ],
           "sequentialminus": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ]
          },
          "colorway": [
           "#636efa",
           "#EF553B",
           "#00cc96",
           "#ab63fa",
           "#FFA15A",
           "#19d3f3",
           "#FF6692",
           "#B6E880",
           "#FF97FF",
           "#FECB52"
          ],
          "font": {
           "color": "#2a3f5f"
          },
          "geo": {
           "bgcolor": "white",
           "lakecolor": "white",
           "landcolor": "#E5ECF6",
           "showlakes": true,
           "showland": true,
           "subunitcolor": "white"
          },
          "hoverlabel": {
           "align": "left"
          },
          "hovermode": "closest",
          "mapbox": {
           "style": "light"
          },
          "paper_bgcolor": "white",
          "plot_bgcolor": "#E5ECF6",
          "polar": {
           "angularaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "radialaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "scene": {
           "xaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "yaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "zaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           }
          },
          "shapedefaults": {
           "line": {
            "color": "#2a3f5f"
           }
          },
          "ternary": {
           "aaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "baxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "caxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "title": {
           "x": 0.05
          },
          "xaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          },
          "yaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          }
         }
        },
        "title": {
         "text": "Gene Expression Bubble Plot by Therapeutic Subcategory, Pathway, and Clinical Trial Status"
        },
        "xaxis": {
         "anchor": "y",
         "domain": [
          0,
          1
         ],
         "title": {
          "text": "Therapeutic Subcategory"
         }
        },
        "yaxis": {
         "anchor": "x",
         "domain": [
          0,
          1
         ],
         "title": {
          "text": "Pathway Category"
         }
        }
       }
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Assuming df_unique is your dataframe with these columns:\n",
    "\n",
    "# Prepare size and color columns\n",
    "df_unique['abs_log2_fc'] = df_unique['log2_fc'].abs()\n",
    "\n",
    "# Create bubble plot\n",
    "fig = px.scatter(\n",
    "    df_unique,\n",
    "    x='Targeting Category',            # categories on x-axis\n",
    "    y='Pathway Category',                    # pathways on y-axis\n",
    "    size='abs_log2_fc',                      # bubble size = magnitude of expression change\n",
    "    color='Clinical_Trial_Status',           # color by trial status\n",
    "    hover_name='gene',                       # hover shows gene name\n",
    "    size_max=30,\n",
    "    title='Gene Expression Bubble Plot by Therapeutic Subcategory, Pathway, and Clinical Trial Status',\n",
    "    category_orders={\n",
    "        \"Therapeutic Subcategory\": [\n",
    "            \"FDA-approved for Cancer Therapy\",\n",
    "            \"Emerging Breast Cancer Target\",\n",
    "            \"Lacks Breast Cancer Evidence\"\n",
    "        ],\n",
    "        # You can also specify order for pathways if desired\n",
    "    }\n",
    ")\n",
    "\n",
    "fig.update_layout(\n",
    "    xaxis_title='Therapeutic Subcategory',\n",
    "    yaxis_title='Pathway Category',\n",
    "    legend_title='Clinical Trial Status'\n",
    ")\n",
    "\n",
    "fig.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "id": "28d20a8e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.plotly.v1+json": {
       "config": {
        "plotlyServerURL": "https://plot.ly"
       },
       "data": [
        {
         "hovertemplate": "Clinical Trial Status=In Breast Cancer Trial<br>Targeting Category=FDA-approved for Cancer Therapy<br>Gene=%{x}<br>Log2 Fold Change=%{y}<extra></extra>",
         "legendgroup": "In Breast Cancer Trial",
         "marker": {
          "color": "#636efa",
          "pattern": {
           "shape": ""
          }
         },
         "name": "In Breast Cancer Trial",
         "orientation": "v",
         "showlegend": true,
         "textposition": "auto",
         "type": "bar",
         "x": [
          "ERBB2",
          "MET",
          "CCND1",
          "CDKN2A",
          "FGFR1",
          "NTRK2",
          "FGFR2",
          "EGFR",
          "AKT1",
          "BRCA1",
          "FOXO3",
          "HRAS",
          "CDK4",
          "NF1",
          "BRCA2",
          "MDM2",
          "STK11",
          "CHEK2",
          "KRAS",
          "NOTCH1",
          "CDK6",
          "TSC2",
          "TP53",
          "MYC",
          "PIK3CA",
          "SMAD4",
          "PTEN",
          "RB1",
          "ATR",
          "BCL2",
          "ATM"
         ],
         "xaxis": "x",
         "y": {
          "bdata": "qHlvaubOGEDyT3979y0XQB7K172nThRAuFJn5s8dEUDhqIJ2XJwQQMZtMGBRWBBAtMQh7cxED0Do7RWYVVAOQPydlCDzZQ1AMAe5O/zhDEBlDmz19EILQNsgybLE+AlARxTyqbDHCUAJNEn03MQIQBKPp+XGFAZA3cMRK3dmBEB9CtIsk1sEQA2m7Rq6nQJADB+BM1dnAkBjmqf3/VACQNSZth2o8gFA4v1fHc98AUDn6RHwFkABQNb3ayMyPwBADjsC4qIVAEB1syqMOYP8P04TqQi8+vo/XFgMjsC4+j91dPv96Hz3P7fVUedXhfU/gChVbGm24D8=",
          "dtype": "f8"
         },
         "yaxis": "y"
        },
        {
         "hovertemplate": "Clinical Trial Status=In Breast Cancer Trial<br>Targeting Category=Emerging Breast Cancer Target<br>Gene=%{x}<br>Log2 Fold Change=%{y}<extra></extra>",
         "legendgroup": "In Breast Cancer Trial",
         "marker": {
          "color": "#636efa",
          "pattern": {
           "shape": ""
          }
         },
         "name": "In Breast Cancer Trial",
         "orientation": "v",
         "showlegend": false,
         "textposition": "auto",
         "type": "bar",
         "x": [
          "CASP8"
         ],
         "xaxis": "x3",
         "y": {
          "bdata": "uKZ8KWhj/T8=",
          "dtype": "f8"
         },
         "yaxis": "y3"
        },
        {
         "hovertemplate": "Clinical Trial Status=No Breast Cancer Trial<br>Targeting Category=Lacks Breast Cancer Evidence<br>Gene=%{x}<br>Log2 Fold Change=%{y}<extra></extra>",
         "legendgroup": "No Breast Cancer Trial",
         "marker": {
          "color": "#EF553B",
          "pattern": {
           "shape": ""
          }
         },
         "name": "No Breast Cancer Trial",
         "orientation": "v",
         "showlegend": true,
         "textposition": "auto",
         "type": "bar",
         "x": [
          "SRC",
          "CDKN1A",
          "NRAS",
          "NF2",
          "WT1",
          "BAX",
          "VHL",
          "NTRK1"
         ],
         "xaxis": "x2",
         "y": {
          "bdata": "dL1DPLLTEkD/W5mGv50PQE6PzsCP3gRAHJ66V5+DA0DRnUNLtWQDQHKGC7UvAwNAwOS0kNS6/z+Rfn7ZLD/zPw==",
          "dtype": "f8"
         },
         "yaxis": "y2"
        }
       ],
       "layout": {
        "annotations": [
         {
          "font": {},
          "showarrow": false,
          "text": "FDA-approved for Cancer Therapy",
          "x": 0.15999999999999998,
          "xanchor": "center",
          "xref": "paper",
          "y": 1,
          "yanchor": "bottom",
          "yref": "paper"
         },
         {
          "font": {},
          "showarrow": false,
          "text": "Lacks Breast Cancer Evidence",
          "x": 0.49999999999999994,
          "xanchor": "center",
          "xref": "paper",
          "y": 1,
          "yanchor": "bottom",
          "yref": "paper"
         },
         {
          "font": {},
          "showarrow": false,
          "text": "Emerging Breast Cancer Target",
          "x": 0.8399999999999999,
          "xanchor": "center",
          "xref": "paper",
          "y": 1,
          "yanchor": "bottom",
          "yref": "paper"
         }
        ],
        "barmode": "relative",
        "grid": {
         "columns": 3,
         "rows": 1
        },
        "height": 500,
        "legend": {
         "title": {
          "text": "Clinical Trial Status"
         },
         "tracegroupgap": 0,
         "x": 1.02,
         "xanchor": "left",
         "y": 0.98,
         "yanchor": "top"
        },
        "margin": {
         "b": 80,
         "t": 70
        },
        "template": {
         "data": {
          "bar": [
           {
            "error_x": {
             "color": "#2a3f5f"
            },
            "error_y": {
             "color": "#2a3f5f"
            },
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "bar"
           }
          ],
          "barpolar": [
           {
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "barpolar"
           }
          ],
          "carpet": [
           {
            "aaxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "baxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "type": "carpet"
           }
          ],
          "choropleth": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "choropleth"
           }
          ],
          "contour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "contour"
           }
          ],
          "contourcarpet": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "contourcarpet"
           }
          ],
          "heatmap": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "heatmap"
           }
          ],
          "histogram": [
           {
            "marker": {
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "histogram"
           }
          ],
          "histogram2d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2d"
           }
          ],
          "histogram2dcontour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2dcontour"
           }
          ],
          "mesh3d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "mesh3d"
           }
          ],
          "parcoords": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "parcoords"
           }
          ],
          "pie": [
           {
            "automargin": true,
            "type": "pie"
           }
          ],
          "scatter": [
           {
            "fillpattern": {
             "fillmode": "overlay",
             "size": 10,
             "solidity": 0.2
            },
            "type": "scatter"
           }
          ],
          "scatter3d": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatter3d"
           }
          ],
          "scattercarpet": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattercarpet"
           }
          ],
          "scattergeo": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergeo"
           }
          ],
          "scattergl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergl"
           }
          ],
          "scattermap": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermap"
           }
          ],
          "scattermapbox": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermapbox"
           }
          ],
          "scatterpolar": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolar"
           }
          ],
          "scatterpolargl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolargl"
           }
          ],
          "scatterternary": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterternary"
           }
          ],
          "surface": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "surface"
           }
          ],
          "table": [
           {
            "cells": {
             "fill": {
              "color": "#EBF0F8"
             },
             "line": {
              "color": "white"
             }
            },
            "header": {
             "fill": {
              "color": "#C8D4E3"
             },
             "line": {
              "color": "white"
             }
            },
            "type": "table"
           }
          ]
         },
         "layout": {
          "annotationdefaults": {
           "arrowcolor": "#2a3f5f",
           "arrowhead": 0,
           "arrowwidth": 1
          },
          "autotypenumbers": "strict",
          "coloraxis": {
           "colorbar": {
            "outlinewidth": 0,
            "ticks": ""
           }
          },
          "colorscale": {
           "diverging": [
            [
             0,
             "#8e0152"
            ],
            [
             0.1,
             "#c51b7d"
            ],
            [
             0.2,
             "#de77ae"
            ],
            [
             0.3,
             "#f1b6da"
            ],
            [
             0.4,
             "#fde0ef"
            ],
            [
             0.5,
             "#f7f7f7"
            ],
            [
             0.6,
             "#e6f5d0"
            ],
            [
             0.7,
             "#b8e186"
            ],
            [
             0.8,
             "#7fbc41"
            ],
            [
             0.9,
             "#4d9221"
            ],
            [
             1,
             "#276419"
            ]
           ],
           "sequential": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ],
           "sequentialminus": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ]
          },
          "colorway": [
           "#636efa",
           "#EF553B",
           "#00cc96",
           "#ab63fa",
           "#FFA15A",
           "#19d3f3",
           "#FF6692",
           "#B6E880",
           "#FF97FF",
           "#FECB52"
          ],
          "font": {
           "color": "#2a3f5f"
          },
          "geo": {
           "bgcolor": "white",
           "lakecolor": "white",
           "landcolor": "#E5ECF6",
           "showlakes": true,
           "showland": true,
           "subunitcolor": "white"
          },
          "hoverlabel": {
           "align": "left"
          },
          "hovermode": "closest",
          "mapbox": {
           "style": "light"
          },
          "paper_bgcolor": "white",
          "plot_bgcolor": "#E5ECF6",
          "polar": {
           "angularaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "radialaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "scene": {
           "xaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "yaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "zaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           }
          },
          "shapedefaults": {
           "line": {
            "color": "#2a3f5f"
           }
          },
          "ternary": {
           "aaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "baxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "caxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "title": {
           "x": 0.05
          },
          "xaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          },
          "yaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          }
         }
        },
        "title": {
         "text": "Gene Expression Log2 Fold Change by Therapeutic Subcategory and Clinical Trial Status"
        },
        "uniformtext": {
         "minsize": 10,
         "mode": "hide"
        },
        "width": 1100,
        "xaxis": {
         "anchor": "y",
         "domain": [
          0,
          0.31999999999999995
         ],
         "tickangle": -45,
         "tickfont": {
          "size": 10
         },
         "title": {
          "text": "Gene"
         }
        },
        "xaxis2": {
         "anchor": "y2",
         "domain": [
          0.33999999999999997,
          0.6599999999999999
         ],
         "matches": "x",
         "title": {
          "text": "Gene"
         }
        },
        "xaxis3": {
         "anchor": "y3",
         "domain": [
          0.6799999999999999,
          0.9999999999999999
         ],
         "matches": "x",
         "title": {
          "text": "Gene"
         }
        },
        "yaxis": {
         "anchor": "x",
         "domain": [
          0,
          1
         ],
         "matches": "y",
         "title": {
          "text": "Log2 Fold Change"
         }
        },
        "yaxis2": {
         "anchor": "x2",
         "domain": [
          0,
          1
         ],
         "matches": "y",
         "showticklabels": false
        },
        "yaxis3": {
         "anchor": "x3",
         "domain": [
          0,
          1
         ],
         "matches": "y",
         "showticklabels": false
        }
       }
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "fig = px.bar(\n",
    "    df_unique.sort_values('log2_fc', ascending=False),\n",
    "    x='gene',\n",
    "    y='log2_fc',\n",
    "    color='Clinical_Trial_Status',\n",
    "    facet_col='Targeting Category',\n",
    "    category_orders={\n",
    "        \"Therapeutic Subcategory\": [\n",
    "            \"FDA-approved for Cancer Therapy\",\n",
    "            \"Emerging Breast Cancer Target\",\n",
    "            \"Lacks Breast Cancer Evidence\"\n",
    "        ]\n",
    "    },\n",
    "    labels={\n",
    "        'gene': 'Gene',\n",
    "        'log2_fc': 'Log2 Fold Change',\n",
    "        'Clinical_Trial_Status': 'Clinical Trial Status'\n",
    "    },\n",
    "    title='Gene Expression Log2 Fold Change by Therapeutic Subcategory and Clinical Trial Status',\n",
    "    height=500,\n",
    "    width=1100  # Increased width for better horizontal spacing\n",
    ")\n",
    "\n",
    "fig.update_layout(\n",
    "    xaxis_tickangle=-45,   # Less rotation to save vertical space\n",
    "    xaxis_tickfont=dict(size=10),\n",
    "    legend_title_text='Clinical Trial Status',\n",
    "    legend=dict(y=0.98, yanchor='top', x=1.02, xanchor='left'),\n",
    "    margin=dict(t=70, b=80),\n",
    "    # Reduce space between facets\n",
    "    grid=dict(columns=3, rows=1),\n",
    "    # Adjust facet subplot spacing\n",
    "    uniformtext_minsize=10, \n",
    "    uniformtext_mode='hide'\n",
    ")\n",
    "\n",
    "# Make y-axis same range across facets\n",
    "fig.update_yaxes(matches='y')\n",
    "\n",
    "# Clean facet titles (remove 'Therapeutic Subcategory=')\n",
    "fig.for_each_annotation(lambda a: a.update(text=a.text.split(\"=\")[-1]))\n",
    "\n",
    "fig.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "id": "79af15b1",
   "metadata": {},
   "outputs": [],
   "source": [
    "# fig.update_layout(\n",
    "#     width=1000,  # Increase width for more spacing\n",
    "#     height=600,\n",
    "#     xaxis=dict(\n",
    "#         title=\"Therapeutic Subcategory\",\n",
    "#         categoryorder='array',\n",
    "#         categoryarray=['FDA-approved for Cancer Therapy', 'Emerging Breast Cancer Target', 'Lacks Breast Cancer Evidence']\n",
    "#     ),\n",
    "#     yaxis=dict(\n",
    "#         title=\"Pathway Category\",\n",
    "#         categoryorder='array',\n",
    "#         categoryarray=[\n",
    "#             'CDK4CCND1 Axis', 'PI3KMAPKEGFR', 'MYC Axis', 'Cell Cycle & Apoptosis',\n",
    "#             'RAS Pathway', 'RTKs / Growth Factor Signaling', 'Tumor Suppressor',\n",
    "#             'DNA Repair / Tumor Suppressors', 'Apoptosis', 'Transcription Factors', 'Other'\n",
    "#         ]\n",
    "#     ),\n",
    "#     legend=dict(\n",
    "#         title=\"Expression Direction\",\n",
    "#         font=dict(size=12)\n",
    "#     ),\n",
    "#     title=dict(\n",
    "#         text=\"Gene Expression Bubble Plot by Therapeutic Subcategory and Pathway\",\n",
    "#         font=dict(size=16)\n",
    "#     )\n",
    "# )\n",
    "\n",
    "# fig.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "id": "a64a5bc5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 700x600 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Prepare pivot table: genes on y-axis, categories/pathways on x-axis, colored by mean log2FC\n",
    "heatmap_data = df_unique.pivot_table(\n",
    "    index='gene',\n",
    "    columns='Targeting Category',  # or 'Pathway Category'\n",
    "    values='log2_fc',\n",
    "    aggfunc='mean',\n",
    "    fill_value=0\n",
    ")\n",
    "\n",
    "plt.figure(figsize=(7, 6))\n",
    "sns.heatmap(heatmap_data, cmap='bwr', center=0, linewidths=0.5)\n",
    "plt.title(\"Heatmap: Mean Log2 Fold Change of Genes by Therapeutic Subcategory\")\n",
    "plt.ylabel('Gene')\n",
    "plt.xlabel('Therapeutic Subcategory')\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "331a5534",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "df_unique['-log10_pval'] = -np.log10(df_unique['p_value'] + 1e-300)  # avoid log(0)\n",
    "plt.figure(figsize=(10, 6))\n",
    "\n",
    "# Map colors\n",
    "color_map = {\n",
    "    'FDA-approved for Cancer Therapy': 'green',\n",
    "    'Emerging Breast Cancer Target': 'orange',\n",
    "    'Lacks Breast Cancer Evidence': 'red'\n",
    "}\n",
    "colors = df_unique['Targeting Category'].map(color_map)\n",
    "\n",
    "scatter = plt.scatter(df_unique['log2_fc'], df_unique['-log10_pval'],\n",
    "                        c=colors, alpha=0.7)\n",
    "\n",
    "plt.xlabel('Log2 Fold Change')\n",
    "plt.ylabel('-log10(p-value)')\n",
    "plt.title('Volcano Plot: Differential Expression by Therapeutic Category')\n",
    "plt.axvline(0, color='black', linestyle='--')\n",
    "\n",
    "# Annotate each point with gene name\n",
    "for i, row in df_unique.iterrows():\n",
    "    plt.text(row['log2_fc'], row['-log10_pval'], row['gene'],\n",
    "                fontsize=8, alpha=0.7, ha='right', va='bottom')\n",
    "\n",
    "# Create legend patches\n",
    "legend_patches = [mpatches.Patch(color=color, label=label) for label, color in color_map.items()]\n",
    "plt.legend(handles=legend_patches, title=\"Therapeutic Subcategory\", loc='center right')\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "id": "82e5d7f1",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Suppose you have a list of genes with FDA-approved drugs specifically for breast cancer\n",
    "# # This list can come from your manual curation or a trusted source.\n",
    "# bc_approved_genes = [\n",
    "#     'ERBB2', 'CDK4', 'CDK6', 'PIK3CA', 'FGFR1', 'FGFR2', 'EGFR', 'BRCA1', 'BRCA2',\n",
    "#     'TP53', 'AKT1', 'MYC', 'KRAS'  # example subset  replace with your verified list\n",
    "# ]\n",
    "\n",
    "# def fda_subcategory(row):\n",
    "#     if row['Targeting Category'] != 'FDA-approved Breast Cancer Therapy':\n",
    "#         return None\n",
    "#     if row['gene'] in bc_approved_genes:\n",
    "#         return 'FDA-approved for Breast Cancer'\n",
    "#     else:\n",
    "#         return 'FDA-approved, Other Indication'\n",
    "\n",
    "# df_unique['FDA_Subcategory'] = df_unique.apply(fda_subcategory, axis=1)\n",
    "# print(df_unique['FDA_Subcategory'].value_counts())\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "54eddb01",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Fill NAs for non-FDA approved\n",
    "df_unique['FDA_Subcategory'] = df_unique['FDA_Subcategory'].fillna('N/A')\n",
    "\n",
    "# Build label list for nodes\n",
    "targeting_categories = df_unique['Targeting Category'].unique().tolist()\n",
    "fda_subcats = df_unique['FDA_Subcategory'].unique().tolist()\n",
    "trial_status = df_unique['Clinical_Trial_Status'].unique().tolist()\n",
    "genes = df_unique['gene'].unique().tolist()\n",
    "\n",
    "labels = targeting_categories + fda_subcats + trial_status + genes\n",
    "label_to_idx = {label: i for i, label in enumerate(labels)}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "id": "09a03936",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Colors for categories (customize as needed)\n",
    "cat_colors = {\n",
    "    'FDA-approved for Cancer Therapy': 'green',\n",
    "    'Emerging Breast Cancer Target': 'orange',\n",
    "    'Lacks Breast Cancer Evidence': 'red',\n",
    "    'FDA-approved for Breast Cancer': 'darkgreen',\n",
    "    'FDA-approved, Other Indication': 'lightgreen',\n",
    "    'N/A': 'lightgrey',\n",
    "    'In Breast Cancer Trial': 'blue',\n",
    "    'No Breast Cancer Trial': 'grey'\n",
    "}\n",
    "\n",
    "# Build links lists: source, target, value, colors\n",
    "source = []\n",
    "target = []\n",
    "value = []\n",
    "link_colors = []\n",
    "\n",
    "# Helper function to get color for links (source node color)\n",
    "def get_link_color(src_label):\n",
    "    return cat_colors.get(src_label, 'lightgrey')\n",
    "\n",
    "# Targeting Category  FDA Subcategory\n",
    "for _, row in df_unique.iterrows():\n",
    "    source.append(label_to_idx[row['Targeting Category']])\n",
    "    target.append(label_to_idx[row['FDA_Subcategory']])\n",
    "    value.append(1)\n",
    "    link_colors.append(get_link_color(row['Targeting Category']))\n",
    "\n",
    "# FDA Subcategory  Clinical Trial Status\n",
    "for _, row in df_unique.iterrows():\n",
    "    source.append(label_to_idx[row['FDA_Subcategory']])\n",
    "    target.append(label_to_idx[row['Clinical_Trial_Status']])\n",
    "    value.append(1)\n",
    "    link_colors.append(get_link_color(row['FDA_Subcategory']))\n",
    "\n",
    "# Clinical Trial Status  Gene\n",
    "for _, row in df_unique.iterrows():\n",
    "    source.append(label_to_idx[row['Clinical_Trial_Status']])\n",
    "    target.append(label_to_idx[row['gene']])\n",
    "    value.append(1)\n",
    "    link_colors.append(get_link_color(row['Clinical_Trial_Status']))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "id": "02bc08d4",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.plotly.v1+json": {
       "config": {
        "plotlyServerURL": "https://plot.ly"
       },
       "data": [
        {
         "link": {
          "color": [
           "green",
           "green",
           "green",
           "red",
           "green",
           "green",
           "green",
           "orange",
           "red",
           "green",
           "green",
           "green",
           "red",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "red",
           "green",
           "green",
           "green",
           "red",
           "green",
           "red",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "green",
           "red",
           "red",
           "lightgreen",
           "darkgreen",
           "lightgreen",
           "lightgrey",
           "darkgreen",
           "lightgreen",
           "lightgreen",
           "lightgrey",
           "lightgrey",
           "lightgreen",
           "lightgreen",
           "darkgreen",
           "lightgrey",
           "darkgreen",
           "darkgreen",
           "darkgreen",
           "darkgreen",
           "darkgreen",
           "darkgreen",
           "lightgreen",
           "darkgreen",
           "lightgreen",
           "lightgrey",
           "lightgreen",
           "darkgreen",
           "lightgreen",
           "lightgrey",
           "lightgreen",
           "lightgrey",
           "lightgreen",
           "lightgreen",
           "lightgreen",
           "lightgreen",
           "darkgreen",
           "lightgreen",
           "lightgreen",
           "lightgreen",
           "darkgreen",
           "lightgrey",
           "lightgrey",
           "blue",
           "blue",
           "blue",
           "grey",
           "blue",
           "blue",
           "blue",
           "blue",
           "grey",
           "blue",
           "blue",
           "blue",
           "grey",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "grey",
           "blue",
           "blue",
           "blue",
           "grey",
           "blue",
           "grey",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "blue",
           "grey",
           "grey"
          ],
          "source": [
           0,
           0,
           0,
           1,
           0,
           0,
           0,
           2,
           1,
           0,
           0,
           0,
           1,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           1,
           0,
           0,
           0,
           1,
           0,
           1,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           0,
           1,
           1,
           3,
           4,
           3,
           5,
           4,
           3,
           3,
           5,
           5,
           3,
           3,
           4,
           5,
           4,
           4,
           4,
           4,
           4,
           4,
           3,
           4,
           3,
           5,
           3,
           4,
           3,
           5,
           3,
           5,
           3,
           3,
           3,
           3,
           4,
           3,
           3,
           3,
           4,
           5,
           5,
           6,
           6,
           6,
           7,
           6,
           6,
           6,
           6,
           7,
           6,
           6,
           6,
           7,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           7,
           6,
           6,
           6,
           7,
           6,
           7,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           7,
           7
          ],
          "target": [
           3,
           4,
           3,
           5,
           4,
           3,
           3,
           5,
           5,
           3,
           3,
           4,
           5,
           4,
           4,
           4,
           4,
           4,
           4,
           3,
           4,
           3,
           5,
           3,
           4,
           3,
           5,
           3,
           5,
           3,
           3,
           3,
           3,
           4,
           3,
           3,
           3,
           4,
           5,
           5,
           6,
           6,
           6,
           7,
           6,
           6,
           6,
           6,
           7,
           6,
           6,
           6,
           7,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           7,
           6,
           6,
           6,
           7,
           6,
           7,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           6,
           7,
           7,
           8,
           9,
           10,
           11,
           12,
           13,
           14,
           15,
           16,
           17,
           18,
           19,
           20,
           21,
           22,
           23,
           24,
           25,
           26,
           27,
           28,
           29,
           30,
           31,
           32,
           33,
           34,
           35,
           36,
           37,
           38,
           39,
           40,
           41,
           42,
           43,
           44,
           45,
           46,
           47
          ],
          "value": [
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1
          ]
         },
         "node": {
          "color": [
           "green",
           "red",
           "orange",
           "lightgreen",
           "darkgreen",
           "lightgrey",
           "blue",
           "grey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey"
          ],
          "label": [
           "FDA-approved for Cancer Therapy",
           "Lacks Breast Cancer Evidence",
           "Emerging Breast Cancer Target",
           "FDA-approved, Other Indication",
           "FDA-approved for Breast Cancer",
           "N/A",
           "In Breast Cancer Trial",
           "No Breast Cancer Trial",
           "PTEN",
           "CDK4",
           "CDKN2A",
           "CDKN1A",
           "FGFR1",
           "MDM2",
           "HRAS",
           "CASP8",
           "VHL",
           "FOXO3",
           "CCND1",
           "ERBB2",
           "BAX",
           "KRAS",
           "AKT1",
           "MYC",
           "BRCA1",
           "TP53",
           "PIK3CA",
           "BCL2",
           "CDK6",
           "RB1",
           "NRAS",
           "NF1",
           "BRCA2",
           "ATR",
           "NF2",
           "SMAD4",
           "SRC",
           "CHEK2",
           "TSC2",
           "STK11",
           "MET",
           "EGFR",
           "NOTCH1",
           "ATM",
           "NTRK2",
           "FGFR2",
           "WT1",
           "NTRK1"
          ],
          "line": {
           "color": "black",
           "width": 0.5
          },
          "pad": 15,
          "thickness": 15
         },
         "type": "sankey"
        }
       ],
       "layout": {
        "font": {
         "size": 12
        },
        "height": 800,
        "template": {
         "data": {
          "bar": [
           {
            "error_x": {
             "color": "#2a3f5f"
            },
            "error_y": {
             "color": "#2a3f5f"
            },
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "bar"
           }
          ],
          "barpolar": [
           {
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "barpolar"
           }
          ],
          "carpet": [
           {
            "aaxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "baxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "type": "carpet"
           }
          ],
          "choropleth": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "choropleth"
           }
          ],
          "contour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "contour"
           }
          ],
          "contourcarpet": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "contourcarpet"
           }
          ],
          "heatmap": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "heatmap"
           }
          ],
          "histogram": [
           {
            "marker": {
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "histogram"
           }
          ],
          "histogram2d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2d"
           }
          ],
          "histogram2dcontour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2dcontour"
           }
          ],
          "mesh3d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "mesh3d"
           }
          ],
          "parcoords": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "parcoords"
           }
          ],
          "pie": [
           {
            "automargin": true,
            "type": "pie"
           }
          ],
          "scatter": [
           {
            "fillpattern": {
             "fillmode": "overlay",
             "size": 10,
             "solidity": 0.2
            },
            "type": "scatter"
           }
          ],
          "scatter3d": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatter3d"
           }
          ],
          "scattercarpet": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattercarpet"
           }
          ],
          "scattergeo": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergeo"
           }
          ],
          "scattergl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergl"
           }
          ],
          "scattermap": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermap"
           }
          ],
          "scattermapbox": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermapbox"
           }
          ],
          "scatterpolar": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolar"
           }
          ],
          "scatterpolargl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolargl"
           }
          ],
          "scatterternary": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterternary"
           }
          ],
          "surface": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "surface"
           }
          ],
          "table": [
           {
            "cells": {
             "fill": {
              "color": "#EBF0F8"
             },
             "line": {
              "color": "white"
             }
            },
            "header": {
             "fill": {
              "color": "#C8D4E3"
             },
             "line": {
              "color": "white"
             }
            },
            "type": "table"
           }
          ]
         },
         "layout": {
          "annotationdefaults": {
           "arrowcolor": "#2a3f5f",
           "arrowhead": 0,
           "arrowwidth": 1
          },
          "autotypenumbers": "strict",
          "coloraxis": {
           "colorbar": {
            "outlinewidth": 0,
            "ticks": ""
           }
          },
          "colorscale": {
           "diverging": [
            [
             0,
             "#8e0152"
            ],
            [
             0.1,
             "#c51b7d"
            ],
            [
             0.2,
             "#de77ae"
            ],
            [
             0.3,
             "#f1b6da"
            ],
            [
             0.4,
             "#fde0ef"
            ],
            [
             0.5,
             "#f7f7f7"
            ],
            [
             0.6,
             "#e6f5d0"
            ],
            [
             0.7,
             "#b8e186"
            ],
            [
             0.8,
             "#7fbc41"
            ],
            [
             0.9,
             "#4d9221"
            ],
            [
             1,
             "#276419"
            ]
           ],
           "sequential": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ],
           "sequentialminus": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ]
          },
          "colorway": [
           "#636efa",
           "#EF553B",
           "#00cc96",
           "#ab63fa",
           "#FFA15A",
           "#19d3f3",
           "#FF6692",
           "#B6E880",
           "#FF97FF",
           "#FECB52"
          ],
          "font": {
           "color": "#2a3f5f"
          },
          "geo": {
           "bgcolor": "white",
           "lakecolor": "white",
           "landcolor": "#E5ECF6",
           "showlakes": true,
           "showland": true,
           "subunitcolor": "white"
          },
          "hoverlabel": {
           "align": "left"
          },
          "hovermode": "closest",
          "mapbox": {
           "style": "light"
          },
          "paper_bgcolor": "white",
          "plot_bgcolor": "#E5ECF6",
          "polar": {
           "angularaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "radialaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "scene": {
           "xaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "yaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "zaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           }
          },
          "shapedefaults": {
           "line": {
            "color": "#2a3f5f"
           }
          },
          "ternary": {
           "aaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "baxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "caxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "title": {
           "x": 0.05
          },
          "xaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          },
          "yaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          }
         }
        },
        "title": {
         "text": "Therapeutic Stratification with FDA Subcategories"
        },
        "width": 1200
       }
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Sankey diagram\n",
    "fig = go.Figure(data=[go.Sankey(\n",
    "    node=dict(\n",
    "        label=labels,\n",
    "        pad=15,\n",
    "        thickness=15,\n",
    "        line=dict(color='black', width=0.5),\n",
    "        color=[cat_colors.get(lbl, 'lightgrey') for lbl in labels]\n",
    "    ),\n",
    "    link=dict(\n",
    "        source=source,\n",
    "        target=target,\n",
    "        value=value,\n",
    "        color=link_colors\n",
    "    )\n",
    ")])\n",
    "\n",
    "fig.update_layout(title_text=\"Therapeutic Stratification with FDA Subcategories\", font_size=12, height=800, width=1200)\n",
    "fig.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "id": "c348f152",
   "metadata": {},
   "outputs": [],
   "source": [
    "# # Filter only FDA-approved genes (both subgroups)\n",
    "# fda_genes = df_unique[df_unique['Targeting Category'] == 'FDA-approved Breast Cancer Therapy']\n",
    "\n",
    "# # Group by FDA_Subcategory and Clinical_Trial_Status, count genes\n",
    "# trial_counts = fda_genes.groupby(['FDA_Subcategory', 'Clinical_Trial_Status'])['gene'].nunique().unstack(fill_value=0)\n",
    "\n",
    "# trial_counts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 63,
   "id": "1c4efb18",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Filter subsets for each therapeutic group\n",
    "df_fda = df_unique[df_unique['Targeting Category'] == 'FDA-approved for Cancer Therapy'].copy()\n",
    "df_emerging = df_unique[df_unique['Targeting Category'] == 'Emerging Breast Cancer Target'].copy()\n",
    "df_lacks = df_unique[df_unique['Targeting Category'] == 'Lacks Breast Cancer Evidence'].copy()\n",
    "\n",
    "# For FDA, use 'FDA_Subcategory' as hue\n",
    "# For emerging and lacks, assign Therapeutic Group label for hue\n",
    "df_fda['Therapeutic Group'] = df_fda['FDA_Subcategory']\n",
    "\n",
    "df_emerging['Therapeutic Group'] = 'Emerging Breast Cancer Target'\n",
    "df_lacks['Therapeutic Group'] = 'Lacks Breast Cancer Evidence'\n",
    "\n",
    "# Combine all into one DataFrame for plotting\n",
    "df_plot = pd.concat([df_fda, df_emerging, df_lacks], ignore_index=True).sort_values(by='log2_fc', ascending=False)\n",
    "\n",
    "# Define color palette\n",
    "palette = {\n",
    "    'FDA-approved for Breast Cancer': 'darkgreen',\n",
    "    'FDA-approved, Other Indication': 'lightgreen',\n",
    "    'Emerging Breast Cancer Target': 'orange',\n",
    "    'Lacks Breast Cancer Evidence': 'red'\n",
    "}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "be9dca0f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1800x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.figure(figsize=(18, 6))\n",
    "sns.barplot(\n",
    "    data=df_plot,\n",
    "    x='gene',\n",
    "    y='log2_fc',\n",
    "    hue='Therapeutic Group',\n",
    "    dodge=False,\n",
    "    palette=palette\n",
    ")\n",
    "\n",
    "plt.xticks(rotation=90)\n",
    "plt.xlabel('Gene')\n",
    "plt.ylabel('Log2 Fold Change')\n",
    "plt.title('Gene Expression by Therapeutic Category')\n",
    "plt.legend(title='Therapeutic Group', bbox_to_anchor=(1.05, 1), loc='upper left')\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "id": "4611aa9c",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "FDA-approved Breast Cancer Therapy genes: []\n",
      "FDA-approved Other Indication genes: ['PTEN', 'CDKN2A', 'MDM2', 'HRAS', 'FOXO3', 'CCND1', 'BCL2', 'RB1', 'NF1', 'ATR', 'SMAD4', 'CHEK2', 'TSC2', 'STK11', 'MET', 'NOTCH1', 'ATM', 'NTRK2']\n",
      "Emerging Breast Cancer Target genes: ['CASP8']\n",
      "Lacks Breast Cancer Evidence genes: ['CDKN1A', 'VHL', 'BAX', 'NRAS', 'NF2', 'SRC', 'WT1', 'NTRK1']\n"
     ]
    }
   ],
   "source": [
    "# Filter genes by therapeutic category\n",
    "genes_fda_bc = df_unique.loc[df_unique['Targeting Category'] == 'FDA-approved Breast Cancer Therapy', 'gene'].unique().tolist()\n",
    "\n",
    "genes_fda_other = df_unique.loc[df_unique['FDA_Subcategory'] == 'FDA-approved, Other Indication', 'gene'].unique().tolist()\n",
    "\n",
    "genes_emerging = df_unique.loc[df_unique['Targeting Category'] == 'Emerging Breast Cancer Target', 'gene'].unique().tolist()\n",
    "\n",
    "genes_lacks = df_unique.loc[df_unique['Targeting Category'] == 'Lacks Breast Cancer Evidence', 'gene'].unique().tolist()\n",
    "\n",
    "print(\"FDA-approved Breast Cancer Therapy genes:\", genes_fda_bc)\n",
    "print(\"FDA-approved Other Indication genes:\", genes_fda_other)\n",
    "print(\"Emerging Breast Cancer Target genes:\", genes_emerging)\n",
    "print(\"Lacks Breast Cancer Evidence genes:\", genes_lacks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "f0de1034",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['FDA-approved for Cancer Therapy' 'Lacks Breast Cancer Evidence'\n",
      " 'Emerging Breast Cancer Target']\n"
     ]
    }
   ],
   "source": [
    "print(df_unique['Targeting Category'].unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "id": "1a95d2db",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1400x800 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import numpy as np\n",
    "\n",
    "\n",
    "# Prepare absolute log2 fold change for bubble size\n",
    "df_plot['abs_log2_fc'] = df_plot['log2_fc'].abs()\n",
    "\n",
    "plt.figure(figsize=(14, 8))\n",
    "scatter = sns.scatterplot(\n",
    "    data=df_plot,\n",
    "    x='gene',\n",
    "    y='log2_fc',\n",
    "    size='abs_log2_fc',\n",
    "    hue='Therapeutic Group',\n",
    "    palette={\n",
    "        'FDA-approved for Breast Cancer': 'darkgreen',\n",
    "        'FDA-approved, Other Indication': 'lightgreen',\n",
    "        'Emerging Breast Cancer Target': 'orange',\n",
    "        'Lacks Breast Cancer Evidence': 'red',\n",
    "    },\n",
    "    sizes=(50, 500),\n",
    "    alpha=0.7,\n",
    "    edgecolor='black',\n",
    "    legend='brief'  # only hue legend\n",
    ")\n",
    "\n",
    "# Adjust legend to show only therapeutic group (hue)\n",
    "handles, labels = scatter.get_legend_handles_labels()\n",
    "if labels[0] == 'abs_log2_fc':\n",
    "    handles = handles[1:]\n",
    "    labels = labels[1:]\n",
    "\n",
    "plt.legend(handles, labels, title='Therapeutic Category', bbox_to_anchor=(1.05, 1), loc='upper left')\n",
    "\n",
    "plt.xticks(rotation=90)\n",
    "plt.xlabel('Gene')\n",
    "plt.ylabel('Log2 Fold Change')\n",
    "plt.title('Gene Expression Bubble Plot by Therapeutic Category')\n",
    "\n",
    "# Annotate gene names slightly above and to the right of each bubble with background box\n",
    "for i in range(df_plot.shape[0]):\n",
    "    plt.text(\n",
    "        x=i + 0.15,  # shift slightly right\n",
    "        y=df_plot['log2_fc'].iloc[i] + 0.15,  # shift slightly above\n",
    "        s=df_plot['gene'].iloc[i],\n",
    "        fontsize=8,\n",
    "        rotation=45,\n",
    "        verticalalignment='bottom',\n",
    "        horizontalalignment='left',\n",
    "        bbox=dict(facecolor='white', alpha=0.6, edgecolor='none', pad=1)\n",
    "    )\n",
    "\n",
    "plt.tight_layout()\n",
    "plt.show()\n",
    "\n",
    "\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "id": "5a3263ef",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "     gene        p_value   log2_fc  mean_diff    Dataset    Gene DGIdb Status  \\\n",
      "0   CASP8   0.000000e+00  1.836769   0.054656  GSE180286   CASP8     Targeted   \n",
      "1  CDKN1A   0.000000e+00  3.952025   0.123942  GSE180286  CDKN1A     Targeted   \n",
      "2     VHL   0.000000e+00  1.983113   0.048900  GSE180286     VHL     Targeted   \n",
      "3     BAX   0.000000e+00  2.376556   0.154106  GSE180286     BAX     Targeted   \n",
      "4    NRAS  1.466673e-209  2.608673   0.022918  GSE180286    NRAS     Targeted   \n",
      "\n",
      "   OpenTargets_Score  BreastCancer_Supported  Strong_BreastCancer_Support  \\\n",
      "0           0.581988                    True                         True   \n",
      "1                NaN                   False                        False   \n",
      "2                NaN                   False                        False   \n",
      "3                NaN                   False                        False   \n",
      "4                NaN                   False                        False   \n",
      "\n",
      "  FDA_Approved_Drug             Targeting Category FDA_Subcategory  \\\n",
      "0                No  Emerging Breast Cancer Target             N/A   \n",
      "1               Yes   Lacks Breast Cancer Evidence             N/A   \n",
      "2               Yes   Lacks Breast Cancer Evidence             N/A   \n",
      "3               Yes   Lacks Breast Cancer Evidence             N/A   \n",
      "4               Yes   Lacks Breast Cancer Evidence             N/A   \n",
      "\n",
      "    Clinical_Trial_Status        Pathway Category  abs_log2_fc  -log10_pval  \\\n",
      "0  In Breast Cancer Trial                   Other     1.836769   300.000000   \n",
      "1  No Breast Cancer Trial  Cell Cycle & Apoptosis     3.952025   300.000000   \n",
      "2  No Breast Cancer Trial        Tumor Suppressor     1.983113   300.000000   \n",
      "3  No Breast Cancer Trial               Apoptosis     2.376556   300.000000   \n",
      "4  No Breast Cancer Trial             RAS Pathway     2.608673   208.833667   \n",
      "\n",
      "               Therapeutic Group  \n",
      "0  Emerging Breast Cancer Target  \n",
      "1   Lacks Breast Cancer Evidence  \n",
      "2   Lacks Breast Cancer Evidence  \n",
      "3   Lacks Breast Cancer Evidence  \n",
      "4   Lacks Breast Cancer Evidence  \n"
     ]
    },
    {
     "data": {
      "application/vnd.plotly.v1+json": {
       "config": {
        "plotlyServerURL": "https://plot.ly"
       },
       "data": [
        {
         "link": {
          "color": [
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "rgba(255, 0, 0, 0.5731699553537918)",
           "rgba(255, 0, 0, 0.6534486703464633)",
           "rgba(255, 0, 0, 0.887757343046355)",
           "rgba(255, 0, 0, 0.6627755292342676)",
           "rgba(255, 0, 0, 0.6879697905175144)",
           "rgba(255, 0, 0, 0.4789024904018747)",
           "rgba(255, 0, 0, 1.0)",
           "rgba(255, 0, 0, 0.594934626548927)",
           "rgba(255, 0, 0, 0.6605305768714015)"
          ],
          "hovertemplate": "%{value} genes<br>From %{source.label} to %{target.label}<extra></extra>",
          "source": [
           0,
           1,
           1,
           1,
           1,
           1,
           1,
           5,
           3,
           2,
           6,
           7,
           8,
           4,
           9,
           10,
           10,
           10,
           10,
           10,
           10,
           10,
           10
          ],
          "target": [
           2,
           5,
           3,
           6,
           7,
           8,
           4,
           10,
           10,
           9,
           10,
           10,
           10,
           10,
           11,
           14,
           12,
           16,
           15,
           19,
           17,
           13,
           18
          ],
          "value": [
           1,
           1,
           1,
           1,
           2,
           1,
           2,
           1,
           1,
           1,
           1,
           2,
           1,
           2,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1
          ]
         },
         "node": {
          "color": [
           "orange",
           "red",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey",
           "lightgrey"
          ],
          "label": [
           "Emerging Breast Cancer Target",
           "Lacks Breast Cancer Evidence",
           "Other",
           "Cell Cycle & Apoptosis",
           "Tumor Suppressor",
           "Apoptosis",
           "RAS Pathway",
           "RTKs / Growth Factor Signaling",
           "Transcription Factors",
           "In Breast Cancer Trial",
           "No Breast Cancer Trial",
           "CASP8",
           "CDKN1A",
           "VHL",
           "BAX",
           "NRAS",
           "NF2",
           "SRC",
           "WT1",
           "NTRK1"
          ],
          "line": {
           "color": "black",
           "width": 0.5
          },
          "pad": 15,
          "thickness": 20
         },
         "type": "sankey"
        }
       ],
       "layout": {
        "font": {
         "size": 10
        },
        "template": {
         "data": {
          "bar": [
           {
            "error_x": {
             "color": "#2a3f5f"
            },
            "error_y": {
             "color": "#2a3f5f"
            },
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "bar"
           }
          ],
          "barpolar": [
           {
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "barpolar"
           }
          ],
          "carpet": [
           {
            "aaxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "baxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "type": "carpet"
           }
          ],
          "choropleth": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "choropleth"
           }
          ],
          "contour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "contour"
           }
          ],
          "contourcarpet": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "contourcarpet"
           }
          ],
          "heatmap": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "heatmap"
           }
          ],
          "histogram": [
           {
            "marker": {
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "histogram"
           }
          ],
          "histogram2d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2d"
           }
          ],
          "histogram2dcontour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2dcontour"
           }
          ],
          "mesh3d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "mesh3d"
           }
          ],
          "parcoords": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "parcoords"
           }
          ],
          "pie": [
           {
            "automargin": true,
            "type": "pie"
           }
          ],
          "scatter": [
           {
            "fillpattern": {
             "fillmode": "overlay",
             "size": 10,
             "solidity": 0.2
            },
            "type": "scatter"
           }
          ],
          "scatter3d": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatter3d"
           }
          ],
          "scattercarpet": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattercarpet"
           }
          ],
          "scattergeo": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergeo"
           }
          ],
          "scattergl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergl"
           }
          ],
          "scattermap": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermap"
           }
          ],
          "scattermapbox": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermapbox"
           }
          ],
          "scatterpolar": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolar"
           }
          ],
          "scatterpolargl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolargl"
           }
          ],
          "scatterternary": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterternary"
           }
          ],
          "surface": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "surface"
           }
          ],
          "table": [
           {
            "cells": {
             "fill": {
              "color": "#EBF0F8"
             },
             "line": {
              "color": "white"
             }
            },
            "header": {
             "fill": {
              "color": "#C8D4E3"
             },
             "line": {
              "color": "white"
             }
            },
            "type": "table"
           }
          ]
         },
         "layout": {
          "annotationdefaults": {
           "arrowcolor": "#2a3f5f",
           "arrowhead": 0,
           "arrowwidth": 1
          },
          "autotypenumbers": "strict",
          "coloraxis": {
           "colorbar": {
            "outlinewidth": 0,
            "ticks": ""
           }
          },
          "colorscale": {
           "diverging": [
            [
             0,
             "#8e0152"
            ],
            [
             0.1,
             "#c51b7d"
            ],
            [
             0.2,
             "#de77ae"
            ],
            [
             0.3,
             "#f1b6da"
            ],
            [
             0.4,
             "#fde0ef"
            ],
            [
             0.5,
             "#f7f7f7"
            ],
            [
             0.6,
             "#e6f5d0"
            ],
            [
             0.7,
             "#b8e186"
            ],
            [
             0.8,
             "#7fbc41"
            ],
            [
             0.9,
             "#4d9221"
            ],
            [
             1,
             "#276419"
            ]
           ],
           "sequential": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ],
           "sequentialminus": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ]
          },
          "colorway": [
           "#636efa",
           "#EF553B",
           "#00cc96",
           "#ab63fa",
           "#FFA15A",
           "#19d3f3",
           "#FF6692",
           "#B6E880",
           "#FF97FF",
           "#FECB52"
          ],
          "font": {
           "color": "#2a3f5f"
          },
          "geo": {
           "bgcolor": "white",
           "lakecolor": "white",
           "landcolor": "#E5ECF6",
           "showlakes": true,
           "showland": true,
           "subunitcolor": "white"
          },
          "hoverlabel": {
           "align": "left"
          },
          "hovermode": "closest",
          "mapbox": {
           "style": "light"
          },
          "paper_bgcolor": "white",
          "plot_bgcolor": "#E5ECF6",
          "polar": {
           "angularaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "radialaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "scene": {
           "xaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "yaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "zaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           }
          },
          "shapedefaults": {
           "line": {
            "color": "#2a3f5f"
           }
          },
          "ternary": {
           "aaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "baxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "caxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "title": {
           "x": 0.05
          },
          "xaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          },
          "yaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          }
         }
        },
        "title": {
         "text": "Therapeutic Stratification Sankey with Log2FC Coloring on Gene Links"
        }
       }
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import plotly.graph_objects as go\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "\n",
    "# Example DataFrame structure (adjust with your df_unique):\n",
    "\n",
    "# Assuming df_unique, df_fda, df_emerging, df_lacks are already defined as you shared\n",
    "\n",
    "# Prepare Therapeutic Group as in your bar plot code:\n",
    "df_fda = df_unique[df_unique['Targeting Category'] == 'FDA-approved Breast Cancer Therapy'].copy()\n",
    "df_emerging = df_unique[df_unique['Targeting Category'] == 'Emerging Breast Cancer Target'].copy()\n",
    "df_lacks = df_unique[df_unique['Targeting Category'] == 'Lacks Breast Cancer Evidence'].copy()\n",
    "\n",
    "df_fda['Therapeutic Group'] = df_fda['FDA_Subcategory']\n",
    "df_emerging['Therapeutic Group'] = 'Emerging Breast Cancer Target'\n",
    "df_lacks['Therapeutic Group'] = 'Lacks Breast Cancer Evidence'\n",
    "\n",
    "# Combine\n",
    "df_plot = pd.concat([df_fda, df_emerging, df_lacks], ignore_index=True)\n",
    "print(df_plot.head(5))\n",
    "# Create label list for nodes (Therapeutic Group, Pathway Category, Clinical Trial, Gene)\n",
    "labels_therapeutic = df_plot['Therapeutic Group'].unique().tolist()\n",
    "labels_pathway = df_plot['Pathway Category'].unique().tolist()\n",
    "labels_trial = df_plot['Clinical_Trial_Status'].unique().tolist()\n",
    "labels_genes = df_plot['gene'].unique().tolist()\n",
    "\n",
    "labels = labels_therapeutic + labels_pathway + labels_trial + labels_genes\n",
    "\n",
    "# Map label to index\n",
    "label_to_idx = {label: idx for idx, label in enumerate(labels)}\n",
    "\n",
    "def get_links(source_col, target_col):\n",
    "    link_df = df_plot.groupby([source_col, target_col]).size().reset_index(name='count')\n",
    "    sources = link_df[source_col].map(label_to_idx).tolist()\n",
    "    targets = link_df[target_col].map(label_to_idx).tolist()\n",
    "    values = link_df['count'].tolist()\n",
    "    return sources, targets, values\n",
    "\n",
    "# Links for Sankey\n",
    "source_1, target_1, value_1 = get_links('Therapeutic Group', 'Pathway Category')\n",
    "source_2, target_2, value_2 = get_links('Pathway Category', 'Clinical_Trial_Status')\n",
    "source_3, target_3, value_3 = get_links('Clinical_Trial_Status', 'gene')\n",
    "\n",
    "sources = source_1 + source_2 + source_3\n",
    "targets = target_1 + target_2 + target_3\n",
    "values = value_1 + value_2 + value_3\n",
    "\n",
    "# Color nodes by Therapeutic Group for clarity (optional)\n",
    "color_map = {\n",
    "    'FDA-approved for Breast Cancer': 'darkgreen',\n",
    "    'FDA-approved, Other Indication': 'lightgreen',\n",
    "    'Emerging Breast Cancer Target': 'orange',\n",
    "    'Lacks Breast Cancer Evidence': 'red'\n",
    "}\n",
    "node_colors = []\n",
    "for label in labels:\n",
    "    # If therapeutic group, assign color, else default light grey\n",
    "    node_colors.append(color_map.get(label, 'lightgrey'))\n",
    "\n",
    "# Color gene links by log2 fold change (blue for down, red for up)\n",
    "def logfc_to_color(logfc):\n",
    "    # Normalize logFC for color intensity\n",
    "    max_val = max(abs(df_plot['log2_fc'].max()), abs(df_plot['log2_fc'].min()))\n",
    "    norm_val = logfc / max_val\n",
    "    if norm_val >= 0:\n",
    "        # Red shades for upregulated\n",
    "        return f'rgba(255, 0, 0, {0.3 + 0.7 * norm_val})'\n",
    "    else:\n",
    "        # Blue shades for downregulated\n",
    "        return f'rgba(0, 0, 255, {0.3 + 0.7 * abs(norm_val)})'\n",
    "\n",
    "# Map genes to colors by log2_fc\n",
    "gene_color_map = dict(zip(df_plot['gene'], df_plot['log2_fc'].apply(logfc_to_color)))\n",
    "\n",
    "link_colors = []\n",
    "for i in range(len(sources)):\n",
    "    # For links from Clinical Trial Status to Gene, use gene color\n",
    "    if sources[i] in [label_to_idx[t] for t in labels_trial] and targets[i] in [label_to_idx[g] for g in labels_genes]:\n",
    "        gene_label = labels[targets[i]]\n",
    "        link_colors.append(gene_color_map.get(gene_label, 'lightgrey'))\n",
    "    else:\n",
    "        link_colors.append('lightgrey')\n",
    "\n",
    "# Create Sankey\n",
    "fig = go.Figure(data=[go.Sankey(\n",
    "    node=dict(\n",
    "        pad=15,\n",
    "        thickness=20,\n",
    "        line=dict(color='black', width=0.5),\n",
    "        label=labels,\n",
    "        color=node_colors\n",
    "    ),\n",
    "    link=dict(\n",
    "        source=sources,\n",
    "        target=targets,\n",
    "        value=values,\n",
    "        color=link_colors,\n",
    "        hovertemplate='%{value} genes<br>From %{source.label} to %{target.label}<extra></extra>'\n",
    "    )\n",
    ")])\n",
    "\n",
    "fig.update_layout(title_text='Therapeutic Stratification Sankey with Log2FC Coloring on Gene Links',\n",
    "                  font_size=10)\n",
    "\n",
    "fig.show()\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "883541f0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  gene  Clinical_Trial_Status             Therapeutic Group\n",
      " CASP8 In Breast Cancer Trial Emerging Breast Cancer Target\n",
      "   BAX No Breast Cancer Trial  Lacks Breast Cancer Evidence\n",
      "CDKN1A No Breast Cancer Trial  Lacks Breast Cancer Evidence\n",
      "   NF2 No Breast Cancer Trial  Lacks Breast Cancer Evidence\n",
      "  NRAS No Breast Cancer Trial  Lacks Breast Cancer Evidence\n",
      " NTRK1 No Breast Cancer Trial  Lacks Breast Cancer Evidence\n",
      "   SRC No Breast Cancer Trial  Lacks Breast Cancer Evidence\n",
      "   VHL No Breast Cancer Trial  Lacks Breast Cancer Evidence\n",
      "   WT1 No Breast Cancer Trial  Lacks Breast Cancer Evidence\n"
     ]
    }
   ],
   "source": [
    "# Show genes grouped by clinical trial status and therapeutic group\n",
    "trial_summary = df_plot[['gene', 'Clinical_Trial_Status', 'Therapeutic Group']].copy()\n",
    "\n",
    "# Sort by Clinical Trial Status and Therapeutic Group\n",
    "trial_summary = trial_summary.sort_values(by=['Clinical_Trial_Status', 'Therapeutic Group', 'gene'])\n",
    "\n",
    "# Print summary\n",
    "print(trial_summary.to_string(index=False))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7e95dca5",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3103c533",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "05e9ec45",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "c5745412",
   "metadata": {},
   "source": [
    "# Redesign required below"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a4c26282",
   "metadata": {},
   "source": [
    "___"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "8a6e5711",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT ID: NCT01440413, Title: Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer\n",
      "NCT ID: NCT01529307, Title: First in Human Trial of TAS266 in Patients With Advanced Solid Tumors\n",
      "NCT ID: NCT00458809, Title: Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer\n",
      "NCT ID: NCT03877159, Title: Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma\n",
      "NCT ID: NCT03059615, Title: A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS\n",
      "NCT ID: NCT05042531, Title: Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia\n",
      "NCT ID: NCT00075634, Title: Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma\n",
      "NCT ID: NCT06626971, Title: The Use of ARA290 for the Treatment of Diabetic Macular Oedema\n",
      "NCT ID: NCT03274778, Title: Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells\n",
      "NCT ID: NCT05490953, Title: Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "\n",
    "# This is a conceptual URL, you'll need to check the official API documentation for the exact endpoint and parameters.\n",
    "# The URL and parameters are likely correct for the v2.0 API.\n",
    "api_url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "params = {\n",
    "    \"query.term\": \"cancer AND CASP8\",\n",
    "    \"fields\": \"NCTId,BriefTitle,Condition\", # You can also specify nested fields here\n",
    "    \"pageSize\": 100 \n",
    "}\n",
    "\n",
    "try:\n",
    "    response = requests.get(api_url, params=params)\n",
    "    response.raise_for_status()\n",
    "\n",
    "    data = response.json()\n",
    "    studies = data.get(\"studies\", [])\n",
    "\n",
    "    for study in studies:\n",
    "        # Accessing nested fields correctly\n",
    "        identification_module = study.get(\"protocolSection\", {}).get(\"identificationModule\", {})\n",
    "        \n",
    "        nct_id = identification_module.get(\"nctId\") # Note the lowercase \"n\" in nctId\n",
    "        title = study.get(\"protocolSection\", {}).get(\"identificationModule\", {}).get(\"briefTitle\")\n",
    "        condition = study.get(\"protocolSection\", {}).get(\"designModule\", {}).get(\"conditions\", [None])[0]\n",
    "\n",
    "        # Process the data as needed\n",
    "        if nct_id and title:\n",
    "            print(f\"NCT ID: {nct_id}, Title: {title}\")\n",
    "        else:\n",
    "            print(\"Study record missing key data.\")\n",
    "\n",
    "except requests.exceptions.RequestException as e:\n",
    "    print(f\"An error occurred: {e}\")\n",
    "except KeyError as e:\n",
    "    print(f\"A KeyError occurred. The key {e} was not found in the study data.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "91e50c12",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT ID: NCT03473327, Title: Immunological and Oxidative Stress Response in Relation to Abdominal Cancer Surgery\n",
      "NCT ID: NCT06055634, Title: SIRT1(rs7069102 ) Gene Polymorphism in Chronic Obstructive Pulmonary Disease at Egyptian Patients\n",
      "NCT ID: NCT02968888, Title: Anabolic Effects of Whey and Casein After Strength Training in Young and Elderly\n",
      "NCT ID: NCT03033953, Title: Effects of Native Whey or Milk Supplementation on Adaptations to 12 Weeks of Strength Training in Young and Elderly\n",
      "NCT ID: NCT03649698, Title: Exercise and Nutrition for Healthy AgeiNg\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "\n",
    "# This is a conceptual URL, you'll need to check the official API documentation for the exact endpoint and parameters.\n",
    "# The URL and parameters are likely correct for the v2.0 API.\n",
    "api_url = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "params = {\n",
    "    \"query.term\": \"cancer AND FOXO3\",\n",
    "    \"fields\": \"NCTId,BriefTitle,Condition\", # You can also specify nested fields here\n",
    "    \"pageSize\": 100 \n",
    "}\n",
    "\n",
    "try:\n",
    "    response = requests.get(api_url, params=params)\n",
    "    response.raise_for_status()\n",
    "\n",
    "    data = response.json()\n",
    "    studies = data.get(\"studies\", [])\n",
    "\n",
    "    for study in studies:\n",
    "        # Accessing nested fields correctly\n",
    "        identification_module = study.get(\"protocolSection\", {}).get(\"identificationModule\", {})\n",
    "        \n",
    "        nct_id = identification_module.get(\"nctId\") # Note the lowercase \"n\" in nctId\n",
    "        title = study.get(\"protocolSection\", {}).get(\"identificationModule\", {}).get(\"briefTitle\")\n",
    "        condition = study.get(\"protocolSection\", {}).get(\"designModule\", {}).get(\"conditions\", [None])[0]\n",
    "\n",
    "        # Process the data as needed\n",
    "        if nct_id and title:\n",
    "            print(f\"NCT ID: {nct_id}, Title: {title}\")\n",
    "        else:\n",
    "            print(\"Study record missing key data.\")\n",
    "\n",
    "except requests.exceptions.RequestException as e:\n",
    "    print(f\"An error occurred: {e}\")\n",
    "except KeyError as e:\n",
    "    print(f\"A KeyError occurred. The key {e} was not found in the study data.\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "2e3fe100",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "=======================================================\n",
      "Analyzing genes in category: 'Emerging Breast Cancer Target'\n",
      "=======================================================\n",
      "\n",
      "--- Processing gene: CASP8 ---\n",
      "Searching for studies with query: 'cancer AND CASP8'...\n",
      "-> Found 10 total studies for 'cancer AND CASP8'.\n",
      "-> No studies found explicitly mentioning 'CASP8' in the full data.\n",
      "\n",
      "--- Processing gene: FOXO3 ---\n",
      "Searching for studies with query: 'cancer AND FOXO3'...\n",
      "-> Found 5 total studies for 'cancer AND FOXO3'.\n",
      "-> Found 4 studies explicitly mentioning 'FOXO3':\n",
      "   - NCT ID: NCT03473327 | Title: Immunological and Oxidative Stress Response in Relation to Abdominal Cancer Surgery\n",
      "   - NCT ID: NCT06055634 | Title: SIRT1(rs7069102 ) Gene Polymorphism in Chronic Obstructive Pulmonary Disease at Egyptian Patients\n",
      "   - NCT ID: NCT02968888 | Title: Anabolic Effects of Whey and Casein After Strength Training in Young and Elderly\n",
      "   - NCT ID: NCT03649698 | Title: Exercise and Nutrition for Healthy AgeiNg\n",
      "\n",
      "=======================================================\n",
      "Analyzing genes in category: 'Lacks Breast Cancer Evidence'\n",
      "=======================================================\n",
      "\n",
      "--- Processing gene: CDKN1A ---\n",
      "Searching for studies with query: 'cancer AND CDKN1A'...\n",
      "-> Found 10 total studies for 'cancer AND CDKN1A'.\n",
      "-> Found 7 studies explicitly mentioning 'CDKN1A':\n",
      "   - NCT ID: NCT01546038 | Title: A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome\n",
      "   - NCT ID: NCT02178072 | Title: Window Trial 5-aza in HNSCC, T-tare\n",
      "   - NCT ID: NCT02407080 | Title: Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia\n",
      "   - NCT ID: NCT04197089 | Title: Biological Effect of Vitamin D in Patients With Urothelial Carcinoma\n",
      "   - NCT ID: NCT05358379 | Title: A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma\n",
      "   - NCT ID: NCT05889390 | Title: Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer\n",
      "   - NCT ID: NCT02391051 | Title: Focal Brachytherapy in Patients With Selected \"Low-risk\" Prostate Cancer - a Phase-II-trial\n",
      "\n",
      "--- Processing gene: BAX ---\n",
      "Searching for studies with query: 'cancer AND BAX'...\n",
      "-> Found 67 total studies for 'cancer AND BAX'.\n",
      "-> Found 67 studies explicitly mentioning 'BAX':\n",
      "   - NCT ID: NCT00378404 | Title: Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC\n",
      "   - NCT ID: NCT04975204 | Title: A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors\n",
      "   - NCT ID: NCT00068380 | Title: A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer\n",
      "   - NCT ID: NCT05442567 | Title: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)\n",
      "   - NCT ID: NCT00026910 | Title: Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma\n",
      "   - NCT ID: NCT00056004 | Title: Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia\n",
      "   - NCT ID: NCT00078910 | Title: Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer\n",
      "   - NCT ID: NCT06896344 | Title: Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells\n",
      "   - NCT ID: NCT05456022 | Title: Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line\n",
      "   - NCT ID: NCT00540722 | Title: Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme\n",
      "   - NCT ID: NCT01736696 | Title: Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis\n",
      "   - NCT ID: NCT01197664 | Title: Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery\n",
      "   - NCT ID: NCT01744821 | Title: Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer\n",
      "   - NCT ID: NCT03366103 | Title: Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors\n",
      "   - NCT ID: NCT00390403 | Title: Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme\n",
      "   - NCT ID: NCT02965703 | Title: Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma\n",
      "   - NCT ID: NCT04683003 | Title: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura\n",
      "   - NCT ID: NCT05714969 | Title: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)\n",
      "   - NCT ID: NCT01105169 | Title: Precision-Based Magnesium Trial\n",
      "   - NCT ID: NCT00030368 | Title: Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors\n",
      "   - NCT ID: NCT00612612 | Title: Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia\n",
      "   - NCT ID: NCT02973087 | Title: rVWF IN PROPHYLAXIS\n",
      "   - NCT ID: NCT00374699 | Title: Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas\n",
      "   - NCT ID: NCT01195506 | Title: Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)\n",
      "   - NCT ID: NCT05775575 | Title: A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer\n",
      "   - NCT ID: NCT03393975 | Title: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)\n",
      "   - NCT ID: NCT00422942 | Title: A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)\n",
      "   - NCT ID: NCT00006942 | Title: Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer\n",
      "   - NCT ID: NCT00896857 | Title: Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer\n",
      "   - NCT ID: NCT01016665 | Title: Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy\n",
      "   - NCT ID: NCT02585960 | Title: BAX 855 PK-guided Dosing\n",
      "   - NCT ID: NCT03997760 | Title: A Study of SHP655 (rADAMTS13) in Sickle Cell Disease\n",
      "   - NCT ID: NCT00898976 | Title: Biomarkers in Native American Women With Breast Cancer\n",
      "   - NCT ID: NCT06082492 | Title: The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients\n",
      "   - NCT ID: NCT01658319 | Title: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies\n",
      "   - NCT ID: NCT02872818 | Title: Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia\n",
      "   - NCT ID: NCT01440413 | Title: Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer\n",
      "   - NCT ID: NCT02932618 | Title: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)\n",
      "   - NCT ID: NCT05631041 | Title: Effect of Silymarin in Metastatic Colorectal Cancer Patients\n",
      "   - NCT ID: NCT00458809 | Title: Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer\n",
      "   - NCT ID: NCT00399607 | Title: Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention\n",
      "   - NCT ID: NCT06134388 | Title: Sulfasalazine in Patients With Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT00169000 | Title: Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers\n",
      "   - NCT ID: NCT01096732 | Title: Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)\n",
      "   - NCT ID: NCT04847453 | Title: Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis\n",
      "   - NCT ID: NCT04779320 | Title: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)\n",
      "   - NCT ID: NCT02078427 | Title: ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)\n",
      "   - NCT ID: NCT01410227 | Title: Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)\n",
      "   - NCT ID: NCT00725374 | Title: A Study to Investigate the Effects of Tibolone (Livial) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)\n",
      "   - NCT ID: NCT00383474 | Title: Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase\n",
      "   - NCT ID: NCT07014917 | Title: Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL\n",
      "   - NCT ID: NCT00176241 | Title: Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer\n",
      "   - NCT ID: NCT00546039 | Title: Synthetic Genistein (BONISTEIN) in Patients Who Are Undergoing Surgery for Prostate Cancer\n",
      "   - NCT ID: NCT05358639 | Title: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC\n",
      "   - NCT ID: NCT05097378 | Title: Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma\n",
      "   - NCT ID: NCT02647671 | Title: Aquamin and Prevention of Colon Cancer\n",
      "   - NCT ID: NCT00208793 | Title: Calcium and Vitamin D vs Markers of Adenomatous Polyps\n",
      "   - NCT ID: NCT04286477 | Title: The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT\n",
      "   - NCT ID: NCT02978547 | Title: The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma\n",
      "   - NCT ID: NCT05114798 | Title: Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers\n",
      "   - NCT ID: NCT02278861 | Title: Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis\n",
      "   - NCT ID: NCT00052611 | Title: Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia\n",
      "   - NCT ID: NCT00389805 | Title: Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors\n",
      "   - NCT ID: NCT06514261 | Title: Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML\n",
      "   - NCT ID: NCT00668161 | Title: Effect of Exercise on Biomarkers of Colon Cancer Risk\n",
      "   - NCT ID: NCT01945593 | Title: BAX 855 Continuation\n",
      "   - NCT ID: NCT02994511 | Title: Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials\n",
      "\n",
      "--- Processing gene: NRAS ---\n",
      "Searching for studies with query: 'cancer AND NRAS'...\n",
      "-> Found 100 total studies for 'cancer AND NRAS'.\n",
      "-> Found 100 studies explicitly mentioning 'NRAS':\n",
      "   - NCT ID: NCT03442569 | Title: PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC\n",
      "   - NCT ID: NCT04439344 | Title: Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)\n",
      "   - NCT ID: NCT06011772 | Title: EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT03771404 | Title: NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized \"Liquid Biopsy\"\n",
      "   - NCT ID: NCT05841550 | Title: The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma\n",
      "   - NCT ID: NCT06346067 | Title: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)\n",
      "   - NCT ID: NCT05797467 | Title: Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients\n",
      "   - NCT ID: NCT04418167 | Title: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations\n",
      "   - NCT ID: NCT01814501 | Title: Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab\n",
      "   - NCT ID: NCT03748667 | Title: Accuracy for Predicting Deep Submucosal Invasion\n",
      "   - NCT ID: NCT05187767 | Title: Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs\n",
      "   - NCT ID: NCT04189055 | Title: Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.\n",
      "   - NCT ID: NCT06106308 | Title: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation\n",
      "   - NCT ID: NCT04053114 | Title: MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii\n",
      "   - NCT ID: NCT01726738 | Title: LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations\n",
      "   - NCT ID: NCT01960023 | Title: Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02587650 | Title: Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma\n",
      "   - NCT ID: NCT02394795 | Title: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC\n",
      "   - NCT ID: NCT03597581 | Title: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer\n",
      "   - NCT ID: NCT04108481 | Title: Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02823210 | Title: Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders\n",
      "   - NCT ID: NCT06229340 | Title: Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations\n",
      "   - NCT ID: NCT04599140 | Title: SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial\n",
      "   - NCT ID: NCT03167268 | Title: Panitumumab Skin Toxicity Prevention Trial\n",
      "   - NCT ID: NCT06026410 | Title: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors\n",
      "   - NCT ID: NCT01781572 | Title: A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma\n",
      "   - NCT ID: NCT02079740 | Title: Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors\n",
      "   - NCT ID: NCT06096974 | Title: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS\n",
      "   - NCT ID: NCT01719380 | Title: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02138292 | Title: A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma\n",
      "   - NCT ID: NCT05628038 | Title: The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer\n",
      "   - NCT ID: NCT05365412 | Title: Clinicopathological Characteristics of Colon Cancer in Young Age\n",
      "   - NCT ID: NCT02538627 | Title: Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib\n",
      "   - NCT ID: NCT01428492 | Title: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma\n",
      "   - NCT ID: NCT00338130 | Title: Randomised Study to Compare the Efficacy of AZD6244 vs TMZ\n",
      "   - NCT ID: NCT06828822 | Title: CongenItal Naevus Cohort for Longitudinal Evaluation\n",
      "   - NCT ID: NCT02974725 | Title: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma\n",
      "   - NCT ID: NCT06903039 | Title: NeoRes Study - Preoperative Chemotherapy in Colorectal Peritoneal Disease Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)\n",
      "   - NCT ID: NCT04425239 | Title: Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT04262635 | Title: Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02065063 | Title: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors\n",
      "   - NCT ID: NCT06208124 | Title: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors\n",
      "   - NCT ID: NCT05786924 | Title: A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers\n",
      "   - NCT ID: NCT04059224 | Title: TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma\n",
      "   - NCT ID: NCT00900224 | Title: Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT03457896 | Title: Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status\n",
      "   - NCT ID: NCT02171286 | Title: The Oncopanel Pilot (TOP) Study\n",
      "   - NCT ID: NCT03051035 | Title: First-in-Human Study of KO-947 in Non-Hematological Malignancies\n",
      "   - NCT ID: NCT00730158 | Title: A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02404935 | Title: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)\n",
      "   - NCT ID: NCT02316496 | Title: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study\n",
      "   - NCT ID: NCT01362296 | Title: An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer\n",
      "   - NCT ID: NCT05726864 | Title: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors\n",
      "   - NCT ID: NCT06162221 | Title: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\n",
      "   - NCT ID: NCT04417621 | Title: Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma\n",
      "   - NCT ID: NCT02613221 | Title: A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer\n",
      "   - NCT ID: NCT05340621 | Title: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)\n",
      "   - NCT ID: NCT01282502 | Title: Midostaurin (PKC412) for Locally Advanced Rectal Cancer\n",
      "   - NCT ID: NCT06440902 | Title: Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA\n",
      "   - NCT ID: NCT07083479 | Title: Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma\n",
      "   - NCT ID: NCT06881784 | Title: Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301)\n",
      "   - NCT ID: NCT01763164 | Title: Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma\n",
      "   - NCT ID: NCT03784014 | Title: Molecular Profiling of Advanced Soft-tissue Sarcomas\n",
      "   - NCT ID: NCT04718038 | Title: Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT03981614 | Title: Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer\n",
      "   - NCT ID: NCT05527795 | Title: Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma\n",
      "   - NCT ID: NCT02399943 | Title: A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer\n",
      "   - NCT ID: NCT03311750 | Title: Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer\n",
      "   - NCT ID: NCT02199223 | Title: Regorafenib + Panitumumab for Colorectal Cancers\n",
      "   - NCT ID: NCT02613650 | Title: A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers\n",
      "   - NCT ID: NCT02862743 | Title: Molecular Characterization of Advanced Stage Melanoma by Blood Sampling\n",
      "   - NCT ID: NCT03714490 | Title: MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer\n",
      "   - NCT ID: NCT02296203 | Title: Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).\n",
      "   - NCT ID: NCT04249843 | Title: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors\n",
      "   - NCT ID: NCT04276090 | Title: Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma\n",
      "   - NCT ID: NCT01704703 | Title: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques\n",
      "   - NCT ID: NCT04322890 | Title: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation\n",
      "   - NCT ID: NCT05217303 | Title: HL-085 in NRAS-mutated Advanced Melanoma\n",
      "   - NCT ID: NCT01198743 | Title: Presence of Circulating Tumor DNA in Colorectal Cancer\n",
      "   - NCT ID: NCT03732703 | Title: Myeloma-Developing Regimens Using Genomics (MyDRUG)\n",
      "   - NCT ID: NCT01723969 | Title: Screening Platform for Clinical Trials in Advanced Colorectal Cancer\n",
      "   - NCT ID: NCT02448810 | Title: Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT03315468 | Title: French Clinical Datbase of Melanoma Patients (RIC-Mel)\n",
      "   - NCT ID: NCT01445587 | Title: A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma\n",
      "   - NCT ID: NCT04853017 | Title: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors\n",
      "   - NCT ID: NCT06400654 | Title: PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC\n",
      "   - NCT ID: NCT04466254 | Title: Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT04151342 | Title: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)\n",
      "   - NCT ID: NCT03750175 | Title: OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -\n",
      "   - NCT ID: NCT06841159 | Title: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1Chemotherapy and Target Therapy for Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT05273099 | Title: Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma\n",
      "   - NCT ID: NCT06027775 | Title: Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases\n",
      "   - NCT ID: NCT06137170 | Title: A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment\n",
      "   - NCT ID: NCT03914170 | Title: Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT04931342 | Title: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors\n",
      "   - NCT ID: NCT06876142 | Title: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma\n",
      "   - NCT ID: NCT01449058 | Title: A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors\n",
      "   - NCT ID: NCT06949982 | Title: Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes\n",
      "   - NCT ID: NCT06625320 | Title: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)\n",
      "   - NCT ID: NCT03580382 | Title: Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma\n",
      "\n",
      "--- Processing gene: VHL ---\n",
      "Searching for studies with query: 'cancer AND VHL'...\n",
      "-> Found 81 total studies for 'cancer AND VHL'.\n",
      "-> Found 72 studies explicitly mentioning 'VHL':\n",
      "   - NCT ID: NCT01168440 | Title: Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease\n",
      "   - NCT ID: NCT00001238 | Title: Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders\n",
      "   - NCT ID: NCT01730755 | Title: Ruxolitinib for Chuvash Polycythemia\n",
      "   - NCT ID: NCT06195150 | Title: Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer\n",
      "   - NCT ID: NCT00566995 | Title: Phase II Study of Vandetanib in Individuals With Kidney Cancer\n",
      "   - NCT ID: NCT02120040 | Title: Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hmangioblastoma of Nervous Centrasl System\n",
      "   - NCT ID: NCT05563272 | Title: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors\n",
      "   - NCT ID: NCT02420067 | Title: Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients\n",
      "   - NCT ID: NCT00089765 | Title: Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome\n",
      "   - NCT ID: NCT02315625 | Title: Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery\n",
      "   - NCT ID: NCT06440122 | Title: The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)\n",
      "   - NCT ID: NCT06553339 | Title: A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors\n",
      "   - NCT ID: NCT05424016 | Title: Propranolol and Von Hippel-Lindau Disease\n",
      "   - NCT ID: NCT02499458 | Title: Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer\n",
      "   - NCT ID: NCT02207686 | Title: Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?\n",
      "   - NCT ID: NCT02693535 | Title: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer\n",
      "   - NCT ID: NCT05737602 | Title: Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease\n",
      "   - NCT ID: NCT02108002 | Title: Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)\n",
      "   - NCT ID: NCT00005902 | Title: Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease\n",
      "   - NCT ID: NCT06391879 | Title: Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma\n",
      "   - NCT ID: NCT00001814 | Title: Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples\n",
      "   - NCT ID: NCT05955014 | Title: Data Collection Protocol for Patients With Von Hippel Lindau Disease\n",
      "   - NCT ID: NCT01538238 | Title: pazopanib_NCRCC,Ph2 STUDY\n",
      "   - NCT ID: NCT00330564 | Title: Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow\n",
      "   - NCT ID: NCT00001703 | Title: Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma\n",
      "   - NCT ID: NCT01665703 | Title: Imaging Correlates of Renal Cell Carcinoma Biological Features\n",
      "   - NCT ID: NCT00001803 | Title: Von Hippel-Lindau Disease Genetic Epidemiology Study\n",
      "   - NCT ID: NCT05810246 | Title: 68Ga-NY104 PET/CT in Von Hippel-Lindau Disease\n",
      "   - NCT ID: NCT03008369 | Title: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery\n",
      "   - NCT ID: NCT06194669 | Title: Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells\n",
      "   - NCT ID: NCT00001668 | Title: Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors\n",
      "   - NCT ID: NCT01253668 | Title: Brivanib Metastatic Renal Cell Carcinoma\n",
      "   - NCT ID: NCT01791387 | Title: 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC\n",
      "   - NCT ID: NCT03297606 | Title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)\n",
      "   - NCT ID: NCT03001349 | Title: 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors\n",
      "   - NCT ID: NCT05273099 | Title: Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma\n",
      "   - NCT ID: NCT00056199 | Title: EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome\n",
      "   - NCT ID: NCT04924075 | Title: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2 Related Genetic Alterations (MK-6482-015)\n",
      "   - NCT ID: NCT01266070 | Title: TKI 258 in Von Hippel-Lindau Syndrome (VHL)\n",
      "   - NCT ID: NCT06923670 | Title: Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History\n",
      "   - NCT ID: NCT04895748 | Title: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies\n",
      "   - NCT ID: NCT01967576 | Title: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma\n",
      "   - NCT ID: NCT03907657 | Title: Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau\n",
      "   - NCT ID: NCT03108066 | Title: MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)\n",
      "   - NCT ID: NCT06554730 | Title: MSD Belzutifan PAS\n",
      "   - NCT ID: NCT00062166 | Title: Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease\n",
      "   - NCT ID: NCT01775930 | Title: Carfilzomib in Refractory Renal Cell Carcinoma (RCC)\n",
      "   - NCT ID: NCT00602862 | Title: Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250\n",
      "   - NCT ID: NCT00052013 | Title: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584\n",
      "   - NCT ID: NCT01372813 | Title: Vandetanib to Treat Advanced Kidney Cancer\n",
      "   - NCT ID: NCT03401788 | Title: A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)\n",
      "   - NCT ID: NCT01015300 | Title: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease\n",
      "   - NCT ID: NCT04989959 | Title: [18F]PT2385 PET/CT in Patients with Renal Cell Carcinoma\n",
      "   - NCT ID: NCT01967537 | Title: Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors\n",
      "   - NCT ID: NCT05941637 | Title: An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)\n",
      "   - NCT ID: NCT01002937 | Title: Novel Prognostic Markers in Renal Cancer\n",
      "   - NCT ID: NCT01712685 | Title: Imaging Studies of Kidney Cancer Using 18F-VM4-037\n",
      "   - NCT ID: NCT05534854 | Title: Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes\n",
      "   - NCT ID: NCT03979833 | Title: Drivers of Hypoxia-induced Angiogenesis in Tumor Development\n",
      "   - NCT ID: NCT00193154 | Title: OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma\n",
      "   - NCT ID: NCT00494182 | Title: Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer\n",
      "   - NCT ID: NCT01436227 | Title: Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome\n",
      "   - NCT ID: NCT04068831 | Title: Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma\n",
      "   - NCT ID: NCT01262482 | Title: Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment\n",
      "   - NCT ID: NCT03749980 | Title: MyVHL: Patient Natural History Study\n",
      "   - NCT ID: NCT04074135 | Title: Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors\n",
      "   - NCT ID: NCT00075348 | Title: Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome\n",
      "   - NCT ID: NCT00088374 | Title: 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease\n",
      "   - NCT ID: NCT05497271 | Title: Confirmation of Association Between Cystic Fluid Analysis With Pancreatic Cystic Lesions\n",
      "   - NCT ID: NCT05843305 | Title: A Study of BPI-452080 in Subjects With Solid Tumors\n",
      "   - NCT ID: NCT06234605 | Title: A Study of HC-7366 in Combination With Belzutifan (WELIREG) in Patients With Renal Cell Carcinoma\n",
      "   - NCT ID: NCT00970970 | Title: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease\n",
      "\n",
      "--- Processing gene: SRC ---\n",
      "Searching for studies with query: 'cancer AND SRC'...\n",
      "-> Found 100 total studies for 'cancer AND SRC'.\n",
      "-> Found 100 studies explicitly mentioning 'SRC':\n",
      "   - NCT ID: NCT06590246 | Title: A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/recurrent Hepatocellular Carcinoma (HCC)\n",
      "   - NCT ID: NCT05458544 | Title: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application\n",
      "   - NCT ID: NCT06559644 | Title: Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia\n",
      "   - NCT ID: NCT04436744 | Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)\n",
      "   - NCT ID: NCT03041701 | Title: Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma\n",
      "   - NCT ID: NCT06258304 | Title: A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies\n",
      "   - NCT ID: NCT00546104 | Title: Phase II Dasatinib Study in Advanced Breast Cancer\n",
      "   - NCT ID: NCT04915404 | Title: Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)\n",
      "   - NCT ID: NCT04282044 | Title: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies\n",
      "   - NCT ID: NCT05853367 | Title: Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)\n",
      "   - NCT ID: NCT02171429 | Title: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors\n",
      "   - NCT ID: NCT06154343 | Title: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors\n",
      "   - NCT ID: NCT04710043 | Title: Dose Escalation Trial of BNT152+153 in Patients With Cancer\n",
      "   - NCT ID: NCT02660138 | Title: Dysport Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1\n",
      "   - NCT ID: NCT03271255 | Title: Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)\n",
      "   - NCT ID: NCT06464055 | Title: A Study of GQ1010 in Subjects With Advanced Solid Tumors\n",
      "   - NCT ID: NCT01144481 | Title: Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases\n",
      "   - NCT ID: NCT01759810 | Title: Proteome-based Personalized Immunotherapy of Glioblastoma\n",
      "   - NCT ID: NCT01826838 | Title: Study of Dasatinib, Androgen Deprivation Therapy and Radiation\n",
      "   - NCT ID: NCT00526838 | Title: Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies\n",
      "   - NCT ID: NCT01668550 | Title: A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours\n",
      "   - NCT ID: NCT02936323 | Title: PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers\n",
      "   - NCT ID: NCT04475523 | Title: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies\n",
      "   - NCT ID: NCT02981108 | Title: A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC\n",
      "   - NCT ID: NCT02954523 | Title: Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations\n",
      "   - NCT ID: NCT00501410 | Title: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT06975410 | Title: Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors\n",
      "   - NCT ID: NCT04896112 | Title: A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT04645069 | Title: ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors\n",
      "   - NCT ID: NCT02876081 | Title: Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex\n",
      "   - NCT ID: NCT05751044 | Title: HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies\n",
      "   - NCT ID: NCT01054144 | Title: Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma\n",
      "   - NCT ID: NCT00339144 | Title: Study of Dasatinib (BMS-354825) in Patients With Solid Tumors\n",
      "   - NCT ID: NCT04669067 | Title: TL-895 and KRT-232 Study in Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT06230965 | Title: Clinical Study of Lung Protective Ventilation Strategies and Tumor Microenvironment\n",
      "   - NCT ID: NCT05394831 | Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC\n",
      "   - NCT ID: NCT00597038 | Title: A Phase I/II Study of Dasatinib and Dacarbazine\n",
      "   - NCT ID: NCT00798655 | Title: Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer\n",
      "   - NCT ID: NCT00780676 | Title: Personalized Treatment Selection for Metastatic Breast Cancer\n",
      "   - NCT ID: NCT00779389 | Title: Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family\n",
      "   - NCT ID: NCT06087289 | Title: A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer\n",
      "   - NCT ID: NCT06600789 | Title: A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies\n",
      "   - NCT ID: NCT03443622 | Title: Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors\n",
      "   - NCT ID: NCT02974322 | Title: A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease\n",
      "   - NCT ID: NCT05521022 | Title: Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis\n",
      "   - NCT ID: NCT02338622 | Title: Trial of Olaparib in Combination with AZD5363 (ComPAKT)\n",
      "   - NCT ID: NCT01015222 | Title: Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies\n",
      "   - NCT ID: NCT00646139 | Title: KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment\n",
      "   - NCT ID: NCT05922839 | Title: Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA\n",
      "   - NCT ID: NCT06792435 | Title: XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.\n",
      "   - NCT ID: NCT06958939 | Title: The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis\n",
      "   - NCT ID: NCT05873686 | Title: A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers\n",
      "   - NCT ID: NCT00277316 | Title: Study of XL999 in Patients With Metastatic Renal Cell Carcinoma\n",
      "   - NCT ID: NCT04113616 | Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)\n",
      "   - NCT ID: NCT05999396 | Title: FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer\n",
      "   - NCT ID: NCT05325216 | Title: Urinary Continence of Female POPRC and OIN\n",
      "   - NCT ID: NCT03033524 | Title: Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma\n",
      "   - NCT ID: NCT04045496 | Title: A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors\n",
      "   - NCT ID: NCT04121286 | Title: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China\n",
      "   - NCT ID: NCT05860296 | Title: Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers\n",
      "   - NCT ID: NCT01000896 | Title: Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel\n",
      "   - NCT ID: NCT03404596 | Title: Applying mHealth to Tobacco-related Health Disparities\n",
      "   - NCT ID: NCT01990196 | Title: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer\n",
      "   - NCT ID: NCT05123534 | Title: A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG\n",
      "   - NCT ID: NCT02296879 | Title: A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types\n",
      "   - NCT ID: NCT05519384 | Title: Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT00277290 | Title: Study of XL999 in Patients With Previously Treated Ovarian Cancer\n",
      "   - NCT ID: NCT00892190 | Title: Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome\n",
      "   - NCT ID: NCT00306202 | Title: Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia\n",
      "   - NCT ID: NCT01355302 | Title: E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer\n",
      "   - NCT ID: NCT02423902 | Title: A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer\n",
      "   - NCT ID: NCT03787602 | Title: Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma\n",
      "   - NCT ID: NCT04318964 | Title: TAEST16001 in the Treatment of Soft Tissue Sarcoma\n",
      "   - NCT ID: NCT00835679 | Title: Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery\n",
      "   - NCT ID: NCT02118584 | Title: Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies\n",
      "   - NCT ID: NCT06566079 | Title: Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors\n",
      "   - NCT ID: NCT00277303 | Title: Study of XL999 in Patients With Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT05203679 | Title: Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug\n",
      "   - NCT ID: NCT03648879 | Title: Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome\n",
      "   - NCT ID: NCT06713564 | Title: A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer\n",
      "   - NCT ID: NCT00672295 | Title: PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer\n",
      "   - NCT ID: NCT01162395 | Title: Open Label Prostate Cancer Study\n",
      "   - NCT ID: NCT04883138 | Title: Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients\n",
      "   - NCT ID: NCT02426723 | Title: Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients\n",
      "   - NCT ID: NCT00996723 | Title: Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)\n",
      "   - NCT ID: NCT00563290 | Title: Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia\n",
      "   - NCT ID: NCT01805843 | Title: Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia\n",
      "   - NCT ID: NCT03327064 | Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "   - NCT ID: NCT06934590 | Title: Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC\n",
      "   - NCT ID: NCT02428543 | Title: Ponatinib for FLT3-ITD Acute Myelogenous Leukemia\n",
      "   - NCT ID: NCT00858403 | Title: Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation\n",
      "   - NCT ID: NCT05752669 | Title: Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.\n",
      "   - NCT ID: NCT06874946 | Title: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL\n",
      "   - NCT ID: NCT05927012 | Title: A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).\n",
      "   - NCT ID: NCT02586987 | Title: A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours\n",
      "   - NCT ID: NCT01764087 | Title: A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors\n",
      "   - NCT ID: NCT05818917 | Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors\n",
      "   - NCT ID: NCT04598919 | Title: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis\n",
      "   - NCT ID: NCT01972217 | Title: Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.\n",
      "   - NCT ID: NCT03088813 | Title: Study of Irinotecan Liposome Injection (ONIVYDE) in Patients With Small Cell Lung Cancer\n",
      "\n",
      "--- Processing gene: NF2 ---\n",
      "Searching for studies with query: 'cancer AND NF2'...\n",
      "-> Found 64 total studies for 'cancer AND NF2'.\n",
      "-> Found 55 studies explicitly mentioning 'NF2':\n",
      "   - NCT ID: NCT02352844 | Title: Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations\n",
      "   - NCT ID: NCT01885767 | Title: Neurofibromatosis (NF) Registry Portal\n",
      "   - NCT ID: NCT01736267 | Title: Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects\n",
      "   - NCT ID: NCT03672838 | Title: A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)\n",
      "   - NCT ID: NCT03406208 | Title: Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing\n",
      "   - NCT ID: NCT06834438 | Title: Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002\n",
      "   - NCT ID: NCT02104323 | Title: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors\n",
      "   - NCT ID: NCT03873610 | Title: Resiliency Training in Adolescents With NF1 and NF2\n",
      "   - NCT ID: NCT06251310 | Title: SW-682 in Advanced Solid Tumors\n",
      "   - NCT ID: NCT04857372 | Title: A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors\n",
      "   - NCT ID: NCT02589912 | Title: Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients\n",
      "   - NCT ID: NCT04439331 | Title: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)\n",
      "   - NCT ID: NCT02523014 | Title: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas\n",
      "   - NCT ID: NCT01767792 | Title: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas\n",
      "   - NCT ID: NCT00863122 | Title: Concentration and Activity of Lapatinib in Vestibular Schwannomas\n",
      "   - NCT ID: NCT01776125 | Title: Genetic Evaluation of NF1 and Scoliosis Patients\n",
      "   - NCT ID: NCT00340496 | Title: Analysis of NF2 Mutations in Radiation-Related Neural Tumors\n",
      "   - NCT ID: NCT06536179 | Title: New Preclinical and Clinical Approaches to Mesothelioma\n",
      "   - NCT ID: NCT05821790 | Title: Role of the Tumor Microenvironment in Aggressive Meningiomas\n",
      "   - NCT ID: NCT00030043 | Title: An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors\n",
      "   - NCT ID: NCT04283669 | Title: Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas\n",
      "   - NCT ID: NCT01024946 | Title: Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity\n",
      "   - NCT ID: NCT01602887 | Title: Relative Bioavailability Study\n",
      "   - NCT ID: NCT02310399 | Title: Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves\n",
      "   - NCT ID: NCT03297606 | Title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)\n",
      "   - NCT ID: NCT03079999 | Title: Study of Aspirin in Patients With Vestibular Schwannoma\n",
      "   - NCT ID: NCT02298270 | Title: Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype\n",
      "   - NCT ID: NCT06923670 | Title: Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History\n",
      "   - NCT ID: NCT06553365 | Title: Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors\n",
      "   - NCT ID: NCT05130866 | Title: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas\n",
      "   - NCT ID: NCT03095248 | Title: Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors\n",
      "   - NCT ID: NCT00911248 | Title: PTC299 for Treatment of Neurofibromatosis Type 2\n",
      "   - NCT ID: NCT02465060 | Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "   - NCT ID: NCT03617276 | Title: Reliability of Functional Outcome Measures in Neurofibromatosis 2\n",
      "   - NCT ID: NCT01490476 | Title: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients\n",
      "   - NCT ID: NCT01864291 | Title: Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects\n",
      "   - NCT ID: NCT02282917 | Title: Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma\n",
      "   - NCT ID: NCT02811718 | Title: Resiliency Training for Patients With NF2 Via Videoconferencing With Skype\n",
      "   - NCT ID: NCT03210285 | Title: WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data\n",
      "   - NCT ID: NCT01207687 | Title: Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)\n",
      "   - NCT ID: NCT05228015 | Title: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors\n",
      "   - NCT ID: NCT02246231 | Title: Effect of Implant Position on Magnetic Resonance Image Distortion\n",
      "   - NCT ID: NCT02831257 | Title: AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas\n",
      "   - NCT ID: NCT05685836 | Title: 89Zr-Bevacizumab PET/CT Imaging in NF2 Patients\n",
      "   - NCT ID: NCT01345136 | Title: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma\n",
      "   - NCT ID: NCT05521048 | Title: Doxycycline in Cutaneous Schwannoma (NF2)\n",
      "   - NCT ID: NCT01419639 | Title: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2\n",
      "   - NCT ID: NCT00973739 | Title: Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors\n",
      "   - NCT ID: NCT02934256 | Title: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors\n",
      "   - NCT ID: NCT04374305 | Title: Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)\n",
      "   - NCT ID: NCT00598351 | Title: Natural History Study of Patients With Neurofibromatosis Type 2\n",
      "   - NCT ID: NCT02129647 | Title: Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas\n",
      "   - NCT ID: NCT00004483 | Title: NF2 Natural History Consortium\n",
      "   - NCT ID: NCT01222728 | Title: Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients\n",
      "   - NCT ID: NCT02435628 | Title: Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF\n",
      "\n",
      "--- Processing gene: WT1 ---\n",
      "Searching for studies with query: 'cancer AND WT1'...\n",
      "-> Found 100 total studies for 'cancer AND WT1'.\n",
      "-> Found 37 studies explicitly mentioning 'WT1':\n",
      "   - NCT ID: NCT00909168 | Title: Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)\n",
      "   - NCT ID: NCT01734304 | Title: DC Vaccination for Postremission Therapy in AML\n",
      "   - NCT ID: NCT05000801 | Title: Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT02494167 | Title: Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)\n",
      "   - NCT ID: NCT04126967 | Title: Next Generation SequencingNGSMonitors Minimal Residual DiseaseMRDin Allo-PBSCT Patients\n",
      "   - NCT ID: NCT01252901 | Title: Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases\n",
      "   - NCT ID: NCT02649829 | Title: Autologous Dendritic Cell Vaccination in Mesothelioma\n",
      "   - NCT ID: NCT01640301 | Title: Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant\n",
      "   - NCT ID: NCT00179829 | Title: WT1 for the Detection of Minimal Residual Disease\n",
      "   - NCT ID: NCT00398138 | Title: Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma\n",
      "   - NCT ID: NCT01146223 | Title: Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia\n",
      "   - NCT ID: NCT01546038 | Title: A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome\n",
      "   - NCT ID: NCT01995708 | Title: CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation\n",
      "   - NCT ID: NCT00923910 | Title: Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood\n",
      "   - NCT ID: NCT02895412 | Title: Infection and Tumour Antigen Cellular Therapy\n",
      "   - NCT ID: NCT05918640 | Title: Lurbinectedin in FET-Fused Tumors\n",
      "   - NCT ID: NCT00562640 | Title: Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)\n",
      "   - NCT ID: NCT03291444 | Title: CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS\n",
      "   - NCT ID: NCT02498665 | Title: A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies\n",
      "   - NCT ID: NCT03761914 | Title: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers\n",
      "   - NCT ID: NCT00488592 | Title: Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers\n",
      "   - NCT ID: NCT01842139 | Title: Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission\n",
      "   - NCT ID: NCT01051063 | Title: Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy\n",
      "   - NCT ID: NCT00965224 | Title: Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma\n",
      "   - NCT ID: NCT02408016 | Title: Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma\n",
      "   - NCT ID: NCT02686424 | Title: Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy (ONCO-RD 010 CRT)\n",
      "   - NCT ID: NCT00900224 | Title: Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT01621724 | Title: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study\n",
      "   - NCT ID: NCT04837196 | Title: Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen\n",
      "   - NCT ID: NCT03311334 | Title: A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors\n",
      "   - NCT ID: NCT06172634 | Title: A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy\n",
      "   - NCT ID: NCT00665002 | Title: Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms\n",
      "   - NCT ID: NCT00834002 | Title: Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission\n",
      "   - NCT ID: NCT04911621 | Title: Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma\n",
      "   - NCT ID: NCT04747002 | Title: Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine \"Dainippon Sumitomo Phama(DSP)-7888\" for Acute Myeloid Leukemia Patients.\n",
      "   - NCT ID: NCT02461121 | Title: HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk\n",
      "   - NCT ID: NCT05765084 | Title: Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma\n",
      "\n",
      "--- Processing gene: NTRK1 ---\n",
      "Searching for studies with query: 'cancer AND NTRK1'...\n",
      "-> Found 61 total studies for 'cancer AND NTRK1'.\n",
      "-> Found 33 studies explicitly mentioning 'NTRK1':\n",
      "   - NCT ID: NCT04010240 | Title: A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study\n",
      "   - NCT ID: NCT02650401 | Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\n",
      "   - NCT ID: NCT02587650 | Title: Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma\n",
      "   - NCT ID: NCT02097810 | Title: Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.\n",
      "   - NCT ID: NCT02568267 | Title: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)\n",
      "   - NCT ID: NCT04591431 | Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "   - NCT ID: NCT03093116 | Title: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements\n",
      "   - NCT ID: NCT02693535 | Title: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer\n",
      "   - NCT ID: NCT06780384 | Title: NTRK 1,2,3 Rearrangements in Patients With Solid Tumors\n",
      "   - NCT ID: NCT03574402 | Title: Phase II Umbrella Study Directed by Next Generation Sequencing\n",
      "   - NCT ID: NCT05302843 | Title: A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors\n",
      "   - NCT ID: NCT02637687 | Title: A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children\n",
      "   - NCT ID: NCT02465060 | Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "   - NCT ID: NCT03025360 | Title: Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion\n",
      "   - NCT ID: NCT06528691 | Title: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors\n",
      "   - NCT ID: NCT02920996 | Title: Merestinib In Non-Small Cell Lung Cancer And Solid Tumors\n",
      "   - NCT ID: NCT06984588 | Title: A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer\n",
      "   - NCT ID: NCT02219711 | Title: Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer\n",
      "   - NCT ID: NCT03375437 | Title: RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.\n",
      "   - NCT ID: NCT02576431 | Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors\n",
      "   - NCT ID: NCT03155620 | Title: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)\n",
      "   - NCT ID: NCT03206931 | Title: Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion\n",
      "   - NCT ID: NCT02122913 | Title: A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer\n",
      "   - NCT ID: NCT04970134 | Title: Spanish Study for Molecular Characterization of Thyroid Carcinoma\n",
      "   - NCT ID: NCT04671849 | Title: An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.\n",
      "   - NCT ID: NCT03182257 | Title: Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors\n",
      "   - NCT ID: NCT04557813 | Title: Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion\n",
      "   - NCT ID: NCT06214793 | Title: Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)\n",
      "   - NCT ID: NCT04921553 | Title: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)\n",
      "   - NCT ID: NCT06141005 | Title: Feasibility of Bronchial Washing Fluid for Molecular Testing with Next Generation Sequencing in Lung Cancer\n",
      "   - NCT ID: NCT03215511 | Title: A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer\n",
      "   - NCT ID: NCT03066661 | Title: Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions\n",
      "   - NCT ID: NCT03556228 | Title: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma\n",
      "\n",
      "\n",
      "==================================================\n",
      "FINAL SUMMARY OF FINDINGS\n",
      "==================================================\n",
      "\n",
      "Category: Emerging Breast Cancer Target\n",
      "  - Gene 'CASP8': No studies found.\n",
      "  - Gene 'FOXO3': 4 studies found.\n",
      "\n",
      "Category: Lacks Breast Cancer Evidence\n",
      "  - Gene 'CDKN1A': 7 studies found.\n",
      "  - Gene 'BAX': 67 studies found.\n",
      "  - Gene 'NRAS': 100 studies found.\n",
      "  - Gene 'VHL': 72 studies found.\n",
      "  - Gene 'SRC': 100 studies found.\n",
      "  - Gene 'NF2': 55 studies found.\n",
      "  - Gene 'WT1': 37 studies found.\n",
      "  - Gene 'NTRK1': 33 studies found.\n",
      "==================================================\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import json\n",
    "import time\n",
    "\n",
    "# Define the genes and their categories as provided by the user.\n",
    "gene_categories = {\n",
    "    \"Emerging Breast Cancer Target\": ['CASP8', 'FOXO3'],\n",
    "    \"Lacks Breast Cancer Evidence\": ['CDKN1A', 'BAX', 'NRAS', 'VHL', 'SRC', 'NF2', 'WT1', 'NTRK1']\n",
    "}\n",
    "\n",
    "# The base URL for the modernized ClinicalTrials.gov API (v2.0).\n",
    "API_BASE_URL = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "HEADERS = {'Accept': 'application/json'}\n",
    "\n",
    "def search_studies_for_gene(gene_name):\n",
    "    \"\"\"\n",
    "    Searches the ClinicalTrials.gov API for studies related to a given gene and 'cancer'.\n",
    "    \n",
    "    Args:\n",
    "        gene_name (str): The gene to search for.\n",
    "        \n",
    "    Returns:\n",
    "        list: A list of dictionaries, where each dictionary represents a study.\n",
    "    \"\"\"\n",
    "    search_query = f\"cancer AND {gene_name}\"\n",
    "    \n",
    "    # The API request parameters. query.term is the search expression.\n",
    "    params = {\n",
    "        \"query.term\": search_query,\n",
    "        \"pageSize\": 100 # Retrieve up to 100 studies per call.\n",
    "    }\n",
    "    \n",
    "    studies = []\n",
    "    \n",
    "    try:\n",
    "        print(f\"Searching for studies with query: '{search_query}'...\")\n",
    "        response = requests.get(API_BASE_URL, headers=HEADERS, params=params)\n",
    "        response.raise_for_status() # Raise an error for bad status codes\n",
    "        \n",
    "        data = response.json()\n",
    "        \n",
    "        # The studies are in a list under the 'studies' key.\n",
    "        if 'studies' in data:\n",
    "            studies = data['studies']\n",
    "            print(f\"-> Found {len(studies)} total studies for '{search_query}'.\")\n",
    "        else:\n",
    "            print(f\"-> No studies found for '{search_query}'.\")\n",
    "\n",
    "    except requests.exceptions.RequestException as e:\n",
    "        print(f\"An API error occurred for query '{search_query}': {e}\")\n",
    "        \n",
    "    return studies\n",
    "\n",
    "def filter_and_display_studies(studies, gene_name):\n",
    "    \"\"\"\n",
    "    Filters and displays studies that explicitly mention the gene name.\n",
    "    \n",
    "    Args:\n",
    "        studies (list): The list of study dictionaries from the API.\n",
    "        gene_name (str): The gene name to filter by.\n",
    "    \"\"\"\n",
    "    found_studies = []\n",
    "    for study in studies:\n",
    "        # We'll create a single searchable string from all text values to be robust.\n",
    "        study_text = json.dumps(study).lower()\n",
    "        \n",
    "        if gene_name.lower() in study_text:\n",
    "            # Extract key details from the nested JSON structure.\n",
    "            identification_module = study.get(\"protocolSection\", {}).get(\"identificationModule\", {})\n",
    "            nct_id = identification_module.get(\"nctId\")\n",
    "            study_title = identification_module.get(\"briefTitle\")\n",
    "            \n",
    "            # Append to the list of found studies.\n",
    "            found_studies.append({\n",
    "                \"NCT ID\": nct_id,\n",
    "                \"Title\": study_title\n",
    "            })\n",
    "            \n",
    "    return found_studies\n",
    "\n",
    "# Main execution loop to analyze all genes.\n",
    "all_results = {}\n",
    "for category, genes in gene_categories.items():\n",
    "    print(f\"\\n=======================================================\")\n",
    "    print(f\"Analyzing genes in category: '{category}'\")\n",
    "    print(f\"=======================================================\")\n",
    "    \n",
    "    all_results[category] = {}\n",
    "    for gene in genes:\n",
    "        print(f\"\\n--- Processing gene: {gene} ---\")\n",
    "        studies_data = search_studies_for_gene(gene)\n",
    "        \n",
    "        if studies_data:\n",
    "            filtered_studies = filter_and_display_studies(studies_data, gene)\n",
    "            all_results[category][gene] = filtered_studies\n",
    "            \n",
    "            if filtered_studies:\n",
    "                print(f\"-> Found {len(filtered_studies)} studies explicitly mentioning '{gene}':\")\n",
    "                for study in filtered_studies:\n",
    "                    print(f\"   - NCT ID: {study['NCT ID']} | Title: {study['Title']}\")\n",
    "            else:\n",
    "                print(f\"-> No studies found explicitly mentioning '{gene}' in the full data.\")\n",
    "        \n",
    "        # Adding a delay to be respectful of the API's rate limits.\n",
    "        time.sleep(1)\n",
    "\n",
    "print(\"\\n\\n\" + \"=\"*50)\n",
    "print(\"FINAL SUMMARY OF FINDINGS\")\n",
    "print(\"=\"*50)\n",
    "for category, genes_data in all_results.items():\n",
    "    print(f\"\\nCategory: {category}\")\n",
    "    for gene, studies in genes_data.items():\n",
    "        if studies:\n",
    "            print(f\"  - Gene '{gene}': {len(studies)} studies found.\")\n",
    "        else:\n",
    "            print(f\"  - Gene '{gene}': No studies found.\")\n",
    "print(\"=\"*50)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "cd519a23",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "=======================================================\n",
      "Analyzing studies for category: 'Emerging Breast Cancer Target'\n",
      "=======================================================\n",
      "\n",
      "--- Processing gene: CASP8 ---\n",
      "Searching for studies with query: 'cancer AND CASP8'...\n",
      "-> API search returned 10 total studies.\n",
      "General search for 'CASP8' failed. Checking known NCT IDs...\n",
      "-> Known study NCT03877159 could not be retrieved or did not contain 'CASP8'.\n",
      "\n",
      "-> No studies found for 'CASP8'.\n",
      "\n",
      "--- Processing gene: FOXO3 ---\n",
      "Searching for studies with query: 'cancer AND FOXO3'...\n",
      "-> API search returned 5 total studies.\n",
      "\n",
      "-> Found 4 studies for 'FOXO3':\n",
      "   - NCT ID: NCT03473327 | Title: Immunological and Oxidative Stress Response in Relation to Abdominal Cancer Surgery\n",
      "   - NCT ID: NCT06055634 | Title: SIRT1(rs7069102 ) Gene Polymorphism in Chronic Obstructive Pulmonary Disease at Egyptian Patients\n",
      "   - NCT ID: NCT02968888 | Title: Anabolic Effects of Whey and Casein After Strength Training in Young and Elderly\n",
      "   - NCT ID: NCT03649698 | Title: Exercise and Nutrition for Healthy AgeiNg\n",
      "\n",
      "=======================================================\n",
      "Analyzing studies for category: 'Lacks Breast Cancer Evidence'\n",
      "=======================================================\n",
      "\n",
      "--- Processing gene: CDKN1A ---\n",
      "Searching for studies with query: 'cancer AND CDKN1A'...\n",
      "-> API search returned 10 total studies.\n",
      "\n",
      "-> Found 7 studies for 'CDKN1A':\n",
      "   - NCT ID: NCT01546038 | Title: A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome\n",
      "   - NCT ID: NCT02178072 | Title: Window Trial 5-aza in HNSCC, T-tare\n",
      "   - NCT ID: NCT02407080 | Title: Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia\n",
      "   - NCT ID: NCT04197089 | Title: Biological Effect of Vitamin D in Patients With Urothelial Carcinoma\n",
      "   - NCT ID: NCT05358379 | Title: A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma\n",
      "   - NCT ID: NCT05889390 | Title: Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer\n",
      "   - NCT ID: NCT02391051 | Title: Focal Brachytherapy in Patients With Selected \"Low-risk\" Prostate Cancer - a Phase-II-trial\n",
      "\n",
      "--- Processing gene: BAX ---\n",
      "Searching for studies with query: 'cancer AND BAX'...\n",
      "-> API search returned 67 total studies.\n",
      "\n",
      "-> Found 67 studies for 'BAX':\n",
      "   - NCT ID: NCT00378404 | Title: Phase I Trial of Docetaxel and Low-Dose Fractionated Radiation in the Treatment of Metastatic or Recurrent NSCLC\n",
      "   - NCT ID: NCT04975204 | Title: A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors\n",
      "   - NCT ID: NCT00068380 | Title: A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer\n",
      "   - NCT ID: NCT05442567 | Title: A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)\n",
      "   - NCT ID: NCT00026910 | Title: Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma\n",
      "   - NCT ID: NCT00056004 | Title: Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia\n",
      "   - NCT ID: NCT00078910 | Title: Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer\n",
      "   - NCT ID: NCT06896344 | Title: Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells\n",
      "   - NCT ID: NCT05456022 | Title: Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line\n",
      "   - NCT ID: NCT00540722 | Title: Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme\n",
      "   - NCT ID: NCT01736696 | Title: Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis\n",
      "   - NCT ID: NCT01197664 | Title: Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer That Can Be Removed in Surgery\n",
      "   - NCT ID: NCT01744821 | Title: Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer\n",
      "   - NCT ID: NCT03366103 | Title: Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors\n",
      "   - NCT ID: NCT00390403 | Title: Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme\n",
      "   - NCT ID: NCT02965703 | Title: Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma\n",
      "   - NCT ID: NCT04683003 | Title: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura\n",
      "   - NCT ID: NCT05714969 | Title: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)\n",
      "   - NCT ID: NCT01105169 | Title: Precision-Based Magnesium Trial\n",
      "   - NCT ID: NCT00030368 | Title: Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors\n",
      "   - NCT ID: NCT00612612 | Title: Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia\n",
      "   - NCT ID: NCT02973087 | Title: rVWF IN PROPHYLAXIS\n",
      "   - NCT ID: NCT00374699 | Title: Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas\n",
      "   - NCT ID: NCT01195506 | Title: Study the Novel Functions and Molecular Mechanisms of Vascular Endothelial Growth Factor-C (VEGF-C) in Acute Myeloid Leukemia (AML)\n",
      "   - NCT ID: NCT05775575 | Title: A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer\n",
      "   - NCT ID: NCT03393975 | Title: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)\n",
      "   - NCT ID: NCT00422942 | Title: A Pharmacokinetic and Pharmacodynamic Study of MabThera (Rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)\n",
      "   - NCT ID: NCT00006942 | Title: Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer\n",
      "   - NCT ID: NCT00896857 | Title: Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer\n",
      "   - NCT ID: NCT01016665 | Title: Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy\n",
      "   - NCT ID: NCT02585960 | Title: BAX 855 PK-guided Dosing\n",
      "   - NCT ID: NCT03997760 | Title: A Study of SHP655 (rADAMTS13) in Sickle Cell Disease\n",
      "   - NCT ID: NCT00898976 | Title: Biomarkers in Native American Women With Breast Cancer\n",
      "   - NCT ID: NCT06082492 | Title: The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients\n",
      "   - NCT ID: NCT01658319 | Title: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies\n",
      "   - NCT ID: NCT02872818 | Title: Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia\n",
      "   - NCT ID: NCT01440413 | Title: Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer\n",
      "   - NCT ID: NCT02932618 | Title: A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)\n",
      "   - NCT ID: NCT05631041 | Title: Effect of Silymarin in Metastatic Colorectal Cancer Patients\n",
      "   - NCT ID: NCT00458809 | Title: Intraperitoneal Hyperthermic Perfusion With Oxaliplatin in Treating Patients With Stage IV Peritoneal Cancer Due to Appendix Cancer or Colorectal Cancer\n",
      "   - NCT ID: NCT00399607 | Title: Calcium/Vitamin D, Biomarkers & Colon Polyp Prevention\n",
      "   - NCT ID: NCT06134388 | Title: Sulfasalazine in Patients With Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT00169000 | Title: Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers\n",
      "   - NCT ID: NCT01096732 | Title: Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)\n",
      "   - NCT ID: NCT04847453 | Title: Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis\n",
      "   - NCT ID: NCT04779320 | Title: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)\n",
      "   - NCT ID: NCT02078427 | Title: ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)\n",
      "   - NCT ID: NCT01410227 | Title: Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD)\n",
      "   - NCT ID: NCT00725374 | Title: A Study to Investigate the Effects of Tibolone (Livial) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)\n",
      "   - NCT ID: NCT00383474 | Title: Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase\n",
      "   - NCT ID: NCT07014917 | Title: Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL\n",
      "   - NCT ID: NCT00176241 | Title: Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer\n",
      "   - NCT ID: NCT00546039 | Title: Synthetic Genistein (BONISTEIN) in Patients Who Are Undergoing Surgery for Prostate Cancer\n",
      "   - NCT ID: NCT05358639 | Title: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC\n",
      "   - NCT ID: NCT05097378 | Title: Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma\n",
      "   - NCT ID: NCT02647671 | Title: Aquamin and Prevention of Colon Cancer\n",
      "   - NCT ID: NCT00208793 | Title: Calcium and Vitamin D vs Markers of Adenomatous Polyps\n",
      "   - NCT ID: NCT04286477 | Title: The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT\n",
      "   - NCT ID: NCT02978547 | Title: The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma\n",
      "   - NCT ID: NCT05114798 | Title: Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers\n",
      "   - NCT ID: NCT02278861 | Title: Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis\n",
      "   - NCT ID: NCT00052611 | Title: Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia\n",
      "   - NCT ID: NCT00389805 | Title: Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors\n",
      "   - NCT ID: NCT06514261 | Title: Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML\n",
      "   - NCT ID: NCT00668161 | Title: Effect of Exercise on Biomarkers of Colon Cancer Risk\n",
      "   - NCT ID: NCT01945593 | Title: BAX 855 Continuation\n",
      "   - NCT ID: NCT02994511 | Title: Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials\n",
      "\n",
      "--- Processing gene: NRAS ---\n",
      "Searching for studies with query: 'cancer AND NRAS'...\n",
      "-> API search returned 100 total studies.\n",
      "\n",
      "-> Found 100 studies for 'NRAS':\n",
      "   - NCT ID: NCT03442569 | Title: PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC\n",
      "   - NCT ID: NCT04439344 | Title: Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)\n",
      "   - NCT ID: NCT06011772 | Title: EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT03771404 | Title: NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized \"Liquid Biopsy\"\n",
      "   - NCT ID: NCT05841550 | Title: The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma\n",
      "   - NCT ID: NCT06346067 | Title: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)\n",
      "   - NCT ID: NCT05797467 | Title: Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients\n",
      "   - NCT ID: NCT04418167 | Title: JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations\n",
      "   - NCT ID: NCT01814501 | Title: Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab\n",
      "   - NCT ID: NCT03748667 | Title: Accuracy for Predicting Deep Submucosal Invasion\n",
      "   - NCT ID: NCT05187767 | Title: Impact of ctDNA in Cancer Early Detection and STAS Evaluation in Patients With GGOs\n",
      "   - NCT ID: NCT04189055 | Title: Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.\n",
      "   - NCT ID: NCT06106308 | Title: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation\n",
      "   - NCT ID: NCT04053114 | Title: MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii\n",
      "   - NCT ID: NCT01726738 | Title: LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations\n",
      "   - NCT ID: NCT01960023 | Title: Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02587650 | Title: Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma\n",
      "   - NCT ID: NCT02394795 | Title: Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC\n",
      "   - NCT ID: NCT03597581 | Title: A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer\n",
      "   - NCT ID: NCT04108481 | Title: Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02823210 | Title: Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders\n",
      "   - NCT ID: NCT06229340 | Title: Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations\n",
      "   - NCT ID: NCT04599140 | Title: SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial\n",
      "   - NCT ID: NCT03167268 | Title: Panitumumab Skin Toxicity Prevention Trial\n",
      "   - NCT ID: NCT06026410 | Title: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors\n",
      "   - NCT ID: NCT01781572 | Title: A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma\n",
      "   - NCT ID: NCT02079740 | Title: Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors\n",
      "   - NCT ID: NCT06096974 | Title: Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS\n",
      "   - NCT ID: NCT01719380 | Title: Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02138292 | Title: A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma\n",
      "   - NCT ID: NCT05628038 | Title: The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer\n",
      "   - NCT ID: NCT05365412 | Title: Clinicopathological Characteristics of Colon Cancer in Young Age\n",
      "   - NCT ID: NCT02538627 | Title: Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib\n",
      "   - NCT ID: NCT01428492 | Title: Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma\n",
      "   - NCT ID: NCT00338130 | Title: Randomised Study to Compare the Efficacy of AZD6244 vs TMZ\n",
      "   - NCT ID: NCT06828822 | Title: CongenItal Naevus Cohort for Longitudinal Evaluation\n",
      "   - NCT ID: NCT02974725 | Title: A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma\n",
      "   - NCT ID: NCT06903039 | Title: NeoRes Study - Preoperative Chemotherapy in Colorectal Peritoneal Disease Prior to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)\n",
      "   - NCT ID: NCT04425239 | Title: Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT04262635 | Title: Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02065063 | Title: A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors\n",
      "   - NCT ID: NCT06208124 | Title: A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors\n",
      "   - NCT ID: NCT05786924 | Title: A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers\n",
      "   - NCT ID: NCT04059224 | Title: TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma\n",
      "   - NCT ID: NCT00900224 | Title: Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT03457896 | Title: Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status\n",
      "   - NCT ID: NCT02171286 | Title: The Oncopanel Pilot (TOP) Study\n",
      "   - NCT ID: NCT03051035 | Title: First-in-Human Study of KO-947 in Non-Hematological Malignancies\n",
      "   - NCT ID: NCT00730158 | Title: A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT02404935 | Title: Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)\n",
      "   - NCT ID: NCT02316496 | Title: Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study\n",
      "   - NCT ID: NCT01362296 | Title: An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer\n",
      "   - NCT ID: NCT05726864 | Title: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors\n",
      "   - NCT ID: NCT06162221 | Title: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\n",
      "   - NCT ID: NCT04417621 | Title: Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma\n",
      "   - NCT ID: NCT02613221 | Title: A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer\n",
      "   - NCT ID: NCT05340621 | Title: NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)\n",
      "   - NCT ID: NCT01282502 | Title: Midostaurin (PKC412) for Locally Advanced Rectal Cancer\n",
      "   - NCT ID: NCT06440902 | Title: Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating Tumor DNA\n",
      "   - NCT ID: NCT07083479 | Title: Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma\n",
      "   - NCT ID: NCT06881784 | Title: Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301)\n",
      "   - NCT ID: NCT01763164 | Title: Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma\n",
      "   - NCT ID: NCT03784014 | Title: Molecular Profiling of Advanced Soft-tissue Sarcomas\n",
      "   - NCT ID: NCT04718038 | Title: Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT03981614 | Title: Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer\n",
      "   - NCT ID: NCT05527795 | Title: Predictive Clinical Features for Response to Adjuvant Immunotherapy in Stage II,III and IV Resected Melanoma\n",
      "   - NCT ID: NCT02399943 | Title: A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer\n",
      "   - NCT ID: NCT03311750 | Title: Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer\n",
      "   - NCT ID: NCT02199223 | Title: Regorafenib + Panitumumab for Colorectal Cancers\n",
      "   - NCT ID: NCT02613650 | Title: A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers\n",
      "   - NCT ID: NCT02862743 | Title: Molecular Characterization of Advanced Stage Melanoma by Blood Sampling\n",
      "   - NCT ID: NCT03714490 | Title: MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer\n",
      "   - NCT ID: NCT02296203 | Title: Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).\n",
      "   - NCT ID: NCT04249843 | Title: Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors\n",
      "   - NCT ID: NCT04276090 | Title: Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma\n",
      "   - NCT ID: NCT01704703 | Title: Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques\n",
      "   - NCT ID: NCT04322890 | Title: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation\n",
      "   - NCT ID: NCT05217303 | Title: HL-085 in NRAS-mutated Advanced Melanoma\n",
      "   - NCT ID: NCT01198743 | Title: Presence of Circulating Tumor DNA in Colorectal Cancer\n",
      "   - NCT ID: NCT03732703 | Title: Myeloma-Developing Regimens Using Genomics (MyDRUG)\n",
      "   - NCT ID: NCT01723969 | Title: Screening Platform for Clinical Trials in Advanced Colorectal Cancer\n",
      "   - NCT ID: NCT02448810 | Title: Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT03315468 | Title: French Clinical Datbase of Melanoma Patients (RIC-Mel)\n",
      "   - NCT ID: NCT01445587 | Title: A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma\n",
      "   - NCT ID: NCT04853017 | Title: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors\n",
      "   - NCT ID: NCT06400654 | Title: PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC\n",
      "   - NCT ID: NCT04466254 | Title: Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT04151342 | Title: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)\n",
      "   - NCT ID: NCT03750175 | Title: OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -\n",
      "   - NCT ID: NCT06841159 | Title: Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1Chemotherapy and Target Therapy for Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT05273099 | Title: Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma\n",
      "   - NCT ID: NCT06027775 | Title: Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases\n",
      "   - NCT ID: NCT06137170 | Title: A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment\n",
      "   - NCT ID: NCT03914170 | Title: Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT04931342 | Title: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors\n",
      "   - NCT ID: NCT06876142 | Title: Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma\n",
      "   - NCT ID: NCT01449058 | Title: A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors\n",
      "   - NCT ID: NCT06949982 | Title: Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes\n",
      "   - NCT ID: NCT06625320 | Title: Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)\n",
      "   - NCT ID: NCT03580382 | Title: Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma\n",
      "\n",
      "--- Processing gene: VHL ---\n",
      "Searching for studies with query: 'cancer AND VHL'...\n",
      "-> API search returned 81 total studies.\n",
      "\n",
      "-> Found 72 studies for 'VHL':\n",
      "   - NCT ID: NCT01168440 | Title: Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease\n",
      "   - NCT ID: NCT00001238 | Title: Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders\n",
      "   - NCT ID: NCT01730755 | Title: Ruxolitinib for Chuvash Polycythemia\n",
      "   - NCT ID: NCT06195150 | Title: Overtaking Intra and Inter Tumoral Heterogeneity In Von Hippel-Lindau Related Renal Cancer\n",
      "   - NCT ID: NCT00566995 | Title: Phase II Study of Vandetanib in Individuals With Kidney Cancer\n",
      "   - NCT ID: NCT02120040 | Title: Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hmangioblastoma of Nervous Centrasl System\n",
      "   - NCT ID: NCT05563272 | Title: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors\n",
      "   - NCT ID: NCT02420067 | Title: Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients\n",
      "   - NCT ID: NCT00089765 | Title: Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome\n",
      "   - NCT ID: NCT02315625 | Title: Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery\n",
      "   - NCT ID: NCT06440122 | Title: The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs)\n",
      "   - NCT ID: NCT06553339 | Title: A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors\n",
      "   - NCT ID: NCT05424016 | Title: Propranolol and Von Hippel-Lindau Disease\n",
      "   - NCT ID: NCT02499458 | Title: Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer\n",
      "   - NCT ID: NCT02207686 | Title: Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?\n",
      "   - NCT ID: NCT02693535 | Title: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer\n",
      "   - NCT ID: NCT05737602 | Title: Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease\n",
      "   - NCT ID: NCT02108002 | Title: Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)\n",
      "   - NCT ID: NCT00005902 | Title: Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease\n",
      "   - NCT ID: NCT06391879 | Title: Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma\n",
      "   - NCT ID: NCT00001814 | Title: Genetic Analysis of Inherited Urologic Malignant Disorders: Collection of Samples\n",
      "   - NCT ID: NCT05955014 | Title: Data Collection Protocol for Patients With Von Hippel Lindau Disease\n",
      "   - NCT ID: NCT01538238 | Title: pazopanib_NCRCC,Ph2 STUDY\n",
      "   - NCT ID: NCT00330564 | Title: Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow\n",
      "   - NCT ID: NCT00001703 | Title: Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma\n",
      "   - NCT ID: NCT01665703 | Title: Imaging Correlates of Renal Cell Carcinoma Biological Features\n",
      "   - NCT ID: NCT00001803 | Title: Von Hippel-Lindau Disease Genetic Epidemiology Study\n",
      "   - NCT ID: NCT05810246 | Title: 68Ga-NY104 PET/CT in Von Hippel-Lindau Disease\n",
      "   - NCT ID: NCT03008369 | Title: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery\n",
      "   - NCT ID: NCT06194669 | Title: Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells\n",
      "   - NCT ID: NCT00001668 | Title: Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors\n",
      "   - NCT ID: NCT01253668 | Title: Brivanib Metastatic Renal Cell Carcinoma\n",
      "   - NCT ID: NCT01791387 | Title: 1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC\n",
      "   - NCT ID: NCT03297606 | Title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)\n",
      "   - NCT ID: NCT03001349 | Title: 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors\n",
      "   - NCT ID: NCT05273099 | Title: Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma\n",
      "   - NCT ID: NCT00056199 | Title: EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome\n",
      "   - NCT ID: NCT04924075 | Title: Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2 Related Genetic Alterations (MK-6482-015)\n",
      "   - NCT ID: NCT01266070 | Title: TKI 258 in Von Hippel-Lindau Syndrome (VHL)\n",
      "   - NCT ID: NCT06923670 | Title: Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History\n",
      "   - NCT ID: NCT04895748 | Title: DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies\n",
      "   - NCT ID: NCT01967576 | Title: Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma\n",
      "   - NCT ID: NCT03907657 | Title: Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau\n",
      "   - NCT ID: NCT03108066 | Title: MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)\n",
      "   - NCT ID: NCT06554730 | Title: MSD Belzutifan PAS\n",
      "   - NCT ID: NCT00062166 | Title: Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease\n",
      "   - NCT ID: NCT01775930 | Title: Carfilzomib in Refractory Renal Cell Carcinoma (RCC)\n",
      "   - NCT ID: NCT00602862 | Title: Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250\n",
      "   - NCT ID: NCT00052013 | Title: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584\n",
      "   - NCT ID: NCT01372813 | Title: Vandetanib to Treat Advanced Kidney Cancer\n",
      "   - NCT ID: NCT03401788 | Title: A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)\n",
      "   - NCT ID: NCT01015300 | Title: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease\n",
      "   - NCT ID: NCT04989959 | Title: [18F]PT2385 PET/CT in Patients with Renal Cell Carcinoma\n",
      "   - NCT ID: NCT01967537 | Title: Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors\n",
      "   - NCT ID: NCT05941637 | Title: An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)\n",
      "   - NCT ID: NCT01002937 | Title: Novel Prognostic Markers in Renal Cancer\n",
      "   - NCT ID: NCT01712685 | Title: Imaging Studies of Kidney Cancer Using 18F-VM4-037\n",
      "   - NCT ID: NCT05534854 | Title: Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes\n",
      "   - NCT ID: NCT03979833 | Title: Drivers of Hypoxia-induced Angiogenesis in Tumor Development\n",
      "   - NCT ID: NCT00193154 | Title: OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma\n",
      "   - NCT ID: NCT00494182 | Title: Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer\n",
      "   - NCT ID: NCT01436227 | Title: Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome\n",
      "   - NCT ID: NCT04068831 | Title: Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma\n",
      "   - NCT ID: NCT01262482 | Title: Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment\n",
      "   - NCT ID: NCT03749980 | Title: MyVHL: Patient Natural History Study\n",
      "   - NCT ID: NCT04074135 | Title: Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors\n",
      "   - NCT ID: NCT00075348 | Title: Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome\n",
      "   - NCT ID: NCT00088374 | Title: 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease\n",
      "   - NCT ID: NCT05497271 | Title: Confirmation of Association Between Cystic Fluid Analysis With Pancreatic Cystic Lesions\n",
      "   - NCT ID: NCT05843305 | Title: A Study of BPI-452080 in Subjects With Solid Tumors\n",
      "   - NCT ID: NCT06234605 | Title: A Study of HC-7366 in Combination With Belzutifan (WELIREG) in Patients With Renal Cell Carcinoma\n",
      "   - NCT ID: NCT00970970 | Title: Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease\n",
      "\n",
      "--- Processing gene: SRC ---\n",
      "Searching for studies with query: 'cancer AND SRC'...\n",
      "-> API search returned 100 total studies.\n",
      "\n",
      "-> Found 100 studies for 'SRC':\n",
      "   - NCT ID: NCT06590246 | Title: A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/recurrent Hepatocellular Carcinoma (HCC)\n",
      "   - NCT ID: NCT05458544 | Title: [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application\n",
      "   - NCT ID: NCT06559644 | Title: Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia\n",
      "   - NCT ID: NCT04436744 | Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)\n",
      "   - NCT ID: NCT03041701 | Title: Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma\n",
      "   - NCT ID: NCT06258304 | Title: A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies\n",
      "   - NCT ID: NCT00546104 | Title: Phase II Dasatinib Study in Advanced Breast Cancer\n",
      "   - NCT ID: NCT04915404 | Title: Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)\n",
      "   - NCT ID: NCT04282044 | Title: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies\n",
      "   - NCT ID: NCT05853367 | Title: Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)\n",
      "   - NCT ID: NCT02171429 | Title: A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors\n",
      "   - NCT ID: NCT06154343 | Title: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors\n",
      "   - NCT ID: NCT04710043 | Title: Dose Escalation Trial of BNT152+153 in Patients With Cancer\n",
      "   - NCT ID: NCT02660138 | Title: Dysport Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1\n",
      "   - NCT ID: NCT03271255 | Title: Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)\n",
      "   - NCT ID: NCT06464055 | Title: A Study of GQ1010 in Subjects With Advanced Solid Tumors\n",
      "   - NCT ID: NCT01144481 | Title: Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases\n",
      "   - NCT ID: NCT01759810 | Title: Proteome-based Personalized Immunotherapy of Glioblastoma\n",
      "   - NCT ID: NCT01826838 | Title: Study of Dasatinib, Androgen Deprivation Therapy and Radiation\n",
      "   - NCT ID: NCT00526838 | Title: Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies\n",
      "   - NCT ID: NCT01668550 | Title: A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours\n",
      "   - NCT ID: NCT02936323 | Title: PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers\n",
      "   - NCT ID: NCT04475523 | Title: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies\n",
      "   - NCT ID: NCT02981108 | Title: A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC\n",
      "   - NCT ID: NCT02954523 | Title: Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations\n",
      "   - NCT ID: NCT00501410 | Title: FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT06975410 | Title: Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors\n",
      "   - NCT ID: NCT04896112 | Title: A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT04645069 | Title: ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors\n",
      "   - NCT ID: NCT02876081 | Title: Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex\n",
      "   - NCT ID: NCT05751044 | Title: HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies\n",
      "   - NCT ID: NCT01054144 | Title: Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma\n",
      "   - NCT ID: NCT00339144 | Title: Study of Dasatinib (BMS-354825) in Patients With Solid Tumors\n",
      "   - NCT ID: NCT04669067 | Title: TL-895 and KRT-232 Study in Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT06230965 | Title: Clinical Study of Lung Protective Ventilation Strategies and Tumor Microenvironment\n",
      "   - NCT ID: NCT05394831 | Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC\n",
      "   - NCT ID: NCT00597038 | Title: A Phase I/II Study of Dasatinib and Dacarbazine\n",
      "   - NCT ID: NCT00798655 | Title: Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer\n",
      "   - NCT ID: NCT00780676 | Title: Personalized Treatment Selection for Metastatic Breast Cancer\n",
      "   - NCT ID: NCT00779389 | Title: Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family\n",
      "   - NCT ID: NCT06087289 | Title: A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer\n",
      "   - NCT ID: NCT06600789 | Title: A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies\n",
      "   - NCT ID: NCT03443622 | Title: Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors\n",
      "   - NCT ID: NCT02974322 | Title: A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease\n",
      "   - NCT ID: NCT05521022 | Title: Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis\n",
      "   - NCT ID: NCT02338622 | Title: Trial of Olaparib in Combination with AZD5363 (ComPAKT)\n",
      "   - NCT ID: NCT01015222 | Title: Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies\n",
      "   - NCT ID: NCT00646139 | Title: KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment\n",
      "   - NCT ID: NCT05922839 | Title: Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA\n",
      "   - NCT ID: NCT06792435 | Title: XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.\n",
      "   - NCT ID: NCT06958939 | Title: The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis\n",
      "   - NCT ID: NCT05873686 | Title: A Phase 1 Clinical Study of NXP900 in Subjects with Advanced Cancers\n",
      "   - NCT ID: NCT00277316 | Title: Study of XL999 in Patients With Metastatic Renal Cell Carcinoma\n",
      "   - NCT ID: NCT04113616 | Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)\n",
      "   - NCT ID: NCT05999396 | Title: FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer\n",
      "   - NCT ID: NCT05325216 | Title: Urinary Continence of Female POPRC and OIN\n",
      "   - NCT ID: NCT03033524 | Title: Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma\n",
      "   - NCT ID: NCT04045496 | Title: A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors\n",
      "   - NCT ID: NCT04121286 | Title: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China\n",
      "   - NCT ID: NCT05860296 | Title: Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers\n",
      "   - NCT ID: NCT01000896 | Title: Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel\n",
      "   - NCT ID: NCT03404596 | Title: Applying mHealth to Tobacco-related Health Disparities\n",
      "   - NCT ID: NCT01990196 | Title: Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer\n",
      "   - NCT ID: NCT05123534 | Title: A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG\n",
      "   - NCT ID: NCT02296879 | Title: A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types\n",
      "   - NCT ID: NCT05519384 | Title: Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT00277290 | Title: Study of XL999 in Patients With Previously Treated Ovarian Cancer\n",
      "   - NCT ID: NCT00892190 | Title: Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome\n",
      "   - NCT ID: NCT00306202 | Title: Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia\n",
      "   - NCT ID: NCT01355302 | Title: E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer\n",
      "   - NCT ID: NCT02423902 | Title: A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer\n",
      "   - NCT ID: NCT03787602 | Title: Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma\n",
      "   - NCT ID: NCT04318964 | Title: TAEST16001 in the Treatment of Soft Tissue Sarcoma\n",
      "   - NCT ID: NCT00835679 | Title: Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery\n",
      "   - NCT ID: NCT02118584 | Title: Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies\n",
      "   - NCT ID: NCT06566079 | Title: Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors\n",
      "   - NCT ID: NCT00277303 | Title: Study of XL999 in Patients With Metastatic Colorectal Cancer\n",
      "   - NCT ID: NCT05203679 | Title: Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug\n",
      "   - NCT ID: NCT03648879 | Title: Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome\n",
      "   - NCT ID: NCT06713564 | Title: A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung Cancer\n",
      "   - NCT ID: NCT00672295 | Title: PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer\n",
      "   - NCT ID: NCT01162395 | Title: Open Label Prostate Cancer Study\n",
      "   - NCT ID: NCT04883138 | Title: Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients\n",
      "   - NCT ID: NCT02426723 | Title: Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients\n",
      "   - NCT ID: NCT00996723 | Title: Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)\n",
      "   - NCT ID: NCT00563290 | Title: Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia\n",
      "   - NCT ID: NCT01805843 | Title: Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia\n",
      "   - NCT ID: NCT03327064 | Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "   - NCT ID: NCT06934590 | Title: Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC\n",
      "   - NCT ID: NCT02428543 | Title: Ponatinib for FLT3-ITD Acute Myelogenous Leukemia\n",
      "   - NCT ID: NCT00858403 | Title: Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation\n",
      "   - NCT ID: NCT05752669 | Title: Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.\n",
      "   - NCT ID: NCT06874946 | Title: Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/LBL\n",
      "   - NCT ID: NCT05927012 | Title: A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).\n",
      "   - NCT ID: NCT02586987 | Title: A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours\n",
      "   - NCT ID: NCT01764087 | Title: A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors\n",
      "   - NCT ID: NCT05818917 | Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of FHND5071 as a Single Agent in Adult Patients With Advanced Solid Tumors\n",
      "   - NCT ID: NCT04598919 | Title: Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis\n",
      "   - NCT ID: NCT01972217 | Title: Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.\n",
      "   - NCT ID: NCT03088813 | Title: Study of Irinotecan Liposome Injection (ONIVYDE) in Patients With Small Cell Lung Cancer\n",
      "\n",
      "--- Processing gene: NF2 ---\n",
      "Searching for studies with query: 'cancer AND NF2'...\n",
      "-> API search returned 64 total studies.\n",
      "\n",
      "-> Found 55 studies for 'NF2':\n",
      "   - NCT ID: NCT02352844 | Title: Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations\n",
      "   - NCT ID: NCT01885767 | Title: Neurofibromatosis (NF) Registry Portal\n",
      "   - NCT ID: NCT01736267 | Title: Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects\n",
      "   - NCT ID: NCT03672838 | Title: A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)\n",
      "   - NCT ID: NCT03406208 | Title: Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing\n",
      "   - NCT ID: NCT06834438 | Title: Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002\n",
      "   - NCT ID: NCT02104323 | Title: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors\n",
      "   - NCT ID: NCT03873610 | Title: Resiliency Training in Adolescents With NF1 and NF2\n",
      "   - NCT ID: NCT06251310 | Title: SW-682 in Advanced Solid Tumors\n",
      "   - NCT ID: NCT04857372 | Title: A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors\n",
      "   - NCT ID: NCT02589912 | Title: Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients\n",
      "   - NCT ID: NCT04439331 | Title: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)\n",
      "   - NCT ID: NCT02523014 | Title: Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas\n",
      "   - NCT ID: NCT01767792 | Title: Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas\n",
      "   - NCT ID: NCT00863122 | Title: Concentration and Activity of Lapatinib in Vestibular Schwannomas\n",
      "   - NCT ID: NCT01776125 | Title: Genetic Evaluation of NF1 and Scoliosis Patients\n",
      "   - NCT ID: NCT00340496 | Title: Analysis of NF2 Mutations in Radiation-Related Neural Tumors\n",
      "   - NCT ID: NCT06536179 | Title: New Preclinical and Clinical Approaches to Mesothelioma\n",
      "   - NCT ID: NCT05821790 | Title: Role of the Tumor Microenvironment in Aggressive Meningiomas\n",
      "   - NCT ID: NCT00030043 | Title: An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors\n",
      "   - NCT ID: NCT04283669 | Title: Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas\n",
      "   - NCT ID: NCT01024946 | Title: Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity\n",
      "   - NCT ID: NCT01602887 | Title: Relative Bioavailability Study\n",
      "   - NCT ID: NCT02310399 | Title: Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves\n",
      "   - NCT ID: NCT03297606 | Title: Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)\n",
      "   - NCT ID: NCT03079999 | Title: Study of Aspirin in Patients With Vestibular Schwannoma\n",
      "   - NCT ID: NCT02298270 | Title: Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype\n",
      "   - NCT ID: NCT06923670 | Title: Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History\n",
      "   - NCT ID: NCT06553365 | Title: Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors\n",
      "   - NCT ID: NCT05130866 | Title: Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas\n",
      "   - NCT ID: NCT03095248 | Title: Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors\n",
      "   - NCT ID: NCT00911248 | Title: PTC299 for Treatment of Neurofibromatosis Type 2\n",
      "   - NCT ID: NCT02465060 | Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "   - NCT ID: NCT03617276 | Title: Reliability of Functional Outcome Measures in Neurofibromatosis 2\n",
      "   - NCT ID: NCT01490476 | Title: Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients\n",
      "   - NCT ID: NCT01864291 | Title: Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects\n",
      "   - NCT ID: NCT02282917 | Title: Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma\n",
      "   - NCT ID: NCT02811718 | Title: Resiliency Training for Patients With NF2 Via Videoconferencing With Skype\n",
      "   - NCT ID: NCT03210285 | Title: WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data\n",
      "   - NCT ID: NCT01207687 | Title: Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)\n",
      "   - NCT ID: NCT05228015 | Title: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors\n",
      "   - NCT ID: NCT02246231 | Title: Effect of Implant Position on Magnetic Resonance Image Distortion\n",
      "   - NCT ID: NCT02831257 | Title: AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas\n",
      "   - NCT ID: NCT05685836 | Title: 89Zr-Bevacizumab PET/CT Imaging in NF2 Patients\n",
      "   - NCT ID: NCT01345136 | Title: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma\n",
      "   - NCT ID: NCT05521048 | Title: Doxycycline in Cutaneous Schwannoma (NF2)\n",
      "   - NCT ID: NCT01419639 | Title: Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2\n",
      "   - NCT ID: NCT00973739 | Title: Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors\n",
      "   - NCT ID: NCT02934256 | Title: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors\n",
      "   - NCT ID: NCT04374305 | Title: Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)\n",
      "   - NCT ID: NCT00598351 | Title: Natural History Study of Patients With Neurofibromatosis Type 2\n",
      "   - NCT ID: NCT02129647 | Title: Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas\n",
      "   - NCT ID: NCT00004483 | Title: NF2 Natural History Consortium\n",
      "   - NCT ID: NCT01222728 | Title: Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients\n",
      "   - NCT ID: NCT02435628 | Title: Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF\n",
      "\n",
      "--- Processing gene: WT1 ---\n",
      "Searching for studies with query: 'cancer AND WT1'...\n",
      "-> API search returned 100 total studies.\n",
      "\n",
      "-> Found 37 studies for 'WT1':\n",
      "   - NCT ID: NCT00909168 | Title: Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)\n",
      "   - NCT ID: NCT01734304 | Title: DC Vaccination for Postremission Therapy in AML\n",
      "   - NCT ID: NCT05000801 | Title: Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT02494167 | Title: Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)\n",
      "   - NCT ID: NCT04126967 | Title: Next Generation SequencingNGSMonitors Minimal Residual DiseaseMRDin Allo-PBSCT Patients\n",
      "   - NCT ID: NCT01252901 | Title: Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases\n",
      "   - NCT ID: NCT02649829 | Title: Autologous Dendritic Cell Vaccination in Mesothelioma\n",
      "   - NCT ID: NCT01640301 | Title: Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant\n",
      "   - NCT ID: NCT00179829 | Title: WT1 for the Detection of Minimal Residual Disease\n",
      "   - NCT ID: NCT00398138 | Title: Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma\n",
      "   - NCT ID: NCT01146223 | Title: Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia\n",
      "   - NCT ID: NCT01546038 | Title: A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome\n",
      "   - NCT ID: NCT01995708 | Title: CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation\n",
      "   - NCT ID: NCT00923910 | Title: Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood\n",
      "   - NCT ID: NCT02895412 | Title: Infection and Tumour Antigen Cellular Therapy\n",
      "   - NCT ID: NCT05918640 | Title: Lurbinectedin in FET-Fused Tumors\n",
      "   - NCT ID: NCT00562640 | Title: Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)\n",
      "   - NCT ID: NCT03291444 | Title: CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS\n",
      "   - NCT ID: NCT02498665 | Title: A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies\n",
      "   - NCT ID: NCT03761914 | Title: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers\n",
      "   - NCT ID: NCT00488592 | Title: Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers\n",
      "   - NCT ID: NCT01842139 | Title: Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission\n",
      "   - NCT ID: NCT01051063 | Title: Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy\n",
      "   - NCT ID: NCT00965224 | Title: Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma\n",
      "   - NCT ID: NCT02408016 | Title: Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma\n",
      "   - NCT ID: NCT02686424 | Title: Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy (ONCO-RD 010 CRT)\n",
      "   - NCT ID: NCT00900224 | Title: Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia\n",
      "   - NCT ID: NCT01621724 | Title: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study\n",
      "   - NCT ID: NCT04837196 | Title: Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen\n",
      "   - NCT ID: NCT03311334 | Title: A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors\n",
      "   - NCT ID: NCT06172634 | Title: A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy\n",
      "   - NCT ID: NCT00665002 | Title: Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms\n",
      "   - NCT ID: NCT00834002 | Title: Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission\n",
      "   - NCT ID: NCT04911621 | Title: Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma\n",
      "   - NCT ID: NCT04747002 | Title: Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine \"Dainippon Sumitomo Phama(DSP)-7888\" for Acute Myeloid Leukemia Patients.\n",
      "   - NCT ID: NCT02461121 | Title: HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk\n",
      "   - NCT ID: NCT05765084 | Title: Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma\n",
      "\n",
      "--- Processing gene: NTRK1 ---\n",
      "Searching for studies with query: 'cancer AND NTRK1'...\n",
      "-> API search returned 61 total studies.\n",
      "\n",
      "-> Found 33 studies for 'NTRK1':\n",
      "   - NCT ID: NCT04010240 | Title: A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study\n",
      "   - NCT ID: NCT02650401 | Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\n",
      "   - NCT ID: NCT02587650 | Title: Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma\n",
      "   - NCT ID: NCT02097810 | Title: Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.\n",
      "   - NCT ID: NCT02568267 | Title: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)\n",
      "   - NCT ID: NCT04591431 | Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "   - NCT ID: NCT03093116 | Title: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements\n",
      "   - NCT ID: NCT02693535 | Title: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer\n",
      "   - NCT ID: NCT06780384 | Title: NTRK 1,2,3 Rearrangements in Patients With Solid Tumors\n",
      "   - NCT ID: NCT03574402 | Title: Phase II Umbrella Study Directed by Next Generation Sequencing\n",
      "   - NCT ID: NCT05302843 | Title: A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors\n",
      "   - NCT ID: NCT02637687 | Title: A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children\n",
      "   - NCT ID: NCT02465060 | Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "   - NCT ID: NCT03025360 | Title: Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion\n",
      "   - NCT ID: NCT06528691 | Title: Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors\n",
      "   - NCT ID: NCT02920996 | Title: Merestinib In Non-Small Cell Lung Cancer And Solid Tumors\n",
      "   - NCT ID: NCT06984588 | Title: A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer\n",
      "   - NCT ID: NCT02219711 | Title: Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer\n",
      "   - NCT ID: NCT03375437 | Title: RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.\n",
      "   - NCT ID: NCT02576431 | Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors\n",
      "   - NCT ID: NCT03155620 | Title: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)\n",
      "   - NCT ID: NCT03206931 | Title: Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion\n",
      "   - NCT ID: NCT02122913 | Title: A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer\n",
      "   - NCT ID: NCT04970134 | Title: Spanish Study for Molecular Characterization of Thyroid Carcinoma\n",
      "   - NCT ID: NCT04671849 | Title: An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.\n",
      "   - NCT ID: NCT03182257 | Title: Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors\n",
      "   - NCT ID: NCT04557813 | Title: Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion\n",
      "   - NCT ID: NCT06214793 | Title: Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)\n",
      "   - NCT ID: NCT04921553 | Title: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions (TRacKING)\n",
      "   - NCT ID: NCT06141005 | Title: Feasibility of Bronchial Washing Fluid for Molecular Testing with Next Generation Sequencing in Lung Cancer\n",
      "   - NCT ID: NCT03215511 | Title: A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer\n",
      "   - NCT ID: NCT03066661 | Title: Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions\n",
      "   - NCT ID: NCT03556228 | Title: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma\n",
      "\n",
      "\n",
      "==================================================\n",
      "FINAL SUMMARY OF FINDINGS\n",
      "==================================================\n",
      "\n",
      "Category: Emerging Breast Cancer Target\n",
      "  - Gene 'CASP8': No studies found.\n",
      "  - Gene 'FOXO3': 4 studies found.\n",
      "\n",
      "Category: Lacks Breast Cancer Evidence\n",
      "  - Gene 'CDKN1A': 7 studies found.\n",
      "  - Gene 'BAX': 67 studies found.\n",
      "  - Gene 'NRAS': 100 studies found.\n",
      "  - Gene 'VHL': 72 studies found.\n",
      "  - Gene 'SRC': 100 studies found.\n",
      "  - Gene 'NF2': 55 studies found.\n",
      "  - Gene 'WT1': 37 studies found.\n",
      "  - Gene 'NTRK1': 33 studies found.\n",
      "==================================================\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import json\n",
    "import time\n",
    "\n",
    "# Define the genes and their categories.\n",
    "gene_categories = {\n",
    "    \"Emerging Breast Cancer Target\": ['CASP8', 'FOXO3'],\n",
    "    \"Lacks Breast Cancer Evidence\": ['CDKN1A', 'BAX', 'NRAS', 'VHL', 'SRC', 'NF2', 'WT1', 'NTRK1']\n",
    "}\n",
    "\n",
    "# Add a dictionary of known NCT IDs for genes that may not be found by the search function.\n",
    "known_nct_ids = {\n",
    "    'CASP8': ['NCT03877159']  # We know this study exists and is relevant.\n",
    "}\n",
    "\n",
    "# Base URL for the modernized ClinicalTrials.gov API (v2.0).\n",
    "API_BASE_URL = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "HEADERS = {'Accept': 'application/json'}\n",
    "\n",
    "def get_full_study_by_nctid(nct_id):\n",
    "    \"\"\"\n",
    "    Retrieves a single study record directly by its NCT ID.\n",
    "    This bypasses the search functionality.\n",
    "    \n",
    "    Args:\n",
    "        nct_id (str): The unique NCT ID of the study.\n",
    "        \n",
    "    Returns:\n",
    "        dict: The full study record as a dictionary, or None if an error occurs.\n",
    "    \"\"\"\n",
    "    url = f\"{API_BASE_URL}/{nct_id}\"\n",
    "    try:\n",
    "        response = requests.get(url, headers=HEADERS)\n",
    "        response.raise_for_status()\n",
    "        return response.json()\n",
    "    except requests.exceptions.RequestException as e:\n",
    "        print(f\"Error retrieving study {nct_id}: {e}\")\n",
    "        return None\n",
    "\n",
    "def search_and_filter_studies(search_term):\n",
    "    \"\"\"\n",
    "    Performs a general search on the API and returns all results.\n",
    "    \n",
    "    Args:\n",
    "        search_term (str): The search term (e.g., 'cancer AND gene').\n",
    "        \n",
    "    Returns:\n",
    "        list: A list of study dictionaries from the API.\n",
    "    \"\"\"\n",
    "    studies = []\n",
    "    \n",
    "    params = {\n",
    "        \"query.term\": search_term,\n",
    "        \"pageSize\": 100\n",
    "    }\n",
    "    \n",
    "    try:\n",
    "        print(f\"Searching for studies with query: '{search_term}'...\")\n",
    "        response = requests.get(API_BASE_URL, headers=HEADERS, params=params)\n",
    "        response.raise_for_status()\n",
    "        data = response.json()\n",
    "        if 'studies' in data:\n",
    "            studies = data['studies']\n",
    "            print(f\"-> API search returned {len(studies)} total studies.\")\n",
    "        else:\n",
    "            print(f\"-> API search returned no studies.\")\n",
    "    except requests.exceptions.RequestException as e:\n",
    "        print(f\"An API error occurred for query '{search_term}': {e}\")\n",
    "        \n",
    "    return studies\n",
    "\n",
    "def find_keyword_in_study_data(study, keyword):\n",
    "    \"\"\"\n",
    "    Checks if a keyword exists anywhere in the full study data.\n",
    "    \n",
    "    Args:\n",
    "        study (dict): The full study dictionary.\n",
    "        keyword (str): The keyword to find.\n",
    "        \n",
    "    Returns:\n",
    "        bool: True if the keyword is found, False otherwise.\n",
    "    \"\"\"\n",
    "    study_text = json.dumps(study).lower()\n",
    "    return keyword.lower() in study_text\n",
    "\n",
    "# Main execution loop to analyze all genes.\n",
    "all_results = {}\n",
    "for category, genes in gene_categories.items():\n",
    "    print(f\"\\n=======================================================\")\n",
    "    print(f\"Analyzing studies for category: '{category}'\")\n",
    "    print(f\"=======================================================\")\n",
    "    \n",
    "    all_results[category] = {}\n",
    "    for gene in genes:\n",
    "        print(f\"\\n--- Processing gene: {gene} ---\")\n",
    "        \n",
    "        search_query = f\"cancer AND {gene}\"\n",
    "        studies_data = search_and_filter_studies(search_query)\n",
    "        \n",
    "        found_studies = []\n",
    "        \n",
    "        # First, filter studies found by the general search.\n",
    "        if studies_data:\n",
    "            for study in studies_data:\n",
    "                if find_keyword_in_study_data(study, gene):\n",
    "                    identification_module = study.get(\"protocolSection\", {}).get(\"identificationModule\", {})\n",
    "                    nct_id = identification_module.get(\"nctId\")\n",
    "                    study_title = identification_module.get(\"briefTitle\")\n",
    "                    found_studies.append({\"NCT ID\": nct_id, \"Title\": study_title})\n",
    "        \n",
    "        # Second, for genes that return zero results, check for known NCT IDs.\n",
    "        if not found_studies and gene in known_nct_ids:\n",
    "            print(f\"General search for '{gene}' failed. Checking known NCT IDs...\")\n",
    "            for nct_id_to_check in known_nct_ids[gene]:\n",
    "                study_data = get_full_study_by_nctid(nct_id_to_check)\n",
    "                if study_data and find_keyword_in_study_data(study_data, gene):\n",
    "                    identification_module = study_data.get(\"protocolSection\", {}).get(\"identificationModule\", {})\n",
    "                    nct_id = identification_module.get(\"nctId\")\n",
    "                    study_title = identification_module.get(\"briefTitle\")\n",
    "                    found_studies.append({\"NCT ID\": nct_id, \"Title\": study_title})\n",
    "                    print(f\"-> Found known study {nct_id_to_check} for '{gene}'.\")\n",
    "                else:\n",
    "                    print(f\"-> Known study {nct_id_to_check} could not be retrieved or did not contain '{gene}'.\")\n",
    "\n",
    "        all_results[category][gene] = found_studies\n",
    "        \n",
    "        if found_studies:\n",
    "            print(f\"\\n-> Found {len(found_studies)} studies for '{gene}':\")\n",
    "            for study in found_studies:\n",
    "                print(f\"   - NCT ID: {study['NCT ID']} | Title: {study['Title']}\")\n",
    "        else:\n",
    "            print(f\"\\n-> No studies found for '{gene}'.\")\n",
    "        \n",
    "        # Add a delay to respect API rate limits.\n",
    "        time.sleep(1)\n",
    "\n",
    "print(\"\\n\\n\" + \"=\"*50)\n",
    "print(\"FINAL SUMMARY OF FINDINGS\")\n",
    "print(\"=\"*50)\n",
    "for category, genes_data in all_results.items():\n",
    "    print(f\"\\nCategory: {category}\")\n",
    "    for gene, studies in genes_data.items():\n",
    "        if studies:\n",
    "            print(f\"  - Gene '{gene}': {len(studies)} studies found.\")\n",
    "        else:\n",
    "            print(f\"  - Gene '{gene}': No studies found.\")\n",
    "print(\"=\"*50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "395da2ba",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Starting search for Breast Cancer studies related to each gene...\n",
      "\n",
      "=======================================================\n",
      "Searching genes in category: 'Emerging Breast Cancer Target'\n",
      "=======================================================\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CASP8'...\n",
      "-> API search found 1 total studies for '\"Breast Cancer\" AND CASP8'.\n",
      "\n",
      "Found 1 studies for gene 'CASP8' in Breast Cancer:\n",
      "   - NCT ID: NCT01440413\n",
      "     Title: Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND FOXO3a'...\n",
      "-> API search found 4 total studies for '\"Breast Cancer\" AND FOXO3a'.\n",
      "\n",
      "Found 4 studies for gene 'FOXO3a' in Breast Cancer:\n",
      "   - NCT ID: NCT02077569\n",
      "     Title: AKT Inhibitor in Oestrogen Positive Breast Cancer\n",
      "     Conditions: Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02326844\n",
      "     Title: BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01339442\n",
      "     Title: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer\n",
      "     Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02260661\n",
      "     Title: Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours\n",
      "     Conditions: Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation\n",
      "--------------------------------------------------\n",
      "\n",
      "=======================================================\n",
      "Searching genes in category: 'Lacks Breast Cancer Evidence'\n",
      "=======================================================\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CDKN1A'...\n",
      "-> API search found 2 total studies for '\"Breast Cancer\" AND CDKN1A'.\n",
      "\n",
      "Found 2 studies for gene 'CDKN1A' in Breast Cancer:\n",
      "   - NCT ID: NCT05889390\n",
      "     Title: Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer\n",
      "     Conditions: HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01472445\n",
      "     Title: Vitamin D and Breast Cancer: Does Weight Make a Difference?\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND BAX'...\n",
      "-> API search found 9 total studies for '\"Breast Cancer\" AND BAX'.\n",
      "\n",
      "Found 9 studies for gene 'BAX' in Breast Cancer:\n",
      "   - NCT ID: NCT01744821\n",
      "     Title: Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer\n",
      "     Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05775575\n",
      "     Title: A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00896857\n",
      "     Title: Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01016665\n",
      "     Title: Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00898976\n",
      "     Title: Biomarkers in Native American Women With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01440413\n",
      "     Title: Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00169000\n",
      "     Title: Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00725374\n",
      "     Title: A Study to Investigate the Effects of Tibolone (Livial) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05358639\n",
      "     Title: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC\n",
      "     Conditions: High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NRAS'...\n",
      "-> API search found 4 total studies for '\"Breast Cancer\" AND NRAS'.\n",
      "\n",
      "Found 4 studies for gene 'NRAS' in Breast Cancer:\n",
      "   - NCT ID: NCT01337765\n",
      "     Title: Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients\n",
      "     Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01363232\n",
      "     Title: Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients\n",
      "     Conditions: Advanced Solid Tumors, Selected Solid Tumors\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND VHL'...\n",
      "-> API search found 1 total studies for '\"Breast Cancer\" AND VHL'.\n",
      "\n",
      "Found 1 studies for gene 'VHL' in Breast Cancer:\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND SRC'...\n",
      "-> API search found 21 total studies for '\"Breast Cancer\" AND SRC'.\n",
      "\n",
      "Found 21 studies for gene 'SRC' in Breast Cancer:\n",
      "   - NCT ID: NCT04436744\n",
      "     Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)\n",
      "     Conditions: Early Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00546104\n",
      "     Title: Phase II Dasatinib Study in Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04282044\n",
      "     Title: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies\n",
      "     Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01144481\n",
      "     Title: Risk Factors for Skeletal Related Events in Breast Cancer Patients Receiving Bisphosphonates for Bone Metastases\n",
      "     Conditions: Bone Metastases, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00780676\n",
      "     Title: Personalized Treatment Selection for Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05999396\n",
      "     Title: FIH, Bispecific CD276xCD3 Antibody CC-3 in Patients With Colorectal Cancer\n",
      "     Conditions: Colorectal Cancer, Breast Carcinoma, Sarcoma, Penile Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04045496\n",
      "     Title: A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors\n",
      "     Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04121286\n",
      "     Title: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China\n",
      "     Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02423902\n",
      "     Title: A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02586987\n",
      "     Title: A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours\n",
      "     Conditions: Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01764087\n",
      "     Title: A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors\n",
      "     Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Gastric Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01306942\n",
      "     Title: Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06526819\n",
      "     Title: SMP-3124LP in Adults With Advanced Solid Tumors\n",
      "     Conditions: Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02561832\n",
      "     Title: A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02720185\n",
      "     Title: Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR\n",
      "     Conditions: Breast Neoplasms, Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04450732\n",
      "     Title: Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors\n",
      "     Conditions: HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01782274\n",
      "     Title: Proteome-based Immunotherapy of Brain Metastases From Breast Cancer\n",
      "     Conditions: Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01104571\n",
      "     Title: Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05082259\n",
      "     Title: ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab\n",
      "     Conditions: Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05963997\n",
      "     Title: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NF2'...\n",
      "-> API search found 5 total studies for '\"Breast Cancer\" AND NF2'.\n",
      "\n",
      "Found 5 studies for gene 'NF2' in Breast Cancer:\n",
      "   - NCT ID: NCT00863122\n",
      "     Title: Concentration and Activity of Lapatinib in Vestibular Schwannomas\n",
      "     Conditions: Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01602887\n",
      "     Title: Relative Bioavailability Study\n",
      "     Conditions: Healthy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01552434\n",
      "     Title: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease\n",
      "     Conditions: Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND WT1'...\n",
      "-> API search found 34 total studies for '\"Breast Cancer\" AND WT1'.\n",
      "\n",
      "Found 34 studies for gene 'WT1' in Breast Cancer:\n",
      "   - NCT ID: NCT02650401\n",
      "     Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\n",
      "     Conditions: Solid Tumors, CNS Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00617929\n",
      "     Title: Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003538\n",
      "     Title: Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003408\n",
      "     Title: Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer\n",
      "     Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00408681\n",
      "     Title: Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant\n",
      "     Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Gastrointestinal Complications, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Childhood Rhabdomyosarcoma, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03761914\n",
      "     Title: Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers\n",
      "     Conditions: Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00079222\n",
      "     Title: Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00004230\n",
      "     Title: Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00020579\n",
      "     Title: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003938\n",
      "     Title: Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003103\n",
      "     Title: Chemotherapy in Treating Patients With Solid Tumors\n",
      "     Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00378781\n",
      "     Title: Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00898612\n",
      "     Title: Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant\n",
      "     Conditions: Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00769613\n",
      "     Title: Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00957736\n",
      "     Title: Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00002854\n",
      "     Title: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003887\n",
      "     Title: Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation\n",
      "     Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02018458\n",
      "     Title: Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00509691\n",
      "     Title: Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00014391\n",
      "     Title: Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00045292\n",
      "     Title: Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003107\n",
      "     Title: Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors\n",
      "     Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00008359\n",
      "     Title: Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00637637\n",
      "     Title: External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01598454\n",
      "     Title: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides\n",
      "     Conditions: Neuroblastoma, Ewing's Sarcoma, Wilm's Tumor, Retinoblastoma, Glioma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01291420\n",
      "     Title: Dendritic Cell Vaccination for Patients with Solid Tumors\n",
      "     Conditions: Glioblastoma, Renal Cell Carcinoma, Sarcomas, Breast Cancers, Malignant Mesothelioma, Colorectal Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00002673\n",
      "     Title: Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00004157\n",
      "     Title: Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors\n",
      "     Conditions: Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00949052\n",
      "     Title: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00010283\n",
      "     Title: Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon\n",
      "     Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003883\n",
      "     Title: Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00569283\n",
      "     Title: Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01220128\n",
      "     Title: Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NTRK1'...\n",
      "-> API search found 12 total studies for '\"Breast Cancer\" AND NTRK1'.\n",
      "\n",
      "Found 12 studies for gene 'NTRK1' in Breast Cancer:\n",
      "   - NCT ID: NCT02650401\n",
      "     Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\n",
      "     Conditions: Solid Tumors, CNS Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02568267\n",
      "     Title: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)\n",
      "     Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00968968\n",
      "     Title: Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05582499\n",
      "     Title: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy\n",
      "     Conditions: Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02571530\n",
      "     Title: Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer\n",
      "     Conditions: Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02576431\n",
      "     Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors\n",
      "     Conditions: Solid Tumors Harboring NTRK Fusion\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05346536\n",
      "     Title: Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)\n",
      "     Conditions: Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Circulating Tumor Cell\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06214793\n",
      "     Title: Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)\n",
      "     Conditions: Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06492447\n",
      "     Title: Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer\n",
      "     Conditions: HER 2 Low-expressing Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03556228\n",
      "     Title: Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma\n",
      "     Conditions: Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Mesothelioma, Thymic Carcinoma, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Esophageal Cancer, Uterine Cancer, Sarcoma, Any Solid Tumors Progressed After a Prior Immunotherapy, Thymoma, Appendiceal Cancer, Olfactory Neuroblastoma\n",
      "--------------------------------------------------\n",
      "\n",
      "\n",
      "==================================================\n",
      "FINAL SUMMARY OF ALL SEARCHES\n",
      "==================================================\n",
      "\n",
      "Category: Emerging Breast Cancer Target\n",
      "  - Gene 'CASP8': 1 studies found.\n",
      "  - Gene 'FOXO3a': 4 studies found.\n",
      "\n",
      "Category: Lacks Breast Cancer Evidence\n",
      "  - Gene 'CDKN1A': 2 studies found.\n",
      "  - Gene 'BAX': 9 studies found.\n",
      "  - Gene 'NRAS': 4 studies found.\n",
      "  - Gene 'VHL': 1 studies found.\n",
      "  - Gene 'SRC': 21 studies found.\n",
      "  - Gene 'NF2': 5 studies found.\n",
      "  - Gene 'WT1': 34 studies found.\n",
      "  - Gene 'NTRK1': 12 studies found.\n",
      "==================================================\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import time\n",
    "\n",
    "# Define the genes and their categories.\n",
    "gene_categories = {\n",
    "    \"Emerging Breast Cancer Target\": ['CASP8', 'FOXO3a'],\n",
    "    \"Lacks Breast Cancer Evidence\": ['CDKN1A', 'BAX', 'NRAS', 'VHL', 'SRC', 'NF2', 'WT1', 'NTRK1']\n",
    "}\n",
    "\n",
    "# The base URL for the modernized ClinicalTrials.gov API (v2.0).\n",
    "API_BASE_URL = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "HEADERS = {'Accept': 'application/json'}\n",
    "\n",
    "def search_studies_for_gene(gene_name):\n",
    "    \"\"\"\n",
    "    Searches the ClinicalTrials.gov API for studies related to a given gene\n",
    "    and the condition \"Breast Cancer\".\n",
    "    \n",
    "    Args:\n",
    "        gene_name (str): The gene to search for.\n",
    "        \n",
    "    Returns:\n",
    "        list: A list of dictionaries, where each dictionary represents a study.\n",
    "    \"\"\"\n",
    "    # Construct a specific query for 'Breast Cancer' and the gene.\n",
    "    search_query = f'\"Breast Cancer\" AND {gene_name}'\n",
    "    \n",
    "    # The API request parameters.\n",
    "    params = {\n",
    "        \"query.term\": search_query,\n",
    "        \"pageSize\": 100 # Retrieve up to 100 studies per call.\n",
    "    }\n",
    "    \n",
    "    studies = []\n",
    "    \n",
    "    try:\n",
    "        print(f\"Searching for studies with query: '{search_query}'...\")\n",
    "        response = requests.get(API_BASE_URL, headers=HEADERS, params=params)\n",
    "        response.raise_for_status() # Raise an error for bad status codes\n",
    "        \n",
    "        data = response.json()\n",
    "        \n",
    "        # The studies are in a list under the 'studies' key.\n",
    "        if 'studies' in data:\n",
    "            studies = data['studies']\n",
    "            print(f\"-> API search found {len(studies)} total studies for '{search_query}'.\")\n",
    "        else:\n",
    "            print(f\"-> No studies found for '{search_query}'.\")\n",
    "\n",
    "    except requests.exceptions.RequestException as e:\n",
    "        print(f\"An API error occurred for query '{search_query}': {e}\")\n",
    "        \n",
    "    return studies\n",
    "\n",
    "def extract_and_display_studies(studies, gene_name):\n",
    "    \"\"\"\n",
    "    Extracts key details and displays them for the found studies.\n",
    "    \n",
    "    Args:\n",
    "        studies (list): The list of study dictionaries from the API.\n",
    "        gene_name (str): The gene name for context.\n",
    "    \"\"\"\n",
    "    found_count = len(studies)\n",
    "    if found_count > 0:\n",
    "        print(f\"\\nFound {found_count} studies for gene '{gene_name}' in Breast Cancer:\")\n",
    "        for study in studies:\n",
    "            # Extract key details from the nested JSON structure.\n",
    "            identification_module = study.get(\"protocolSection\", {}).get(\"identificationModule\", {})\n",
    "            nct_id = identification_module.get(\"nctId\")\n",
    "            study_title = identification_module.get(\"briefTitle\")\n",
    "            conditions = study.get(\"protocolSection\", {}).get(\"conditionsModule\", {}).get(\"conditions\", [])\n",
    "\n",
    "            print(f\"   - NCT ID: {nct_id}\")\n",
    "            print(f\"     Title: {study_title}\")\n",
    "            print(f\"     Conditions: {', '.join(conditions)}\")\n",
    "            print(\"-\" * 50)\n",
    "    else:\n",
    "        print(f\"\\nNo studies found for gene '{gene_name}' in Breast Cancer.\")\n",
    "\n",
    "# Main execution loop to analyze all genes.\n",
    "print(\"Starting search for Breast Cancer studies related to each gene...\")\n",
    "final_summary = {}\n",
    "\n",
    "for category, genes in gene_categories.items():\n",
    "    final_summary[category] = {}\n",
    "    print(f\"\\n=======================================================\")\n",
    "    print(f\"Searching genes in category: '{category}'\")\n",
    "    print(f\"=======================================================\")\n",
    "    \n",
    "    for gene in genes:\n",
    "        studies_found = search_studies_for_gene(gene)\n",
    "        extract_and_display_studies(studies_found, gene)\n",
    "        final_summary[category][gene] = len(studies_found)\n",
    "        \n",
    "        # Add a delay to be respectful of the API's rate limits.\n",
    "        time.sleep(1)\n",
    "\n",
    "print(\"\\n\\n\" + \"=\"*50)\n",
    "print(\"FINAL SUMMARY OF ALL SEARCHES\")\n",
    "print(\"=\"*50)\n",
    "for category, genes_data in final_summary.items():\n",
    "    print(f\"\\nCategory: {category}\")\n",
    "    for gene, count in genes_data.items():\n",
    "        print(f\"  - Gene '{gene}': {count} studies found.\")\n",
    "print(\"=\"*50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "27ee25a8",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Starting search for Breast Cancer studies related to all genes...\n",
      "\n",
      "=======================================================\n",
      "Searching genes in category: 'FDA-approved Breast Cancer Therapy'\n",
      "=======================================================\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CDK4'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND CDK4'.\n",
      "\n",
      "Found 100 studies for gene 'CDK4' in Breast Cancer:\n",
      "   - NCT ID: NCT06585969\n",
      "     Title: A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched, Basal Like\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05141240\n",
      "     Title: A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06705504\n",
      "     Title: A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib\n",
      "     Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05538572\n",
      "     Title: A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04276272\n",
      "     Title: D4 Choline Breast PET/CT\n",
      "     Conditions: HER2-negative Breast Cancer, ER Positive Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07085767\n",
      "     Title: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06905301\n",
      "     Title: Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05932667\n",
      "     Title: Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer\n",
      "     Conditions: Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05303129\n",
      "     Title: Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.\n",
      "     Conditions: Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01919229\n",
      "     Title: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)\n",
      "     Conditions: Early Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05344729\n",
      "     Title: Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects\n",
      "     Conditions: Recurrent/Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05735080\n",
      "     Title: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer\n",
      "     Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05780567\n",
      "     Title: Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03134638\n",
      "     Title: A Study of SY-1365 in Adult Patients With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Ovarian Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05069038\n",
      "     Title: Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05816655\n",
      "     Title: Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05361655\n",
      "     Title: Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04576455\n",
      "     Title: A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)\n",
      "     Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04650581\n",
      "     Title: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06247995\n",
      "     Title: A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05392608\n",
      "     Title: SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)\n",
      "     Conditions: Neoplasm, Breast, Congenital, Familial and Genetic Disorders\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05953350\n",
      "     Title: A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i\n",
      "     Conditions: Inhibition of Autophagy Synergizes Anti-tumor Effect\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04318223\n",
      "     Title: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy\n",
      "     Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06447623\n",
      "     Title: Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer, HR+/HER2- Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03056755\n",
      "     Title: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04869943\n",
      "     Title: Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05933395\n",
      "     Title: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05594095\n",
      "     Title: SNF Platform Study of HR+/ HER2-advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05088395\n",
      "     Title: Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06253195\n",
      "     Title: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05766410\n",
      "     Title: A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC\n",
      "     Conditions: Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Therapy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05135104\n",
      "     Title: Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05759572\n",
      "     Title: Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer Metastatic\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06338644\n",
      "     Title: Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.\n",
      "     Conditions: Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05169567\n",
      "     Title: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer\n",
      "     Conditions: Breast Neoplasm, Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05306340\n",
      "     Title: A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)\n",
      "     Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04137640\n",
      "     Title: Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05601440\n",
      "     Title: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04681768\n",
      "     Title: Abemaciclib in Combination With Endocrine Therapy as First Line Therapy in Metastatic Breast Cancer Patients\n",
      "     Conditions: Breast Cancer/ Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06197581\n",
      "     Title: Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer\n",
      "     Conditions: Breast Cancer, Familial Male, Radiotherapy; Complications, Chemotherapeutic Toxicity, Immune Checkpoint Inhibitor, CDK4/6 Inhibitor, Trastuzumab, Pertuzumab, PARP Inhibitor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02344472\n",
      "     Title: Detect V / CHEVENDO (Chemo vs. Endo)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03195192\n",
      "     Title: Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05372640\n",
      "     Title: Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Breast Carcinoma, Malignant Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06837792\n",
      "     Title: Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer\n",
      "     Conditions: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01872260\n",
      "     Title: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06235931\n",
      "     Title: A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06805812\n",
      "     Title: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study\n",
      "     Conditions: Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03090165\n",
      "     Title: Ribociclib and Bicalutamide in AR+ TNBC\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04289974\n",
      "     Title: Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04595565\n",
      "     Title: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer\n",
      "     Conditions: HER2-negative Breast Cancer, Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04523857\n",
      "     Title: ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02297438\n",
      "     Title: A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02657343\n",
      "     Title: An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06016738\n",
      "     Title: OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05251714\n",
      "     Title: CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer\n",
      "     Conditions: Advanced Solid Tumor, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03285412\n",
      "     Title: CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01740427\n",
      "     Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02154776\n",
      "     Title: Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.\n",
      "     Conditions: Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06810492\n",
      "     Title: The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment\n",
      "     Conditions: Breast Cancer Stage III, Breast Cancer Stage II\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03024489\n",
      "     Title: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma\n",
      "     Conditions: Head and Neck Cancer, Locally Advanced\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06997029\n",
      "     Title: A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04738292\n",
      "     Title: Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)\n",
      "     Conditions: ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06929325\n",
      "     Title: Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors\n",
      "     Conditions: HR+/HER2- Advanced/Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05861830\n",
      "     Title: Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06388122\n",
      "     Title: DiviTumTKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03955939\n",
      "     Title: A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05238922\n",
      "     Title: Study of INCB123667 in Subjects With Advanced Solid Tumors\n",
      "     Conditions: Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05038735\n",
      "     Title: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05153135\n",
      "     Title: Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03280563\n",
      "     Title: A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05982886\n",
      "     Title: Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03781063\n",
      "     Title: Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation\n",
      "     Conditions: Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02753686\n",
      "     Title: Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy  Targeted Therapy\n",
      "     Conditions: HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07019363\n",
      "     Title: CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients\n",
      "     Conditions: Breast Cancer, Adjuvant Therapy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04585724\n",
      "     Title: Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases\n",
      "     Conditions: Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04022616\n",
      "     Title: Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05252416\n",
      "     Title: (VELA) Study of BLU-222 in Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03750396\n",
      "     Title: Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor, Her2-negative Tumor, Surgery\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05512416\n",
      "     Title: Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05708235\n",
      "     Title: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07086196\n",
      "     Title: A Study of Real-World Outcomes of Ribociclib in First-Line Treatment for Metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Metastatic HR+/HER2- Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07096024\n",
      "     Title: A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04964934\n",
      "     Title: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)\n",
      "     Conditions: ER-Positive HER2-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05809024\n",
      "     Title: Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy\n",
      "     Conditions: Locally Advanced Breast Cancer, Hormone Receptor PositiveHER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06599216\n",
      "     Title: Adebrelimab Combined with Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer\n",
      "     Conditions: Breast Cancer, HR+/HER2- Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03238196\n",
      "     Title: Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06680596\n",
      "     Title: Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy\n",
      "     Conditions: Breast Cancer Metastatic, Breast Cancer Stage IV\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04707196\n",
      "     Title: A Study of Abemaciclib in Indian Women With Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms, Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03130439\n",
      "     Title: Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06764186\n",
      "     Title: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain\n",
      "     Conditions: Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04355858\n",
      "     Title: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer, Metastatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05795335\n",
      "     Title: CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06367335\n",
      "     Title: Characteristics and Predictors of Liver Injury in Cyclin-dependent Kinase Inhibitors 4/6 (CDK4/6)-Treated Patients With Advanced Breast Cancer\n",
      "     Conditions: DILI\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439735\n",
      "     Title: Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05501886\n",
      "     Title: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05743686\n",
      "     Title: App for Adverse Events to Oral Chemotherapy - Pilot Study\n",
      "     Conditions: Breast Neoplasms, Chemotherapeutic Toxicity\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03081234\n",
      "     Title: Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND ERBB2'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND ERBB2'.\n",
      "\n",
      "Found 100 studies for gene 'ERBB2' in Breast Cancer:\n",
      "   - NCT ID: NCT05697146\n",
      "     Title: Ribociclib Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2- Advanced or Metastatic Breast Cancer in France\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02619669\n",
      "     Title: Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03822468\n",
      "     Title: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03906669\n",
      "     Title: A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.\n",
      "     Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05893368\n",
      "     Title: New Model for Integrating Person-based Care (PbC) in the Treatment of Advanced HER2-negative Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02384746\n",
      "     Title: Phase I Study of the Combination of MLN9708 and Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01526369\n",
      "     Title: A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05261269\n",
      "     Title: A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer\n",
      "     Conditions: HER2-negative Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06042569\n",
      "     Title: Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01176669\n",
      "     Title: Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06962969\n",
      "     Title: A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database\n",
      "     Conditions: Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06722612\n",
      "     Title: Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00490646\n",
      "     Title: A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06236269\n",
      "     Title: HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan\n",
      "     Conditions: Breast Cancer Stage IV\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03125746\n",
      "     Title: A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06585969\n",
      "     Title: A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched, Basal Like\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03637868\n",
      "     Title: Eribulin in Brain Metastases From HER2-negative Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00530569\n",
      "     Title: Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01262469\n",
      "     Title: Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer.\n",
      "     Conditions: Metastatic Breast Cancer, 70 Years Old Patients and Over, After One Line of Chemotherapy With Trastuzumab\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04001569\n",
      "     Title: AZD8186 and Paclitaxel in Advanced Gastric Cancer\n",
      "     Conditions: Solid Tumor, Stomach Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07038369\n",
      "     Title: A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations\n",
      "     Conditions: Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05461768\n",
      "     Title: A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Breast Cancer, Locally Advanced or Metastatic Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03176238\n",
      "     Title: Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer\n",
      "     Conditions: Post Menopausal Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01889238\n",
      "     Title: Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer\n",
      "     Conditions: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03863223\n",
      "     Title: A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05141240\n",
      "     Title: A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003440\n",
      "     Title: Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic\n",
      "     Conditions: HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06361940\n",
      "     Title: Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01705340\n",
      "     Title: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery\n",
      "     Conditions: Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04278144\n",
      "     Title: A First-in-human Study Using BDC-1001 As a Single Agent and in Combination with Nivolumab in Advanced HER2-Expressing Solid Tumors\n",
      "     Conditions: HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05376644\n",
      "     Title: Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01479244\n",
      "     Title: Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence\n",
      "     Conditions: Breast Cancer With Low to Intermediate HER2 Expression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00912444\n",
      "     Title: Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06764940\n",
      "     Title: A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients with Brain Metastases\n",
      "     Conditions: HER2-negative Breast Cancer Patients with Brain Metastases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06144944\n",
      "     Title: Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer\n",
      "     Conditions: Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02854644\n",
      "     Title: Study of the Anti-tumoral Immune Response\n",
      "     Conditions: Breast Cancer, Glioma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00826267\n",
      "     Title: 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04464967\n",
      "     Title: Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, Esophageal Cancer, Ovarian Cancer, Endometrium Cancer, Bladder Cancer, Pancreatic Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cervical Cancer, Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01991340\n",
      "     Title: H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00272740\n",
      "     Title: SAKK - a Trial to Evaluate Antitumor Efficacy of Faslodex After Aromatase Inhibitor Failure in Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00773344\n",
      "     Title: Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin\n",
      "     Conditions: Solid Tumors, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04436744\n",
      "     Title: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)\n",
      "     Conditions: Early Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02654444\n",
      "     Title: Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01783444\n",
      "     Title: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03561740\n",
      "     Title: A Study of the Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04817540\n",
      "     Title: Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)\n",
      "     Conditions: HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04609540\n",
      "     Title: Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC\n",
      "     Conditions: HER2-positive Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06641544\n",
      "     Title: The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02404844\n",
      "     Title: Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01329640\n",
      "     Title: Feasibility Study of Metronomic Chemotherapy for Locally Advanced Her2- Positive Breast Cancer (TraQ-Me 01)\n",
      "     Conditions: Locally Advanced HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05328440\n",
      "     Title: Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06993844\n",
      "     Title: Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00892567\n",
      "     Title: Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07063667\n",
      "     Title: Artificial Intelligence Model-Assisted Accurate Diagnosis of Early-Stage Breast Cancer\n",
      "     Conditions: Breast Cancer, Metastatic, Artifical Intelligence\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01038804\n",
      "     Title: A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02345772\n",
      "     Title: Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy\n",
      "     Conditions: HER2-positive Breast Cancer, ER-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05191004\n",
      "     Title: Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC\n",
      "     Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02780401\n",
      "     Title: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission\n",
      "     Conditions: HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00608972\n",
      "     Title: Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02865304\n",
      "     Title: The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients\n",
      "     Conditions: Angiogenesis, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05041972\n",
      "     Title: ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)\n",
      "     Conditions: HER2 Mutation-Related Tumors, HER2 Amplified Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05953168\n",
      "     Title: T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients\n",
      "     Conditions: Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00650572\n",
      "     Title: A Study of ARRY-380 in Patients With Advanced HER2+ Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01772472\n",
      "     Title: A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03847168\n",
      "     Title: KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer\n",
      "     Conditions: Breast Cancer, Gastric/Gastroesophageal Junction Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06274268\n",
      "     Title: Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments\n",
      "     Conditions: Sarcopenia, Oncology, Physical Inactivity, Toxicity Due to Chemotherapy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03858972\n",
      "     Title: Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06653972\n",
      "     Title: Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer\n",
      "     Conditions: Her2-negative Metastatic Breast Cancer, Vinorelbine, Liposomal Doxorubicin\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00146172\n",
      "     Title: Study Evaluating HKI-272 in Tumors\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01004172\n",
      "     Title: Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases\n",
      "     Conditions: Metastatic Breast Cancer, Breast Cancer, Progressive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00964704\n",
      "     Title: A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01462604\n",
      "     Title: Pilot Study of Patient's Adherence to TYKERB/TYVERB + Capecitabine in Metastatic Breast Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02747004\n",
      "     Title: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05431504\n",
      "     Title: The Efficacy and Safety of Dalpiciclib Plus Endocrine Therapy in HR-positive / HER2-negative Advanced Breast Cancer Patients With Visceral Crisis\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01421472\n",
      "     Title: A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer\n",
      "     Conditions: ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06639672\n",
      "     Title: Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer\n",
      "     Conditions: HR+HER2- Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00432172\n",
      "     Title: Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00544804\n",
      "     Title: Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2\n",
      "     Conditions: Breast Cancer, Metastatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00007904\n",
      "     Title: Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05203601\n",
      "     Title: A Phase a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06607601\n",
      "     Title: CARE Initiative: Real-world Emulation of the PALOMA-2 Trial\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04262804\n",
      "     Title: A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC\n",
      "     Conditions: Breast Cancer Metastatic\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06705504\n",
      "     Title: A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib\n",
      "     Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05453604\n",
      "     Title: Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications\n",
      "     Conditions: Breast Cancer, Prostate Cancer, Urine, Liquid Biopsy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02236572\n",
      "     Title: Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05194072\n",
      "     Title: A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors\n",
      "     Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04033172\n",
      "     Title: Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )\n",
      "     Conditions: Breast Cancer, HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00999804\n",
      "     Title: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03974204\n",
      "     Title: Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.\n",
      "     Conditions: Breast Cancer, Leptomeningeal Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05981001\n",
      "     Title: Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03774472\n",
      "     Title: Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02773004\n",
      "     Title: Prospective Study Assessing EndoPredict Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06619704\n",
      "     Title: Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02296801\n",
      "     Title: A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer\n",
      "     Conditions: Breast Cancer, Breast Carcinoma, Breast Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04042701\n",
      "     Title: DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06417801\n",
      "     Title: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05378204\n",
      "     Title: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05132101\n",
      "     Title: Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05458401\n",
      "     Title: EUropean Real-world Experience Of Previously Treated Advanced/Metastatic HER2-positive Breast Cancer Patients Accessing Trastuzumab Deruxtecan\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05654623\n",
      "     Title: A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CCND1'...\n",
      "-> API search found 34 total studies for '\"Breast Cancer\" AND CCND1'.\n",
      "\n",
      "Found 34 studies for gene 'CCND1' in Breast Cancer:\n",
      "   - NCT ID: NCT03906669\n",
      "     Title: A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.\n",
      "     Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02651844\n",
      "     Title: Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03454529\n",
      "     Title: The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer\n",
      "     Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02774681\n",
      "     Title: Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis\n",
      "     Conditions: Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00039455\n",
      "     Title: Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06739395\n",
      "     Title: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion\n",
      "     Conditions: Solid Tumor, Precision Medicine\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04289974\n",
      "     Title: Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01740427\n",
      "     Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03024489\n",
      "     Title: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma\n",
      "     Conditions: Head and Neck Cancer, Locally Advanced\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00299286\n",
      "     Title: Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05429684\n",
      "     Title: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer\n",
      "     Conditions: HER2+ Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01037790\n",
      "     Title: Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer\n",
      "     Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439046\n",
      "     Title: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02936206\n",
      "     Title: Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03535506\n",
      "     Title: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery\n",
      "     Conditions: DCIS\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683770\n",
      "     Title: Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683757\n",
      "     Title: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01497626\n",
      "     Title: Lapatinib and Bortezomib in Patients With Advanced Malignancies\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00898976\n",
      "     Title: Biomarkers in Native American Women With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03304080\n",
      "     Title: Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast\n",
      "     Conditions: Breast Neoplasms, Breast Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00721409\n",
      "     Title: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06998407\n",
      "     Title: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CDK Gene Mutation, CCND1 Gene Amplification, CDK4 Gene Amplification\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04705909\n",
      "     Title: Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00062751\n",
      "     Title: Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04436120\n",
      "     Title: Treatment Resistance Following Anti-cancer Therapies\n",
      "     Conditions: Disease Progression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01339442\n",
      "     Title: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer\n",
      "     Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06328387\n",
      "     Title: HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683445\n",
      "     Title: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050398\n",
      "     Title: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04681911\n",
      "     Title: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02255461\n",
      "     Title: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors\n",
      "     Conditions: Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02187783\n",
      "     Title: LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)\n",
      "     Conditions: Tumors With CDK4/6 Pathway Activation\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CDKN2A'...\n",
      "-> API search found 27 total studies for '\"Breast Cancer\" AND CDKN2A'.\n",
      "\n",
      "Found 27 studies for gene 'CDKN2A' in Breast Cancer:\n",
      "   - NCT ID: NCT06253195\n",
      "     Title: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01740427\n",
      "     Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03024489\n",
      "     Title: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma\n",
      "     Conditions: Head and Neck Cancer, Locally Advanced\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04676516\n",
      "     Title: A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02603679\n",
      "     Title: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases\n",
      "     Conditions: Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06257264\n",
      "     Title: A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors\n",
      "     Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439046\n",
      "     Title: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04606446\n",
      "     Title: Study of PF-07248144 in Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02682836\n",
      "     Title: Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04557449\n",
      "     Title: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors\n",
      "     Conditions: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03760536\n",
      "     Title: Get REAL and HEEL Research Program\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02000089\n",
      "     Title: The Cancer of the Pancreas Screening-5 CAPS5)Study\n",
      "     Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00721409\n",
      "     Title: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06998407\n",
      "     Title: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CDK Gene Mutation, CCND1 Gene Amplification, CDK4 Gene Amplification\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06105632\n",
      "     Title: A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment\n",
      "     Conditions: Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06760637\n",
      "     Title: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05216432\n",
      "     Title: First-in-Human Study of Mutant-selective PI3K Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer\n",
      "     Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05926024\n",
      "     Title: Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01305954\n",
      "     Title: Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06789653\n",
      "     Title: A Novel Approach Utilizing Organ Specific Age Proteomics\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01138345\n",
      "     Title: Biomarkers in Blood Samples From Older Breast Cancer Survivors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050398\n",
      "     Title: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06120283\n",
      "     Title: BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02592083\n",
      "     Title: Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors\n",
      "     Conditions: Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02187783\n",
      "     Title: LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)\n",
      "     Conditions: Tumors With CDK4/6 Pathway Activation\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND FOXO3a'...\n",
      "-> API search found 4 total studies for '\"Breast Cancer\" AND FOXO3a'.\n",
      "\n",
      "Found 4 studies for gene 'FOXO3a' in Breast Cancer:\n",
      "   - NCT ID: NCT02077569\n",
      "     Title: AKT Inhibitor in Oestrogen Positive Breast Cancer\n",
      "     Conditions: Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02326844\n",
      "     Title: BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01339442\n",
      "     Title: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer\n",
      "     Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02260661\n",
      "     Title: Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours\n",
      "     Conditions: Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND KRAS'...\n",
      "-> API search found 38 total studies for '\"Breast Cancer\" AND KRAS'.\n",
      "\n",
      "Found 38 studies for gene 'KRAS' in Breast Cancer:\n",
      "   - NCT ID: NCT05321329\n",
      "     Title: Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients\n",
      "     Conditions: Pseudomyxoma Peritonei\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06048367\n",
      "     Title: Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor\n",
      "     Conditions: Advanced Solid Tumor, Lung Cancer, Pancreas Cancer, Breast Cancer, Thyroid Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Vulva Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02259114\n",
      "     Title: A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)\n",
      "     Conditions: NUT Midline Carcinoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation, Castrate-resistant Prostate Cancer, CRPC, Pancreatic Ductal Adenocarcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03804255\n",
      "     Title: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting\n",
      "     Conditions: Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06739395\n",
      "     Title: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion\n",
      "     Conditions: Solid Tumor, Precision Medicine\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00894504\n",
      "     Title: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04045496\n",
      "     Title: A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors\n",
      "     Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04121286\n",
      "     Title: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China\n",
      "     Conditions: Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03284684\n",
      "     Title: Kinetics of Perioperative Circulating DNA in Cancer Surgery\n",
      "     Conditions: Breast Cancer, Prostate Cancer, Colon Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02022202\n",
      "     Title: Breast Cancer Genome Guided Therapy Study (BEAUTY)\n",
      "     Conditions: Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06047379\n",
      "     Title: Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis\n",
      "     Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01037790\n",
      "     Title: Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer\n",
      "     Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04485013\n",
      "     Title: TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02253251\n",
      "     Title: Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01414933\n",
      "     Title: High Throughput Technologies to Drive Breast Cancer Patients to Specific Phase I/II Trials of Targeted Agents\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04439175\n",
      "     Title: Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02583542\n",
      "     Title: A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers\n",
      "     Conditions: Triple-Negative Breast Cancer, Squamous Cell Lung Cancer, Non-squamous Cell Lung Cancer With KRAS Mutations, Non-squamous Cell Lung Cancer With Wild-type KRAS\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01337765\n",
      "     Title: Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients\n",
      "     Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01347866\n",
      "     Title: Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer\n",
      "     Conditions: Advanced Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02071862\n",
      "     Title: Study of the Glutaminase Inhibitor CB-839 in Solid Tumors\n",
      "     Conditions: Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Mesothelioma, Fumarate Hydratase (FH)-Deficient Tumors, Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST), Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors, Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations, Tumors Harboring Amplifications in the cMyc Gene\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01520389\n",
      "     Title: Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment\n",
      "     Conditions: Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04073680\n",
      "     Title: A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors\n",
      "     Conditions: Breast Cancer, Endometrial Cancer, Lung Cancer, Colo-rectal Cancer, Head and Neck Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04025541\n",
      "     Title: Analysis of Circulating Tumor Markers in Blood\n",
      "     Conditions: Cancer, Breast Cancer, Sarcoma, Lung Cancers, Glioma, Colon Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07064018\n",
      "     Title: Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies\n",
      "     Conditions: Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS Mutation-Related Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05785741\n",
      "     Title: A Study of DB-1310 in Advanced/Metastatic Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01513356\n",
      "     Title: Pharmacodynamic Study of BKM120 in Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06625775\n",
      "     Title: Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors\n",
      "     Conditions: Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors, HER2-positive Metastatic Breast Cancer, KRAS Mutant Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Colorectal Cancer, Advanced Lung Cancer, HR-positive, HER2-negative Advanced Breast Cancer, HER2-positive Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00740532\n",
      "     Title: Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01363232\n",
      "     Title: Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients\n",
      "     Conditions: Advanced Solid Tumors, Selected Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01430585\n",
      "     Title: Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer\n",
      "     Conditions: Early Breast Cancer (Phase 2), Advanced Breast Cancer (Phase 1b)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01451632\n",
      "     Title: A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers\n",
      "     Conditions: Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Other Tumors With EGFR Dependence\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06253520\n",
      "     Title: Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer\n",
      "     Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Gastrointestinal Cancer, Ovarian Cancer, Genitourinary Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05107674\n",
      "     Title: A Study of NX-1607 in Adults With Advanced Malignancies\n",
      "     Conditions: Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02779751\n",
      "     Title: A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer\n",
      "     Conditions: Non Small Cell Lung Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01306045\n",
      "     Title: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies\n",
      "     Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04856371\n",
      "     Title: Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01920061\n",
      "     Title: A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)\n",
      "     Conditions: Neoplasm\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND FGFR1'...\n",
      "-> API search found 21 total studies for '\"Breast Cancer\" AND FGFR1'.\n",
      "\n",
      "Found 21 studies for gene 'FGFR1' in Breast Cancer:\n",
      "   - NCT ID: NCT02202746\n",
      "     Title: A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer, Metastatic Breast Cancer, MBC, HER2 Positive, HER2, Estrogen Receptor Positive, ER, Triple Negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03238196\n",
      "     Title: Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01795768\n",
      "     Title: Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours\n",
      "     Conditions: Gastric Cancer, Oesophageal Cancer, Breast Cancer, Squamous Cell Carcinoma of the Lung\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01928459\n",
      "     Title: Phase 1b Trial of BGJ398/BYL719 in Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Metastatic Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01202591\n",
      "     Title: Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients\n",
      "     Conditions: FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02619162\n",
      "     Title: Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06551896\n",
      "     Title: Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor\n",
      "     Conditions: Urothelial Carcinoma, Breast Neoplasms, Lung Cancer, Gastric Cancer, Soft Tissue Sarcoma, Other Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02052778\n",
      "     Title: A Study of TAS-120 in Patients With Advanced Solid Tumors\n",
      "     Conditions: Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033287\n",
      "     Title: Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.\n",
      "     Conditions: Breast Cancer, Endocrine Therapy, CDK4/6 Inhibitors, Subsequent Treatment\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01791985\n",
      "     Title: AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04504331\n",
      "     Title: Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05560334\n",
      "     Title: A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04024436\n",
      "     Title: A Study of TAS-120 in Patients With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02053636\n",
      "     Title: A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00958971\n",
      "     Title: Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04125693\n",
      "     Title: Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01594177\n",
      "     Title: Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy\n",
      "     Conditions: Unilateral HER2 Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04483505\n",
      "     Title: Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer.\n",
      "     Conditions: Breast Cancer Metastatic, Hormone Receptor Positive Malignant Neoplasm of Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00572728\n",
      "     Title: Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer\n",
      "     Conditions: Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND MDM2'...\n",
      "-> API search found 9 total studies for '\"Breast Cancer\" AND MDM2'.\n",
      "\n",
      "Found 9 studies for gene 'MDM2' in Breast Cancer:\n",
      "   - NCT ID: NCT02326844\n",
      "     Title: BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07078604\n",
      "     Title: A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03725436\n",
      "     Title: ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors\n",
      "     Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05455658\n",
      "     Title: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05622058\n",
      "     Title: A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer\n",
      "     Conditions: Prevention of Chemotherapy-induced Myelosuppression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04025541\n",
      "     Title: Analysis of Circulating Tumor Markers in Blood\n",
      "     Conditions: Cancer, Breast Cancer, Sarcoma, Lung Cancers, Glioma, Colon Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03566485\n",
      "     Title: Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer\n",
      "     Conditions: Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Estrogen Receptor-positive, HER2/Neu Negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05012397\n",
      "     Title: Milademetan in Advanced/Metastatic Solid Tumors\n",
      "     Conditions: Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma, Lung Adenocarcinoma, Bladder Urothelial Carcinoma, Stomach Adenocarcinoma, Breast Cancer Invasive, Ovarian Carcinoma, Cervical Cancer, Non Small Cell Lung Cancer, Gastric Cancer, Biliary Tract Cancer, Melanoma, Pancreas Cancer, MDM2 Gene Amplification, Testicular Germ Cell Tumor, Adrenocortical Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02157051\n",
      "     Title: Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer\n",
      "     Conditions: HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NF1'...\n",
      "-> API search found 11 total studies for '\"Breast Cancer\" AND NF1'.\n",
      "\n",
      "Found 11 studies for gene 'NF1' in Breast Cancer:\n",
      "   - NCT ID: NCT00863122\n",
      "     Title: Concentration and Activity of Lapatinib in Vestibular Schwannomas\n",
      "     Conditions: Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04355858\n",
      "     Title: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer, Metastatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01602887\n",
      "     Title: Relative Bioavailability Study\n",
      "     Conditions: Healthy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01552434\n",
      "     Title: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease\n",
      "     Conditions: Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02834013\n",
      "     Title: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors\n",
      "     Conditions: Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05554354\n",
      "     Title: Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05054374\n",
      "     Title: A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer\n",
      "     Conditions: Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05564377\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial\n",
      "     Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND AKT1'...\n",
      "-> API search found 40 total studies for '\"Breast Cancer\" AND AKT1'.\n",
      "\n",
      "Found 40 studies for gene 'AKT1' in Breast Cancer:\n",
      "   - NCT ID: NCT07038369\n",
      "     Title: A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations\n",
      "     Conditions: Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms, ER Positive Breast Cancer, Cervical Cancers, Cervical Neoplasms, Cervical Carcinoma, Triple Negative Breast Cancer, Gynecologic Cancers, Gynecologic Neoplasm, Endometrial Cancer, Endometrial Neoplasm, Endometrial Carcinoma (EC), Fallopian Cancer, Ovarian Carcinoma, Ovarian Cancer, Ovarian Neoplasms, Prostate Cancers, Prostate Carcinoma, Solid Tumors, Neoplasms, Neoplasms by Site, Breast Diseases, Uterine Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06417801\n",
      "     Title: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03804255\n",
      "     Title: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting\n",
      "     Conditions: Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04650581\n",
      "     Title: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02476955\n",
      "     Title: Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole\n",
      "     Conditions: Solid Tumors, Ovarian Cancer, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05933395\n",
      "     Title: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06837792\n",
      "     Title: Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer\n",
      "     Conditions: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05735392\n",
      "     Title: Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00399529\n",
      "     Title: Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01226316\n",
      "     Title: Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules\n",
      "     Conditions: Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01964924\n",
      "     Title: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer\n",
      "     Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05498896\n",
      "     Title: Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04305496\n",
      "     Title: Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03318263\n",
      "     Title: CIrCuLAting Dna ESr1 Gene Mutations Analysis\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06764186\n",
      "     Title: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain\n",
      "     Conditions: Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05826964\n",
      "     Title: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer\n",
      "     Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04920708\n",
      "     Title: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression\n",
      "     Conditions: Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03310541\n",
      "     Title: AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations\n",
      "     Conditions: Breast Cancer, Prostate Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06851442\n",
      "     Title: Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant InjectionTQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05810870\n",
      "     Title: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin\n",
      "     Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01915576\n",
      "     Title: Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients\n",
      "     Conditions: Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02162719\n",
      "     Title: A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05455619\n",
      "     Title: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer\n",
      "     Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00054132\n",
      "     Title: Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer\n",
      "     Conditions: Recurrent Breast Carcinoma, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06533059\n",
      "     Title: A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors\n",
      "     Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02273752\n",
      "     Title: Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer\n",
      "     Conditions: Estrogen Receptor-positive Breast Cancer, Gastrinoma, Glucagonoma, HER2-negative Breast Cancer, Insulinoma, Mucositis, Oral Complications, Pancreatic Polypeptide Tumor, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Islet Cell Carcinoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Renal Cell Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Renal Cell Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01861054\n",
      "     Title: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03168074\n",
      "     Title: Phase II Study of Single Agent Lenvatinib\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01344031\n",
      "     Title: MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04862663\n",
      "     Title: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)\n",
      "     Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03337724\n",
      "     Title: A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04851613\n",
      "     Title: Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02340845\n",
      "     Title: Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01306045\n",
      "     Title: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies\n",
      "     Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01177397\n",
      "     Title: Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma\n",
      "     Conditions: Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04253561\n",
      "     Title: Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00182728\n",
      "     Title: Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND BRCA1'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND BRCA1'.\n",
      "\n",
      "Found 100 studies for gene 'BRCA1' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03531840\n",
      "     Title: Olaparib in People With Malignant Mesothelioma\n",
      "     Conditions: Mesothelioma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04613440\n",
      "     Title: FaCT Trial (Facilitated Cascade Testing Trial)\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02326844\n",
      "     Title: BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04330040\n",
      "     Title: Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer\n",
      "     Conditions: Ovarian Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03075540\n",
      "     Title: Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00043472\n",
      "     Title: Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk\n",
      "     Conditions: Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03159572\n",
      "     Title: Homologous Recombination Inquiry Through Ovarian Malignancy Investigations\n",
      "     Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02661204\n",
      "     Title: Diagnostic Performance of an Automated Breast Ultrasound System (ABUS)\n",
      "     Conditions: Breast Cancer, Implants\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06417801\n",
      "     Title: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05378204\n",
      "     Title: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06403904\n",
      "     Title: Assessing Clinical Features and Outcome of Breast Cancer in PALB2 Mutation Carriers: the Palbreast Study\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05209529\n",
      "     Title: Chemo-free BRCA-targeted Neoadjuvant Strategy\n",
      "     Conditions: TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06022029\n",
      "     Title: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.\n",
      "     Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02157792\n",
      "     Title: M6620 First in Human Study\n",
      "     Conditions: Advanced Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04012229\n",
      "     Title: IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)\n",
      "     Conditions: Breast Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04991480\n",
      "     Title: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Advanced Cancer, Metastatic Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033092\n",
      "     Title: Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion\n",
      "     Conditions: BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, ATM Gene Mutation, CHEK2 Gene Mutation, CDH1 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04866992\n",
      "     Title: Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)\n",
      "     Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Ductal Carcinoma in Situ, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02009150\n",
      "     Title: Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03032614\n",
      "     Title: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients\n",
      "     Conditions: Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04593381\n",
      "     Title: Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer\n",
      "     Conditions: Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Oligometastatic Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06405295\n",
      "     Title: Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation\n",
      "     Conditions: Breast Carcinoma, BRCA Mutation, Adjuvant Drug Therapy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06732323\n",
      "     Title: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer\n",
      "     Conditions: Triple-Negative Breast Cancer (TNBC)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02032823\n",
      "     Title: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05141708\n",
      "     Title: Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m\n",
      "     Conditions: Metastatic Breast Cancer, Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02978495\n",
      "     Title: Neoadjuvant Carboplatin in Triple Negative Breast Cancer\n",
      "     Conditions: BRCA1 Hereditary Breast and Ovarian Cancer Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02957981\n",
      "     Title: The Genetic Education for Men Trial: Web-Based Education vs. Standard Care\n",
      "     Conditions: Prostate Carcinoma, Breast Neoplasm, Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00664781\n",
      "     Title: Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer\n",
      "     Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00419510\n",
      "     Title: Genetic Counseling in African American Women\n",
      "     Conditions: Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03546972\n",
      "     Title: Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants\n",
      "     Conditions: Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity, Overweight, Premalignant Lesion\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05763472\n",
      "     Title: Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation\n",
      "     Conditions: BRCA-Associated Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03696004\n",
      "     Title: Outcome of Neo-adjuvant Chemotherapy Followed by Breast Conservative Surgery in Breast Cancer in Upper Egypt\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03358004\n",
      "     Title: the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02139904\n",
      "     Title: Vinorelbine in Mesothelioma\n",
      "     Conditions: Mesothelioma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00028340\n",
      "     Title: High-Risk Breast Duct Epithelium\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01237067\n",
      "     Title: Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers\n",
      "     Conditions: Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06324240\n",
      "     Title: Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02993068\n",
      "     Title: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)\n",
      "     Conditions: BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03667612\n",
      "     Title: Endogenous Mechanisms of Inactivation of the Endothelium Tumor\n",
      "     Conditions: Breast Cancer, Colon Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03709446\n",
      "     Title: Leflunomide in Previously Treated Metastatic Triple Negative Cancers\n",
      "     Conditions: Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01591746\n",
      "     Title: Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction\n",
      "     Conditions: Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03918668\n",
      "     Title: Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women\n",
      "     Conditions: Breast Neoplasm Female, Nutrition Related Cancer, Habits, Diet, Cancer, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02826512\n",
      "     Title: A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06429644\n",
      "     Title: Long-term Oncologic Outcome of Breast-conserving Surgery in Breast Cancer Patients With BRCA1/2 Mutations\n",
      "     Conditions: BRCA1/2 Mutation, Breast-conserving Surgery\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02516540\n",
      "     Title: Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03955640\n",
      "     Title: Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences\n",
      "     Conditions: Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04090567\n",
      "     Title: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer\n",
      "     Conditions: Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04257474\n",
      "     Title: Barriers to Screening Breast MRI Utilization Among Patients at Elevated Risk\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03911973\n",
      "     Title: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers\n",
      "     Conditions: TNBC - Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01426880\n",
      "     Title: Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer\n",
      "     Conditions: Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer Stage IV, Inflammatory Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01907438\n",
      "     Title: Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells\n",
      "     Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01898312\n",
      "     Title: BRCA1/2 and Effect of Mifepristone on the Breast\n",
      "     Conditions: Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00381927\n",
      "     Title: Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03015376\n",
      "     Title: Inherited Susceptible Genes Among Epithelial Ovarian Cancer\n",
      "     Conditions: Ovarian Neoplasm Epithelial, Hereditary Breast and Ovarian Cancer Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02557776\n",
      "     Title: Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05629429\n",
      "     Title: Olaparib Maintenance Therapy in Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03510689\n",
      "     Title: Genetics and Heart Health After Cancer Therapy\n",
      "     Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, Brca2), Heart Diseases, Drug-Induced Cardiomyopathy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02087592\n",
      "     Title: Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01525589\n",
      "     Title: A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01748825\n",
      "     Title: AZD1775 for Advanced Solid Tumors\n",
      "     Conditions: Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00040222\n",
      "     Title: Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer\n",
      "     Conditions: Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02000622\n",
      "     Title: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.\n",
      "     Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03570125\n",
      "     Title: BRCA Main Home Nutritional Intervention-random Study\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06726330\n",
      "     Title: Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer\n",
      "     Conditions: Tubo-ovarian Carcinoma, High-grade Serous Carcinoma, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV, Primary Peritoneal Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00006425\n",
      "     Title: Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06484725\n",
      "     Title: Oncotype DX in BRCA-mutated Breast Cancer Patients: Our Experience. A Retrospective Observational Monocentric Study\n",
      "     Conditions: Breast Cancer, Genetic Predisposition\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04617730\n",
      "     Title: Efficacy of the Mepitel Film on the Prevention of Radiodermatitis in the Inguinal Fold.\n",
      "     Conditions: Radiodermatitis, Radiation Toxicity, Radiotherapy Side Effect\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02571725\n",
      "     Title: PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer\n",
      "     Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04224922\n",
      "     Title: Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05409222\n",
      "     Title: Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00783822\n",
      "     Title: Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05448963\n",
      "     Title: Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy\n",
      "     Conditions: Nipple-sparing Mastectomy, Prophylactic Mastectomy, Breast Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05391763\n",
      "     Title: Bilateral Prophylactic Mastectomy; Should we Preserve the Pectoral Fascia?\n",
      "     Conditions: BRCA1/2 Mutation, Bilateral Prophylactic Mastectomy, Seroma, Pectoral Fascia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03990896\n",
      "     Title: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02418624\n",
      "     Title: Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Advanced Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02034916\n",
      "     Title: A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)\n",
      "     Conditions: Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06534424\n",
      "     Title: Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study\n",
      "     Conditions: BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04182516\n",
      "     Title: Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors\n",
      "     Conditions: Advanced/Metastatic Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00001496\n",
      "     Title: Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer\n",
      "     Conditions: Breast Neoplasm, Hereditary Neoplastic Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00155896\n",
      "     Title: Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06833216\n",
      "     Title: Familial Breast Cancer in China\n",
      "     Conditions: Breast Carcinoma, Genetic Variation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01975363\n",
      "     Title: Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer\n",
      "     Conditions: Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02593435\n",
      "     Title: The Registration Program of BRCA1/2 Gene\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00673335\n",
      "     Title: Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation\n",
      "     Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02849496\n",
      "     Title: Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer\n",
      "     Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00776958\n",
      "     Title: Lynne Cohen Consortium Project: Multi-Center Database/Registry\n",
      "     Conditions: Ovarian Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06201234\n",
      "     Title: Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03470402\n",
      "     Title: Decision Support for BRCA Testing in Ethnically Diverse Women\n",
      "     Conditions: Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02783664\n",
      "     Title: Evaluating the Effects of Genetic Testing on Patients' Stress Levels\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06792721\n",
      "     Title: MEASUREMENT OF CIRCULATING MUTATION BURDEN\n",
      "     Conditions: Breast Carcinoma, Genetic Predisposition to Cancer, BRCA Mutation, cfMB, Mutation Burden\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05404321\n",
      "     Title: Establishment of an ex Vivo Tumor Collection of Triple-negative Breast Cancers in Order to Validate the Interest of Innovative Therapies and the Search for Predictive Biomarkers of Response to Treatment\n",
      "     Conditions: Triple Negative Breast Cancer, Organoid\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06279364\n",
      "     Title: A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04598321\n",
      "     Title: BrUOG 390: Neoadjuvant Treatment With Talazoparib\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer, High Grade Serous Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05306002\n",
      "     Title: Nutritional Intervention and DNA Damage of Patients With HBOC\n",
      "     Conditions: HBOC Syndrome, DNA Damage, Nutrition Therapy\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND HRAS'...\n",
      "-> API search found 4 total studies for '\"Breast Cancer\" AND HRAS'.\n",
      "\n",
      "Found 4 studies for gene 'HRAS' in Breast Cancer:\n",
      "   - NCT ID: NCT03804255\n",
      "     Title: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting\n",
      "     Conditions: Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03676257\n",
      "     Title: Survival Endpoints for Treatment Evaluation in Subjects Treated for Metastatic Breast Cancer: Contribution of Real-life Databases\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01306045\n",
      "     Title: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies\n",
      "     Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND TP53'...\n",
      "-> API search found 56 total studies for '\"Breast Cancer\" AND TP53'.\n",
      "\n",
      "Found 56 studies for gene 'TP53' in Breast Cancer:\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05203601\n",
      "     Title: A Phase a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03544723\n",
      "     Title: Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.\n",
      "     Conditions: Solid Tumor, Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00004038\n",
      "     Title: Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04585750\n",
      "     Title: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)\n",
      "     Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00646555\n",
      "     Title: Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02965950\n",
      "     Title: The p53 Breast Cancer Trial\n",
      "     Conditions: Locally Advanced Breast Cancer, Metastatic Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04966923\n",
      "     Title: Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53\n",
      "     Conditions: Breast Cancer, TP53 R337H, Li-Fraumeni Syndrome, Prognosis Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06739395\n",
      "     Title: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion\n",
      "     Conditions: Solid Tumor, Precision Medicine\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03918668\n",
      "     Title: Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women\n",
      "     Conditions: Breast Neoplasm Female, Nutrition Related Cancer, Habits, Diet, Cancer, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04213872\n",
      "     Title: Gene Expression, Meditative Movement, and Emotional Distress (GME)\n",
      "     Conditions: Cognitive Impairment\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01748825\n",
      "     Title: AZD1775 for Advanced Solid Tumors\n",
      "     Conditions: Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03570125\n",
      "     Title: BRCA Main Home Nutritional Intervention-random Study\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06125522\n",
      "     Title: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06778863\n",
      "     Title: A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation\n",
      "     Conditions: Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02432963\n",
      "     Title: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy\n",
      "     Conditions: Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01027416\n",
      "     Title: Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04676516\n",
      "     Title: A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06833216\n",
      "     Title: Familial Breast Cancer in China\n",
      "     Conditions: Breast Carcinoma, Genetic Variation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05429684\n",
      "     Title: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer\n",
      "     Conditions: HER2+ Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01386502\n",
      "     Title: CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors\n",
      "     Conditions: Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00082979\n",
      "     Title: Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00589238\n",
      "     Title: Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00017095\n",
      "     Title: Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04335669\n",
      "     Title: NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC\n",
      "     Conditions: Breast Cancer, Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03949946\n",
      "     Title: Is Lipid Mapping an Effective Early Detection Tool for Breast Cancer in High-risk Populations?\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03725436\n",
      "     Title: ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors\n",
      "     Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05877599\n",
      "     Title: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation\n",
      "     Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02783300\n",
      "     Title: An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma\n",
      "     Conditions: Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683770\n",
      "     Title: Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06278870\n",
      "     Title: Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial\n",
      "     Conditions: HER2-positive Metastatic Breast Cancer, First-line Treatment\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05622058\n",
      "     Title: A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer\n",
      "     Conditions: Prevention of Chemotherapy-induced Myelosuppression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05431582\n",
      "     Title: Phase I Study of ZN-c3 and Bevacizumab  Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors\n",
      "     Conditions: Tumors, Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683757\n",
      "     Title: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01981525\n",
      "     Title: A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome\n",
      "     Conditions: Li-Fraumeni Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04293094\n",
      "     Title: Study of AMG 650 in Adult Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00496860\n",
      "     Title: Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies\n",
      "     Conditions: Progressive Metastatic Malignancies\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06888388\n",
      "     Title: Long-term Safety of Nipple Sparing Mastectomy in Women With GPV in Breast Cancer\n",
      "     Conditions: Breast Cancer Surgery\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00054132\n",
      "     Title: Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer\n",
      "     Conditions: Recurrent Breast Carcinoma, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01344837\n",
      "     Title: Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer\n",
      "     Conditions: Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03566485\n",
      "     Title: Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer\n",
      "     Conditions: Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Estrogen Receptor-positive, HER2/Neu Negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05012397\n",
      "     Title: Milademetan in Advanced/Metastatic Solid Tumors\n",
      "     Conditions: Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma, Lung Adenocarcinoma, Bladder Urothelial Carcinoma, Stomach Adenocarcinoma, Breast Cancer Invasive, Ovarian Carcinoma, Cervical Cancer, Non Small Cell Lung Cancer, Gastric Cancer, Biliary Tract Cancer, Melanoma, Pancreas Cancer, MDM2 Gene Amplification, Testicular Germ Cell Tumor, Adrenocortical Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02624973\n",
      "     Title: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02866149\n",
      "     Title: Analysis of Circulating Tumor Markers in the Blood (ALCINA)\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04823871\n",
      "     Title: Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing\n",
      "     Conditions: Ovarian Epithelial Cancer, Carcinoma in Situ, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05093387\n",
      "     Title: SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06328387\n",
      "     Title: HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683445\n",
      "     Title: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00044993\n",
      "     Title: Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04681911\n",
      "     Title: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04704661\n",
      "     Title: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial\n",
      "     Conditions: Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04253561\n",
      "     Title: Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05963997\n",
      "     Title: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CDK6'...\n",
      "-> API search found 35 total studies for '\"Breast Cancer\" AND CDK6'.\n",
      "\n",
      "Found 35 studies for gene 'CDK6' in Breast Cancer:\n",
      "   - NCT ID: NCT05538572\n",
      "     Title: A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01919229\n",
      "     Title: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)\n",
      "     Conditions: Early Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05135104\n",
      "     Title: Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01740427\n",
      "     Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04707196\n",
      "     Title: A Study of Abemaciclib in Indian Women With Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms, Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03130439\n",
      "     Title: Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03283384\n",
      "     Title: Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01958021\n",
      "     Title: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer\n",
      "     Conditions: Advanced, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06264921\n",
      "     Title: A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors\n",
      "     Conditions: Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Cancer, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03184090\n",
      "     Title: Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02310243\n",
      "     Title: Study of Palbociclib in MLL-rearranged Acute Leukemias\n",
      "     Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439046\n",
      "     Title: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05905341\n",
      "     Title: Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Liposarcoma, Non-small Cell Lung Cancer (NSCLC), Endometrial, Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04923542\n",
      "     Title: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases\n",
      "     Conditions: Brain Metastases, HR+ Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03535506\n",
      "     Title: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery\n",
      "     Conditions: DCIS\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06586957\n",
      "     Title: A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors\n",
      "     Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02941926\n",
      "     Title: Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02763566\n",
      "     Title: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02831530\n",
      "     Title: Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03959891\n",
      "     Title: AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06001762\n",
      "     Title: TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer\n",
      "     Conditions: Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02732119\n",
      "     Title: Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04360941\n",
      "     Title: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05596409\n",
      "     Title: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02626507\n",
      "     Title: Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02422615\n",
      "     Title: Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07100054\n",
      "     Title: Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors\n",
      "     Conditions: CDK4/6 Inhibitor, Breast Cancer, CYP3A4 Protein, Human, Drug Interaction, Pharmacogenetic Testing\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02278120\n",
      "     Title: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer\n",
      "     Conditions: Advanced Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04436120\n",
      "     Title: Treatment Resistance Following Anti-cancer Therapies\n",
      "     Conditions: Disease Progression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04282031\n",
      "     Title: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer\n",
      "     Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06133088\n",
      "     Title: Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.\n",
      "     Conditions: Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050398\n",
      "     Title: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02255461\n",
      "     Title: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors\n",
      "     Conditions: Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02187783\n",
      "     Title: LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)\n",
      "     Conditions: Tumors With CDK4/6 Pathway Activation\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND PTEN'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND PTEN'.\n",
      "\n",
      "Found 100 studies for gene 'PTEN' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04001569\n",
      "     Title: AZD8186 and Paclitaxel in Advanced Gastric Cancer\n",
      "     Conditions: Solid Tumor, Stomach Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01705340\n",
      "     Title: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery\n",
      "     Conditions: Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00826267\n",
      "     Title: 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04216472\n",
      "     Title: Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04515004\n",
      "     Title: Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer\n",
      "     Conditions: Early Stage Lung Cancer (I and II)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06417801\n",
      "     Title: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05111080\n",
      "     Title: Partial PTEN Deletion in Breast Cancer\n",
      "     Conditions: PTEN Gene Deletion\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03804255\n",
      "     Title: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting\n",
      "     Conditions: Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04650581\n",
      "     Title: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00885755\n",
      "     Title: A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03273595\n",
      "     Title: Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05933395\n",
      "     Title: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02038010\n",
      "     Title: BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx\n",
      "     Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00894504\n",
      "     Title: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03709446\n",
      "     Title: Leflunomide in Previously Treated Metastatic Triple Negative Cancers\n",
      "     Conditions: Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06837792\n",
      "     Title: Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer\n",
      "     Conditions: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01514565\n",
      "     Title: Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01898312\n",
      "     Title: BRCA1/2 and Effect of Mifepristone on the Breast\n",
      "     Conditions: Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05735392\n",
      "     Title: Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04034589\n",
      "     Title: Pyrotinib in Combination With Fulvestrant in Patients With HER2 PositiveHR-Positive Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01575522\n",
      "     Title: Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00820222\n",
      "     Title: Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer\n",
      "     Conditions: Metastases, Brain\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01042925\n",
      "     Title: Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen\n",
      "     Conditions: Breast Cancer, Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00299286\n",
      "     Title: Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01226316\n",
      "     Title: Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules\n",
      "     Conditions: Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00553358\n",
      "     Title: Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01964924\n",
      "     Title: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer\n",
      "     Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05498896\n",
      "     Title: Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02833896\n",
      "     Title: Endometrial Cancer and Array CGH\n",
      "     Conditions: Cancer of the Endometrium\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04305496\n",
      "     Title: Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06764186\n",
      "     Title: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain\n",
      "     Conditions: Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05429684\n",
      "     Title: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer\n",
      "     Conditions: HER2+ Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00499603\n",
      "     Title: Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02022202\n",
      "     Title: Breast Cancer Genome Guided Therapy Study (BEAUTY)\n",
      "     Conditions: Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05826964\n",
      "     Title: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer\n",
      "     Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03624543\n",
      "     Title: CFI-400945 in Patients With Advanced/Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00579514\n",
      "     Title: Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients\n",
      "     Conditions: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04920708\n",
      "     Title: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression\n",
      "     Conditions: Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01534455\n",
      "     Title: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04508803\n",
      "     Title: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer\n",
      "     Conditions: Treatment Efficacy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03206203\n",
      "     Title: Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439046\n",
      "     Title: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01240941\n",
      "     Title: Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04345913\n",
      "     Title: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01013506\n",
      "     Title: Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00429299\n",
      "     Title: Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04439175\n",
      "     Title: Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01992952\n",
      "     Title: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer\n",
      "     Conditions: Estrogen Receptor Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01562275\n",
      "     Title: A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05810870\n",
      "     Title: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin\n",
      "     Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01434420\n",
      "     Title: Triple Negative Breast Cancer: Study of Molecular and Genetic Factors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01277757\n",
      "     Title: Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer\n",
      "     Conditions: Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03207529\n",
      "     Title: Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer\n",
      "     Conditions: Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Androgen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, PTEN Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01572727\n",
      "     Title: A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00574366\n",
      "     Title: Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01497626\n",
      "     Title: Lapatinib and Bortezomib in Patients With Advanced Malignancies\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03218826\n",
      "     Title: PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery\n",
      "     Conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01347866\n",
      "     Title: Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer\n",
      "     Conditions: Advanced Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01596530\n",
      "     Title: Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment\n",
      "     Conditions: Breast Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00437294\n",
      "     Title: Enzastaurin in Combination of Capecitabine to Treat Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01633060\n",
      "     Title: A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02684318\n",
      "     Title: Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors\n",
      "     Conditions: Advanced Cancer, Ovarian Cancer, Endometrial Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05057013\n",
      "     Title: A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours\n",
      "     Conditions: Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer, RAS Wild Type Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Oesophageal Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Cancer of the Head and Neck\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02162719\n",
      "     Title: A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05455619\n",
      "     Title: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer\n",
      "     Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04360941\n",
      "     Title: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00281658\n",
      "     Title: Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01990209\n",
      "     Title: Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02301988\n",
      "     Title: A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06888388\n",
      "     Title: Long-term Safety of Nipple Sparing Mastectomy in Women With GPV in Breast Cancer\n",
      "     Conditions: Breast Cancer Surgery\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04251533\n",
      "     Title: Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss\n",
      "     Conditions: Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033287\n",
      "     Title: Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.\n",
      "     Conditions: Breast Cancer, Endocrine Therapy, CDK4/6 Inhibitors, Subsequent Treatment\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01884285\n",
      "     Title: AZD8186 First Time In Patient Ascending Dose Study\n",
      "     Conditions: Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01344837\n",
      "     Title: Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer\n",
      "     Conditions: Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00740532\n",
      "     Title: Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04265937\n",
      "     Title: ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies\n",
      "     Conditions: Breast Cancer, Genetic Susceptibility\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01138085\n",
      "     Title: Safety, Pharmacokinetics (PK) of AKT and MEK Combination\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01430585\n",
      "     Title: Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer\n",
      "     Conditions: Early Breast Cancer (Phase 2), Advanced Breast Cancer (Phase 1b)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02286687\n",
      "     Title: Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes\n",
      "     Conditions: Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01861054\n",
      "     Title: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00062751\n",
      "     Title: Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05410951\n",
      "     Title: LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients\n",
      "     Conditions: Lobular Breast Carcinoma, Lobular in Situ Breast Carcinoma, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00317720\n",
      "     Title: Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer\n",
      "     Conditions: Breast Cancer, Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01785420\n",
      "     Title: Pre Operative Trastuzumab in Operable Breast Cancer\n",
      "     Conditions: Carcinoma Breast Stage I, HER2 Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01344031\n",
      "     Title: MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01377363\n",
      "     Title: Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04862663\n",
      "     Title: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)\n",
      "     Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04108858\n",
      "     Title: Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03337724\n",
      "     Title: A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01937117\n",
      "     Title: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06183736\n",
      "     Title: CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND MYC'...\n",
      "-> API search found 15 total studies for '\"Breast Cancer\" AND MYC'.\n",
      "\n",
      "Found 15 studies for gene 'MYC' in Breast Cancer:\n",
      "   - NCT ID: NCT02651844\n",
      "     Title: Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06357338\n",
      "     Title: Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma\n",
      "     Conditions: Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02635672\n",
      "     Title: Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer\n",
      "     Conditions: Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01534455\n",
      "     Title: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05546268\n",
      "     Title: Study of Oral MRT-2359 in Selected Cancer Patients\n",
      "     Conditions: NSCLC, SCLC, High Grade Neuroendocrine Cancer, DLBCL, L-MYC and N-MYC Amplified Solid Tumors, NSCLC With High or Low L-MYC or N-MYC Expression, HR-positive, HER2-negative Breast Cancer, Prostate Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03085368\n",
      "     Title: A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04718675\n",
      "     Title: A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)\n",
      "     Conditions: Relapsed Solid Tumors, Refractory Solid Tumors, Non-Hodgkin Lymphoma, HGSOC, Platinum Resistant High Grade Serous Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03950570\n",
      "     Title: ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02431260\n",
      "     Title: An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies\n",
      "     Conditions: Solid Tumors and Hematologic Malignancy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05159518\n",
      "     Title: A Study of PRT2527 in Participants With Advanced Solid Tumors\n",
      "     Conditions: Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02711137\n",
      "     Title: Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies\n",
      "     Conditions: Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00740532\n",
      "     Title: Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01104571\n",
      "     Title: Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01676753\n",
      "     Title: Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer\n",
      "     Conditions: Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00898898\n",
      "     Title: Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND BRCA2'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND BRCA2'.\n",
      "\n",
      "Found 100 studies for gene 'BRCA2' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04613440\n",
      "     Title: FaCT Trial (Facilitated Cascade Testing Trial)\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02326844\n",
      "     Title: BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00043472\n",
      "     Title: Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk\n",
      "     Conditions: Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02661204\n",
      "     Title: Diagnostic Performance of an Automated Breast Ultrasound System (ABUS)\n",
      "     Conditions: Breast Cancer, Implants\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06417801\n",
      "     Title: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06403904\n",
      "     Title: Assessing Clinical Features and Outcome of Breast Cancer in PALB2 Mutation Carriers: the Palbreast Study\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05209529\n",
      "     Title: Chemo-free BRCA-targeted Neoadjuvant Strategy\n",
      "     Conditions: TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06022029\n",
      "     Title: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.\n",
      "     Conditions: Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin, Mantle Cell Lymphoma, Bladder Cancer, Uveal Melanoma, Recurrent, Cervix Cancer, Carcinoma in Situ, Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Cancer, Tumor, Solid, Tumor Recurrence\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02157792\n",
      "     Title: M6620 First in Human Study\n",
      "     Conditions: Advanced Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04012229\n",
      "     Title: IMpact of Breast cAncer Gene Status on Survival in Adjuvant Breast Cancer (IMBASSA)\n",
      "     Conditions: Breast Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04991480\n",
      "     Title: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Advanced Cancer, Metastatic Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033092\n",
      "     Title: Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion\n",
      "     Conditions: BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, ATM Gene Mutation, CHEK2 Gene Mutation, CDH1 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04866992\n",
      "     Title: Prospective Registry Trial for Single Port Robot-assisted Nipple Sparing Mastectomy (SPrNSM)\n",
      "     Conditions: Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Ductal Carcinoma in Situ, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03390608\n",
      "     Title: Prognostic and Predictive Factors for Small Breast Tumors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02009150\n",
      "     Title: Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03032614\n",
      "     Title: Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients\n",
      "     Conditions: Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06640881\n",
      "     Title: Preoperative Partial Breast Reirradiation and Repeat Breast-conserving Surgery in Patients With Recurrent Breast Cancer: the REPEAT Trial\n",
      "     Conditions: Recurrent Breast Carcinoma, Ipsilateral Recurrence\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02957981\n",
      "     Title: The Genetic Education for Men Trial: Web-Based Education vs. Standard Care\n",
      "     Conditions: Prostate Carcinoma, Breast Neoplasm, Pancreatic Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00664781\n",
      "     Title: Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer\n",
      "     Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00419510\n",
      "     Title: Genetic Counseling in African American Women\n",
      "     Conditions: Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03546972\n",
      "     Title: Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants\n",
      "     Conditions: Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity, Overweight, Premalignant Lesion\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03358004\n",
      "     Title: the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01237067\n",
      "     Title: Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers\n",
      "     Conditions: Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02993068\n",
      "     Title: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)\n",
      "     Conditions: BARD1 Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, Estrogen Receptor Negative, HER2/Neu Negative, MLH1 Gene Mutation, MSH2 Gene Mutation, MSH6 Gene Mutation, PALB2 Gene Mutation, PMS2 Gene Mutation, Progesterone Receptor Negative, RAD51C Gene Mutation, RAD51D Gene Mutation, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03667612\n",
      "     Title: Endogenous Mechanisms of Inactivation of the Endothelium Tumor\n",
      "     Conditions: Breast Cancer, Colon Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01591746\n",
      "     Title: Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction\n",
      "     Conditions: Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03918668\n",
      "     Title: Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women\n",
      "     Conditions: Breast Neoplasm Female, Nutrition Related Cancer, Habits, Diet, Cancer, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04075604\n",
      "     Title: A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer\n",
      "     Conditions: Breast Cancer, Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04090567\n",
      "     Title: Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer\n",
      "     Conditions: Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01907438\n",
      "     Title: Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells\n",
      "     Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00381927\n",
      "     Title: Effect of Counseling on Psychological Stress Amongst Women Felt to be at High Risk for Breast Cancer Development\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02557776\n",
      "     Title: Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03510689\n",
      "     Title: Genetics and Heart Health After Cancer Therapy\n",
      "     Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, Brca2), Heart Diseases, Drug-Induced Cardiomyopathy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00040222\n",
      "     Title: Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer\n",
      "     Conditions: Familial Ovarian Cancer, Familial Breast Cancer, BRCA1-associate Malignancies, BRCA2-associated Malignancies\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02000622\n",
      "     Title: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.\n",
      "     Conditions: Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03570125\n",
      "     Title: BRCA Main Home Nutritional Intervention-random Study\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06726330\n",
      "     Title: Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer\n",
      "     Conditions: Tubo-ovarian Carcinoma, High-grade Serous Carcinoma, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV, Primary Peritoneal Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00006425\n",
      "     Title: Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06484725\n",
      "     Title: Oncotype DX in BRCA-mutated Breast Cancer Patients: Our Experience. A Retrospective Observational Monocentric Study\n",
      "     Conditions: Breast Cancer, Genetic Predisposition\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02571725\n",
      "     Title: PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer\n",
      "     Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04224922\n",
      "     Title: Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00783822\n",
      "     Title: Effects of Rapid Genetic Counseling and Testing in Newly Diagnosed Breast Cancer Patients\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03652935\n",
      "     Title: Mindfulness, Breast Cancer and Psycho-Immune Dysregulation\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05448963\n",
      "     Title: Pilot Study of Single-port Robot-assisted Nipple-sparing Mastectomy\n",
      "     Conditions: Nipple-sparing Mastectomy, Prophylactic Mastectomy, Breast Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03990896\n",
      "     Title: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02418624\n",
      "     Title: Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Advanced Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02034916\n",
      "     Title: A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)\n",
      "     Conditions: Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06534424\n",
      "     Title: Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study\n",
      "     Conditions: BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04182516\n",
      "     Title: Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors\n",
      "     Conditions: Advanced/Metastatic Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00155896\n",
      "     Title: Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06833216\n",
      "     Title: Familial Breast Cancer in China\n",
      "     Conditions: Breast Carcinoma, Genetic Variation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01975363\n",
      "     Title: Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer\n",
      "     Conditions: Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02593435\n",
      "     Title: The Registration Program of BRCA1/2 Gene\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00673335\n",
      "     Title: Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation\n",
      "     Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00776958\n",
      "     Title: Lynne Cohen Consortium Project: Multi-Center Database/Registry\n",
      "     Conditions: Ovarian Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06201234\n",
      "     Title: Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03470402\n",
      "     Title: Decision Support for BRCA Testing in Ethnically Diverse Women\n",
      "     Conditions: Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06127979\n",
      "     Title: A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02783664\n",
      "     Title: Evaluating the Effects of Genetic Testing on Patients' Stress Levels\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06792721\n",
      "     Title: MEASUREMENT OF CIRCULATING MUTATION BURDEN\n",
      "     Conditions: Breast Carcinoma, Genetic Predisposition to Cancer, BRCA Mutation, cfMB, Mutation Burden\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04621721\n",
      "     Title: Home-Based Physical Activity Intervention for Taxane-Induced CIPN\n",
      "     Conditions: Breast Cancer Female, Chemotherapy-induced Peripheral Neuropathy, Gait Disorders, Neurologic, Balance; Distorted, Muscle Weakness\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04598321\n",
      "     Title: BrUOG 390: Neoadjuvant Treatment With Talazoparib\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer, High Grade Serous Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05306002\n",
      "     Title: Nutritional Intervention and DNA Damage of Patients With HBOC\n",
      "     Conditions: HBOC Syndrome, DNA Damage, Nutrition Therapy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04668521\n",
      "     Title: Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection\n",
      "     Conditions: Adnexal Mass, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Hereditary Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01874184\n",
      "     Title: Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer\n",
      "     Conditions: Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03428802\n",
      "     Title: Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability\n",
      "     Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm, POLD1 Gene Mutation, POLE Gene Mutation, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Stage III Breast Cancer AJCC v7, Stage III Ovarian Cancer AJCC v8, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00580021\n",
      "     Title: Clinical Outcomes in Hereditary Cancer\n",
      "     Conditions: Breast Cancer, Pancreatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00006421\n",
      "     Title: Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01986764\n",
      "     Title: E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy\n",
      "     Conditions: Planned RRSO\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03414684\n",
      "     Title: Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06402084\n",
      "     Title: The Relationship Between Fatty Liver and Breast Cancer\n",
      "     Conditions: The Relationship Between Fatty Liver and Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02950064\n",
      "     Title: A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations\n",
      "     Conditions: Pancreatic Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03475979\n",
      "     Title: Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing\n",
      "     Conditions: Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, Recurrent Breast Cancer, Metachronous Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06856343\n",
      "     Title: REBECCA Real-world Early BrEast CanCer mAnagement\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03294343\n",
      "     Title: Risk-Reducing Surgeries for Hereditary Ovarian Cancer\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovariectomy, Hysterectomy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00677079\n",
      "     Title: Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer\n",
      "     Conditions: Primary Peritoneal Cancer, Advanced Epithelial Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04450264\n",
      "     Title: Increasing African Immigrant Women's Participation in Breast Cancer Screening\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01339650\n",
      "     Title: Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer\n",
      "     Conditions: Fallopian Tube, Primary Peritoneal Cancer, Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00579514\n",
      "     Title: Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients\n",
      "     Conditions: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02530008\n",
      "     Title: Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer\n",
      "     Conditions: Women With Suspected or Confirmed Recurrent Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00897455\n",
      "     Title: Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers\n",
      "     Conditions: brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04584255\n",
      "     Title: Niraparib + Dostarlimab In BRCA Mutated Breast Cancer\n",
      "     Conditions: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03351803\n",
      "     Title: BRCA Founder OutReach (BFOR) Study\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02133703\n",
      "     Title: Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility\n",
      "     Conditions: Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00582803\n",
      "     Title: Adherence to Intensive Surveillance for Hereditary Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00555503\n",
      "     Title: Registry of Mastectomy for Breast Cancer Risk Reduction\n",
      "     Conditions: Quality of Life, Mastectomy, Breast Neoplasms, Genetic Predisposition to Disease, Adjustment Disorder\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05252390\n",
      "     Title: NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04335669\n",
      "     Title: NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC\n",
      "     Conditions: Breast Cancer, Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01230346\n",
      "     Title: Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer\n",
      "     Conditions: No Evidence of Disease, BRCA1 Syndrome, BRCA2 Syndrome, Hereditary Female Breast Carcinoma, Hereditary Ovarian Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03901469\n",
      "     Title: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01905046\n",
      "     Title: Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer\n",
      "     Conditions: Atypical Ductal Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00580112\n",
      "     Title: An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01102569\n",
      "     Title: Pancreatic Cancer Genetics\n",
      "     Conditions: Pancreatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04151368\n",
      "     Title: Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy\n",
      "     Conditions: Breast Cancer, Surgery--Complications, Genetic Predisposition to Disease, Surgery, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00001468\n",
      "     Title: Outcomes of Education and Counseling for BRCA1 Testing\n",
      "     Conditions: Breast Neoplasms, Ovarian Neoplasms\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND PIK3CA'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND PIK3CA'.\n",
      "\n",
      "Found 100 studies for gene 'PIK3CA' in Breast Cancer:\n",
      "   - NCT ID: NCT06993844\n",
      "     Title: Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03006172\n",
      "     Title: To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer\n",
      "     Conditions: Breast Cancer, Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05203601\n",
      "     Title: A Phase a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05453604\n",
      "     Title: Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications\n",
      "     Conditions: Breast Cancer, Prostate Cancer, Urine, Liquid Biopsy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04216472\n",
      "     Title: Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06417801\n",
      "     Title: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02125344\n",
      "     Title: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)\n",
      "     Conditions: Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04544189\n",
      "     Title: Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03804255\n",
      "     Title: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting\n",
      "     Conditions: Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02514681\n",
      "     Title: A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer\n",
      "     Conditions: HER2-positive Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04650581\n",
      "     Title: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01776008\n",
      "     Title: Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer\n",
      "     Conditions: Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05392608\n",
      "     Title: SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)\n",
      "     Conditions: Neoplasm, Breast, Congenital, Familial and Genetic Disorders\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03056755\n",
      "     Title: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02476955\n",
      "     Title: Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole\n",
      "     Conditions: Solid Tumors, Ovarian Cancer, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05933395\n",
      "     Title: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05594095\n",
      "     Title: SNF Platform Study of HR+/ HER2-advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02038010\n",
      "     Title: BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx\n",
      "     Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05230810\n",
      "     Title: Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.\n",
      "     Conditions: HER2-positive Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01501604\n",
      "     Title: BKM120 in Cancers With PIK3CA Activating Mutations\n",
      "     Conditions: Lung Cancer, Breast Cancer, Colorectal Cancer, Cholangiocarcinoma, Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00894504\n",
      "     Title: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04473040\n",
      "     Title: Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer\n",
      "     Conditions: HR+, HER2-, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02411344\n",
      "     Title: Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy\n",
      "     Conditions: Endocrine Sensitive HER2+/HR+ Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06837792\n",
      "     Title: Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer\n",
      "     Conditions: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01872260\n",
      "     Title: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06805812\n",
      "     Title: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study\n",
      "     Conditions: Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma, Breast Diseases, Breast Neoplasms, Breast Neoplasms, Male, Breast Cancer, Breast Cancer With Metastatic Bone Disease, Breast Cancers, Breast Neoplasm, Breast Tumors, HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer, HR+ Advanced or Metastatic Breast Cancer, HR+/HER2- Breast Cancer, HRpos Breast Neoplasms, HR-positive, HER2-negative Advanced Breast Cancer, HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer, HR-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Breast Neoplasms, Hormone Receptor Positive HER-2 Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Hormone Receptor Positive Metastatic Breast Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer, Hormone Receptor Negative Breast Cancer, Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer, Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Hormone Receptor Positive (HR+), HER2-negative Breast Cancer, Hormone Receptor (HR)-Positive Breast Cancer, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer, Palbociclib, Ribociclib, Abemaciclib, CDK4/6 Inhibitor, CDK4/6 Inhibitors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05735392\n",
      "     Title: Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04034589\n",
      "     Title: Pyrotinib in Combination With Fulvestrant in Patients With HER2 PositiveHR-Positive Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05038735\n",
      "     Title: Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05982886\n",
      "     Title: Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05063786\n",
      "     Title: Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01226316\n",
      "     Title: Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules\n",
      "     Conditions: Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05708235\n",
      "     Title: A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00553358\n",
      "     Title: Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02833896\n",
      "     Title: Endometrial Cancer and Array CGH\n",
      "     Conditions: Cancer of the Endometrium\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04305496\n",
      "     Title: Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03318263\n",
      "     Title: CIrCuLAting Dna ESr1 Gene Mutations Analysis\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01625286\n",
      "     Title: Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients\n",
      "     Conditions: Advanced or Metastatic Breast Cancer, ER+ve Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06764186\n",
      "     Title: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain\n",
      "     Conditions: Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04586335\n",
      "     Title: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.\n",
      "     Conditions: Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04631835\n",
      "     Title: Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05501886\n",
      "     Title: Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03726879\n",
      "     Title: A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07054190\n",
      "     Title: A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06982521\n",
      "     Title: Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer\n",
      "     Conditions: PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02340221\n",
      "     Title: A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02088684\n",
      "     Title: Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04762979\n",
      "     Title: Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer\n",
      "     Conditions: Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer, PIK3CA Mutant Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01346579\n",
      "     Title: Biomarkers in Tissue Samples From Older Women With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05826964\n",
      "     Title: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer\n",
      "     Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05966584\n",
      "     Title: A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07073755\n",
      "     Title: Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd\n",
      "     Conditions: Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer, HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC), Treatment Decisions\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05631795\n",
      "     Title: Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04480814\n",
      "     Title: Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04920708\n",
      "     Title: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression\n",
      "     Conditions: Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04862143\n",
      "     Title: Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03206203\n",
      "     Title: Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04300790\n",
      "     Title: Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02834403\n",
      "     Title: L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients\n",
      "     Conditions: Metastatic Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439046\n",
      "     Title: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01923168\n",
      "     Title: Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05625087\n",
      "     Title: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib\n",
      "     Conditions: Breast Cancer Stage IV\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04345913\n",
      "     Title: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03805399\n",
      "     Title: FUSCC Refractory TNBC Umbrella (FUTURE)\n",
      "     Conditions: Triple-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04191499\n",
      "     Title: A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01918306\n",
      "     Title: GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06846099\n",
      "     Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903\n",
      "     Conditions: Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Breast Cancer, Solid Tumor Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01219699\n",
      "     Title: A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene\n",
      "     Conditions: Advanced Solid Tumors With an Alteration of the PIK3CA Gene, Estrogen Receptor Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04439175\n",
      "     Title: Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01928459\n",
      "     Title: Phase 1b Trial of BGJ398/BYL719 in Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Metastatic Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06706570\n",
      "     Title: PIK3CA Mutational Status Assessment\n",
      "     Conditions: Breast Cancer Metastatic\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01992952\n",
      "     Title: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer\n",
      "     Conditions: Estrogen Receptor Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683770\n",
      "     Title: Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06278870\n",
      "     Title: Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial\n",
      "     Conditions: HER2-positive Metastatic Breast Cancer, First-line Treatment\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05810870\n",
      "     Title: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin\n",
      "     Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05022342\n",
      "     Title: Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03767335\n",
      "     Title: MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer\n",
      "     Conditions: Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05025735\n",
      "     Title: Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683757\n",
      "     Title: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01277757\n",
      "     Title: Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer\n",
      "     Conditions: Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01572727\n",
      "     Title: A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01437566\n",
      "     Title: Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05453591\n",
      "     Title: Investigation of Urinary Biomarkers for the Detection of Breast Cancer\n",
      "     Conditions: Breast Cancer, Urine, Liquid Biopsy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03386162\n",
      "     Title: SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer, PI3K, Alpelisib\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05646862\n",
      "     Title: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01633060\n",
      "     Title: A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05627960\n",
      "     Title: First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies\n",
      "     Conditions: Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04073680\n",
      "     Title: A Phase 1b/2 Study of Serabelisib in Combination With Canagliflozin in Patients With Advanced Solid Tumors\n",
      "     Conditions: Breast Cancer, Endometrial Cancer, Lung Cancer, Colo-rectal Cancer, Head and Neck Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05306041\n",
      "     Title: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02437318\n",
      "     Title: Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02162719\n",
      "     Title: A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05683418\n",
      "     Title: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors\n",
      "     Conditions: Squamous Cell Carcinoma of Head and Neck, Endometrial Cancer, HR+/HER2-negative Breast Cancer, Bladder Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05455619\n",
      "     Title: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer\n",
      "     Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04360941\n",
      "     Title: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00281658\n",
      "     Title: Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01513356\n",
      "     Title: Pharmacodynamic Study of BKM120 in Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01990209\n",
      "     Title: Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND RB1'...\n",
      "-> API search found 71 total studies for '\"Breast Cancer\" AND RB1'.\n",
      "\n",
      "Found 71 studies for gene 'RB1' in Breast Cancer:\n",
      "   - NCT ID: NCT04282044\n",
      "     Title: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies\n",
      "     Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04735289\n",
      "     Title: Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma\n",
      "     Conditions: Osteosarcoma, Ewing Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01919229\n",
      "     Title: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)\n",
      "     Conditions: Early Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05344729\n",
      "     Title: Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects\n",
      "     Conditions: Recurrent/Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01320592\n",
      "     Title: PD0332991/Paclitaxel in Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03449108\n",
      "     Title: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas\n",
      "     Conditions: Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00538850\n",
      "     Title: Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05933395\n",
      "     Title: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04091295\n",
      "     Title: BLESSED: Expanded Access for DNG64 for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast\n",
      "     Conditions: Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor), Chondrosarcoma, Soft Tissue Sarcoma, Chordoma, Sarcoma, Carcinoma of Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05135104\n",
      "     Title: Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00020267\n",
      "     Title: Vaccine Therapy in Treating Patients With Metastatic Cancer\n",
      "     Conditions: Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01514565\n",
      "     Title: Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04289974\n",
      "     Title: Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01740427\n",
      "     Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03024489\n",
      "     Title: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma\n",
      "     Conditions: Head and Neck Cancer, Locally Advanced\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00413322\n",
      "     Title: Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01295463\n",
      "     Title: Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00899496\n",
      "     Title: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03130439\n",
      "     Title: Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00049296\n",
      "     Title: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03422679\n",
      "     Title: Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies\n",
      "     Conditions: Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00020579\n",
      "     Title: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04028479\n",
      "     Title: The Registry of Oncology Outcomes Associated with Testing and Treatment\n",
      "     Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00620295\n",
      "     Title: Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors\n",
      "     Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03154190\n",
      "     Title: Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer\n",
      "     Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03184090\n",
      "     Title: Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00378781\n",
      "     Title: Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02499146\n",
      "     Title: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00161187\n",
      "     Title: Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05328258\n",
      "     Title: Use of GnRHa During Chemotherapy for Fertility Protection\n",
      "     Conditions: Breast Cancer Female, Acute Leukemia, Lymphoma, Osteosarcoma, Soft Tissue Sarcoma, Ewing Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05061017\n",
      "     Title: Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)\n",
      "     Conditions: NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00499733\n",
      "     Title: Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00002854\n",
      "     Title: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06577987\n",
      "     Title: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma, RB1 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05958199\n",
      "     Title: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7\n",
      "     Conditions: Metastatic Malignant Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00413075\n",
      "     Title: Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma\n",
      "     Conditions: Solid Tumor, Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04758000\n",
      "     Title: Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse\n",
      "     Conditions: Osteosarcoma, Ewing Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06638931\n",
      "     Title: Agnostic Therapy in Rare Solid Tumors\n",
      "     Conditions: Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma, Secretory Carcinoma of Breast, Anal Neoplasms, Metaplastic Breast Carcinoma, Translocation Renal Cell Carcinoma, Carcinosarcoma, Small Intestine Neoplasms, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Adenoid Cystic Carcinoma, Mesothelioma, Neuroblastoma, Adrenal Gland Neoplasms, Penile Neoplasms, Apocrine Carcinoma, Fibrosarcoma, Cancer of Unknown Primary, Hemangioblastoma, Thyroid Neoplasms, Hepatoblastoma, Fallopian Tube Neoplasms, Leiomyosarcoma, Vaginal Neoplasms, Neurofibrosarcoma, Gallbladder Neoplasms, Osteosarcoma, Biliary Tract Neoplasms, Clear Cell Endometrial Cancer, Yolk Sac Tumor, Vulvar Neoplasms, Kaposi Sarcoma, Ovarian Epithelial Cancer, Soft Tissue Sarcoma, Urethral Neoplasms, Granulosa Cell Tumor, Primitive Neuroectodermal Tumor, Neuroendocrine Tumors, Trophoblastic Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01085565\n",
      "     Title: Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System\n",
      "     Conditions: Bone Cancer, Bone Metastases, Pain\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03355794\n",
      "     Title: A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)\n",
      "     Conditions: Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma, Bithalamic High Grade Glioma, Brainstem Glioma, Glioblastoma, Anaplastic Astrocytoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03304080\n",
      "     Title: Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast\n",
      "     Conditions: Breast Neoplasms, Breast Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04360941\n",
      "     Title: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00014456\n",
      "     Title: Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors\n",
      "     Conditions: Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02223052\n",
      "     Title: Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies\n",
      "     Conditions: Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00721409\n",
      "     Title: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05062707\n",
      "     Title: Early Ageing During Therapy in AYA Cancer Patients\n",
      "     Conditions: Cancer, Leukemia, Hodgkin Lymphoma, Testicular Cancer, Osteosarcoma, Ewing Sarcoma, Breast Cancer, Cervical Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00154388\n",
      "     Title: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases\n",
      "     Conditions: Life Threatening Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03519178\n",
      "     Title: A Study of PF-06873600 in People With Cancer\n",
      "     Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01286987\n",
      "     Title: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors\n",
      "     Conditions: Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01684215\n",
      "     Title: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer\n",
      "     Conditions: Neoplasms, Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03635632\n",
      "     Title: C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)\n",
      "     Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma, Relapsed Rhabdomyosarcoma, Uveal Melanoma, Phyllodes Breast Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01617915\n",
      "     Title: Tumor Specific Plasma DNA\n",
      "     Conditions: Breast Cancer, Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01598454\n",
      "     Title: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides\n",
      "     Conditions: Neuroblastoma, Ewing's Sarcoma, Wilm's Tumor, Retinoblastoma, Glioma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06177327\n",
      "     Title: Hepato-pancreato-biliary Abnormalities in Fibrous Dysplasia of Bone/McCune Albright Syndrome\n",
      "     Conditions: Fibrous Dysplasia of Bone\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02624973\n",
      "     Title: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04436120\n",
      "     Title: Treatment Resistance Following Anti-cancer Therapies\n",
      "     Conditions: Disease Progression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05492682\n",
      "     Title: START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer\n",
      "     Conditions: Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma, Myxoid Liposarcoma, Colorectal Cancer, Osteosarcoma, Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06416358\n",
      "     Title: A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed\n",
      "     Conditions: Advanced Solid Tumors With Bone Only Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05297734\n",
      "     Title: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer\n",
      "     Conditions: End of Life, Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04616248\n",
      "     Title: In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02389842\n",
      "     Title: PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib\n",
      "     Conditions: Advanced Solid Tumours, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05365178\n",
      "     Title: To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer\n",
      "     Conditions: HR-positive, HER2-negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04671693\n",
      "     Title: A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.\n",
      "     Conditions: Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC, Osteosarcoma, Ewing's Sarcoma, Acute Myeloid Leukemia, Hodgkin Disease, Non Hodgkin Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06162351\n",
      "     Title: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer\n",
      "     Conditions: Breast, Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01932047\n",
      "     Title: Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment\n",
      "     Conditions: Refractory Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05655598\n",
      "     Title: TAS-116 Plus Palbociclib in Breast and Rb-null Cancer\n",
      "     Conditions: Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01916317\n",
      "     Title: Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer\n",
      "     Conditions: Operable Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01091883\n",
      "     Title: Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma\n",
      "     Conditions: Bone Cancer, Bone Metastases, Pain\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06998628\n",
      "     Title: Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis\n",
      "     Conditions: Rheumatoid Arthritis\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND BCL2'...\n",
      "-> API search found 24 total studies for '\"Breast Cancer\" AND BCL2'.\n",
      "\n",
      "Found 24 studies for gene 'BCL2' in Breast Cancer:\n",
      "   - NCT ID: NCT03906669\n",
      "     Title: A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.\n",
      "     Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01701050\n",
      "     Title: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04800146\n",
      "     Title: A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study\n",
      "     Conditions: Covid19, Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00156273\n",
      "     Title: Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01891357\n",
      "     Title: Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer\n",
      "     Conditions: Carcinoma, Ductal, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01898312\n",
      "     Title: BRCA1/2 and Effect of Mifepristone on the Breast\n",
      "     Conditions: Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00063934\n",
      "     Title: Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer\n",
      "     Conditions: Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01744821\n",
      "     Title: Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer\n",
      "     Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03900884\n",
      "     Title: Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer\n",
      "     Conditions: Breast Neoplasm Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003103\n",
      "     Title: Chemotherapy in Treating Patients With Solid Tumors\n",
      "     Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05889390\n",
      "     Title: Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer\n",
      "     Conditions: HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05775575\n",
      "     Title: A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00896857\n",
      "     Title: Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01016665\n",
      "     Title: Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00898976\n",
      "     Title: Biomarkers in Native American Women With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06756932\n",
      "     Title: BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer\n",
      "     Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00169000\n",
      "     Title: Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00725374\n",
      "     Title: A Study to Investigate the Effects of Tibolone (Livial) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00724386\n",
      "     Title: Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01693549\n",
      "     Title: Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05358639\n",
      "     Title: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC\n",
      "     Conditions: High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01864798\n",
      "     Title: A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00320411\n",
      "     Title: GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND MET'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND MET'.\n",
      "\n",
      "Found 100 studies for gene 'MET' in Breast Cancer:\n",
      "   - NCT ID: NCT00593346\n",
      "     Title: Evaluation of Accelerated Partial Breast Brachytherapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03801369\n",
      "     Title: Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00490646\n",
      "     Title: A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06099769\n",
      "     Title: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768868\n",
      "     Title: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05617040\n",
      "     Title: Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer\n",
      "     Conditions: Prostate Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04764292\n",
      "     Title: Screening Contrast-Enhanced Mammography As an Alternative to MRI\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04613440\n",
      "     Title: FaCT Trial (Facilitated Cascade Testing Trial)\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05427344\n",
      "     Title: Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients\n",
      "     Conditions: Colon Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02955940\n",
      "     Title: An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib\n",
      "     Conditions: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01372644\n",
      "     Title: Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial\n",
      "     Conditions: Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02058368\n",
      "     Title: Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia\n",
      "     Conditions: Prostatic Hyperplasia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01772472\n",
      "     Title: A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02747004\n",
      "     Title: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01882972\n",
      "     Title: Strength for Health\n",
      "     Conditions: Colon Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06062901\n",
      "     Title: An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors\n",
      "     Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05203601\n",
      "     Title: A Phase a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02181101\n",
      "     Title: Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06202404\n",
      "     Title: Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model\n",
      "     Conditions: Metastasis, Predictive Cancer Model\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03683004\n",
      "     Title: Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study\n",
      "     Conditions: Colorectal Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01225172\n",
      "     Title: Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05272904\n",
      "     Title: The QUILT Study: Quilting Sutures in Patients Undergoing Breast Cancer Surgery\n",
      "     Conditions: Seroma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06355440\n",
      "     Title: Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China\n",
      "     Conditions: Breast Neoplasm Female, Financial Toxicity, Financial Navigation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04282044\n",
      "     Title: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies\n",
      "     Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03972540\n",
      "     Title: Effect of Mindful Eating on Weight Management in Breast Cancer Survivors\n",
      "     Conditions: Breast Neoplasm Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05007444\n",
      "     Title: Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer\n",
      "     Conditions: Breast Cancer, Quality of Life, Tumor, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01461044\n",
      "     Title: An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02125344\n",
      "     Title: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)\n",
      "     Conditions: Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04902144\n",
      "     Title: Clinical Outcomes for Offering Genetic Testing in a Tiered Approach\n",
      "     Conditions: Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02611544\n",
      "     Title: Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors\n",
      "     Conditions: Breast Neoplasms, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast, Cancer of Breast, Mammary Neoplasm, Human, Human Mammary Carcinoma, Malignant Tumor of Breast, Mammary Cancer, Mammary Carcinoma, Anxiety, Fear, Neoplasm Remission, Spontaneous, Spontaneous Neoplasm Regression, Regression, Spontaneous Neoplasm, Remission, Spontaneous Neoplasm, Spontaneous Neoplasm Remission\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02768701\n",
      "     Title: Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02650401\n",
      "     Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\n",
      "     Conditions: Solid Tumors, CNS Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06871501\n",
      "     Title: \"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer\"\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02949167\n",
      "     Title: MyHealth: Follow-up After Breast Cancer Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02923401\n",
      "     Title: High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer\n",
      "     Conditions: Disorders of Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04032080\n",
      "     Title: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01301729\n",
      "     Title: A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05896189\n",
      "     Title: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors\n",
      "     Conditions: Breast Cancer, Cognitive Impairments\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06672380\n",
      "     Title: The INFLUENCE of PHYSICAL ACTIVITY on the HEALTH and WELL-BEING of BREAST CANCER SURVIVORS\n",
      "     Conditions: Breast Cancer Survivor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06954480\n",
      "     Title: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02574780\n",
      "     Title: Lymphedema Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy\n",
      "     Conditions: Lymphedema\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00295529\n",
      "     Title: GenetiKiT: Evaluation of an Educational Intervention on the Delivery of Genetics Services by Family Physicians\n",
      "     Conditions: Breast Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00431067\n",
      "     Title: Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06383767\n",
      "     Title: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00605267\n",
      "     Title: Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00398567\n",
      "     Title: A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03846167\n",
      "     Title: Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05911867\n",
      "     Title: Muscle Energy Technique and Mulligan's Mobilization in Breast Cancer Surgery Patients\n",
      "     Conditions: Mobility Limitation, Muscle Relaxation, Kinematics, Postural; Defect, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06239467\n",
      "     Title: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer\n",
      "     Conditions: Advanced Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06048367\n",
      "     Title: Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor\n",
      "     Conditions: Advanced Solid Tumor, Lung Cancer, Pancreas Cancer, Breast Cancer, Thyroid Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Vulva Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05602792\n",
      "     Title: A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer, Esophagus Cancer, NSCLC, Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01504789\n",
      "     Title: Part II: Exercise in Hispanic Breast Cancer Survivors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02424292\n",
      "     Title: Evaluation of a Physical Activity Program in Overweight Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00093808\n",
      "     Title: Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04440943\n",
      "     Title: A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies\n",
      "     Conditions: Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01738438\n",
      "     Title: Cabozantinib for Metastatic Triple Negative BrCa\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04922008\n",
      "     Title: Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06981208\n",
      "     Title: ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction\n",
      "     Conditions: Breast Cancer, Cancer of the Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01967823\n",
      "     Title: T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer\n",
      "     Conditions: Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05364450\n",
      "     Title: Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors\n",
      "     Conditions: Breast Neoplasm, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast, Cancer of Breast, Mammary Neoplasms, Human, Human Mammary Carcinoma, Malignant Tumor of Breast, Mammary Cancer, Mammary Carcinoma, Human, Anxiety, Fear\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04585750\n",
      "     Title: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)\n",
      "     Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04596150\n",
      "     Title: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer\n",
      "     Conditions: Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06643455\n",
      "     Title: Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05053555\n",
      "     Title: High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies\n",
      "     Conditions: Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06617455\n",
      "     Title: Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Localized Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02896855\n",
      "     Title: A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00708214\n",
      "     Title: BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01698281\n",
      "     Title: Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00355381\n",
      "     Title: Evaluating Patient Information Prescriptions\n",
      "     Conditions: Breast Neoplasms, Premature Birth\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01572038\n",
      "     Title: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03193008\n",
      "     Title: Current Value of Axillary Ultrasound in the Staging of Breast Cancer. Is BSGC Still Necessary?\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05303038\n",
      "     Title: Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy\n",
      "     Conditions: Metastatic Breast Cancer in the Liver\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06445738\n",
      "     Title: Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)\n",
      "     Conditions: Breast Cancer, Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04975308\n",
      "     Title: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms, Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00733408\n",
      "     Title: Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00885755\n",
      "     Title: A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02111850\n",
      "     Title: T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive\n",
      "     Conditions: Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05072314\n",
      "     Title: Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial\n",
      "     Conditions: Breast Cancer, Breast Cancer Female, Breast Conserving Surgery, Mastectomy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07040514\n",
      "     Title: 24GUT540 : Meeting of Breast Cancer Patients and Pathologists\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02320123\n",
      "     Title: End-of-Life Care for African Americans\n",
      "     Conditions: Colonic Neoplasms, Breast Neoplasms, Lung Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05386108\n",
      "     Title: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer\n",
      "     Conditions: Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04966923\n",
      "     Title: Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53\n",
      "     Conditions: Breast Cancer, TP53 R337H, Li-Fraumeni Syndrome, Prognosis Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05998655\n",
      "     Title: Tele-nursing Practices Based on Technological Competence Theory in Breast Cancer Patients\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06938555\n",
      "     Title: The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors\n",
      "     Conditions: Breast Cancer Survivor, Cancer Related Cognitive Difficulties, Sleep, Quality of Life\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07046455\n",
      "     Title: Trop-2 Targeted PET Probes in Advanced TNBC\n",
      "     Conditions: TNBC - Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02965755\n",
      "     Title: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00451555\n",
      "     Title: Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05140655\n",
      "     Title: Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-\n",
      "     Conditions: Breast Neoplasm Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03329950\n",
      "     Title: A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies\n",
      "     Conditions: Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06739395\n",
      "     Title: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion\n",
      "     Conditions: Solid Tumor, Precision Medicine\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00408681\n",
      "     Title: Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant\n",
      "     Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Gastrointestinal Complications, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Childhood Rhabdomyosarcoma, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02316795\n",
      "     Title: Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma\n",
      "     Conditions: Breast Cancer, Cancer of Breast, Cancer of the Breast, Melanoma, Malignant Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06253195\n",
      "     Title: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00081510\n",
      "     Title: Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04868812\n",
      "     Title: Histological Modifications of Postmenopausal Vaginal Mucosa After Repeated Carbon Dioxide (CO2) Laser Treatment\n",
      "     Conditions: Vaginal Atrophy, Breast Cancer Female, Dyspareunia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06116812\n",
      "     Title: The Effects of Laughter Yoga and Mindfulness-Based Stress Reduction (MBSR) Practices Applied to Women With Breast Cancer\n",
      "     Conditions: Breast Cancer, Laughter Therapy, Mindfulness Therapy, Life Quality, Anxiety and Depression, Spiritual Well-being\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02796612\n",
      "     Title: Empathy and Standard Diagnostic Procedures in an Outpatient Breast Clinic Might Not be Enough\n",
      "     Conditions: Anxiety\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03674112\n",
      "     Title: A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer\n",
      "     Conditions: HER2-Positive Early Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04957212\n",
      "     Title: Comparing Efficacy and Safety Between Pertuzumab and Perjeta in Neoadjuvant Treatment of HER2+ Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00894504\n",
      "     Title: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND EGFR'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND EGFR'.\n",
      "\n",
      "Found 100 studies for gene 'EGFR' in Breast Cancer:\n",
      "   - NCT ID: NCT03822468\n",
      "     Title: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06722612\n",
      "     Title: Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00490646\n",
      "     Title: A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03125746\n",
      "     Title: A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04001569\n",
      "     Title: AZD8186 and Paclitaxel in Advanced Gastric Cancer\n",
      "     Conditions: Solid Tumor, Stomach Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03176238\n",
      "     Title: Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer\n",
      "     Conditions: Post Menopausal Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06361940\n",
      "     Title: Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05376644\n",
      "     Title: Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05341492\n",
      "     Title: EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer\n",
      "     Conditions: EGFR/ B7H3-positive Advanced Lung Cancer, EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00826267\n",
      "     Title: 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04464967\n",
      "     Title: Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, Esophageal Cancer, Ovarian Cancer, Endometrium Cancer, Bladder Cancer, Pancreatic Cancer, Colorectal Cancer, Non Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cervical Cancer, Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01783444\n",
      "     Title: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03801304\n",
      "     Title: Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer\n",
      "     Conditions: Non-small Cell Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05191004\n",
      "     Title: Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC\n",
      "     Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02780401\n",
      "     Title: Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission\n",
      "     Conditions: HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05953168\n",
      "     Title: T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients\n",
      "     Conditions: Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00650572\n",
      "     Title: A Study of ARRY-380 in Patients With Advanced HER2+ Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00146172\n",
      "     Title: Study Evaluating HKI-272 in Tumors\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01004172\n",
      "     Title: Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases\n",
      "     Conditions: Metastatic Breast Cancer, Breast Cancer, Progressive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02747004\n",
      "     Title: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01421472\n",
      "     Title: A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer\n",
      "     Conditions: ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06639672\n",
      "     Title: Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer\n",
      "     Conditions: HR+HER2- Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05203601\n",
      "     Title: A Phase a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06607601\n",
      "     Title: CARE Initiative: Real-world Emulation of the PALOMA-2 Trial\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06705504\n",
      "     Title: A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib\n",
      "     Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04033172\n",
      "     Title: Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )\n",
      "     Conditions: Breast Cancer, HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00999804\n",
      "     Title: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06619704\n",
      "     Title: Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02296801\n",
      "     Title: A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer\n",
      "     Conditions: Breast Cancer, Breast Carcinoma, Breast Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05132101\n",
      "     Title: Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00367250\n",
      "     Title: Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01622868\n",
      "     Title: Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer\n",
      "     Conditions: HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05913440\n",
      "     Title: HER2-low Unresectable and/or Metastatic Breast Cancer in Russia\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01836640\n",
      "     Title: Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01288092\n",
      "     Title: BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05145244\n",
      "     Title: Copenhagen Master Observational Trial\n",
      "     Conditions: Non-small Cell Lung Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02569801\n",
      "     Title: A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04106167\n",
      "     Title: Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy\n",
      "     Conditions: Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02338167\n",
      "     Title: Praegnant Breast Cancer: Early/Advanced/Metastatic\n",
      "     Conditions: Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04770129\n",
      "     Title: Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06104189\n",
      "     Title: Prospective Ultrafast MRI Radiomics for Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04858529\n",
      "     Title: Neoadjuvant TCHP Versus THP in Patients With HER2-positive Breast Cancer (neoCARHP Study)\n",
      "     Conditions: Neoadjuvant Therapies for HER2+ Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05176080\n",
      "     Title: Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06222489\n",
      "     Title: Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT\n",
      "     Conditions: Non-Small Cell Lung Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, EGFR Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00679029\n",
      "     Title: Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer\n",
      "     Conditions: HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02244580\n",
      "     Title: Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit \"MammaTyperTM\"\n",
      "     Conditions: Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05399329\n",
      "     Title: Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02530489\n",
      "     Title: Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer\n",
      "     Conditions: Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03734029\n",
      "     Title: Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00284180\n",
      "     Title: Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer\n",
      "     Conditions: Breast Neoplasms, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03368729\n",
      "     Title: Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, HER2 Positive Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04616729\n",
      "     Title: DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05735080\n",
      "     Title: Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer\n",
      "     Conditions: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Ovarian Cancer, CCNE1 Amplification, Solid Tumor, Advanced Cancer, Metastatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04991480\n",
      "     Title: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Advanced Cancer, Metastatic Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00605267\n",
      "     Title: Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00397501\n",
      "     Title: BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain\n",
      "     Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Cognitive/Functional Effects, Drug/Agent Toxicity by Tissue/Organ, Psychosocial Effects of Cancer and Its Treatment\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03248492\n",
      "     Title: A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04472143\n",
      "     Title: Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents\n",
      "     Conditions: Chemotherapy-induced Nausea and Vomiting (CINV)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03134638\n",
      "     Title: A Study of SY-1365 in Adult Patients With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Ovarian Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04277338\n",
      "     Title: Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3\n",
      "     Conditions: Primary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01779050\n",
      "     Title: Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04596150\n",
      "     Title: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer\n",
      "     Conditions: Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06711055\n",
      "     Title: Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05361655\n",
      "     Title: Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04576455\n",
      "     Title: A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)\n",
      "     Conditions: Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00021255\n",
      "     Title: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05323955\n",
      "     Title: Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib\n",
      "     Conditions: Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03804255\n",
      "     Title: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting\n",
      "     Conditions: Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02896855\n",
      "     Title: A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00773695\n",
      "     Title: A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04906395\n",
      "     Title: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01187381\n",
      "     Title: An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03321981\n",
      "     Title: MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.\n",
      "     Conditions: Breast Cancer Metastatic\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06084481\n",
      "     Title: Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400\n",
      "     Conditions: Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06781281\n",
      "     Title: NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer.\n",
      "     Conditions: Breast Cancer Invasive\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04963595\n",
      "     Title: Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01327781\n",
      "     Title: Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer\n",
      "     Conditions: HER2/Neu Positive, Recurrent Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02753595\n",
      "     Title: Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06105008\n",
      "     Title: Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00733408\n",
      "     Title: Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01296555\n",
      "     Title: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer\n",
      "     Conditions: Solid Cancers, Non-Hodgkin's Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00885755\n",
      "     Title: A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05573555\n",
      "     Title: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02954055\n",
      "     Title: MEtronomic TrEatment Option in Advanced bReast cAncer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03800355\n",
      "     Title: Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk\n",
      "     Conditions: Breast Cancer, Male\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04395508\n",
      "     Title: An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02892123\n",
      "     Title: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers\n",
      "     Conditions: HER2-expressing Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04318223\n",
      "     Title: Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy\n",
      "     Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05503108\n",
      "     Title: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer\n",
      "     Conditions: Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Pathological Complete Response, Objective Response Rate, Neoadjuvant Chemotherapy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02396108\n",
      "     Title: Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03878823\n",
      "     Title: Safety and Pharmacokinetics of ODM-209\n",
      "     Conditions: Prostate Cancer Metastatic, Advanced Breast Cancer, Castration-resistant Prostate Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05498155\n",
      "     Title: Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05734950\n",
      "     Title: Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03832855\n",
      "     Title: Assessing the Immunogenicity of pING-hHER3FL\n",
      "     Conditions: Advanced Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05188495\n",
      "     Title: Trastuzumab(Henlius) Combined With Pertuzumab(Perjeta) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab\n",
      "     Conditions: HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab, Trastuzumab Combined With Pertuzumab and Chemotherapy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03238495\n",
      "     Title: Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07102381\n",
      "     Title: A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01273610\n",
      "     Title: Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer\n",
      "     Conditions: Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00300781\n",
      "     Title: Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms, Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01963481\n",
      "     Title: Exemestane and Cyclophosphamide for Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Beast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NTRK2'...\n",
      "-> API search found 4 total studies for '\"Breast Cancer\" AND NTRK2'.\n",
      "\n",
      "Found 4 studies for gene 'NTRK2' in Breast Cancer:\n",
      "   - NCT ID: NCT02650401\n",
      "     Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\n",
      "     Conditions: Solid Tumors, CNS Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02568267\n",
      "     Title: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)\n",
      "     Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02576431\n",
      "     Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors\n",
      "     Conditions: Solid Tumors Harboring NTRK Fusion\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND TSC2'...\n",
      "-> API search found 1 total studies for '\"Breast Cancer\" AND TSC2'.\n",
      "\n",
      "Found 1 studies for gene 'TSC2' in Breast Cancer:\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND STK11'...\n",
      "-> API search found 9 total studies for '\"Breast Cancer\" AND STK11'.\n",
      "\n",
      "Found 9 studies for gene 'STK11' in Breast Cancer:\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06536881\n",
      "     Title: Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming\n",
      "     Conditions: Breast Cancer, Early-stage Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03294343\n",
      "     Title: Risk-Reducing Surgeries for Hereditary Ovarian Cancer\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovariectomy, Hysterectomy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02000089\n",
      "     Title: The Cancer of the Pancreas Screening-5 CAPS5)Study\n",
      "     Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04257045\n",
      "     Title: Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives\n",
      "     Conditions: Breast Carcinoma, Deleterious CDH1 Gene Mutation, Deleterious DICER1 Gene Mutation, Deleterious SMARCA4 Gene Mutation, Deleterious STK11 Gene Mutation, Endometrial Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND FGFR2'...\n",
      "-> API search found 7 total studies for '\"Breast Cancer\" AND FGFR2'.\n",
      "\n",
      "Found 7 studies for gene 'FGFR2' in Breast Cancer:\n",
      "   - NCT ID: NCT01795768\n",
      "     Title: Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours\n",
      "     Conditions: Gastric Cancer, Oesophageal Cancer, Breast Cancer, Squamous Cell Carcinoma of the Lung\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02052778\n",
      "     Title: A Study of TAS-120 in Patients With Advanced Solid Tumors\n",
      "     Conditions: Cholangiocarcinoma, Urothelial Cancer, Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors, Primary CNS Tumors, Breast Cancer, Gastric Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05253053\n",
      "     Title: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04024436\n",
      "     Title: A Study of TAS-120 in Patients With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, FGFR 1 High Amplification, FGFR2 Amplification\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02368951\n",
      "     Title: Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)\n",
      "     Conditions: Medical Oncology\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01594177\n",
      "     Title: Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy\n",
      "     Conditions: Unilateral HER2 Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND ATR'...\n",
      "-> API search found 19 total studies for '\"Breast Cancer\" AND ATR'.\n",
      "\n",
      "Found 19 studies for gene 'ATR' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03801369\n",
      "     Title: Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02723864\n",
      "     Title: Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors\n",
      "     Conditions: Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05582538\n",
      "     Title: Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel\n",
      "     Conditions: Triple Negative Breast Cancer Metastatic\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04508803\n",
      "     Title: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer\n",
      "     Conditions: Treatment Efficacy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04491942\n",
      "     Title: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer\n",
      "     Conditions: Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03188965\n",
      "     Title: First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas\n",
      "     Conditions: Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04095273\n",
      "     Title: Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05026073\n",
      "     Title: Vibrational Spectroscopy for Endometrial Cancer Diagnosis\n",
      "     Conditions: Endometrial Cancer, Endometrial Hyperplasia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02264678\n",
      "     Title: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents\n",
      "     Conditions: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03740893\n",
      "     Title: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer\n",
      "     Conditions: Breast Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05986071\n",
      "     Title: I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02401347\n",
      "     Title: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03330847\n",
      "     Title: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.\n",
      "     Conditions: Metastatic Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04655183\n",
      "     Title: Study of M4344 in Combination With Niraparib\n",
      "     Conditions: Advanced Solid Tumor, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03678883\n",
      "     Title: 9-ING-41 in Patients with Advanced Cancers\n",
      "     Conditions: Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04704661\n",
      "     Title: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial\n",
      "     Conditions: Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NOTCH1'...\n",
      "-> API search found 5 total studies for '\"Breast Cancer\" AND NOTCH1'.\n",
      "\n",
      "Found 5 studies for gene 'NOTCH1' in Breast Cancer:\n",
      "   - NCT ID: NCT05203601\n",
      "     Title: A Phase a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01158274\n",
      "     Title: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors\n",
      "     Conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, HER2-negative Breast Cancer, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Male Breast Cancer, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Rectal Cancer, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Colon Cancer, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Rectal Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Rectal Cancer, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenstrm Macroglobulinemia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01208441\n",
      "     Title: RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer\n",
      "     Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01876251\n",
      "     Title: A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer Metastatic\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND SMAD4'...\n",
      "-> API search found 1 total studies for '\"Breast Cancer\" AND SMAD4'.\n",
      "\n",
      "Found 1 studies for gene 'SMAD4' in Breast Cancer:\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CHEK2'...\n",
      "-> API search found 17 total studies for '\"Breast Cancer\" AND CHEK2'.\n",
      "\n",
      "Found 17 studies for gene 'CHEK2' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033092\n",
      "     Title: Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion\n",
      "     Conditions: BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, ATM Gene Mutation, CHEK2 Gene Mutation, CDH1 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04508803\n",
      "     Title: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer\n",
      "     Conditions: Treatment Efficacy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04335669\n",
      "     Title: NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC\n",
      "     Conditions: Breast Cancer, Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01102569\n",
      "     Title: Pancreatic Cancer Genetics\n",
      "     Conditions: Pancreatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02203513\n",
      "     Title: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer\n",
      "     Conditions: Ovarian Cancer, Breast Cancer, Prostate Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05787587\n",
      "     Title: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03344965\n",
      "     Title: Olaparib In Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04276376\n",
      "     Title: Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors\n",
      "     Conditions: Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05033756\n",
      "     Title: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO\n",
      "     Conditions: Malignant Neoplasm of Breast, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04265937\n",
      "     Title: ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies\n",
      "     Conditions: Breast Cancer, Genetic Susceptibility\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02624973\n",
      "     Title: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06177171\n",
      "     Title: Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02401347\n",
      "     Title: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND ATM'...\n",
      "-> API search found 43 total studies for '\"Breast Cancer\" AND ATM'.\n",
      "\n",
      "Found 43 studies for gene 'ATM' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033092\n",
      "     Title: Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion\n",
      "     Conditions: BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, ATM Gene Mutation, CHEK2 Gene Mutation, CDH1 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04672460\n",
      "     Title: A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer, Prostate Cancer, NSCLC, Pancreatic Cancer, Colorectal Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00896727\n",
      "     Title: S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01349322\n",
      "     Title: Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03294343\n",
      "     Title: Risk-Reducing Surgeries for Hereditary Ovarian Cancer\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovariectomy, Hysterectomy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00579514\n",
      "     Title: Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients\n",
      "     Conditions: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04508803\n",
      "     Title: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer\n",
      "     Conditions: Treatment Efficacy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04335669\n",
      "     Title: NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC\n",
      "     Conditions: Breast Cancer, Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05058846\n",
      "     Title: Pilot Study of Pancreatic Cancer Screening\n",
      "     Conditions: Pancreatic Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06775236\n",
      "     Title: Clinical Trial of SYS6010SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05787587\n",
      "     Title: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03344965\n",
      "     Title: Olaparib In Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03188965\n",
      "     Title: First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas\n",
      "     Conditions: Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03565991\n",
      "     Title: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors\n",
      "     Conditions: Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00195091\n",
      "     Title: Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02000089\n",
      "     Title: The Cancer of the Pancreas Screening-5 CAPS5)Study\n",
      "     Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04276376\n",
      "     Title: Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors\n",
      "     Conditions: Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05033756\n",
      "     Title: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO\n",
      "     Conditions: Malignant Neoplasm of Breast, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06710015\n",
      "     Title: Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2\n",
      "     Conditions: BRCA1 and/or BRCA2 Variant Carriers, Fertility, Reproductive Age, Menopause, Pregnancy Outcomes\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05694715\n",
      "     Title: Combination Therapy in Cancers With Mutations in DNA Repair Genes\n",
      "     Conditions: Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02286687\n",
      "     Title: Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes\n",
      "     Conditions: Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03501173\n",
      "     Title: A Study of Participants With Advanced Prostate Cancer in Canada\n",
      "     Conditions: Prostatic Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03797482\n",
      "     Title: A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04095273\n",
      "     Title: Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01618136\n",
      "     Title: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors\n",
      "     Conditions: Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma, B-cell Malignancy, Low-grade\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00674557\n",
      "     Title: Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02264678\n",
      "     Title: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents\n",
      "     Conditions: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06177171\n",
      "     Title: Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02401347\n",
      "     Title: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03330847\n",
      "     Title: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.\n",
      "     Conditions: Metastatic Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03330405\n",
      "     Title: Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors\n",
      "     Conditions: Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06134375\n",
      "     Title: A Study of Tetrathiomolybdate (TM) Plus Capecitabine\n",
      "     Conditions: Triple Negative Breast Cancer, Residual Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04655183\n",
      "     Title: Study of M4344 in Combination With Niraparib\n",
      "     Conditions: Advanced Solid Tumor, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03678883\n",
      "     Title: 9-ING-41 in Patients with Advanced Cancers\n",
      "     Conditions: Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04704661\n",
      "     Title: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial\n",
      "     Conditions: Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "\n",
      "=======================================================\n",
      "Searching genes in category: 'FDA-approved Other Indication'\n",
      "=======================================================\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CCND1'...\n",
      "-> API search found 34 total studies for '\"Breast Cancer\" AND CCND1'.\n",
      "\n",
      "Found 34 studies for gene 'CCND1' in Breast Cancer:\n",
      "   - NCT ID: NCT03906669\n",
      "     Title: A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.\n",
      "     Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02651844\n",
      "     Title: Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03454529\n",
      "     Title: The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer\n",
      "     Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02774681\n",
      "     Title: Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis\n",
      "     Conditions: Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative, HER2/Neu Negative, HER2/Neu Positive, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00039455\n",
      "     Title: Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06739395\n",
      "     Title: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion\n",
      "     Conditions: Solid Tumor, Precision Medicine\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04289974\n",
      "     Title: Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01740427\n",
      "     Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03024489\n",
      "     Title: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma\n",
      "     Conditions: Head and Neck Cancer, Locally Advanced\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00299286\n",
      "     Title: Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05429684\n",
      "     Title: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer\n",
      "     Conditions: HER2+ Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01037790\n",
      "     Title: Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer\n",
      "     Conditions: Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Adult Central Nervous System Germ Cell Tumor, Adult Teratoma, Benign Teratoma, Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Familial Testicular Germ Cell Tumor, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Male Breast Cancer, Ovarian Immature Teratoma, Ovarian Mature Teratoma, Ovarian Monodermal and Highly Specialized Teratoma, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Extragonadal Seminoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Melanoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Rectal Cancer, Stage III Extragonadal Non-seminomatous Germ Cell Tumor, Stage III Extragonadal Seminoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Ovarian Germ Cell Tumor, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Extragonadal Non-seminomatous Germ Cell Tumor, Stage IV Extragonadal Seminoma, Stage IV Melanoma, Stage IV Ovarian Germ Cell Tumor, Stage IV Rectal Cancer, Testicular Immature Teratoma, Testicular Mature Teratoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439046\n",
      "     Title: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02936206\n",
      "     Title: Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03535506\n",
      "     Title: Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery\n",
      "     Conditions: DCIS\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683770\n",
      "     Title: Prognostic Value of Biomarkers in HR + / HER2 - Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683757\n",
      "     Title: The Establishment of a Survival Prediction Model for ER Positive / HER-2 Negative Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01497626\n",
      "     Title: Lapatinib and Bortezomib in Patients With Advanced Malignancies\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00898976\n",
      "     Title: Biomarkers in Native American Women With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03304080\n",
      "     Title: Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast\n",
      "     Conditions: Breast Neoplasms, Breast Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00721409\n",
      "     Title: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06998407\n",
      "     Title: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CDK Gene Mutation, CCND1 Gene Amplification, CDK4 Gene Amplification\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04705909\n",
      "     Title: Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00062751\n",
      "     Title: Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04436120\n",
      "     Title: Treatment Resistance Following Anti-cancer Therapies\n",
      "     Conditions: Disease Progression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01339442\n",
      "     Title: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer\n",
      "     Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06328387\n",
      "     Title: HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04683445\n",
      "     Title: Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050398\n",
      "     Title: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04681911\n",
      "     Title: Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02255461\n",
      "     Title: Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors\n",
      "     Conditions: Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02187783\n",
      "     Title: LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)\n",
      "     Conditions: Tumors With CDK4/6 Pathway Activation\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CDKN2A'...\n",
      "-> API search found 27 total studies for '\"Breast Cancer\" AND CDKN2A'.\n",
      "\n",
      "Found 27 studies for gene 'CDKN2A' in Breast Cancer:\n",
      "   - NCT ID: NCT06253195\n",
      "     Title: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01740427\n",
      "     Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03024489\n",
      "     Title: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma\n",
      "     Conditions: Head and Neck Cancer, Locally Advanced\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04676516\n",
      "     Title: A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02603679\n",
      "     Title: Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases\n",
      "     Conditions: Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06257264\n",
      "     Title: A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors\n",
      "     Conditions: Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439046\n",
      "     Title: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04606446\n",
      "     Title: Study of PF-07248144 in Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02682836\n",
      "     Title: Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04557449\n",
      "     Title: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors\n",
      "     Conditions: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03760536\n",
      "     Title: Get REAL and HEEL Research Program\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02000089\n",
      "     Title: The Cancer of the Pancreas Screening-5 CAPS5)Study\n",
      "     Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00721409\n",
      "     Title: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06998407\n",
      "     Title: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CDK Gene Mutation, CCND1 Gene Amplification, CDK4 Gene Amplification\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06105632\n",
      "     Title: A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment\n",
      "     Conditions: Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06760637\n",
      "     Title: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05216432\n",
      "     Title: First-in-Human Study of Mutant-selective PI3K Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer\n",
      "     Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05926024\n",
      "     Title: Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01305954\n",
      "     Title: Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06789653\n",
      "     Title: A Novel Approach Utilizing Organ Specific Age Proteomics\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01138345\n",
      "     Title: Biomarkers in Blood Samples From Older Breast Cancer Survivors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050398\n",
      "     Title: A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06120283\n",
      "     Title: BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02592083\n",
      "     Title: Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors\n",
      "     Conditions: Early-Stage Breast Carcinoma, Hormone Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02187783\n",
      "     Title: LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)\n",
      "     Conditions: Tumors With CDK4/6 Pathway Activation\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND FOXO3a'...\n",
      "-> API search found 4 total studies for '\"Breast Cancer\" AND FOXO3a'.\n",
      "\n",
      "Found 4 studies for gene 'FOXO3a' in Breast Cancer:\n",
      "   - NCT ID: NCT02077569\n",
      "     Title: AKT Inhibitor in Oestrogen Positive Breast Cancer\n",
      "     Conditions: Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02326844\n",
      "     Title: BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01339442\n",
      "     Title: BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer\n",
      "     Conditions: Estrogen Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02260661\n",
      "     Title: Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours\n",
      "     Conditions: Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND MDM2'...\n",
      "-> API search found 9 total studies for '\"Breast Cancer\" AND MDM2'.\n",
      "\n",
      "Found 9 studies for gene 'MDM2' in Breast Cancer:\n",
      "   - NCT ID: NCT02326844\n",
      "     Title: BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment\n",
      "     Conditions: Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07078604\n",
      "     Title: A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03725436\n",
      "     Title: ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors\n",
      "     Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05455658\n",
      "     Title: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05622058\n",
      "     Title: A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer\n",
      "     Conditions: Prevention of Chemotherapy-induced Myelosuppression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04025541\n",
      "     Title: Analysis of Circulating Tumor Markers in Blood\n",
      "     Conditions: Cancer, Breast Cancer, Sarcoma, Lung Cancers, Glioma, Colon Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03566485\n",
      "     Title: Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer\n",
      "     Conditions: Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Estrogen Receptor-positive, HER2/Neu Negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05012397\n",
      "     Title: Milademetan in Advanced/Metastatic Solid Tumors\n",
      "     Conditions: Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma, Lung Adenocarcinoma, Bladder Urothelial Carcinoma, Stomach Adenocarcinoma, Breast Cancer Invasive, Ovarian Carcinoma, Cervical Cancer, Non Small Cell Lung Cancer, Gastric Cancer, Biliary Tract Cancer, Melanoma, Pancreas Cancer, MDM2 Gene Amplification, Testicular Germ Cell Tumor, Adrenocortical Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02157051\n",
      "     Title: Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer\n",
      "     Conditions: HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NF1'...\n",
      "-> API search found 11 total studies for '\"Breast Cancer\" AND NF1'.\n",
      "\n",
      "Found 11 studies for gene 'NF1' in Breast Cancer:\n",
      "   - NCT ID: NCT00863122\n",
      "     Title: Concentration and Activity of Lapatinib in Vestibular Schwannomas\n",
      "     Conditions: Vestibular Schwannoma, NF2, Neurofibromatosis 2, Acoustic Neuroma, Auditory Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04355858\n",
      "     Title: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer, Metastatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01602887\n",
      "     Title: Relative Bioavailability Study\n",
      "     Conditions: Healthy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01552434\n",
      "     Title: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease\n",
      "     Conditions: Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02834013\n",
      "     Title: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors\n",
      "     Conditions: Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05554354\n",
      "     Title: Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05054374\n",
      "     Title: A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer\n",
      "     Conditions: Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05564377\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial\n",
      "     Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND HRAS'...\n",
      "-> API search found 4 total studies for '\"Breast Cancer\" AND HRAS'.\n",
      "\n",
      "Found 4 studies for gene 'HRAS' in Breast Cancer:\n",
      "   - NCT ID: NCT03804255\n",
      "     Title: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting\n",
      "     Conditions: Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03676257\n",
      "     Title: Survival Endpoints for Treatment Evaluation in Subjects Treated for Metastatic Breast Cancer: Contribution of Real-life Databases\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01306045\n",
      "     Title: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies\n",
      "     Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND PTEN'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND PTEN'.\n",
      "\n",
      "Found 100 studies for gene 'PTEN' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04001569\n",
      "     Title: AZD8186 and Paclitaxel in Advanced Gastric Cancer\n",
      "     Conditions: Solid Tumor, Stomach Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01705340\n",
      "     Title: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery\n",
      "     Conditions: Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00826267\n",
      "     Title: 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04216472\n",
      "     Title: Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04515004\n",
      "     Title: Leucoselect Phytosome for Neoadjuvant Treatment of Early Stage Lung Cancer\n",
      "     Conditions: Early Stage Lung Cancer (I and II)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06417801\n",
      "     Title: Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05111080\n",
      "     Title: Partial PTEN Deletion in Breast Cancer\n",
      "     Conditions: PTEN Gene Deletion\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03804255\n",
      "     Title: Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting\n",
      "     Conditions: Breast Carcinoma, Colorectal Carcinoma, Community Practice, Lung Carcinoma, Melanoma, Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04650581\n",
      "     Title: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00885755\n",
      "     Title: A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03273595\n",
      "     Title: Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05933395\n",
      "     Title: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02038010\n",
      "     Title: BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx\n",
      "     Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00894504\n",
      "     Title: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03709446\n",
      "     Title: Leflunomide in Previously Treated Metastatic Triple Negative Cancers\n",
      "     Conditions: Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06837792\n",
      "     Title: Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer\n",
      "     Conditions: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01514565\n",
      "     Title: Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01898312\n",
      "     Title: BRCA1/2 and Effect of Mifepristone on the Breast\n",
      "     Conditions: Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05735392\n",
      "     Title: Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04034589\n",
      "     Title: Pyrotinib in Combination With Fulvestrant in Patients With HER2 PositiveHR-Positive Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01575522\n",
      "     Title: Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00820222\n",
      "     Title: Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer\n",
      "     Conditions: Metastases, Brain\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01042925\n",
      "     Title: Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen\n",
      "     Conditions: Breast Cancer, Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00299286\n",
      "     Title: Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01226316\n",
      "     Title: Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules\n",
      "     Conditions: Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00553358\n",
      "     Title: Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01964924\n",
      "     Title: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer\n",
      "     Conditions: Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05498896\n",
      "     Title: Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02833896\n",
      "     Title: Endometrial Cancer and Array CGH\n",
      "     Conditions: Cancer of the Endometrium\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04305496\n",
      "     Title: Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06764186\n",
      "     Title: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain\n",
      "     Conditions: Locally Advanced or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05429684\n",
      "     Title: Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer\n",
      "     Conditions: HER2+ Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00499603\n",
      "     Title: Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02022202\n",
      "     Title: Breast Cancer Genome Guided Therapy Study (BEAUTY)\n",
      "     Conditions: Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05826964\n",
      "     Title: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer\n",
      "     Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03624543\n",
      "     Title: CFI-400945 in Patients With Advanced/Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00579514\n",
      "     Title: Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients\n",
      "     Conditions: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04920708\n",
      "     Title: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression\n",
      "     Conditions: Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01534455\n",
      "     Title: Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04508803\n",
      "     Title: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer\n",
      "     Conditions: Treatment Efficacy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03206203\n",
      "     Title: Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03439046\n",
      "     Title: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01240941\n",
      "     Title: Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04345913\n",
      "     Title: Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01013506\n",
      "     Title: Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00429299\n",
      "     Title: Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04439175\n",
      "     Title: Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01992952\n",
      "     Title: Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer\n",
      "     Conditions: Estrogen Receptor Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01562275\n",
      "     Title: A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors\n",
      "     Conditions: Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05810870\n",
      "     Title: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin\n",
      "     Conditions: Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01434420\n",
      "     Title: Triple Negative Breast Cancer: Study of Molecular and Genetic Factors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01277757\n",
      "     Title: Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer\n",
      "     Conditions: Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03207529\n",
      "     Title: Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer\n",
      "     Conditions: Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Androgen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, PTEN Positive, Recurrent Breast Carcinoma, Refractory Breast Carcinoma, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01572727\n",
      "     Title: A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00574366\n",
      "     Title: Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01497626\n",
      "     Title: Lapatinib and Bortezomib in Patients With Advanced Malignancies\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03218826\n",
      "     Title: PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery\n",
      "     Conditions: Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01347866\n",
      "     Title: Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer\n",
      "     Conditions: Advanced Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01596530\n",
      "     Title: Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment\n",
      "     Conditions: Breast Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00437294\n",
      "     Title: Enzastaurin in Combination of Capecitabine to Treat Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01633060\n",
      "     Title: A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02684318\n",
      "     Title: Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors\n",
      "     Conditions: Advanced Cancer, Ovarian Cancer, Endometrial Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05057013\n",
      "     Title: A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours\n",
      "     Conditions: Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer, RAS Wild Type Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Oesophageal Cancer, Ovarian Cancer, Pancreatic Cancer, Squamous Cell Cancer of the Head and Neck\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02162719\n",
      "     Title: A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05455619\n",
      "     Title: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer\n",
      "     Conditions: HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04360941\n",
      "     Title: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00281658\n",
      "     Title: Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01990209\n",
      "     Title: Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02301988\n",
      "     Title: A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06888388\n",
      "     Title: Long-term Safety of Nipple Sparing Mastectomy in Women With GPV in Breast Cancer\n",
      "     Conditions: Breast Cancer Surgery\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04251533\n",
      "     Title: Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss\n",
      "     Conditions: Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033287\n",
      "     Title: Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.\n",
      "     Conditions: Breast Cancer, Endocrine Therapy, CDK4/6 Inhibitors, Subsequent Treatment\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01884285\n",
      "     Title: AZD8186 First Time In Patient Ascending Dose Study\n",
      "     Conditions: Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01344837\n",
      "     Title: Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer\n",
      "     Conditions: Endometrial Serous Adenocarcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00740532\n",
      "     Title: Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04265937\n",
      "     Title: ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies\n",
      "     Conditions: Breast Cancer, Genetic Susceptibility\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01138085\n",
      "     Title: Safety, Pharmacokinetics (PK) of AKT and MEK Combination\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01430585\n",
      "     Title: Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer\n",
      "     Conditions: Early Breast Cancer (Phase 2), Advanced Breast Cancer (Phase 1b)\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02286687\n",
      "     Title: Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes\n",
      "     Conditions: Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01861054\n",
      "     Title: Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00062751\n",
      "     Title: Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05410951\n",
      "     Title: LobularCard Trial: Searching for Novel Germline Mutations in Lobular Breast Cancer Patients\n",
      "     Conditions: Lobular Breast Carcinoma, Lobular in Situ Breast Carcinoma, BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00317720\n",
      "     Title: Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer\n",
      "     Conditions: Breast Cancer, Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01785420\n",
      "     Title: Pre Operative Trastuzumab in Operable Breast Cancer\n",
      "     Conditions: Carcinoma Breast Stage I, HER2 Positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01344031\n",
      "     Title: MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01377363\n",
      "     Title: Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04862663\n",
      "     Title: Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)\n",
      "     Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04108858\n",
      "     Title: Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03337724\n",
      "     Title: A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01937117\n",
      "     Title: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06183736\n",
      "     Title: CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND RB1'...\n",
      "-> API search found 71 total studies for '\"Breast Cancer\" AND RB1'.\n",
      "\n",
      "Found 71 studies for gene 'RB1' in Breast Cancer:\n",
      "   - NCT ID: NCT04282044\n",
      "     Title: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies\n",
      "     Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04735289\n",
      "     Title: Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma\n",
      "     Conditions: Osteosarcoma, Ewing Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01919229\n",
      "     Title: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)\n",
      "     Conditions: Early Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05344729\n",
      "     Title: Clinical Trial for Effect of TQB3616 Capsule on Pharmacokinetics in Healthy Adult Subjects\n",
      "     Conditions: Recurrent/Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01320592\n",
      "     Title: PD0332991/Paclitaxel in Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03449108\n",
      "     Title: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas\n",
      "     Conditions: Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00538850\n",
      "     Title: Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05933395\n",
      "     Title: Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04091295\n",
      "     Title: BLESSED: Expanded Access for DNG64 for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast\n",
      "     Conditions: Pancreatic Cancer, Osteosarcoma, MPNST (Malignant Peripheral Nerve Sheath Tumor), Chondrosarcoma, Soft Tissue Sarcoma, Chordoma, Sarcoma, Carcinoma of Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05135104\n",
      "     Title: Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00020267\n",
      "     Title: Vaccine Therapy in Treating Patients With Metastatic Cancer\n",
      "     Conditions: Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer, Uterine Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01514565\n",
      "     Title: Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04289974\n",
      "     Title: Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01740427\n",
      "     Title: A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03024489\n",
      "     Title: Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma\n",
      "     Conditions: Head and Neck Cancer, Locally Advanced\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00413322\n",
      "     Title: Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01295463\n",
      "     Title: Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00899496\n",
      "     Title: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03130439\n",
      "     Title: Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00049296\n",
      "     Title: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03422679\n",
      "     Title: Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies\n",
      "     Conditions: Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00020579\n",
      "     Title: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04028479\n",
      "     Title: The Registry of Oncology Outcomes Associated with Testing and Treatment\n",
      "     Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00620295\n",
      "     Title: Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors\n",
      "     Conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03154190\n",
      "     Title: Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer\n",
      "     Conditions: Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma, Head and Neck Carcinoma, HER2/Neu Negative, Hormone-Resistant Prostate Cancer, Limited Stage Small Cell Lung Carcinoma, Myelodysplastic Syndrome, Progesterone Receptor Negative, Progressive Disease, Recurrent Carcinoma, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage IIA Pancreatic Cancer, Stage IIA Rectal Cancer, Stage IIB Pancreatic Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Colon Cancer, Stage III Esophageal Cancer, Stage III Gastric Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Skin Melanoma, Stage IIIA Colon Cancer, Stage IIIA Esophageal Cancer, Stage IIIA Gastric Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Rectal Cancer, Stage IIIA Skin Melanoma, Stage IIIB Colon Cancer, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Rectal Cancer, Stage IIIB Skin Melanoma, Stage IIIC Colon Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Rectal Cancer, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Bone Sarcoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Ovarian Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IV Soft Tissue Sarcoma, Stage IVA Bone Sarcoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Bone Sarcoma, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03184090\n",
      "     Title: Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00378781\n",
      "     Title: Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03050268\n",
      "     Title: Familial Investigations of Childhood Cancer Predisposition\n",
      "     Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02499146\n",
      "     Title: Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00161187\n",
      "     Title: Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05328258\n",
      "     Title: Use of GnRHa During Chemotherapy for Fertility Protection\n",
      "     Conditions: Breast Cancer Female, Acute Leukemia, Lymphoma, Osteosarcoma, Soft Tissue Sarcoma, Ewing Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05061017\n",
      "     Title: Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)\n",
      "     Conditions: NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00499733\n",
      "     Title: Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00002854\n",
      "     Title: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer\n",
      "     Conditions: Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06577987\n",
      "     Title: Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma, RB1 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05958199\n",
      "     Title: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7\n",
      "     Conditions: Metastatic Malignant Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00413075\n",
      "     Title: Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma\n",
      "     Conditions: Solid Tumor, Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04758000\n",
      "     Title: Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse\n",
      "     Conditions: Osteosarcoma, Ewing Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06638931\n",
      "     Title: Agnostic Therapy in Rare Solid Tumors\n",
      "     Conditions: Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma, Secretory Carcinoma of Breast, Anal Neoplasms, Metaplastic Breast Carcinoma, Translocation Renal Cell Carcinoma, Carcinosarcoma, Small Intestine Neoplasms, Cholangiocarcinoma, Sertoli-Leydig Cell Tumor, Adenoid Cystic Carcinoma, Mesothelioma, Neuroblastoma, Adrenal Gland Neoplasms, Penile Neoplasms, Apocrine Carcinoma, Fibrosarcoma, Cancer of Unknown Primary, Hemangioblastoma, Thyroid Neoplasms, Hepatoblastoma, Fallopian Tube Neoplasms, Leiomyosarcoma, Vaginal Neoplasms, Neurofibrosarcoma, Gallbladder Neoplasms, Osteosarcoma, Biliary Tract Neoplasms, Clear Cell Endometrial Cancer, Yolk Sac Tumor, Vulvar Neoplasms, Kaposi Sarcoma, Ovarian Epithelial Cancer, Soft Tissue Sarcoma, Urethral Neoplasms, Granulosa Cell Tumor, Primitive Neuroectodermal Tumor, Neuroendocrine Tumors, Trophoblastic Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01085565\n",
      "     Title: Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System\n",
      "     Conditions: Bone Cancer, Bone Metastases, Pain\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03355794\n",
      "     Title: A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)\n",
      "     Conditions: Diffuse Intrinsic Pontine Glioma, Malignant Glioma of Brain, High Grade Glioma, Bithalamic High Grade Glioma, Brainstem Glioma, Glioblastoma, Anaplastic Astrocytoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03304080\n",
      "     Title: Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast\n",
      "     Conditions: Breast Neoplasms, Breast Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04360941\n",
      "     Title: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00014456\n",
      "     Title: Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors\n",
      "     Conditions: Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02223052\n",
      "     Title: Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies\n",
      "     Conditions: Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00721409\n",
      "     Title: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05062707\n",
      "     Title: Early Ageing During Therapy in AYA Cancer Patients\n",
      "     Conditions: Cancer, Leukemia, Hodgkin Lymphoma, Testicular Cancer, Osteosarcoma, Ewing Sarcoma, Breast Cancer, Cervical Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00154388\n",
      "     Title: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases\n",
      "     Conditions: Life Threatening Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03519178\n",
      "     Title: A Study of PF-06873600 in People With Cancer\n",
      "     Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01286987\n",
      "     Title: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors\n",
      "     Conditions: Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01684215\n",
      "     Title: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer\n",
      "     Conditions: Neoplasms, Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03635632\n",
      "     Title: C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)\n",
      "     Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma, Relapsed Ewing Sarcoma, Relapsed Rhabdomyosarcoma, Uveal Melanoma, Phyllodes Breast Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01617915\n",
      "     Title: Tumor Specific Plasma DNA\n",
      "     Conditions: Breast Cancer, Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01598454\n",
      "     Title: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides\n",
      "     Conditions: Neuroblastoma, Ewing's Sarcoma, Wilm's Tumor, Retinoblastoma, Glioma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06177327\n",
      "     Title: Hepato-pancreato-biliary Abnormalities in Fibrous Dysplasia of Bone/McCune Albright Syndrome\n",
      "     Conditions: Fibrous Dysplasia of Bone\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02624973\n",
      "     Title: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04436120\n",
      "     Title: Treatment Resistance Following Anti-cancer Therapies\n",
      "     Conditions: Disease Progression\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05492682\n",
      "     Title: START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer\n",
      "     Conditions: Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma, Myxoid Liposarcoma, Colorectal Cancer, Osteosarcoma, Sarcoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06416358\n",
      "     Title: A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed\n",
      "     Conditions: Advanced Solid Tumors With Bone Only Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05297734\n",
      "     Title: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer\n",
      "     Conditions: End of Life, Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04616248\n",
      "     Title: In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02389842\n",
      "     Title: PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib\n",
      "     Conditions: Advanced Solid Tumours, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05365178\n",
      "     Title: To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer\n",
      "     Conditions: HR-positive, HER2-negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04671693\n",
      "     Title: A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.\n",
      "     Conditions: Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC, Osteosarcoma, Ewing's Sarcoma, Acute Myeloid Leukemia, Hodgkin Disease, Non Hodgkin Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06162351\n",
      "     Title: A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast Cancer\n",
      "     Conditions: Breast, Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01932047\n",
      "     Title: Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment\n",
      "     Conditions: Refractory Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05655598\n",
      "     Title: TAS-116 Plus Palbociclib in Breast and Rb-null Cancer\n",
      "     Conditions: Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01916317\n",
      "     Title: Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer\n",
      "     Conditions: Operable Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01091883\n",
      "     Title: Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma\n",
      "     Conditions: Bone Cancer, Bone Metastases, Pain\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06998628\n",
      "     Title: Pentoxifylline as Anti-Inflammatory in Patients With Rheumatoid Arthritis\n",
      "     Conditions: Rheumatoid Arthritis\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND BCL2'...\n",
      "-> API search found 24 total studies for '\"Breast Cancer\" AND BCL2'.\n",
      "\n",
      "Found 24 studies for gene 'BCL2' in Breast Cancer:\n",
      "   - NCT ID: NCT03906669\n",
      "     Title: A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.\n",
      "     Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01701050\n",
      "     Title: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04800146\n",
      "     Title: A Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study\n",
      "     Conditions: Covid19, Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00156273\n",
      "     Title: Determine Feasibility of Quantifying Apoptosis and Bcl-2 Expression in CTCs in Women With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01891357\n",
      "     Title: Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer\n",
      "     Conditions: Carcinoma, Ductal, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01898312\n",
      "     Title: BRCA1/2 and Effect of Mifepristone on the Breast\n",
      "     Conditions: Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00063934\n",
      "     Title: Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer\n",
      "     Conditions: Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01744821\n",
      "     Title: Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer\n",
      "     Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03900884\n",
      "     Title: Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer\n",
      "     Conditions: Breast Neoplasm Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00003103\n",
      "     Title: Chemotherapy in Treating Patients With Solid Tumors\n",
      "     Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05889390\n",
      "     Title: Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer\n",
      "     Conditions: HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05775575\n",
      "     Title: A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00896857\n",
      "     Title: Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01016665\n",
      "     Title: Anastrozole Reduced Proliferation and Progesterone Receptor Indexes in Short Term Hormone Therapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00898976\n",
      "     Title: Biomarkers in Native American Women With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06756932\n",
      "     Title: BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer\n",
      "     Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00169000\n",
      "     Title: Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00725374\n",
      "     Title: A Study to Investigate the Effects of Tibolone (Livial) on Breast Tissue in Postmenopausal Women With Breast Cancer (Study 32971)(P06469)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00724386\n",
      "     Title: Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01693549\n",
      "     Title: Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05358639\n",
      "     Title: Combination of Olaparib and Navitoclax in Women with HGSC and TNBC\n",
      "     Conditions: High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01864798\n",
      "     Title: A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00320411\n",
      "     Title: GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer\n",
      "     Conditions: Neoplasms, Breast\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND MET'...\n",
      "-> API search found 100 total studies for '\"Breast Cancer\" AND MET'.\n",
      "\n",
      "Found 100 studies for gene 'MET' in Breast Cancer:\n",
      "   - NCT ID: NCT00593346\n",
      "     Title: Evaluation of Accelerated Partial Breast Brachytherapy\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03801369\n",
      "     Title: Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00490646\n",
      "     Title: A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06099769\n",
      "     Title: A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768868\n",
      "     Title: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05617040\n",
      "     Title: Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer\n",
      "     Conditions: Prostate Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04764292\n",
      "     Title: Screening Contrast-Enhanced Mammography As an Alternative to MRI\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04613440\n",
      "     Title: FaCT Trial (Facilitated Cascade Testing Trial)\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05427344\n",
      "     Title: Effectiveness of Aquatic Exercise on Fatigue, Neuropathy and Quality of Life Among Cancer Patients\n",
      "     Conditions: Colon Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02955940\n",
      "     Title: An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib\n",
      "     Conditions: Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01372644\n",
      "     Title: Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial\n",
      "     Conditions: Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02058368\n",
      "     Title: Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia\n",
      "     Conditions: Prostatic Hyperplasia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01772472\n",
      "     Title: A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02747004\n",
      "     Title: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01882972\n",
      "     Title: Strength for Health\n",
      "     Conditions: Colon Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06062901\n",
      "     Title: An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors\n",
      "     Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05203601\n",
      "     Title: A Phase a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02181101\n",
      "     Title: Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06202404\n",
      "     Title: Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model\n",
      "     Conditions: Metastasis, Predictive Cancer Model\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03683004\n",
      "     Title: Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study\n",
      "     Conditions: Colorectal Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01225172\n",
      "     Title: Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05272904\n",
      "     Title: The QUILT Study: Quilting Sutures in Patients Undergoing Breast Cancer Surgery\n",
      "     Conditions: Seroma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06355440\n",
      "     Title: Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China\n",
      "     Conditions: Breast Neoplasm Female, Financial Toxicity, Financial Navigation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04282044\n",
      "     Title: Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies\n",
      "     Conditions: Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Osteosarcoma, Epithelial Ovarian Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Malignant Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03972540\n",
      "     Title: Effect of Mindful Eating on Weight Management in Breast Cancer Survivors\n",
      "     Conditions: Breast Neoplasm Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05007444\n",
      "     Title: Safety and Efficacy Evaluation of the P2Et Extract in Patients With Breast Cancer\n",
      "     Conditions: Breast Cancer, Quality of Life, Tumor, Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01461044\n",
      "     Title: An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02125344\n",
      "     Title: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)\n",
      "     Conditions: Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04902144\n",
      "     Title: Clinical Outcomes for Offering Genetic Testing in a Tiered Approach\n",
      "     Conditions: Breast Carcinoma, Colon Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02611544\n",
      "     Title: Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors\n",
      "     Conditions: Breast Neoplasms, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast, Cancer of Breast, Mammary Neoplasm, Human, Human Mammary Carcinoma, Malignant Tumor of Breast, Mammary Cancer, Mammary Carcinoma, Anxiety, Fear, Neoplasm Remission, Spontaneous, Spontaneous Neoplasm Regression, Regression, Spontaneous Neoplasm, Remission, Spontaneous Neoplasm, Spontaneous Neoplasm Remission\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02768701\n",
      "     Title: Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02650401\n",
      "     Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\n",
      "     Conditions: Solid Tumors, CNS Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06871501\n",
      "     Title: \"Observational, Retrospective and Prospective, Non-interventional, Multicentre on the Use of Genomic Testing in the Management of Early Stage HR+/HER2- Breast Cancer\"\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02949167\n",
      "     Title: MyHealth: Follow-up After Breast Cancer Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02923401\n",
      "     Title: High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer\n",
      "     Conditions: Disorders of Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04032080\n",
      "     Title: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01301729\n",
      "     Title: A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05896189\n",
      "     Title: Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors\n",
      "     Conditions: Breast Cancer, Cognitive Impairments\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06672380\n",
      "     Title: The INFLUENCE of PHYSICAL ACTIVITY on the HEALTH and WELL-BEING of BREAST CANCER SURVIVORS\n",
      "     Conditions: Breast Cancer Survivor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06954480\n",
      "     Title: Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02574780\n",
      "     Title: Lymphedema Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy\n",
      "     Conditions: Lymphedema\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00295529\n",
      "     Title: GenetiKiT: Evaluation of an Educational Intervention on the Delivery of Genetics Services by Family Physicians\n",
      "     Conditions: Breast Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00431067\n",
      "     Title: Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06383767\n",
      "     Title: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00605267\n",
      "     Title: Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00398567\n",
      "     Title: A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer\n",
      "     Conditions: Advanced Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03846167\n",
      "     Title: Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05911867\n",
      "     Title: Muscle Energy Technique and Mulligan's Mobilization in Breast Cancer Surgery Patients\n",
      "     Conditions: Mobility Limitation, Muscle Relaxation, Kinematics, Postural; Defect, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06239467\n",
      "     Title: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer\n",
      "     Conditions: Advanced Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06048367\n",
      "     Title: Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor\n",
      "     Conditions: Advanced Solid Tumor, Lung Cancer, Pancreas Cancer, Breast Cancer, Thyroid Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Vulva Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05602792\n",
      "     Title: A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer, Esophagus Cancer, NSCLC, Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01504789\n",
      "     Title: Part II: Exercise in Hispanic Breast Cancer Survivors\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02424292\n",
      "     Title: Evaluation of a Physical Activity Program in Overweight Breast Cancer Patients\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00093808\n",
      "     Title: Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04440943\n",
      "     Title: A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies\n",
      "     Conditions: Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01738438\n",
      "     Title: Cabozantinib for Metastatic Triple Negative BrCa\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04922008\n",
      "     Title: Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06981208\n",
      "     Title: ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction\n",
      "     Conditions: Breast Cancer, Cancer of the Breast\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01967823\n",
      "     Title: T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer\n",
      "     Conditions: Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05364450\n",
      "     Title: Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors\n",
      "     Conditions: Breast Neoplasm, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast, Cancer of Breast, Mammary Neoplasms, Human, Human Mammary Carcinoma, Malignant Tumor of Breast, Mammary Cancer, Mammary Carcinoma, Human, Anxiety, Fear\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04585750\n",
      "     Title: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)\n",
      "     Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04596150\n",
      "     Title: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer\n",
      "     Conditions: Neoplasms, Breast Neoplasms, Breast Neoplasms, Triple-Negative, Breast Cancer, Breast Neoplasms, Hormone Receptor Positive/HER2 Negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06643455\n",
      "     Title: Mindfulness Intervention for Improving Nutrition in the Digital Kitchen Among Stage I-III Breast Cancer Survivors, MIND Trial\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05053555\n",
      "     Title: High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies\n",
      "     Conditions: Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06617455\n",
      "     Title: Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial\n",
      "     Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Localized Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02896855\n",
      "     Title: A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00708214\n",
      "     Title: BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01698281\n",
      "     Title: Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00355381\n",
      "     Title: Evaluating Patient Information Prescriptions\n",
      "     Conditions: Breast Neoplasms, Premature Birth\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01572038\n",
      "     Title: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03193008\n",
      "     Title: Current Value of Axillary Ultrasound in the Staging of Breast Cancer. Is BSGC Still Necessary?\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05303038\n",
      "     Title: Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy\n",
      "     Conditions: Metastatic Breast Cancer in the Liver\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06445738\n",
      "     Title: Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)\n",
      "     Conditions: Breast Cancer, Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04975308\n",
      "     Title: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer\n",
      "     Conditions: Breast Neoplasms, Neoplasm Metastasis\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00733408\n",
      "     Title: Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer\n",
      "     Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00885755\n",
      "     Title: A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02111850\n",
      "     Title: T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive\n",
      "     Conditions: Cervical Cancer, Renal Cancer, Urothelial Cancer, Melanoma, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05072314\n",
      "     Title: Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial\n",
      "     Conditions: Breast Cancer, Breast Cancer Female, Breast Conserving Surgery, Mastectomy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07040514\n",
      "     Title: 24GUT540 : Meeting of Breast Cancer Patients and Pathologists\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02320123\n",
      "     Title: End-of-Life Care for African Americans\n",
      "     Conditions: Colonic Neoplasms, Breast Neoplasms, Lung Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05386108\n",
      "     Title: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer\n",
      "     Conditions: Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04966923\n",
      "     Title: Phenotype and Prognosis of Patients With Breast Cancer and Pathogenic Variants of TP53\n",
      "     Conditions: Breast Cancer, TP53 R337H, Li-Fraumeni Syndrome, Prognosis Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05998655\n",
      "     Title: Tele-nursing Practices Based on Technological Competence Theory in Breast Cancer Patients\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06938555\n",
      "     Title: The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors\n",
      "     Conditions: Breast Cancer Survivor, Cancer Related Cognitive Difficulties, Sleep, Quality of Life\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT07046455\n",
      "     Title: Trop-2 Targeted PET Probes in Advanced TNBC\n",
      "     Conditions: TNBC - Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02965755\n",
      "     Title: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00451555\n",
      "     Title: Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05140655\n",
      "     Title: Effectiveness and Safety of Fulvestrant in Postmenopausal Women With Advanced Breast Cancer HR+, HER2-\n",
      "     Conditions: Breast Neoplasm Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03329950\n",
      "     Title: A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies\n",
      "     Conditions: Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06739395\n",
      "     Title: Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion\n",
      "     Conditions: Solid Tumor, Precision Medicine\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00408681\n",
      "     Title: Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant\n",
      "     Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, Breakpoint Cluster Region-abl Translocation (BCR-ABL) Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Gastrointestinal Complications, Juvenile Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Poor Prognosis Metastatic Gestational Trophoblastic Tumor, Previously Treated Childhood Rhabdomyosarcoma, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Neuroblastoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Small Lymphocytic Lymphoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage II Ovarian Epithelial Cancer, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Malignant Testicular Germ Cell Tumor, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Ovarian Epithelial Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Breast Cancer, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Ovarian Epithelial Cancer, Stage IV Small Lymphocytic Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02316795\n",
      "     Title: Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma\n",
      "     Conditions: Breast Cancer, Cancer of Breast, Cancer of the Breast, Melanoma, Malignant Melanoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06253195\n",
      "     Title: BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Hormone-receptor-positive Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00081510\n",
      "     Title: Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04868812\n",
      "     Title: Histological Modifications of Postmenopausal Vaginal Mucosa After Repeated Carbon Dioxide (CO2) Laser Treatment\n",
      "     Conditions: Vaginal Atrophy, Breast Cancer Female, Dyspareunia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06116812\n",
      "     Title: The Effects of Laughter Yoga and Mindfulness-Based Stress Reduction (MBSR) Practices Applied to Women With Breast Cancer\n",
      "     Conditions: Breast Cancer, Laughter Therapy, Mindfulness Therapy, Life Quality, Anxiety and Depression, Spiritual Well-being\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02796612\n",
      "     Title: Empathy and Standard Diagnostic Procedures in an Outpatient Breast Clinic Might Not be Enough\n",
      "     Conditions: Anxiety\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03674112\n",
      "     Title: A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer\n",
      "     Conditions: HER2-Positive Early Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04957212\n",
      "     Title: Comparing Efficacy and Safety Between Pertuzumab and Perjeta in Neoadjuvant Treatment of HER2+ Breast Cancer\n",
      "     Conditions: HER2-positive Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00894504\n",
      "     Title: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NTRK2'...\n",
      "-> API search found 4 total studies for '\"Breast Cancer\" AND NTRK2'.\n",
      "\n",
      "Found 4 studies for gene 'NTRK2' in Breast Cancer:\n",
      "   - NCT ID: NCT02650401\n",
      "     Title: Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options\n",
      "     Conditions: Solid Tumors, CNS Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02568267\n",
      "     Title: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)\n",
      "     Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02576431\n",
      "     Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors\n",
      "     Conditions: Solid Tumors Harboring NTRK Fusion\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND TSC2'...\n",
      "-> API search found 1 total studies for '\"Breast Cancer\" AND TSC2'.\n",
      "\n",
      "Found 1 studies for gene 'TSC2' in Breast Cancer:\n",
      "   - NCT ID: NCT02465060\n",
      "     Title: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)\n",
      "     Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND STK11'...\n",
      "-> API search found 9 total studies for '\"Breast Cancer\" AND STK11'.\n",
      "\n",
      "Found 9 studies for gene 'STK11' in Breast Cancer:\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06536881\n",
      "     Title: Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming\n",
      "     Conditions: Breast Cancer, Early-stage Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03294343\n",
      "     Title: Risk-Reducing Surgeries for Hereditary Ovarian Cancer\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovariectomy, Hysterectomy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02000089\n",
      "     Title: The Cancer of the Pancreas Screening-5 CAPS5)Study\n",
      "     Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04257045\n",
      "     Title: Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives\n",
      "     Conditions: Breast Carcinoma, Deleterious CDH1 Gene Mutation, Deleterious DICER1 Gene Mutation, Deleterious SMARCA4 Gene Mutation, Deleterious STK11 Gene Mutation, Endometrial Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND ATR'...\n",
      "-> API search found 19 total studies for '\"Breast Cancer\" AND ATR'.\n",
      "\n",
      "Found 19 studies for gene 'ATR' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03801369\n",
      "     Title: Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer\n",
      "     Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02723864\n",
      "     Title: Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors\n",
      "     Conditions: Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05582538\n",
      "     Title: Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel\n",
      "     Conditions: Triple Negative Breast Cancer Metastatic\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04508803\n",
      "     Title: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer\n",
      "     Conditions: Treatment Efficacy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04491942\n",
      "     Title: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer\n",
      "     Conditions: Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Advanced Gastric Carcinoma, Advanced Head and Neck Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Advanced Pleural Malignant Mesothelioma, Advanced Urothelial Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Bile Duct Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Penile Cancer AJCC v8, Stage III Pleural Malignant Mesothelioma AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Bile Duct Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Pleural Malignant Mesothelioma AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Urothelial Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03188965\n",
      "     Title: First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas\n",
      "     Conditions: Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04095273\n",
      "     Title: Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05026073\n",
      "     Title: Vibrational Spectroscopy for Endometrial Cancer Diagnosis\n",
      "     Conditions: Endometrial Cancer, Endometrial Hyperplasia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02264678\n",
      "     Title: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents\n",
      "     Conditions: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03740893\n",
      "     Title: PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer\n",
      "     Conditions: Breast Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05986071\n",
      "     Title: I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02401347\n",
      "     Title: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03330847\n",
      "     Title: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.\n",
      "     Conditions: Metastatic Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04655183\n",
      "     Title: Study of M4344 in Combination With Niraparib\n",
      "     Conditions: Advanced Solid Tumor, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03678883\n",
      "     Title: 9-ING-41 in Patients with Advanced Cancers\n",
      "     Conditions: Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04704661\n",
      "     Title: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial\n",
      "     Conditions: Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND NOTCH1'...\n",
      "-> API search found 5 total studies for '\"Breast Cancer\" AND NOTCH1'.\n",
      "\n",
      "Found 5 studies for gene 'NOTCH1' in Breast Cancer:\n",
      "   - NCT ID: NCT05203601\n",
      "     Title: A Phase a Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.\n",
      "     Conditions: Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01158274\n",
      "     Title: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors\n",
      "     Conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Lymphoblastic Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, HER2-negative Breast Cancer, HIV-associated Hodgkin Lymphoma, Intraocular Lymphoma, Male Breast Cancer, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Rectal Cancer, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Colon Cancer, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Rectal Cancer, Stage III Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Rectal Cancer, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenstrm Macroglobulinemia\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01505400\n",
      "     Title: Integrated Molecular Profiling in Advanced Cancers Trial\n",
      "     Conditions: Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer, Pancreatobiliary Gastrointestinal Cancer, Upper Aerodigestive Tract Cancer, Gynecological Cancers, Melanoma Cancers, Rare Cancers, Unknown Primary Cancers\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01208441\n",
      "     Title: RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer\n",
      "     Conditions: Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01876251\n",
      "     Title: A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer Metastatic\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND SMAD4'...\n",
      "-> API search found 1 total studies for '\"Breast Cancer\" AND SMAD4'.\n",
      "\n",
      "Found 1 studies for gene 'SMAD4' in Breast Cancer:\n",
      "   - NCT ID: NCT02664389\n",
      "     Title: Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation\n",
      "     Conditions: Breast Cancer, Ovarian Cancer, Colorectal Cancer, Pediatric Cancers, Multiple Primary Malignant Tumours\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND CHEK2'...\n",
      "-> API search found 17 total studies for '\"Breast Cancer\" AND CHEK2'.\n",
      "\n",
      "Found 17 studies for gene 'CHEK2' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033092\n",
      "     Title: Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion\n",
      "     Conditions: BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, ATM Gene Mutation, CHEK2 Gene Mutation, CDH1 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04508803\n",
      "     Title: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer\n",
      "     Conditions: Treatment Efficacy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04335669\n",
      "     Title: NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC\n",
      "     Conditions: Breast Cancer, Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01102569\n",
      "     Title: Pancreatic Cancer Genetics\n",
      "     Conditions: Pancreatic Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02203513\n",
      "     Title: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer\n",
      "     Conditions: Ovarian Cancer, Breast Cancer, Prostate Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05787587\n",
      "     Title: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03344965\n",
      "     Title: Olaparib In Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04276376\n",
      "     Title: Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors\n",
      "     Conditions: Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05033756\n",
      "     Title: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO\n",
      "     Conditions: Malignant Neoplasm of Breast, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04265937\n",
      "     Title: ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies\n",
      "     Conditions: Breast Cancer, Genetic Susceptibility\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02624973\n",
      "     Title: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06177171\n",
      "     Title: Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02401347\n",
      "     Title: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "Searching for studies with query: '\"Breast Cancer\" AND ATM'...\n",
      "-> API search found 43 total studies for '\"Breast Cancer\" AND ATM'.\n",
      "\n",
      "Found 43 studies for gene 'ATM' in Breast Cancer:\n",
      "   - NCT ID: NCT01989546\n",
      "     Title: Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations\n",
      "     Conditions: Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06045572\n",
      "     Title: Vascular Supply Identification, Lesion Extension and Search for Tumor Similarity at a Distance by VTM in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06033092\n",
      "     Title: Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion\n",
      "     Conditions: BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ, Lobular Carcinoma in Situ, ATM Gene Mutation, CHEK2 Gene Mutation, CDH1 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03495544\n",
      "     Title: Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer\n",
      "     Conditions: Hereditary Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04672460\n",
      "     Title: A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer, Prostate Cancer, NSCLC, Pancreatic Cancer, Colorectal Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04591431\n",
      "     Title: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy\n",
      "     Conditions: Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00896727\n",
      "     Title: S9313A Protein Expression Analysis of Breast Cancer Tissue Microarrays From Clinical Trial SWOG-9313\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01349322\n",
      "     Title: Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06131424\n",
      "     Title: NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients\n",
      "     Conditions: HER2-negative\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03294343\n",
      "     Title: Risk-Reducing Surgeries for Hereditary Ovarian Cancer\n",
      "     Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Ovariectomy, Hysterectomy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00579514\n",
      "     Title: Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients\n",
      "     Conditions: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04508803\n",
      "     Title: Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer\n",
      "     Conditions: Treatment Efficacy\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03327064\n",
      "     Title: A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer\n",
      "     Conditions: Non-melanoma Skin Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04335669\n",
      "     Title: NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC\n",
      "     Conditions: Breast Cancer, Triple Negative Breast Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05058846\n",
      "     Title: Pilot Study of Pancreatic Cancer Screening\n",
      "     Conditions: Pancreatic Carcinoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04996836\n",
      "     Title: Breast Cancer, Omics, and Precision Medicine\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06775236\n",
      "     Title: Clinical Trial of SYS6010SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Advanced Solid Tumors, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05787587\n",
      "     Title: A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors\n",
      "     Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03344965\n",
      "     Title: Olaparib In Metastatic Breast Cancer\n",
      "     Conditions: Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04768426\n",
      "     Title: Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer\n",
      "     Conditions: Triple Negative Breast Cancer, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03188965\n",
      "     Title: First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas\n",
      "     Conditions: Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03565991\n",
      "     Title: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors\n",
      "     Conditions: Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00195091\n",
      "     Title: Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02000089\n",
      "     Title: The Cancer of the Pancreas Screening-5 CAPS5)Study\n",
      "     Conditions: Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04276376\n",
      "     Title: Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors\n",
      "     Conditions: Solid Tumor\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05033756\n",
      "     Title: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO\n",
      "     Conditions: Malignant Neoplasm of Breast, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06710015\n",
      "     Title: Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2\n",
      "     Conditions: BRCA1 and/or BRCA2 Variant Carriers, Fertility, Reproductive Age, Menopause, Pregnancy Outcomes\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT05694715\n",
      "     Title: Combination Therapy in Cancers With Mutations in DNA Repair Genes\n",
      "     Conditions: Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02286687\n",
      "     Title: Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes\n",
      "     Conditions: Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03501173\n",
      "     Title: A Study of Participants With Advanced Prostate Cancer in Canada\n",
      "     Conditions: Prostatic Neoplasms\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03797482\n",
      "     Title: A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer\n",
      "     Conditions: Breast Cancer Female\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04095273\n",
      "     Title: Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug\n",
      "     Conditions: Advanced Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT01618136\n",
      "     Title: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors\n",
      "     Conditions: Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma, B-cell Malignancy, Low-grade\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT00674557\n",
      "     Title: Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer\n",
      "     Conditions: Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02264678\n",
      "     Title: Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents\n",
      "     Conditions: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06177171\n",
      "     Title: Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors\n",
      "     Conditions: BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT02401347\n",
      "     Title: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors\n",
      "     Conditions: Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03330847\n",
      "     Title: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.\n",
      "     Conditions: Metastatic Triple Negative Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03330405\n",
      "     Title: Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors\n",
      "     Conditions: Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT06134375\n",
      "     Title: A Study of Tetrathiomolybdate (TM) Plus Capecitabine\n",
      "     Conditions: Triple Negative Breast Cancer, Residual Disease\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04655183\n",
      "     Title: Study of M4344 in Combination With Niraparib\n",
      "     Conditions: Advanced Solid Tumor, Breast Cancer\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT03678883\n",
      "     Title: 9-ING-41 in Patients with Advanced Cancers\n",
      "     Conditions: Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma\n",
      "--------------------------------------------------\n",
      "   - NCT ID: NCT04704661\n",
      "     Title: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial\n",
      "     Conditions: Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma\n",
      "--------------------------------------------------\n",
      "\n",
      "\n",
      "==================================================\n",
      "FINAL SUMMARY OF ALL SEARCHES\n",
      "==================================================\n",
      "\n",
      "Category: FDA-approved Breast Cancer Therapy\n",
      "  - Gene 'CDK4': 100 studies found.\n",
      "  - Gene 'ERBB2': 100 studies found.\n",
      "  - Gene 'CCND1': 34 studies found.\n",
      "  - Gene 'CDKN2A': 27 studies found.\n",
      "  - Gene 'FOXO3a': 4 studies found.\n",
      "  - Gene 'KRAS': 38 studies found.\n",
      "  - Gene 'FGFR1': 21 studies found.\n",
      "  - Gene 'MDM2': 9 studies found.\n",
      "  - Gene 'NF1': 11 studies found.\n",
      "  - Gene 'AKT1': 40 studies found.\n",
      "  - Gene 'BRCA1': 100 studies found.\n",
      "  - Gene 'HRAS': 4 studies found.\n",
      "  - Gene 'TP53': 56 studies found.\n",
      "  - Gene 'CDK6': 35 studies found.\n",
      "  - Gene 'PTEN': 100 studies found.\n",
      "  - Gene 'MYC': 15 studies found.\n",
      "  - Gene 'BRCA2': 100 studies found.\n",
      "  - Gene 'PIK3CA': 100 studies found.\n",
      "  - Gene 'RB1': 71 studies found.\n",
      "  - Gene 'BCL2': 24 studies found.\n",
      "  - Gene 'MET': 100 studies found.\n",
      "  - Gene 'EGFR': 100 studies found.\n",
      "  - Gene 'NTRK2': 4 studies found.\n",
      "  - Gene 'TSC2': 1 studies found.\n",
      "  - Gene 'STK11': 9 studies found.\n",
      "  - Gene 'FGFR2': 7 studies found.\n",
      "  - Gene 'ATR': 19 studies found.\n",
      "  - Gene 'NOTCH1': 5 studies found.\n",
      "  - Gene 'SMAD4': 1 studies found.\n",
      "  - Gene 'CHEK2': 17 studies found.\n",
      "  - Gene 'ATM': 43 studies found.\n",
      "\n",
      "Category: FDA-approved Other Indication\n",
      "  - Gene 'CCND1': 34 studies found.\n",
      "  - Gene 'CDKN2A': 27 studies found.\n",
      "  - Gene 'FOXO3a': 4 studies found.\n",
      "  - Gene 'MDM2': 9 studies found.\n",
      "  - Gene 'NF1': 11 studies found.\n",
      "  - Gene 'HRAS': 4 studies found.\n",
      "  - Gene 'PTEN': 100 studies found.\n",
      "  - Gene 'RB1': 71 studies found.\n",
      "  - Gene 'BCL2': 24 studies found.\n",
      "  - Gene 'MET': 100 studies found.\n",
      "  - Gene 'NTRK2': 4 studies found.\n",
      "  - Gene 'TSC2': 1 studies found.\n",
      "  - Gene 'STK11': 9 studies found.\n",
      "  - Gene 'ATR': 19 studies found.\n",
      "  - Gene 'NOTCH1': 5 studies found.\n",
      "  - Gene 'SMAD4': 1 studies found.\n",
      "  - Gene 'CHEK2': 17 studies found.\n",
      "  - Gene 'ATM': 43 studies found.\n",
      "==================================================\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import json\n",
    "import time\n",
    "\n",
    "# Define the two new sets of genes and their categories.\n",
    "gene_categories = {\n",
    "    \"FDA-approved Breast Cancer Therapy\": [\n",
    "        'CDK4', 'ERBB2', 'CCND1', 'CDKN2A', 'FOXO3a', 'KRAS', 'FGFR1',\n",
    "        'MDM2', 'NF1', 'AKT1', 'BRCA1', 'HRAS', 'TP53', 'CDK6', 'PTEN',\n",
    "        'MYC', 'BRCA2', 'PIK3CA', 'RB1', 'BCL2', 'MET', 'EGFR', 'NTRK2',\n",
    "        'TSC2', 'STK11', 'FGFR2', 'ATR', 'NOTCH1', 'SMAD4', 'CHEK2', 'ATM'\n",
    "    ],\n",
    "    \"FDA-approved Other Indication\": [\n",
    "        'CCND1', 'CDKN2A', 'FOXO3a', 'MDM2', 'NF1', 'HRAS', 'PTEN', 'RB1',\n",
    "        'BCL2', 'MET', 'NTRK2', 'TSC2', 'STK11', 'ATR', 'NOTCH1', 'SMAD4',\n",
    "        'CHEK2', 'ATM'\n",
    "    ]\n",
    "}\n",
    "\n",
    "# The base URL for the modernized ClinicalTrials.gov API (v2.0).\n",
    "API_BASE_URL = \"https://clinicaltrials.gov/api/v2/studies\"\n",
    "HEADERS = {'Accept': 'application/json'}\n",
    "\n",
    "def search_studies_for_gene(gene_name, condition=\"Breast Cancer\"):\n",
    "    \"\"\"\n",
    "    Searches the ClinicalTrials.gov API for studies related to a given gene\n",
    "    and a specified condition.\n",
    "    \n",
    "    Args:\n",
    "        gene_name (str): The gene to search for.\n",
    "        condition (str): The condition to search for. Defaults to \"Breast Cancer\".\n",
    "        \n",
    "    Returns:\n",
    "        list: A list of dictionaries, where each dictionary represents a study.\n",
    "    \"\"\"\n",
    "    # Construct a specific query for the condition and the gene.\n",
    "    # The API's 'query.term' parameter is used for a broad text search.\n",
    "    search_query = f'\"{condition}\" AND {gene_name}'\n",
    "    \n",
    "    params = {\n",
    "        \"query.term\": search_query,\n",
    "        \"pageSize\": 100  # Retrieve up to 100 studies per call for a broad search.\n",
    "    }\n",
    "    \n",
    "    studies = []\n",
    "    \n",
    "    try:\n",
    "        print(f\"Searching for studies with query: '{search_query}'...\")\n",
    "        response = requests.get(API_BASE_URL, headers=HEADERS, params=params)\n",
    "        response.raise_for_status() # Raise an error for bad status codes\n",
    "        \n",
    "        data = response.json()\n",
    "        \n",
    "        if 'studies' in data:\n",
    "            studies = data['studies']\n",
    "            print(f\"-> API search found {len(studies)} total studies for '{search_query}'.\")\n",
    "        else:\n",
    "            print(f\"-> No studies found for '{search_query}'.\")\n",
    "\n",
    "    except requests.exceptions.RequestException as e:\n",
    "        print(f\"An API error occurred for query '{search_query}': {e}\")\n",
    "        \n",
    "    return studies\n",
    "\n",
    "def extract_and_display_studies(studies, gene_name):\n",
    "    \"\"\"\n",
    "    Extracts key details and displays them for the found studies.\n",
    "    \n",
    "    Args:\n",
    "        studies (list): The list of study dictionaries from the API.\n",
    "        gene_name (str): The gene name for context.\n",
    "    \"\"\"\n",
    "    found_count = len(studies)\n",
    "    if found_count > 0:\n",
    "        print(f\"\\nFound {found_count} studies for gene '{gene_name}' in Breast Cancer:\")\n",
    "        for study in studies:\n",
    "            # Extract key details from the nested JSON structure.\n",
    "            identification_module = study.get(\"protocolSection\", {}).get(\"identificationModule\", {})\n",
    "            nct_id = identification_module.get(\"nctId\")\n",
    "            study_title = identification_module.get(\"briefTitle\")\n",
    "            \n",
    "            # The conditions are now in a new nested path in the API v2.0\n",
    "            conditions_module = study.get(\"protocolSection\", {}).get(\"conditionsModule\", {})\n",
    "            conditions = conditions_module.get(\"conditions\", [])\n",
    "\n",
    "            print(f\"   - NCT ID: {nct_id}\")\n",
    "            print(f\"     Title: {study_title}\")\n",
    "            print(f\"     Conditions: {', '.join(conditions)}\")\n",
    "            print(\"-\" * 50)\n",
    "    else:\n",
    "        print(f\"\\nNo studies found for gene '{gene_name}' in Breast Cancer.\")\n",
    "\n",
    "# Main execution loop to analyze all genes.\n",
    "print(\"Starting search for Breast Cancer studies related to all genes...\")\n",
    "final_summary = {}\n",
    "\n",
    "for category, genes in gene_categories.items():\n",
    "    final_summary[category] = {}\n",
    "    print(f\"\\n=======================================================\")\n",
    "    print(f\"Searching genes in category: '{category}'\")\n",
    "    print(f\"=======================================================\")\n",
    "    \n",
    "    for gene in genes:\n",
    "        studies_found = search_studies_for_gene(gene)\n",
    "        extract_and_display_studies(studies_found, gene)\n",
    "        final_summary[category][gene] = len(studies_found)\n",
    "        \n",
    "        # Add a delay to be respectful of the API's rate limits.\n",
    "        time.sleep(1)\n",
    "\n",
    "print(\"\\n\\n\" + \"=\"*50)\n",
    "print(\"FINAL SUMMARY OF ALL SEARCHES\")\n",
    "print(\"=\"*50)\n",
    "for category, genes_data in final_summary.items():\n",
    "    print(f\"\\nCategory: {category}\")\n",
    "    for gene, count in genes_data.items():\n",
    "        print(f\"  - Gene '{gene}': {count} studies found.\")\n",
    "print(\"=\"*50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "id": "657d6fb9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1800x900 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "\n",
    "# Define the data with the final, updated study counts.\n",
    "# NOTE: To avoid the ValueError, all lists must have the same length.\n",
    "# Each gene is now assigned to a single, final category for clear visualization.\n",
    "data = {\n",
    "    'gene': [\n",
    "        'CDK4', 'ERBB2', 'PIK3CA', 'MET', 'BRCA1', 'BRCA2', 'PTEN', 'RB1',\n",
    "        'TP53', 'ATM', 'AKT1', 'KRAS', 'CDK6', 'CCND1', 'CDKN2A', 'BCL2', \n",
    "        'FGFR1', 'CHEK2', 'ATR', 'MYC', 'NF1', 'STK11', 'FGFR2', 'NOTCH1', \n",
    "        'HRAS', 'NTRK2', 'BAX', 'WT1', 'CDKN1A', 'SRC', 'NF2', 'NTRK1', 'SMAD4', \n",
    "        'TSC2', 'VHL', 'CASP8', 'FOXO3a'\n",
    "    ],\n",
    "    'studies': [\n",
    "        100, 100, 100, 100, 100, 100, 100, 71,\n",
    "        56, 43, 40, 38, 34, 34, 27, 24, 21, 17,\n",
    "        19, 15, 11, 9, 7, 5, 4, 4, 9, 34, 2, 21, 5, 12, 1,\n",
    "        1, 1, 1, 4\n",
    "    ],\n",
    "    'category': [\n",
    "        'FDA-approved Breast Cancer Therapy', 'FDA-approved Breast Cancer Therapy', 'FDA-approved Breast Cancer Therapy',\n",
    "        'FDA-approved Breast Cancer Therapy', 'FDA-approved Breast Cancer Therapy', 'FDA-approved Breast Cancer Therapy',\n",
    "        'FDA-approved Breast Cancer Therapy', 'FDA-approved Breast Cancer Therapy', 'FDA-approved Breast Cancer Therapy',\n",
    "        'FDA-approved Breast Cancer Therapy', 'FDA-approved Breast Cancer Therapy', 'FDA-approved Breast Cancer Therapy',\n",
    "        'FDA-approved Other Indication', 'FDA-approved Other Indication', 'FDA-approved Other Indication',\n",
    "        'FDA-approved Other Indication', 'FDA-approved Other Indication', 'FDA-approved Other Indication',\n",
    "        'FDA-approved Other Indication', 'FDA-approved Other Indication', 'FDA-approved Other Indication',\n",
    "        'FDA-approved Other Indication', 'FDA-approved Other Indication', 'FDA-approved Other Indication',\n",
    "        'FDA-approved Other Indication', 'FDA-approved Other Indication', 'Lacks Breast Cancer Evidence', \n",
    "        'Lacks Breast Cancer Evidence', 'Lacks Breast Cancer Evidence', 'Lacks Breast Cancer Evidence', \n",
    "        'Lacks Breast Cancer Evidence', 'Lacks Breast Cancer Evidence', 'Lacks Breast Cancer Evidence', \n",
    "        'Lacks Breast Cancer Evidence', 'Lacks Breast Cancer Evidence', 'Emerging Breast Cancer Target',\n",
    "        'Emerging Breast Cancer Target'\n",
    "    ]\n",
    "}\n",
    "\n",
    "# Create a pandas DataFrame.\n",
    "df = pd.DataFrame(data)\n",
    "\n",
    "# Sort the data first by category and then by the number of studies within each category.\n",
    "category_order = [\n",
    "    'FDA-approved Breast Cancer Therapy', \n",
    "    'FDA-approved Other Indication', \n",
    "    'Emerging Breast Cancer Target', \n",
    "    'Lacks Breast Cancer Evidence'\n",
    "]\n",
    "df['category'] = pd.Categorical(df['category'], categories=category_order, ordered=True)\n",
    "df = df.sort_values(by=['category', 'studies'], ascending=[True, False])\n",
    "\n",
    "# Create a color map for the categories.\n",
    "category_colors = {\n",
    "    'FDA-approved Breast Cancer Therapy': '#1f77b4',  # Blue\n",
    "    'FDA-approved Other Indication': '#2ca02c',      # Green\n",
    "    'Emerging Breast Cancer Target': '#ff7f0e',      # Orange\n",
    "    'Lacks Breast Cancer Evidence': '#d62728'        # Red\n",
    "}\n",
    "colors = df['category'].map(category_colors)\n",
    "\n",
    "# Create the plot.\n",
    "plt.figure(figsize=(18, 9))\n",
    "plt.bar(df['gene'], df['studies'], color=colors)\n",
    "\n",
    "# Add labels and title for clarity.\n",
    "plt.title('Number of Clinical Studies for Breast Cancer Genes by Therapeutic Category', fontsize=16)\n",
    "plt.xlabel('Gene', fontsize=12)\n",
    "plt.ylabel('Number of Studies Found', fontsize=12)\n",
    "\n",
    "# Rotate x-axis labels to prevent overlap.\n",
    "plt.xticks(rotation=45, ha='right')\n",
    "\n",
    "# Add vertical lines to separate the categories.\n",
    "category_boundaries = df['category'].value_counts(sort=False).cumsum().tolist()\n",
    "for x_pos in category_boundaries[:-1]:\n",
    "    plt.axvline(x=x_pos - 0.5, color='gray', linestyle='--', linewidth=1.5)\n",
    "\n",
    "# Create a custom legend.\n",
    "handles = [plt.Rectangle((0, 0), 1, 1, color=category_colors[label]) for label in category_order]\n",
    "plt.legend(handles, category_order, title=\"Therapeutic Category\")\n",
    "\n",
    "plt.tight_layout()\n",
    "plt.show()\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "id": "a5b7d20e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.plotly.v1+json": {
       "config": {
        "plotlyServerURL": "https://plot.ly"
       },
       "data": [
        {
         "link": {
          "color": [
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(255, 127, 14, 0.8)",
           "rgba(255, 127, 14, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(31, 119, 180, 0.8)"
          ],
          "source": [
           0,
           1,
           2,
           3,
           4,
           5,
           6,
           7,
           8,
           9,
           10,
           11,
           12,
           13,
           14,
           15,
           16,
           17,
           18,
           19,
           20,
           21,
           22,
           23,
           24,
           25,
           26,
           27,
           28,
           29,
           30,
           31,
           32,
           33,
           34,
           35,
           36,
           37,
           0,
           12,
           1,
           2,
           4,
           5,
           3,
           6,
           11,
           15,
           21,
           8
          ],
          "target": [
           39,
           39,
           39,
           39,
           39,
           39,
           39,
           39,
           39,
           39,
           39,
           39,
           39,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           40,
           38,
           38,
           41,
           41,
           41,
           41,
           41,
           41,
           41,
           41,
           47,
           47,
           50,
           42,
           46,
           46,
           43,
           42,
           48,
           51,
           45,
           49
          ],
          "value": [
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1,
           1
          ]
         },
         "node": {
          "color": [
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(31, 119, 180, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(44, 160, 44, 0.8)",
           "rgba(255, 127, 14, 0.8)",
           "rgba(255, 127, 14, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "rgba(214, 39, 40, 0.8)",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray",
           "lightgray"
          ],
          "label": [
           "CDK4",
           "ERBB2",
           "PIK3CA",
           "MET",
           "BRCA1",
           "BRCA2",
           "PTEN",
           "RB1",
           "TP53",
           "ATM",
           "AKT1",
           "KRAS",
           "CDK6",
           "CCND1",
           "CDKN2A",
           "BCL2",
           "FGFR1",
           "FGFR2",
           "MDM2",
           "NF1",
           "HRAS",
           "NTRK2",
           "TSC2",
           "STK11",
           "ATR",
           "NOTCH1",
           "SMAD4",
           "CHEK2",
           "CASP8",
           "FOXO3a",
           "CDKN1A",
           "BAX",
           "NRAS",
           "VHL",
           "SRC",
           "NF2",
           "WT1",
           "NTRK1",
           "Emerging Breast Cancer Target",
           "FDA-approved Breast Cancer Therapy",
           "FDA-approved Other Indication",
           "Lacks Breast Cancer Evidence",
           "Alpelisib (Piqray)",
           "Crizotinib (Xalkori)",
           "Gefitinib (Iressa)",
           "Larotrectinib (Vitrakvi)",
           "Olaparib (Lynparza)",
           "Palbociclib (Ibrance)",
           "Sotorasib (Lumakras)",
           "Therapies for TP53",
           "Trastuzumab (Herceptin)",
           "Venetoclax (Venclexta)"
          ],
          "line": {
           "color": "black",
           "width": 0.5
          },
          "pad": 15,
          "thickness": 20
         },
         "type": "sankey"
        }
       ],
       "layout": {
        "font": {
         "size": 10
        },
        "height": 800,
        "template": {
         "data": {
          "bar": [
           {
            "error_x": {
             "color": "#2a3f5f"
            },
            "error_y": {
             "color": "#2a3f5f"
            },
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "bar"
           }
          ],
          "barpolar": [
           {
            "marker": {
             "line": {
              "color": "#E5ECF6",
              "width": 0.5
             },
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "barpolar"
           }
          ],
          "carpet": [
           {
            "aaxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "baxis": {
             "endlinecolor": "#2a3f5f",
             "gridcolor": "white",
             "linecolor": "white",
             "minorgridcolor": "white",
             "startlinecolor": "#2a3f5f"
            },
            "type": "carpet"
           }
          ],
          "choropleth": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "choropleth"
           }
          ],
          "contour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "contour"
           }
          ],
          "contourcarpet": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "contourcarpet"
           }
          ],
          "heatmap": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "heatmap"
           }
          ],
          "histogram": [
           {
            "marker": {
             "pattern": {
              "fillmode": "overlay",
              "size": 10,
              "solidity": 0.2
             }
            },
            "type": "histogram"
           }
          ],
          "histogram2d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2d"
           }
          ],
          "histogram2dcontour": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "histogram2dcontour"
           }
          ],
          "mesh3d": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "type": "mesh3d"
           }
          ],
          "parcoords": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "parcoords"
           }
          ],
          "pie": [
           {
            "automargin": true,
            "type": "pie"
           }
          ],
          "scatter": [
           {
            "fillpattern": {
             "fillmode": "overlay",
             "size": 10,
             "solidity": 0.2
            },
            "type": "scatter"
           }
          ],
          "scatter3d": [
           {
            "line": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatter3d"
           }
          ],
          "scattercarpet": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattercarpet"
           }
          ],
          "scattergeo": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergeo"
           }
          ],
          "scattergl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattergl"
           }
          ],
          "scattermap": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermap"
           }
          ],
          "scattermapbox": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scattermapbox"
           }
          ],
          "scatterpolar": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolar"
           }
          ],
          "scatterpolargl": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterpolargl"
           }
          ],
          "scatterternary": [
           {
            "marker": {
             "colorbar": {
              "outlinewidth": 0,
              "ticks": ""
             }
            },
            "type": "scatterternary"
           }
          ],
          "surface": [
           {
            "colorbar": {
             "outlinewidth": 0,
             "ticks": ""
            },
            "colorscale": [
             [
              0,
              "#0d0887"
             ],
             [
              0.1111111111111111,
              "#46039f"
             ],
             [
              0.2222222222222222,
              "#7201a8"
             ],
             [
              0.3333333333333333,
              "#9c179e"
             ],
             [
              0.4444444444444444,
              "#bd3786"
             ],
             [
              0.5555555555555556,
              "#d8576b"
             ],
             [
              0.6666666666666666,
              "#ed7953"
             ],
             [
              0.7777777777777778,
              "#fb9f3a"
             ],
             [
              0.8888888888888888,
              "#fdca26"
             ],
             [
              1,
              "#f0f921"
             ]
            ],
            "type": "surface"
           }
          ],
          "table": [
           {
            "cells": {
             "fill": {
              "color": "#EBF0F8"
             },
             "line": {
              "color": "white"
             }
            },
            "header": {
             "fill": {
              "color": "#C8D4E3"
             },
             "line": {
              "color": "white"
             }
            },
            "type": "table"
           }
          ]
         },
         "layout": {
          "annotationdefaults": {
           "arrowcolor": "#2a3f5f",
           "arrowhead": 0,
           "arrowwidth": 1
          },
          "autotypenumbers": "strict",
          "coloraxis": {
           "colorbar": {
            "outlinewidth": 0,
            "ticks": ""
           }
          },
          "colorscale": {
           "diverging": [
            [
             0,
             "#8e0152"
            ],
            [
             0.1,
             "#c51b7d"
            ],
            [
             0.2,
             "#de77ae"
            ],
            [
             0.3,
             "#f1b6da"
            ],
            [
             0.4,
             "#fde0ef"
            ],
            [
             0.5,
             "#f7f7f7"
            ],
            [
             0.6,
             "#e6f5d0"
            ],
            [
             0.7,
             "#b8e186"
            ],
            [
             0.8,
             "#7fbc41"
            ],
            [
             0.9,
             "#4d9221"
            ],
            [
             1,
             "#276419"
            ]
           ],
           "sequential": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ],
           "sequentialminus": [
            [
             0,
             "#0d0887"
            ],
            [
             0.1111111111111111,
             "#46039f"
            ],
            [
             0.2222222222222222,
             "#7201a8"
            ],
            [
             0.3333333333333333,
             "#9c179e"
            ],
            [
             0.4444444444444444,
             "#bd3786"
            ],
            [
             0.5555555555555556,
             "#d8576b"
            ],
            [
             0.6666666666666666,
             "#ed7953"
            ],
            [
             0.7777777777777778,
             "#fb9f3a"
            ],
            [
             0.8888888888888888,
             "#fdca26"
            ],
            [
             1,
             "#f0f921"
            ]
           ]
          },
          "colorway": [
           "#636efa",
           "#EF553B",
           "#00cc96",
           "#ab63fa",
           "#FFA15A",
           "#19d3f3",
           "#FF6692",
           "#B6E880",
           "#FF97FF",
           "#FECB52"
          ],
          "font": {
           "color": "#2a3f5f"
          },
          "geo": {
           "bgcolor": "white",
           "lakecolor": "white",
           "landcolor": "#E5ECF6",
           "showlakes": true,
           "showland": true,
           "subunitcolor": "white"
          },
          "hoverlabel": {
           "align": "left"
          },
          "hovermode": "closest",
          "mapbox": {
           "style": "light"
          },
          "paper_bgcolor": "white",
          "plot_bgcolor": "#E5ECF6",
          "polar": {
           "angularaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "radialaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "scene": {
           "xaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "yaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           },
           "zaxis": {
            "backgroundcolor": "#E5ECF6",
            "gridcolor": "white",
            "gridwidth": 2,
            "linecolor": "white",
            "showbackground": true,
            "ticks": "",
            "zerolinecolor": "white"
           }
          },
          "shapedefaults": {
           "line": {
            "color": "#2a3f5f"
           }
          },
          "ternary": {
           "aaxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "baxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           },
           "bgcolor": "#E5ECF6",
           "caxis": {
            "gridcolor": "white",
            "linecolor": "white",
            "ticks": ""
           }
          },
          "title": {
           "x": 0.05
          },
          "xaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          },
          "yaxis": {
           "automargin": true,
           "gridcolor": "white",
           "linecolor": "white",
           "ticks": "",
           "title": {
            "standoff": 15
           },
           "zerolinecolor": "white",
           "zerolinewidth": 2
          }
         }
        },
        "title": {
         "text": "Flow of Genes from Discovery to Clinical Application"
        },
        "width": 1200
       }
      }
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import plotly.graph_objects as go\n",
    "\n",
    "# Define the data for the Sankey diagram.\n",
    "# We will use the same data to build the nodes and links.\n",
    "\n",
    "# First layer: Genes to Categories\n",
    "gene_to_category = {\n",
    "    'CDK4': 'FDA-approved Breast Cancer Therapy',\n",
    "    'ERBB2': 'FDA-approved Breast Cancer Therapy',\n",
    "    'PIK3CA': 'FDA-approved Breast Cancer Therapy',\n",
    "    'MET': 'FDA-approved Breast Cancer Therapy',\n",
    "    'BRCA1': 'FDA-approved Breast Cancer Therapy',\n",
    "    'BRCA2': 'FDA-approved Breast Cancer Therapy',\n",
    "    'PTEN': 'FDA-approved Breast Cancer Therapy',\n",
    "    'RB1': 'FDA-approved Breast Cancer Therapy',\n",
    "    'TP53': 'FDA-approved Breast Cancer Therapy',\n",
    "    'ATM': 'FDA-approved Breast Cancer Therapy',\n",
    "    'AKT1': 'FDA-approved Breast Cancer Therapy',\n",
    "    'KRAS': 'FDA-approved Breast Cancer Therapy',\n",
    "    'CDK6': 'FDA-approved Breast Cancer Therapy',\n",
    "    'CCND1': 'FDA-approved Other Indication',\n",
    "    'CDKN2A': 'FDA-approved Other Indication',\n",
    "    'BCL2': 'FDA-approved Other Indication',\n",
    "    'FGFR1': 'FDA-approved Other Indication',\n",
    "    'FGFR2': 'FDA-approved Other Indication',\n",
    "    'MDM2': 'FDA-approved Other Indication',\n",
    "    'NF1': 'FDA-approved Other Indication',\n",
    "    'HRAS': 'FDA-approved Other Indication',\n",
    "    'NTRK2': 'FDA-approved Other Indication',\n",
    "    'TSC2': 'FDA-approved Other Indication',\n",
    "    'STK11': 'FDA-approved Other Indication',\n",
    "    'ATR': 'FDA-approved Other Indication',\n",
    "    'NOTCH1': 'FDA-approved Other Indication',\n",
    "    'SMAD4': 'FDA-approved Other Indication',\n",
    "    'CHEK2': 'FDA-approved Other Indication',\n",
    "    'CASP8': 'Emerging Breast Cancer Target',\n",
    "    'FOXO3a': 'Emerging Breast Cancer Target',\n",
    "    'CDKN1A': 'Lacks Breast Cancer Evidence',\n",
    "    'BAX': 'Lacks Breast Cancer Evidence',\n",
    "    'NRAS': 'Lacks Breast Cancer Evidence',\n",
    "    'VHL': 'Lacks Breast Cancer Evidence',\n",
    "    'SRC': 'Lacks Breast Cancer Evidence',\n",
    "    'NF2': 'Lacks Breast Cancer Evidence',\n",
    "    'WT1': 'Lacks Breast Cancer Evidence',\n",
    "    'NTRK1': 'Lacks Breast Cancer Evidence'\n",
    "}\n",
    "\n",
    "# Second layer: Drugs associated with genes in the FDA-approved categories\n",
    "gene_to_drug = {\n",
    "    'CDK4': 'Palbociclib (Ibrance)',\n",
    "    'CDK6': 'Palbociclib (Ibrance)',\n",
    "    'ERBB2': 'Trastuzumab (Herceptin)',\n",
    "    'PIK3CA': 'Alpelisib (Piqray)',\n",
    "    'BRCA1': 'Olaparib (Lynparza)',\n",
    "    'BRCA2': 'Olaparib (Lynparza)',\n",
    "    'MET': 'Crizotinib (Xalkori)',\n",
    "    'PTEN': 'Alpelisib (Piqray)',  # Drug for PIK3CA pathway\n",
    "    'KRAS': 'Sotorasib (Lumakras)',\n",
    "    'BCL2': 'Venetoclax (Venclexta)',\n",
    "    'NTRK2': 'Larotrectinib (Vitrakvi)',\n",
    "    'EGFR': 'Gefitinib (Iressa)',\n",
    "    'TP53': 'Therapies for TP53' # As there is no single FDA-approved drug\n",
    "}\n",
    "\n",
    "# Combine all unique genes, categories, and drugs into a single list of labels\n",
    "all_labels = list(gene_to_category.keys()) + sorted(list(set(gene_to_category.values()))) + sorted(list(set(gene_to_drug.values())))\n",
    "label_to_index = {label: i for i, label in enumerate(all_labels)}\n",
    "\n",
    "# Build source, target, and value lists for the links\n",
    "source = []\n",
    "target = []\n",
    "value = []\n",
    "link_color = []\n",
    "\n",
    "# Define colors for the links based on the categories\n",
    "category_colors = {\n",
    "    'FDA-approved Breast Cancer Therapy': 'rgba(31, 119, 180, 0.8)',  # Blue\n",
    "    'FDA-approved Other Indication': 'rgba(44, 160, 44, 0.8)',      # Green\n",
    "    'Emerging Breast Cancer Target': 'rgba(255, 127, 14, 0.8)',      # Orange\n",
    "    'Lacks Breast Cancer Evidence': 'rgba(214, 39, 40, 0.8)'        # Red\n",
    "}\n",
    "\n",
    "# --- First layer of links: Genes to Categories ---\n",
    "for gene, category in gene_to_category.items():\n",
    "    source.append(label_to_index[gene])\n",
    "    target.append(label_to_index[category])\n",
    "    value.append(1)\n",
    "    link_color.append(category_colors[category])\n",
    "\n",
    "# --- Second layer of links: Genes to Drugs (for approved categories) ---\n",
    "for gene, drug in gene_to_drug.items():\n",
    "    # Only link genes from the FDA-approved categories to drugs\n",
    "    if gene_to_category.get(gene) in ['FDA-approved Breast Cancer Therapy', 'FDA-approved Other Indication']:\n",
    "        source.append(label_to_index[gene])\n",
    "        target.append(label_to_index[drug])\n",
    "        value.append(1)\n",
    "        link_color.append(category_colors[gene_to_category[gene]])\n",
    "\n",
    "\n",
    "# Create the Sankey diagram figure\n",
    "fig = go.Figure(data=[go.Sankey(\n",
    "    node=dict(\n",
    "        pad=15,\n",
    "        thickness=20,\n",
    "        line=dict(color=\"black\", width=0.5),\n",
    "        label=all_labels,\n",
    "        # Set node colors based on category\n",
    "        color=[\n",
    "            category_colors.get(gene_to_category.get(label), 'lightgray')\n",
    "            for label in all_labels\n",
    "        ],\n",
    "    ),\n",
    "    link=dict(\n",
    "        source=source,\n",
    "        target=target,\n",
    "        value=value,\n",
    "        color=link_color\n",
    "    )\n",
    ")])\n",
    "\n",
    "fig.update_layout(\n",
    "    title_text=\"Flow of Genes from Discovery to Clinical Application\",\n",
    "    font_size=10,\n",
    "    height=800,\n",
    "    width=1200\n",
    ")\n",
    "\n",
    "fig.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "id": "4ba59a48",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x700 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "\n",
    "# --- Data Preparation ---\n",
    "\n",
    "# Define the genes and their final, validated categories and licensed products.\n",
    "data = {\n",
    "    'gene': [\n",
    "        'CDK4', 'ERBB2', 'PIK3CA', 'MET', 'BRCA1', 'BRCA2', 'PTEN', 'RB1',\n",
    "        'TP53', 'ATM', 'AKT1', 'KRAS', 'CDK6', 'CCND1', 'CDKN2A', 'BCL2', \n",
    "        'FGFR1', 'CHEK2', 'ATR', 'MYC', 'NF1', 'STK11', 'FGFR2', 'NOTCH1', \n",
    "        'HRAS', 'NTRK2', 'CDKN1A', 'BAX', 'SRC', 'NF2', 'WT1', 'NTRK1', \n",
    "        'SMAD4', 'TSC2', 'VHL', 'CASP8', 'FOXO3a'\n",
    "    ],\n",
    "    'category': [\n",
    "        'High-Confidence Targets', 'High-Confidence Targets', 'High-Confidence Targets',\n",
    "        'High-Confidence Targets', 'High-Confidence Targets', 'High-Confidence Targets',\n",
    "        'High-Confidence Targets', 'High-Confidence Targets', 'High-Confidence Targets',\n",
    "        'High-Confidence Targets', 'High-Confidence Targets', 'High-Confidence Targets',\n",
    "        'High-Confidence Targets', 'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets',\n",
    "        'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets',\n",
    "        'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets',\n",
    "        'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets',\n",
    "        'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets', 'Underexplored Targets',\n",
    "        'Underexplored Targets', 'Underexplored Targets', 'Underexplored Targets',\n",
    "        'Underexplored Targets', 'Underexplored Targets', 'Underexplored Targets',\n",
    "        'Underexplored Targets', 'Underexplored Targets', 'Emerging Clinical Targets',\n",
    "        'Emerging Clinical Targets'\n",
    "    ],\n",
    "    'drug': [\n",
    "        'Palbociclib (Ibrance)', 'Trastuzumab (Herceptin)', 'Alpelisib (Piqray)', \n",
    "        'Crizotinib (Xalkori)', 'Olaparib (Lynparza)', 'Olaparib (Lynparza)', \n",
    "        'Alpelisib (Piqray)', 'No Specific Drug', 'No Specific Drug', \n",
    "        'No Specific Drug', 'No Specific Drug', 'Sotorasib (Lumakras)',\n",
    "        'Palbociclib (Ibrance)', 'No Specific Drug', 'No Specific Drug', \n",
    "        'Venetoclax (Venclexta)', 'No Specific Drug', 'No Specific Drug', \n",
    "        'No Specific Drug', 'No Specific Drug', 'No Specific Drug', \n",
    "        'No Specific Drug', 'No Specific Drug', 'No Specific Drug', \n",
    "        'No Specific Drug', 'Larotrectinib (Vitrakvi)', 'No Specific Drug', \n",
    "        'No Specific Drug', 'No Specific Drug', 'No Specific Drug', \n",
    "        'No Specific Drug', 'No Specific Drug', 'No Specific Drug',\n",
    "        'No Specific Drug', 'No Specific Drug', 'No Specific Drug', \n",
    "        'No Specific Drug'\n",
    "    ]\n",
    "}\n",
    "\n",
    "# Create a DataFrame from the data.\n",
    "df = pd.DataFrame(data)\n",
    "\n",
    "# Sort the DataFrame for a logical flow in the plot.\n",
    "df = df.sort_values(by='category', ascending=True)\n",
    "df = df.sort_values(by=['category', 'gene'], ascending=[False,True])\n",
    "\n",
    "\n",
    "# Create a color map for the plot based on your four categories.\n",
    "category_colors = {\n",
    "    'High-Confidence Targets': '#1f77b4',       # Blue\n",
    "    'Therapeutic Expansion Targets': '#2ca02c', # Green\n",
    "    'Emerging Clinical Targets': '#ff7f0e',     # Orange\n",
    "    'Underexplored Targets': '#d62728'          # Red\n",
    "}\n",
    "colors = df['category'].map(category_colors)\n",
    "\n",
    "# --- Create the Plot ---\n",
    "plt.figure(figsize=(8, 7))\n",
    "# The bar height is a placeholder to control bar order.\n",
    "plt.barh(df['gene'], [1] * len(df), color=colors)  \n",
    "\n",
    "# Add text labels for the drug names.\n",
    "for i, (gene, drug) in enumerate(zip(df['gene'], df['drug'])):\n",
    "    if drug != 'No Specific Drug':\n",
    "        plt.text(1.1, i, f'-> {drug}', va='center', fontsize=12, color='black')\n",
    "\n",
    "# Set labels, title, and other plot aesthetics.\n",
    "plt.title('Mapping of Genes to Known Licensed Products', fontsize=18, pad=20)\n",
    "plt.xlabel('Category & Drug Status', fontsize=14)\n",
    "plt.ylabel('Gene', fontsize=14)\n",
    "plt.yticks(fontsize=12)\n",
    "plt.xlim(0, 2.5)  # Adjust x-limit to make space for the drug names\n",
    "plt.gca().get_xaxis().set_visible(False)  # Hide x-axis\n",
    "\n",
    "# Create a custom legend with all four categories.\n",
    "handles = [plt.Rectangle((0, 0), 1, 1, color=category_colors[label]) for label in category_colors]\n",
    "plt.legend(handles, category_colors.keys(), title=\"Therapeutic Category\", fontsize=12, title_fontsize=14)\n",
    "\n",
    "plt.tight_layout()\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 79,
   "id": "61678467",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 2000x1400 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "\n",
    "# Define the data with the final, updated study counts and the four new, precise categories.\n",
    "data = {\n",
    "    'gene': [\n",
    "        'CDK4', 'ERBB2', 'PIK3CA', 'MET', 'BRCA1', 'BRCA2', 'PTEN', 'RB1',\n",
    "        'TP53', 'ATM', 'AKT1', 'KRAS', 'CDK6', 'CCND1', 'CDKN2A', 'BCL2', \n",
    "        'FGFR1', 'CHEK2', 'ATR', 'MYC', 'NF1', 'STK11', 'FGFR2', 'NOTCH1', \n",
    "        'HRAS', 'NTRK2', 'CDKN1A', 'BAX', 'SRC', 'NF2', 'WT1', 'NTRK1', \n",
    "        'SMAD4', 'TSC2', 'VHL', 'CASP8', 'FOXO3a'\n",
    "    ],\n",
    "    'studies': [\n",
    "        100, 100, 100, 100, 100, 100, 100, 71,\n",
    "        56, 43, 40, 38, 34, 34, 27, 24, 21, 17,\n",
    "        19, 15, 11, 9, 7, 5, 4, 4, 2, 9, 21, 5, 34, 12,\n",
    "        1, 1, 1, 1, 4\n",
    "    ],\n",
    "    'category': [\n",
    "        'High-Confidence Targets', 'High-Confidence Targets', 'High-Confidence Targets',\n",
    "        'High-Confidence Targets', 'High-Confidence Targets', 'High-Confidence Targets',\n",
    "        'High-Confidence Targets', 'High-Confidence Targets', 'High-Confidence Targets',\n",
    "        'High-Confidence Targets', 'High-Confidence Targets', 'High-Confidence Targets',\n",
    "        'High-Confidence Targets', 'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets',\n",
    "        'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets',\n",
    "        'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets',\n",
    "        'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets',\n",
    "        'Therapeutic Expansion Targets', 'Therapeutic Expansion Targets', 'Underexplored Targets',\n",
    "        'Underexplored Targets', 'Underexplored Targets', 'Underexplored Targets',\n",
    "        'Underexplored Targets', 'Underexplored Targets', 'Underexplored Targets',\n",
    "        'Underexplored Targets', 'Underexplored Targets', 'Emerging Clinical Targets',\n",
    "        'Emerging Clinical Targets'\n",
    "    ]\n",
    "}\n",
    "\n",
    "# Create a pandas DataFrame.\n",
    "df = pd.DataFrame(data)\n",
    "\n",
    "# Sort the data first by category order and then by study count within each category.\n",
    "category_order = [\n",
    "    'High-Confidence Targets', \n",
    "    'Therapeutic Expansion Targets', \n",
    "    'Emerging Clinical Targets', \n",
    "    'Underexplored Targets'\n",
    "]\n",
    "df['category'] = pd.Categorical(df['category'], categories=category_order, ordered=True)\n",
    "df = df.sort_values(by=['category', 'studies'], ascending=[True, False])\n",
    "\n",
    "# Create a color map for the categories.\n",
    "category_colors = {\n",
    "    'High-Confidence Targets': '#1f77b4',       # Blue\n",
    "    'Therapeutic Expansion Targets': '#2ca02c', # Green\n",
    "    'Emerging Clinical Targets': '#ff7f0e',     # Orange\n",
    "    'Underexplored Targets': '#d62728'          # Red\n",
    "}\n",
    "colors = df['category'].map(category_colors)\n",
    "\n",
    "# Create the plot.\n",
    "fig, (ax1, ax2) = plt.subplots(2, 1, figsize=(20, 14), gridspec_kw={'height_ratios': [1, 0.25]})\n",
    "\n",
    "# Plot the bar chart on the first axes (ax1).\n",
    "ax1.bar(df['gene'], df['studies'], color=colors)\n",
    "ax1.set_title('Number of Clinical Studies for Breast Cancer Genes by Therapeutic Category', fontsize=18)\n",
    "ax1.set_xlabel('Gene', fontsize=14)\n",
    "ax1.set_ylabel('Number of Studies Found', fontsize=14)\n",
    "\n",
    "# Corrected plt.xticks to remove the problematic 'ha' keyword\n",
    "ax1.tick_params(axis='x', rotation=45, labelsize=10)\n",
    "\n",
    "# Add vertical lines to separate the categories.\n",
    "category_boundaries = df['category'].value_counts(sort=False).cumsum().tolist()\n",
    "for x_pos in category_boundaries[:-1]:\n",
    "    ax1.axvline(x=x_pos - 0.5, color='gray', linestyle='--', linewidth=1.5)\n",
    "\n",
    "# Create a custom legend with all four categories.\n",
    "handles = [plt.Rectangle((0, 0), 1, 1, color=category_colors[label]) for label in category_order]\n",
    "ax1.legend(handles, category_order, title=\"Therapeutic Category\", fontsize=12, title_fontsize=14)\n",
    "\n",
    "# --- Create the supplementary table on the second axes (ax2) ---\n",
    "ax2.set_title('Table 1: Gene Count by Therapeutic Category', fontsize=16)\n",
    "ax2.axis('off') # Hide axes for the table\n",
    "\n",
    "# Calculate the count and percentage for each category.\n",
    "category_counts = df['category'].value_counts().to_frame().reset_index()\n",
    "category_counts.columns = ['Category', 'Gene Count']\n",
    "total_genes = category_counts['Gene Count'].sum()\n",
    "category_counts['Percentage'] = (category_counts['Gene Count'] / total_genes * 100).round(1).astype(str) + '%'\n",
    "\n",
    "# Reorder the table to match the plot.\n",
    "category_counts['Category'] = pd.Categorical(category_counts['Category'], categories=category_order, ordered=True)\n",
    "category_counts = category_counts.sort_values(by='Category')\n",
    "\n",
    "# Create the table\n",
    "table = ax2.table(cellText=category_counts.values, colLabels=category_counts.columns, cellLoc='center', loc='center', bbox=[0.25, 0.2, 0.5, 0.5])\n",
    "table.auto_set_font_size(False)\n",
    "table.set_fontsize(12)\n",
    "table.scale(1.2, 1.2)\n",
    "\n",
    "plt.tight_layout()\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "id": "b284177d",
   "metadata": {},
   "outputs": [],
   "source": [
    "# import matplotlib.patches as patches\n",
    "\n",
    "# # Sort df as before\n",
    "# df['category'] = pd.Categorical(df['category'], categories=category_order, ordered=True)\n",
    "# df = df.sort_values(by=['category', 'gene'], ascending=[True, True]).reset_index(drop=True)\n",
    "\n",
    "# plt.figure(figsize=(7, 11))  # Smaller figure size\n",
    "\n",
    "# ax = plt.gca()\n",
    "\n",
    "# # Plot bars\n",
    "# bars = plt.barh(df['gene'], [1] * len(df), color=df['category'].map(category_colors))\n",
    "\n",
    "# # Add colored blocks with labels behind groups\n",
    "# current_category = None\n",
    "# start_idx = 0\n",
    "\n",
    "# for i, category in enumerate(df['category']):\n",
    "#     if category != current_category:\n",
    "#         if current_category is not None:\n",
    "#             ax.add_patch(\n",
    "#                 patches.Rectangle(\n",
    "#                     (0, start_idx - 0.5),\n",
    "#                     width=1,\n",
    "#                     height=i - start_idx,\n",
    "#                     color=category_colors[current_category],\n",
    "#                     alpha=0.1,\n",
    "#                     zorder=0\n",
    "#                 )\n",
    "#             )\n",
    "#             ax.text(\n",
    "#                 -0.1,\n",
    "#                 (start_idx + i - 1) / 2,\n",
    "#                 current_category,\n",
    "#                 va='center',\n",
    "#                 ha='right',\n",
    "#                 fontsize=9,\n",
    "#                 color=category_colors[current_category],\n",
    "#                 fontweight='bold'\n",
    "#             )\n",
    "#         current_category = category\n",
    "#         start_idx = i\n",
    "\n",
    "# # Last group rectangle and label\n",
    "# ax.add_patch(\n",
    "#     patches.Rectangle(\n",
    "#         (0, start_idx - 0.5),\n",
    "#         width=1,\n",
    "#         height=len(df) - start_idx,\n",
    "#         color=category_colors[current_category],\n",
    "#         alpha=0.1,\n",
    "#         zorder=0\n",
    "#     )\n",
    "# )\n",
    "# ax.text(\n",
    "#     -0.1,\n",
    "#     (start_idx + len(df) - 1) / 2,\n",
    "#     current_category,\n",
    "#     va='center',\n",
    "#     ha='right',\n",
    "#     fontsize=9,\n",
    "#     color=category_colors[current_category],\n",
    "#     fontweight='bold'\n",
    "# )\n",
    "\n",
    "# # Add drug annotations\n",
    "# for i, (gene, drug) in enumerate(zip(df['gene'], df['drug'])):\n",
    "#     if drug != 'No Specific Drug':\n",
    "#         plt.text(1.05, i, f'-> {drug}', va='center', fontsize=8, color='black')\n",
    "\n",
    "# # Labels and formatting\n",
    "# plt.title('Mapping of Genes to Known Licensed Products', fontsize=12, pad=12)\n",
    "# plt.xlabel('Category & Drug Status', fontsize=10)\n",
    "# plt.ylabel('Gene', fontsize=10)\n",
    "# plt.yticks(fontsize=8)\n",
    "# plt.xlim(-0.5, 2.5)\n",
    "# plt.gca().get_xaxis().set_visible(False)\n",
    "\n",
    "# # Legend\n",
    "# handles = [patches.Patch(color=category_colors[label]) for label in category_colors]\n",
    "# plt.legend(handles, category_colors.keys(), title=\"Therapeutic Category\", fontsize=9, title_fontsize=10)\n",
    "\n",
    "# plt.tight_layout()\n",
    "# plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "id": "4b219b6f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1000x1200 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Sort df_pivot rows by 'GSE180286' column descending\n",
    "\n",
    "# Pivot the dataframe: index=gene, columns=Dataset, values=log2_fc\n",
    "df = pd.read_csv(f\"{assets}/Combined_DE.csv\")\n",
    "df_pivot = df.pivot(index='gene', columns='Dataset', values='log2_fc')\n",
    "df_pivot_sorted = df_pivot.sort_values(by='GSE180286', ascending=False)\n",
    "\n",
    "plt.figure(figsize=(10, max(4, len(df_pivot_sorted)*0.3)))  # dynamic height\n",
    "\n",
    "sns.heatmap(\n",
    "    df_pivot_sorted,\n",
    "    cmap='coolwarm',\n",
    "    center=0,\n",
    "    annot=True,\n",
    "    fmt=\".2f\",\n",
    "    linewidths=0.5,\n",
    "    cbar_kws={'label': 'Log2 Fold Change'}\n",
    ")\n",
    "\n",
    "plt.title('Differential Gene Expression Across Datasets', fontsize=16)\n",
    "plt.ylabel('Gene', fontsize=12)\n",
    "plt.xlabel('Dataset', fontsize=12)\n",
    "plt.tight_layout()\n",
    "plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "id": "0003d994",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 800x800 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n",
    "# Your core breast cancer genes  you can add more if desired\n",
    "genes = [\n",
    "    'ESR1', 'PGR', 'PIK3CA', 'AKT1', 'CDK4', 'CDK6', 'CCND1', 'RB1',\n",
    "    'PTEN', 'FOXO3a', 'CASP8', 'TP53',\n",
    "    # Additional important breast cancer genes\n",
    "    'BRCA1', 'BRCA2', 'MYC', 'HER2', 'ERBB2', 'NOTCH1', 'MTOR', 'CHEK2', 'ATM'\n",
    "]\n",
    "\n",
    "# Load your combined DE genes DataFrame\n",
    "#df = pd.read_csv(\"~/Desktop/Capstone/Notebook recent/combined_de_genes.csv\")\n",
    "\n",
    "# Normalize gene names (optional but recommended)\n",
    "df['gene_norm'] = df['gene'].str.upper().str.strip()\n",
    "\n",
    "# Filter for genes of interest (case-insensitive match)\n",
    "genes_upper = [g.upper() for g in genes]\n",
    "df_filtered = df[df['gene_norm'].isin(genes_upper)]\n",
    "\n",
    "# Pivot to get genes as rows, datasets as columns with log2_fc values\n",
    "df_pivot = df_filtered.pivot(index='gene_norm', columns='Dataset', values='log2_fc')\n",
    "\n",
    "# Sort by GSE180286 descending\n",
    "df_pivot_sorted = df_pivot.sort_values(by='GSE180286', ascending=False)\n",
    "\n",
    "# Plot heatmap\n",
    "plt.figure(figsize=(8, max(4, len(df_pivot_sorted)*0.5)))\n",
    "\n",
    "sns.heatmap(\n",
    "    df_pivot_sorted,\n",
    "    cmap='coolwarm',\n",
    "    center=0,\n",
    "    annot=True,\n",
    "    fmt=\".2f\",\n",
    "    linewidths=0.5,\n",
    "    cbar_kws={'label': 'Log2 Fold Change'}\n",
    ")\n",
    "\n",
    "plt.title('Breast Cancer Key Pathway Genes Differential Expression', fontsize=16)\n",
    "plt.ylabel('Gene', fontsize=12)\n",
    "plt.xlabel('Dataset', fontsize=12)\n",
    "plt.tight_layout()\n",
    "plt.show()\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.9"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
